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SUMMARY 
 
HIV/AIDS was discovered almost a quarter of a century ago and has so far claimed the lives of 
more than 25 million people worldwide. Developing countries remain disproportionately affected, 
with sub-Saharan Africa contributing more than two-thirds of infections globally. Sexual 
transmission is the primary route of HIV/AIDS acquisition, and women bear the greatest burden of 
this pandemic. We are now at a stage where biotechnological advances are needed that can either 
cure HIV/AIDS, stimulate the immune system to produce anti-HIV-antibodies by vaccination, or 
prevent HIV infections. One of these advances has been the development of various microbicides. 
However, a lack of effective drug delivery systems for these agents has remained as a rate-limiting 
step towards successful HIV prevention. In an attempt to overcome this problem, this study aimed 
at designing and developing a novel intravaginal bioadhesive polymeric device (IBPD) as a 
delivery system to effectively deliver a microbicide {polystyrene sulfonate (PSS)} and antiretroviral 
(ARV) {3'-azido-3'-deoxythymidine (AZT)} combination to the vagina. The development of a 
successful intravaginal microbicidal drug delivery system requires the design of a formulation to 
deliver the microbicide-ARV combination in a safe, effective, and consistent manner. The first step 
therefore was to undertake extensive preliminary screening studies on various polymeric materials 
using a one variable at a time (OVAT) approach to find suitable polymers for developing an IBPD. 
Initially 18 biodegradable and biocompatible polymers were employed to produce 62 formulations 
that were further screened through the OVAT approach to result in 15 lead formulations.  
Two major concerns of this study were the attainment of satisfactory residence time of the IBPD in 
the vagina as well as the ability of the IBPD to contain and release the microbicide-ARV in a 
controlled manner. Therefore, optimization of the IBPD was based on these two requirements for 
which proper matrix integrity was a pre-requisite. Artificial neural networks (ANNs), a computational 
technique that is able to simulate the neurological processing ability of the human brain through 
mathematical modeling, was employed for optimization. The ANN approach confirmed that 5 of the 
18 studied polymers could be suitable for the development of an optimized IBPD. To finally attain 
good vaginal retention for the developed delivery system, extensive bioadhesivity testing was 
undertaken on the optimized device. Thorough in vitro and ex vivo bioadhesivity analysis was 
conducted using physicomechanics and computational structural modeling. Allyl penta erythritol-
crosslinked poly acrylic acid (APE-PAA) appeared to contribute most to the bioadhesivity. Apart 
from being employed as a matrix component, PAA was further used as a coating agent to achieve 
extended bioadhesivity within the posterior fornix of the vagina. Since prolonged release and 
suitable permeation of the microbicide-ARV across the vaginal tissue was a critical requirement of 
this study, the device was designed to provide a controlled and prolonged drug release. Prolonged 
release for up to 72 days was achieved. Furthermore, the design was constructed to ensure that 
the released drug could permeate into the vaginal tissue and be retained substantially. This was 
determined by measuring drug flux through ex-vivo permeation studies using freshly excised pig 
vaginal tissue in a Franz Diffusion Cell (FDC) apparatus.  
The ultimate aim of the study was to have the IBPD well accommodated in the vagina for 
successful prevention of STIs and HIV infection. Achievement of this aim was ensured by 
undertaking extensive in vivo studies in Large White pig model. The IBPDs were inserted under 
anaesthesia into the posterior fornix of the vagina, using a novel applicator. To detect the retention 
of the IBPDs and determine their sequential biodegradation pattern in the vagina, X-ray imaging 
was employed, using radio-opaque Barium Sulphate (BaSO4). To demonstrate that the developed 
drug delivery system acted locally and was only minimally absorbed systemically, blood samples 
were taken from the jugular vein of each pig at pre-determined time intervals and subjected to 
UPLC analysis. The drug content in the vaginal tissue at the end of the study was also determined. 
Histopathological evaluation was carried out on vaginal epithelium to access the potential for 
toxicity of the IBPDs. The drug content analysis revealed that greater amounts of AZT and PSS 
were retained in the vaginal tissue with relatively small quantities (AZT:17%; PSS:13%) crossing 
into the systemic circulation. The results from the toxicity studies showed that the IBPDs were safe 
for use. This suggests that the developed drug delivery system (the IBPD) may be suitable for 
application in the prevention of STIs and HIV infections. 
 xvi
 
ACKNOWLEDGEMENTS 
 
This work would not have been possible to undertake and accomplish if it was not due to 
endeavored support and encouragement from various people. I would therefore first and foremost 
like to express my deepest gratitude to my supervisor, Professor Viness Pillay for his distinguished 
guidance, exciting sensitization towards devotion for excellence, eminent supervision, invaluable 
advice and support throughout this study. I am highly indebted to his vision and commitment in 
ensuring the successful accomplishment of this work right from the beginning to the end. He 
opened new highways for my scientific, academic career and the personal life. Words are very little 
to describe my thanks and appreciation for what he has done for me which is absolutely next to 
impossible to forget. I do not have anything equivalent to offer as a return but rather my constant 
prayers to God to enable him continue with the same pace of deliverance. 
 
 I am most grateful to my co-supervisor, Prof. Eckhart Buchmann for his thorough advice and 
support towards the success of this work.  Being a gynecologist/obstetrician, he played a leading 
role in bridging pharmaceutical and clinical expertise. His contribution to this thesis is 
unforgettable. 
My esteemed gratitude goes to Prof. Michael P. Danckwerts, Head and Chair: Department of 
Pharmacy and Pharmacology, for his invaluable encouragement, support and advice that he 
rendered to me as a leader which in one way or another facilitated the accomplishment of this 
work. His excellent leadership skills contributed substantially towards my success. I am grateful to 
Mr. David Bayever for his professional advice and assistance in legal and ethical pertaining issues 
and Dr. Sandy van Vuuren for her advice. 
 I would like to extend my sincere and special thanks to Dr. Leith C.R. Meyer, Director: Central 
Animal Services (CAS), whose endeavored and tireless efforts made the in vivo aspect of this 
study possible. His contribution towards the success of this work will never ever be forgotten. I 
would also like to thank the rest of the CAS team including Sister Mary-Ann Costello, Patrick 
Selahle, Ammelia Rammekwa, Lorrain Setimo and Kershnee Chetty. Be blessed for all of your 
efforts towards making this work a success.  
 xvii
 
I would also like to extend my special thanks and appreciation to the entire management of 
PharmaNatura (Pty) Ltd, in particular Mr. Uwe Rosin, Director: Research and Development (R&D) 
Unit, and Mr. Peter Setlaelo, former Principal Technician (R&D) for making it possible to undertake 
the production of the IBPDs at their facilities. 
It will be very difficult to forget the contributions that were made in one way or another by my PhD 
colleagues, Mr. Yahya E. Choonara, Mrs. Oluwatoyin Adeleke and Ms Lisa du Toit. May the 
Almighty reward them an equivalency in terms of academic achievement.  In this regard, I also 
thank my other PhD colleagues, Ms Ndidi  Ngwuluka, Mr. Steven Mufamadi and the entire group of 
Masters students, particularly Ms Samantha Pillay, Priya Bawa, Zaheeda Khan, Bongani B. 
Sibeko, Shivaan Cooppan, Pius Fasinu and Thiresen Govender. Their charisma, encouragement 
and well maintained spirit of comradely made life a bit easier for me in the Department.  
My special attributes go to Prof. Thirumala Govender, School of Pharmacy and Pharmacology, 
University of Kwazulu-Natal, who was the first person I had made contact with, regarding my 
intention to pursue a PhD in South Africa. I thank her for leading me to the proper channel through 
which I have been able to accomplish my objective. In this regard, I would also like to thank the 
following people who in one way or another contributed to the success of this work particularly at 
the initial stages: Professor Bruce Davidson, former Chairman: Animal Ethics Committee, 
University of the Witwatersrand; Prof. Michael Witcomb, Head: Microscopy and Microanalysis Unit, 
University of the Witwatersrand; Ms Caroline Lalkhan, Microscopy and Microanalysis Unit; Dr. 
Geoffrey Candy, Department of Surgery, University of the Witwatersrand, Prof. Josias Hamman, 
Tshwane University of Technology, Pretoria, Dr. Eugene Olivier, Head: Department of 
Pharmaceutics, Tshwane University of Technology, Pretoria, Prof. Mary Justin-Temu, Muhimbili 
University of Health and Allied Sciences (MUHAS), Prof. Amos Massele, MUHAS, Dr.Thecla Kohi, 
MUHAS, Ms Jovita Temba, MUHAS and Mr. Dennis Busuguli, Ministry of Health, Tanzania . I will 
be short of gratitude if I don’t remember to thank the support members of staff in our Department, 
particularly Ms Busi Nompumelelo Damane, Mr. Sello Ramarumo, Mrs Lehlohonolo Tebogo 
Chandu and the rest. They all made my studies manageable and easier in one way or another.  
  
 xviii
 
Certainly these studies would not have been possible to undertake if it were not for the 
sponsorship that was offered to me by the Norwegian Agency for Development Co-operation 
(NORAD)-NORWAY, through the University of Dar-es-Salaam (UDSM) and the logistic support 
from Muhimbili National Hospital (MNH) and MUHAS (particularly School of Pharmaceutical 
Sciences), Tanzania. I highly acknowledge and thank NORAD, MNH and the Vice chancellors of 
UDSM and MUHAS together with their entire administration teams in this regard. Special thanks go 
to Mr.Leo K. Kingalu, former Head: Staff Training and Development Unit (STDU), Directorate of 
Human Resource Management, UDSM, Mrs Neema G. Mshingeni, Head: STDU and Mr. Evarist F. 
Lyagala, STDU, UDSM, for ensuring smooth running of the NORAD scholarship. I would like to 
express my special gratitude to the University of the Witwatersrand not only for providing me with 
an opportunity to undertake these studies but also for granting me the Postgraduate Merit and 
Bradlow awards and the Medical Faculty Research Endowment Fund (MFREF), which apart from 
adding up to my inspiration towards my work, also assisted in facilitating my studies. Noteworthy, is 
the prestigious award that was offered to me by Novartis (South Africa) to attend the BioCamp 
Seminar at Massachusetts Institute of Technology (MIT), USA, October 2009, which allowed me to 
exchange and reap substantial knowledge related to my work. 
 
Coming to this end, I would like to express my special gratitude, thanks and gratefulness to my 
wife Christine, my daughter Karen and my son Collins, for being pillars of strength during my study 
period, for accepting to undergo the endurance of staying without me for the whole period of my 
studies and for their constant love, persistent prayers, support and encouragement during this 
meandering arduous journey. May this achievement be a reward for their endurance. I am also 
highly endeavored to my Dad, Mum and my Mother-in-law for their constant prayers, wisdom, love, 
encouragement and support throughout my studies. I am sure that this work makes them very 
happy and proud. I also extend my thanks to my brothers, sisters, brother-in-laws and sister-in-law 
for their love and support towards this achievement. 
 
Last but certainly not the least, I would like to thank the Almighty God and his son Jesus Christ for 
what They have bestowed upon me.  
 
 xix
 
ANIMAL ETHICS DECLARATION 
 
I hereby confirm that the following study entitled “A Novel Controlled Release Intravaginal 
Polymeric Bioadhesive Device” had received the approval from the Animal Ethics 
Committee of the University of the Witwatersrand with ethics clearance number 
2007/25/05. (Appendix D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xx
 
 TABLE OF CONTENTS 
 
 
 
Declaration 
 
Page 
 
ii 
Dedication iii 
Research Outputs, Patent and Accolades iv 
Summary xv 
Acknowledgements xvi 
Animal Ethics Declaration xix 
List of Figures xxxvi 
List of Tables xLiii 
  
Chapter One 
Background, Rationale and Motivation for this Study 
 
1.1           Introduction 1 
1.1.1        Current status of the therapeutic management of HIV/AID  6 
1.1.1.1     Combination therapy in HIV/AIDS  8 
1.1.2        Anatomy and physiology of the vagina in relation to drug delivery 9 
1.1.3        The vaginal mucus in relation to bioadhesion 12 
1.1.4        Vagina as an application site for drug delivery  13 
1.1.4.1     Advantages and disadvantages of vaginal drug delivery 15 
1.2           Statement of the problem 17 
1.3           Rationale and motivation of this study 19 
1.4           Aim and objectives of this study 23 
1.5         Overview of the thesis 24 
1.6           Concluding remarks 27 
 xxi
 
 
Chapter Two 
Literature Review of Current Intravaginal Drug Delivery Approaches 
Employed for the Prophylaxis of HIV/AIDS and Prevention of Sexually 
Transmitted Infections 
 
 
   
2.1            Introduction 28 
2.2 The rationale for the development of intravaginal microbicidal  
delivery systems  
 
30 
2.3            Current intravaginal microbicide delivery approaches for 
                 preventing the transmission of STIs and HIV 
 
31 
2.4            Design of intravaginal microbicide delivery systems 33 
2.4.1         Creams and gels 34 
2.4.2         Tablets and suppositories 35 
2.4.3         Vaginal rings 36 
2.5            Bioadhesive intravaginal systems 37 
2.6            Compounds Delivered Intravaginally as Microbicides 39 
2.7            Dual-function polymeric gel-based formulations employed in the 
                 design of intravaginal microbicide delivery systems: As 
                 excipients with potential therapeutic activity 
 
 
40 
2.7.1         Carageenan-based gel formulations   41 
2.7.1.1      A carageenan vaginal gel formulation for HIV and Human 
                 Papilloma Virus inhibition 
 
42 
2.7.1.2      A combinatory gel formulation of carageenan and a Non- 
                 Nucleoside Reverse Transcriptase Inhibitor 
 
45 
2.7.1.3      A topical non-contraceptive carageenan gel formulation  45 
2.7.2         A Polyacrylic acid-based gel formulation 46 
 xxii
 
2.7.3         A    Lactobacillus Crispatus soft-gel capsule formulation   47 
2.7.4         Thermosensitive gel formulations  48 
2.7.5         Long-chain sulfated polysaccharides and sulfonated polymeric  
                 formulation 
 
49 
2.7.6 A carbomer, lactic acid and naphthalene sulfonate gel 
                 formulation 
 
50 
2.7.7         A micronized cellulose acetate phthalate gel formulation  51 
2.7.8         A monocaprin-loaded hydrogel formulation  52 
2.7.9         Polystyrene sulfonate vaginal tablets 52 
2.8            Non-polymeric intravaginal microbicide delivery systems for 
                 preventing the transmission of STIs and HIV  
 
53 
2.8.1         A cetyl betaine and myristamine oxide combinatory cream  
                 formulation 
 
53 
2.8.2          A non-nucleoside reverse transcriptase inhibitor-loaded gel 
                 formulation 
 
53 
2.8.3         A nucleotide analogue-loaded gel formulation 55 
2.8.4         A novel synthetically derived aryl phosphate-loaded gel  
                 formulation 
 
55 
2.8.5         A cyanovirin-N gel formulation for chemotherapeutic and 
                 immunoprophylactic prevention of HIV 
 
56 
2.8.6         Sodium lauryl sulfate as an Invisible Condom TM gel-like 
                 formulation 
 
56 
2.8.7         Dapivirine anti-HIV vaginal rings 57 
2.8.8         Polyherbal anti-HIV Praneem-loaded vaginal tablets 57 
2.9            Nanotechnology-based intravaginal microbicide delivery systems 58 
2.9.1         A dendrimer-based microbicide formulation 58 
2.9.2         Silver nanoparticles employed as microbicide delivery systems 59 
 xxiii
 
2.9.3         Polystyrene nanospheres as microbicide delivery systems 60 
2.9.4 A gel-like molecular condom formulation as a barrier for STIs  
                 and HIV  transmission 
 
60 
2.10          Other microbicidal compounds currently under investigation 61 
2.10.1       A secretory leukocyte protease inhibitor  61 
2.10.2       Thrombospondin-1 as a barrier to mucosal transmission of HIV-1 62 
2.10.3       Short interfering RNA as potential liposomal microbicide delivery 
                 systems 
 
63 
2.10.4       Thiophen-Thiourea: A non-nucleoside reverse transcriptase 
                 Inhibitor 
 
64 
2.10.5       Monoclonal antibodies as microbicides 67 
2.10.6       Lime juice as a microbicide 67 
2.10.7       Yoghurt as a microbicide 68 
2.11          Concluding Remarks 69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xxiv
 
 
Chapter Three 
Preformulation Investigations for the Development of Lead  
Intravaginal Bioadhesive Polymeric Devices 
 
3.1            Introduction 70 
3.2            Materials and methods 74 
3.2.1         Materials 74 
3.2.1.1      Synthesis of modified polyamide 6,10 75 
3.2.2         Methods 76 
3.2.2.1      Selection of formulation components 76 
3.2.2.2    Preparation of preliminary lead intravaginal bioadhesive  
  Polymeric devices 
 
79 
3.2.2.3      Equilibrium swelling studies conducted on the preliminary 
                 formulations as a critical indicator of the formulation’s matrix 
                 stability 
 
 
82 
3.2.2.4      Effect of changing the formulation components of the IBPD on 
                 the equilibrium swelling ratio 
 
83 
3.2.2.4.1   Effect of the elimination of carrageenan 83 
3.2.2.4.2   Effect of addition of ethylcellulose  84 
3.2.2.4.3   Effect of elimination of polyethylene oxide 84 
3.2.2.4.4   Effect of addition of polyvinyl alcohol 85 
3.2.2.4.5   Effect of addition of polyvinyl povidone 85 
3.2.2.4.6   Effect of addition of the xanthan gum 86 
3.2.2.4.7   Effect of the addition of guar gum 86 
3,2.2.4.8   Effect of the addition of gelatin 87 
3.2.2.4.9   Effect of the addition of beeswax 88 
 xxv
 
3.2.2.4.10 Effect of the addition of tragacanth 88 
3.2.2.4.11 Effect of the addition of methyl cellulose, hydroxyethylcellulose,    
                 hydroxypropylcellulose, hydroxypropylmethylcellulose, 
                 Eudragit® S100 Eudragit®  RS100 as substitutes for gelatin 
 
 
89 
3.2.2.4.12 Effect of addition of a binary polymer combination to the 
                 formulation 
 
90 
3.2.2.4.13 Effect of the addition of a tertiary polymer combination to the 
                 formulation 
 
90 
3.3            Results and discussions 91 
3.3.1         Physical properties of mPA 6,10 and in-process validation tests 92 
3.3.2     The influence of different polymeric composition on the 
                 equilibrium swelling ratio 
 
94 
3.3.2.1     The influence of carageenan, polyethylene oxide and 
                 ethylcellulose on the matrix stability 
 
94 
3.3.2.2     The influence of guar gum, polyvinyl povidone, tragacanth and 
                  polyvinyl alcohol on matrix stability 
 
94 
3.3.2.3     The influence of xanthan gum, beeswax and gelatin on the 
                 matrix stability 
 
94 
3.3.2.4      The influence of the addition of of methylcellulose, 
                 hydroxyethlycellulose, hydroxypropylcellulose and 
                 hydroxypropymethyllcellulose in the formulations on matrix  
                 stability 
 
 
 
95 
3.3.2.5      Influence of Eudragit® S100 and Eudragit® RS 100  on matrix  
                 swelling 
 
95 
3.3.2.6      Equilibrium swelling ratios of the best selected fifteen lead 
                 formulations screened through the OVAT approach  
 
96 
3.4            Concluding remarks 98 
 xxvi
 
 
Chapter Four 
Application of Artificial Neural Networks for the Elucidation of an 
Optimized Synergistic Polymer Combination for Effective 
Performance of the Intravaginal Bioadhesive Polymeric Device 
 
 
4.1            Introduction 99 
4.2            Materials and methods 101 
4.2.1         Materials 101
4.2.2         Methods 101 
4.2.2.1      Preparation of the intravaginal polymeric device 101
4.2.3         In process validation tests 102 
4.2.3.1      Determination of the Brinell hardness number 102 
4.2.4         In vitro matrix erosion of the intravaginal bioadhesive polymeric 
                 device  
 
104 
4.2.5         Optimization by ANN for the best polymer combination selection 105 
4.3.           Results and discussions 107 
4.3.1         In process validation test 107 
4.3.2         Matrix erosion evaluation 108 
4.3.3         Selection of polymer combinations as per ANN optimization 110 
4.4            Concluding remarks 118 
 
 
 
 
 
 
 
 xxvii
 
 
Chapter 5 
In Vitro and Ex vivo Bioadhesivity Analysis on the Optimized 
Intravaginal Bioadhesive Polymeric Device Composed of Different 
Crosslinked Polyacrylic Acids 
 
5.1            Introduction 119 
5.2            Materials and methods 121
5.2.1         Materials 121
5.2.2         Methods 121 
5.2.2.1      Preparation of the IBPD caplets composed of allyl sucrose  
                 and allyl penta erythritol-crosslinked PAA  
 
121 
5.2.2.2      In-process validation tests of the IBPD caplets 122 
5.2.2.3      In vitro and ex-vivo bioadhesivity analysis 123 
5.2.2.4      Removal of vaginal tissue from the pig model for bioadhesivity 
                 testing 
 
123 
5.2.2.5      Rheological analysis of hydrated AS-PAA and APE-PAA 
                 polymers 
 
125 
5.2.2.6      Mechanistic postulation of caplet bioadhesion employing 
                 chemometric and molecular modeling and associated interactive 
                 energy paradigms 
 
 
126 
5.3            Results and Discussion 127 
5.3.1         Assessment of caplet bioadhesivity 127 
5.3.2      Response optimization and textural analysis of the optimized  
                 AS-PAA and APE-PAA caplets 
 
128 
5.3.3         Ex-vivo bioadhesivity analysis of the optimized APE-PAA caplets 
                 on freshly excised vaginal tissue 
 
130 
 xxviii
 
5.3.4      Rheological analysis of the hydrated AS-PAA and APE-PAA 
                 polymer solutions 
 
131 
5.3.5      Postulative Chemometric and molecular modeling of the 
                 mechanisms of caplet bioadhesion and the associated  
                 interactive energy paradigms 
 
 
132 
5.4            Concluding remarks 136 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xxix
 
 
Chapter 6 
Investigation of the Physicochemical and Physicomechanical 
Properties of the Optimized Intravaginal Bioadhesive Polymeric 
Device 
 
6.1            Introduction 138 
6.2            Materials and methods 140 
6.2.1         Materials 140 
6.2.2         Methods 141 
6.2.2.1      Preparation of the intravaginal bioadhesive polymeric device 141 
6.2.2.2      Pan coating of the intravaginal bioadhesive polymeric device  141 
6.2.2.3      Influence of the intravaginal polymeric device on the micro- 
                 environmental pH of the vagina 
 
142 
6.2.2.4      Thermal analysis of the polymeric composition and the coated 
                 intravaginal bioadhesive polymeric device  
 
143 
6.2.2.5      Ex-vivo biodhesivity testing of the coated drug-loaded 
                 intravaginal bioadhesive polymeric Device 
 
144 
6.2.2.6      Textural profiling analysis to determine the bioadhesivity of the 
                 intravaginal bioadhesive polymeric device  
 
144 
6.2.2.7      Insertion of the intravaginal bioadhesive polymeric device into 
                 the vagina of the pig  
 
144 
6.2.7.7.1   X-ray imaging of the pig for detection of the intravaginal 
                 bioadhesive polymeric device 
 
145 
6.2.2.8    In vitro drug release from the coated and uncoated the 
                 intravaginal bioadhesive polymeric device 
 
145 
6.2.2.8.1    Analysis of the effect of device coating on the drug release 145 
 xxx
 
6.2.2.8.2    Analysis of the drug release from the coated devices 
                  containing AZT and PSS separately and in combination 
 
146 
6.2.2.8.3    Chromatographic conditions for the analysis of AZT and PSS 
                  concentration 
 
146 
6.2.2.8.4    Preparation of standard solutions and calibration curves 147 
6.2.2.8.5 The solid phase extraction procedure employed in the extraction 
                  of the drugs from simulated vaginal fluid samples for UPLC  
                  analysis 
 
 
149 
6.2.2.9      Ex-vivo drug permeation studies through pig vaginal tissue from 
                  the intravaginal bioadhesive polymeric device using the Franz 
                  Diffusion Cell apparatus 
 
 
149 
6.2.2.9.1    Chromatographic conditions for the analysis of AZT and PSS 
                  concentration 
 
151 
6.2.2.9.2    Preparation of standard solutions and calibration curves 151 
6.2.2.9.3 The solid phase extraction procedure employed in the extraction  
                  of the drugs from simulated plasma fluid samples for UPLC  
                  analysis 
 
 
 
152 
6.2.2.10     Postulated mechanistic deduction of the drug diffusion and 
                  dissolution dynamics from the IBPD employing chemometric  
                  and  molecular modeling 
 
 
153 
6.3             Results and discussion 153 
6.3.1          Coating of the intravaginal bioadhesive polymeric device 153 
6.3.2    Micro-environmental pH variation analysis within the simulated  
                  vaginal fluid 
 
153 
6.3.3          Thermal analysis of the polymer constituents of the intravaginal 
                  bioadhesive polymeric device  
 
155 
 xxxi
 
6.3.3.1       Thermal characterization of the native unhydrated polymer 
                  constituents of the intravaginal bioadhesive polymeric device 
 
156 
6.3.3.1.1    Ethylcellulose  156 
6.3.3.1.2    Modified Polyamide 6,10  157 
6.3.3.1.3    Poly(lactic-co-glycolic acid)  158 
6.3.3.1.4    Polyvinyl alcohol  159 
6.3.3.1.5    Allyl pentaerythritol-crosslinked poly(acrylic acid)  160 
6.3.3.2      Thermal characterization of the unhydrated intravaginal 
                  bioadhesive polymeric device 
 
161 
6.3.3.3     Thermal characterization of unhydrated and hydrated physical 
                  polymer blends as well as hydrated intravaginal bioadhesive 
                  polymeric device 
 
 
162 
6.3.4    Analysis of the drug release behavior from the coated and 
                  uncoated optimized drug-loaded intravaginal bioadhesive 
                  polymeric device 
 
 
165 
6.3.4.1       Chromatographic separation of 3'-azido-3'-deoxythymidine and 
                  polystyrene sulphonate with methyparaben as an internal  
                  standard 
 
 
165 
6.3.4.2       Assessment of the effect of coating on the drug release from the 
                  intravaginal bioadhesive polymeric device 
 
167 
6.3.4.3       Analysis of the drug release behavior from the optimized coated 
                  intravaginal bioadhesive polymeric device containing AZT and 
                  PSS separately and in combination 
 
 
168 
6.3.5          Assessment of drug permeation across the pig vaginal tissue  170 
6.3.6          Ex-vivo bioadhesivity analysis of the intravaginal bioadhesive 
                  polymeric device 
 
171 
6.3.7    Retention of the intravaginal bioadhesive polymeric device  
 xxxii
 
                  within   the pig vagina 172 
6.3.8    Chemometric and molecular modeling of the intravaginal  
                  bioadhesive polymeric device drug dissolution and diffusion  
 
174 
6.3.8.1    Postulation of dissolution dynamics and subsequent effect on 
                  drug release 
 
174 
6.3.8.2    Diffusion kinetics depicting the drug flux mechanism during ex 
                  vivo studies 
 
176 
6.4             Concluding remarks 179 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xxxiii
 
 
Chapter 7 
In vivo Drug Content Analysis and Histopathological Evaluation of the 
Intravaginal Bioadhesive Polymeric Device  
 
 
7.1             Introduction 180 
7.2             Materials and methods 182 
7.2.1          Materials 182 
7.2.2          Methods 182 
7.2.2.1       In vivo animal studies in the pig model using  
                  the drug-loaded intravaginal bioadhesive polymeric device 
 
182 
7.2.2.2       Anesthesia, X-rays and blood sampling  184 
7.2.2.3     Vaginal tissue removal for drug analysis and histopathological   
                  studies 
 
186 
7.2.2.4  Quantitative analysis of AZT and PSS in the blood and the    
                  vaginal tissue of the  pig  
 
186 
7.2.2.4.1    Preparation of standard solutions and calibration curves 186 
7.2.2.4.2 The drug extraction method from the plasma samples for UPLC  
analysis 
 
187 
7.2.2.4.3    The drug extraction method from the vaginal tissues for UPLC 
                  analysis 
 
188 
7.2.2.4.4    Instrumentation and chromatographic conditions for the 
                  quantitative analysis of AZT and PSS from plasma and vaginal 
                  tissue samples 
 
 
189 
7.2.2.4.5    Histopathological evaluation of the vaginal mucosa 190 
7.3.0          Results and discussion 190 
7.3.1      Chromatographic separation and retention times of AZT and  
 xxxiv
 
                  PSS from methylparaben (MP) (internal standard) 190 
7.3.2          AZT and PSS contents in the blood and vaginal tissue of the pig  
                   model 
 
192 
7.3.3          Histopathological evaluation of the vaginal tissue 196 
7.4             Concluding remarks 199 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xxxv
 
Chapter 8 
Conclusions and Recommendations 
 
 
8.1         Conclusions 201 
8.2         Recommendations 203 
  
References 206 
  
Appendices 301 
  
Appendix A 
Abstracts of papers published/submitted from this thesis  
302 
 
  
Appendix B 
Abstracts of conferences proceedings 
309 
 
  
Appendix C 
Additional Outputs from Collaborative Research 
323 
  
Appendix D 
Animal ethics clearance certificate 
349 
 
 
 
 
 
 
 
 
 
 xxxvi
 
LIST OF FIGURES 
   
Page 
1.1 A schematic of vagina vaginal wall showing 1) capillary vessels, 2) artery   
and 3) Vein. 
 
11 
1.2 A schematic of the upper vagina region depicting the posterior fornix as 
the site of IBPD application. 
 
23 
2.1 Schematic depicting the various mechanisms of preventing the 
transmission of sexually transmitted infections and HIV by employing 
microbicide delivery systems. 
 
 
31 
2.2 Microscopic images of gram-stained vaginal smears depicting different 
categories of vaginal microflora. a) and b), grade 1a Lactobacillus 
crispatus cell types; c) and d), grade 1b non-L. crispatus cell types; e) and 
f), grade 1ab mixtures of L. crispatus and non-L. crispatus cell types; g) 
and h), grade 1-like Gram positive rods; i) and j), grade 2 mixture of 
Lactobacillus cell types and bacterial vaginosis-associated bacteria cell 
types; k) and l), grade 3 bacterial vaginosis. 
 
 
 
 
 
 
48 
2.3 Schematic of the trimeric-sulphated glycoprotein Thrombospondin-1 with 
five distinct extracellular matrix adhesion molecules. 
 
64 
3.1 A computationally-derived model predicted in our laboratories depicting 
the polymer coiling stages a) polymer strands, b)  identification of 
molecular sites, c) initial stages of coiling, d) secondary and  tertiary 
coiling randomizations and patterns where (C-1)-(C-7) is non-breaded 
non-rope coiling and (C-8)-(C-12) is breaded rope coiling. The number of 
coil arm may vary in (C-1)-(C-5). 
 
 
 
 
 
71 
3.2 Synthesis of polyamide 6,10 by interfacial polymerization. 76 
3.3 a) 3'-azido-3'-deoxythymidine (AZT) and b) Polystyrene Sulfonate (PSS) 79 
 xxxvii
 
3.4 The intravaginal bioadhesive polymeric devices (IBPDs) a) Planar view b) 
Side view c) Oblique view and d) Longitudinal view. 
 
92 
4.1 Typical force-distance profiles employed in the determination of matrix 
indentation hardness of the IBPD. 
 
104 
4.2 Constructed multilayer perceptron.  105 
4.3 Network Topology depicting the hidden input and output layers. 105 
4.4 A chemometric structural model developed in our laboratories for glyco-
protein structure showing attachment of cellular surface protein (red) 
bound to the saccharide part of the glyco-protein (blue) and both (surface) 
protein and glyco-protein (green) bound to the polymer (here PAA) (white) 
for non-evenly distributed applied force during adhesion, with non-smooth 
and unevenly contacted two interacting surfaces with non-evenly 
distributed and non-constant, non-steadily (applied) force for the adhesion 
shown in a 3D optimized state with ball model. The coiling loop distortion 
for both protein and glycoprotein are also shown. 
 
 
 
 
 
 
 
 
110 
4.5   a) MSE for the primary ANN training, b) Average MSE for the primary 
ANN training with standard deviations for 10,000 epochs. 
 
111 
4.6 A profile depicting a) desired and b) actual network output. 113 
4.7 A typical bar chart graph depicting the sensitivity coefficients of each 
polymer   type on the matrix integrity following the primary training. 
 
113 
4.8     a) MSE for the secondary ANN training, b) Average MSE for the 
secondary training with standard deviations for 10,000 epochs.   
 
115 
4.9 A typical bar chart graph depicting the sensitivity coefficients of each 
polymer type on the matrix integrity following the secondary training.  
 
116 
4.10 Correlation between matrix erosion and polymer quantity. 117 
5.1 The dissection process to remove the vaginal tissue from the pig 124 
5.2 Textural analysis method employed to generate Force-Distance profiles  
 xxxviii
 
for assessing the caplet bioadhesivity to freshly excised pig vaginal tissue 
indicating a) blue paint design b) actual process. 
 
125 
5.3 A comparison of work of adhesion (AUCFD) (J) between the AS-PAA and 
APE- PAA caplets. 
 
128 
5.4 A typical response optimization plot for the AS-PAA and APE-PAA 
caplets. 
 
129 
5.5 Typical textural profiles elucidating the peak adhesive force (PAF) (N) and 
work of adhesion (AUCFD) (J) for the optimized composed of: a) AS-PAA, 
and b) APE-PAA. 
 
130 
5.6 Typical textural profile elucidating the force (N) and work of adhesion 
(AUCFD)  (J) for the optimized APE-PAA caplets on freshly excised vaginal 
tissue.  
 
 
131 
5.7 Rheological behavior of 2%w/v AS-PAA and APE-PAA solutions at a shear 
rate between 0-500s-1. 
 
132 
5.8 A chemometric structural model depicting caplet bioadhesion to freshly 
excised pig vaginal tissue with muco-epithelial cell secretions and surface 
bio-molecule interactions. 
 
 
134 
5.9 Energy estimates for the mechanism of bioadhesion. A) compartment  
A=interactions at physical forces levels, B=ionic interactions and ion-
exchanges producing bioadhesion, C= chemical interaction involving 
covalent bonding between the xenobiotic polymer and cellular protein, 
D=interaction with surface collagen in the tissue substrate includes 
polymer-protein-collagen interactions. 
 
 
 
 
 
135 
6.1 Digital images depicting a) insertion of the IBPD into the vagina of the pig 
and b) tracking the location of the IBPD in the vagina using as a 
speculum. 
 
 
145 
6.2 a) Calibration curves for a) AZT in simulated vaginal fluid 267nm, b)  
 xxxix
 
PSS in simulated vaginal fluid 244nm.  148 
6.3 Permeation studies of AZT and PSS across pig vaginal tissue using a 
Franz Diffusion Cell apparatus. 
 
151 
6.4 a) Calibration curves for a) AZT in simulated plasma fluid 267nm b)  
PSS in simulated plasma fluid 244nm.  
 
152 
6.5 Micro-environmental pH variation in the simulated vaginal fluid containing 
the IBPD. 
 
155 
6.6 TMDSC thermogram for the unhydrated ethylcellulose.  157 
6.7 TMDSC thermogram for the unhydrated polyamide 6,10 . 158 
6.8 TMDSC thermogram for the unhydrated poly (lactic-co-glycolic acid). 159 
6.9 TMDSC thermogram for the unhydrated polyvinyl alcohol. 160 
6.10 TMDSC thermogram for the unhydrated poly (acrylic acid) (PAA). 160 
6.11 TMDSC thermogram for the unhydrated IBPD. 161 
6.12 TMDSC thermogram for a) the hydrated physical polymer blend, b) the 
hydrated IBPD. 
 
163 
6.13 TMDSC thermogram for a) the unhydrated physical polymer blend, b the 
unhydrated IBPD. 
 
164 
6.14 A typical 3D UPLC profile showing a complete separation between AZT 
and MP (internal standard). 
 
166 
6.15 UPLC chromatograms depicting the separation of a) AZT and MP (internal 
standard) and b) PSS and MP (internal standard) in simulated vaginal 
fluid (pH 4.5; 37°C). 
 
 
167 
6.16 A typical profile showing the effect of coating on the model hydrophilic 
drug  AZT from a) uncoated IBPD and b) shellac/APE-PAA-coated IBPD 
in simulated vaginal fluid. 
 
 
168 
6.17 Drug release profiles of a) AZT (AZT-loaded IBPD), b) AZT (AZT/PSS- 
loaded IBPD), c) PSS (AZT/PSS-loaded IBPD) and d) PSS (PSS-loaded 
 
 
 xl
 
IBPD), in simulated vagina fluid (pH 4.5; 37°C).  170 
6.18 Profiles showing the flux of AZT and PSS across pig vaginal tissue over a 
period of 24 hours. 
 
171 
6.19 Typical Force-Distance textural profiles used for computing the Peak 
Adhesion Force (PAF) and Work of Adhesion (AUCFD) for a) uncoated 
devices and b) PAA-coated devices on freshly excised pig vaginal tissue. 
 
 
172 
6.20 X-ray images depicting the presence of the intravaginal bioadhesive 
Polymeric device at a) day 1, b) day 14 and c) day 30 after insertion into 
the posterior fornix of the pig vagina. 
 
 
173 
6.21 Molecular model mechanistically depicting the IBPD dissolution process 
with lesser H-bond formation due to the excessive of simulated vaginal 
fluid providing more freedom to polymeric strands to disentangle. 
 
 
174 
6.22 A 3D model representing the IBPD matrix under dissolution along with 
drug associations: a) the polymer matrix, b) fluid interactions producing 
hydrophilic pockets and swelling of the device, c) generation of 
hydrophobic areas in the matrix due to critical formulation excipients and 
d) the drug molecule (AZT) in association at hydrophilic sites prior to 
release. 
 
 
 
 
 
175 
6.23 Chemometric models depicting a) dissoluted polymeric strands and b) 
AZT molecules (grey-colored circles) and PSS (white-colored circles) in 
the free float and associated forms with the loosely interacting polymeric 
strands in the dissolution medium.  
 
 
 
176 
6.24 Chemometric model depicting the development of a diffusion channel 
with a) A single polymer strand P, situated perpendicularly to a forming 
pore C, b) a group of strands also denoted collectively as P giving rise to 
the channel C which is formed perpendicular to the polymer strands 
backbone with F=the direction of flow from the starting point S to form a  
 
 
 
 
 
 xli
 
networked 3D channel and c) a polymeric strand with the generated 
diffusion channel. 
 
177 
6.25 3D models depicting the generation of diffusion channels with the IBPD 
matrix with a) polymeric strands, b) inter-strand physicochemical 
interactions, c) stereo-orientation within a group of associated polymeric 
strands generating an inter-polymeric cavity d) the cavity formed, e) 
associations between different polymeric strands and f) the blocked cavity 
due to excessive associative networking at various localized sites 
incorporating other components such as drug in different associative 
settings. 
 
 
 
 
 
 
 
178 
6.26 Qualitative status of energy paradigms and energy-time relationship for 
the IBPD matrix with a) stable energy status as a solid matrix, b) energy 
change following dissolution and c) energy transaction and changes for 
the drug diffusion across the pig vaginal tissue with the static energy 
status at equilibrium without flux also shown.    
 
 
 
 
178 
7.1 Summary of the in vivo study. 184 
7.2 a) X-Ray imaging process and b) blood sampling procedure from the 
jugular vein of the pig. 
 
185 
7.3 Calibration curves for: a) AZT in blank plasma 267nm, b) PSS in blank 
plasma 244nm. 
 
187 
7.4 UPLC chromatograms depicting the retention times for the standard 
solutions of a) AZT, b) PSS and MP as an internal standard in blank 
plasma. 
 
 
191 
7.5 a) AZT and PSS plasma concentration profiles, and 28, b) AZT and PSS 
mean vaginal tissue and plasma concentration values on day 28. 
 
193 
7.6 A typical profile depicting the content of PSS in the vaginal tissue. 193 
7.7 Correlation between a) AZT, b) PSS contents in the blood and vaginal  
 xlii
 
tissue. 194 
7.8 A schematic modeled in our laboratory depicting the mechanistic 
approach of adhesion between a polymer and the vaginal epithelium. 
 
195 
7.9 Intravaginal Bioadhesive Polymeric Device (IBPD) as observed in the 
excised pig vagina on the 28th day. 
 
196 
7.10 Histological images of haematoxylin and eosin stained pig vaginal tissue 
samples depicting a) Epithelial hyperplasia of the vagina x 40, b) Epithelial 
hyperplasia, exocytosis and superficial exudate x 40, c) Lamina propria 
with no inflammatory cells and normal vagial epithelium x 20, d) 
Hyperplastic epithelium with exocytosis x 40, e) Mononuclear cell 
infiltrates in the lamina propria and f) Perivascular inflammation in the 
submucosal wall x 40. 
 
 
 
 
 
 
198 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xliii
 
LIST OF TABLES 
  Page 
2.1 Desirable criteria for ideal intravaginal microbicidal delivery systems 32 
2.2 Classification of the numerous intravaginal compounds delivered 
intravaginally 
 
39 
2.3 Chemical structures of polymeric microbicide compounds 44 
2.4 Structures of non-polymeric microbicide compounds 54 
2.5 Chemical structures of other novel microbicide compounds 66 
3.1 Polymers, properties and rationale for selection 78 
3.2 Sixty two formulations obtained from different polymer combinations 81 
3.3 Constituents used to prepare the simulated human vaginal and seminal 
fluids 
 
83 
3.4 Formulations without carrageenan 84 
3.5 Formulations in which carrageenan was substituted with ethylcellulose     84 
3.6 Formulations without polyethylene oxide 85 
3.7 Formulations containing polyvinyl alcohol 85 
3.8   Formulations containing polyvinyl povidone 86 
3.9 Formulations containing xanthan gum 86 
3.10 Formulations containing guar gum 87 
3.11 Formulations in which xanthan gum was substituted with gelatin 87 
3.12 Formulations in which gelatin was substituted with beeswax 88 
3.13 Formulations containing tragacanth 88 
3.14 Formulations containing methylcellulose, hydroxyethlycellulose, 
hydroxypropylcellulose, hydroxypropylmethylcellulose, Eudragit® S100 
and Eudragit® RS 100  
 
 
90 
3.15 Formulations with a binary polymer combination among gelatin, 
beeswax, xanthan gum and Eudragit® S 100 
 
90 
 xliv
 
3.16 Formulations with a tertiary polymer combination among gelatin, 
beeswax, xanthan gum and Eudragit® S 100 
 
91 
3.17 Mass, friability and diametric hardness of the sixty two caplet 
formulations 
 
93 
3.18 The equilibrium swelling ratios for the sixty two formulations that were 
subjected to screening using the OVAT approach  
 
96 
3.19 The selected fifteen lead formulations screened through the OVAT 
approach 
 
98 
4.1 The Polymer combinations employed in the production of the intravaginal 
bioadhesive polymeric devices 
102 
4.2 Textural settings employed for BHN value calculations 103 
4.3 The input matrix erosion data that was trained by the Multilayer 
Perceptron network 
 
106 
4.4   Artificial neural network construction parameters employing a neural 
builder 
 
107 
4.5 Brinell hardness number, mass and friability, of the intravaginal 
bioadhesive polymeric device 
 
108 
4.6   Neural network indicators characterizing the efficiency and performance 
of data in the primary training as per ANN 
 
112 
4.7  Actual and desired network performance criterion data from the primary 
training 
 
112 
5.1 Extreme Vertices Mixture Formulation Template for caplet preparation 122 
5.2 Comparative in vitro and ex-vivo bioadhesivity results for the optimized 
caplets 
 
129 
6.1 Parameters and settings employed for coating the intravaginal 
bioadhesive polymeric device 
 
142 
6.2 Temperature modulated differential scanning calorimetry settings  
 xlv
 
employed for thermal analysis of the intravaginal bioadhesive polymeric 
device and its formulation components 
 
143 
6.3 Chromatographic mobile phase gradient settings used for the separation 
of AZT 
 
147 
6.4 Constituents used to prepare the simulated plasma fluid 151 
6.5 Critical thermal events evidenced by diverse temperature inflection 
peaks for the polymer constituents of the intravaginal bioadhesive 
polymeric device. 
 
 
156 
7.1 Parameter settings for the AZT gradient method. 190 
7.2 Histopathological findings in the vaginal tissue 199 
 
 1 
CHAPTER ONE 
 
B AC K G R OUND, R ATIONAL E  AND MOTIV ATION F OR  THIS  S TUDY 
 
1.1 Introduction 
Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) and 
other sexually transmitted infections (STIs) are a burgeoning problem globally (Nicoll et 
al., 2000; Liu et al., 2005; Pusch et al., 2005; Todd et al., 2006; Becker et al., 2008; 
Lazarus et al., 2008; Bártolo et al., 2009; Nijhawan et al., 2009). AIDS has caused the 
mortality of more than 25 million people since it was first recognized in 1981 and has 
become one of the most destructive pandemics in history (UNAIDS/WHO, 2006a). With 
reference to the recent global estimates, more than 42 million people have contracted 
HIV/AIDS (90% of these in developing countries), 5 million became infected in 2005 and 
more than 3 million deaths occurred from HIV-related diseases in 2005 (Malcolm et al., 
2006; Nikolic et al., 2007). According to a UNAIDS report, more than 6,800 people 
become infected with HIV daily (UNAIDS, 2007a and b). Furthermore, it has been 
estimated that heterosexual transmission of HIV accounts for over 90% of adult infections 
worldwide and that male-to-female transmission is eight times more likely to occur than 
female-to-male transmission. The biological reason is that women are more susceptible to 
STIs and HIV/AIDS than men due to larger mucosal exposure to seminal fluids as a result 
of the anatomical structure of the vagina. According to the recent UNAIDS/WHO global 
report, over 19 million women worldwide are currently living with HIV/AIDS, meaning that 
the proportion of HIV/AIDS occuring in women is now nearly 50% (UNAIDS/WHO, 2006b; 
UNFPA, 2006; Ambrose et al., 2008). The impact of HIV/AIDS on women continues to 
gain significance in terms of the number of women that become infected everyday and the 
implications thereof to their children and sex partners (Weeks et al., 2004; Chakraborty, 
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2008; Skoler-Karpoff et al., 2008). Once infected with an STI, many women are 
asymptomatic and may remain untreated, thus increasing their susceptibility to HIV 
infection. The effects of untreated STIs in women tend to be more serious than in men. 
For instance, it may result in the development of pelvic inflammatory disease (PID), which 
can subsequently lead to infertility or a life-threatening ectopic pregnancy. In addition, 
women living in low socio-economic settings are more vulnerable to STIs and HIV/AIDS 
than men because of their lower social status that may be related to their lower income 
and gender discrimination, which may render them the inability to refuse unsafe sexual 
practices in some cultures. In view of the above, coupled with a lack of effective protective 
measures, it is apparent that many women are at high risk of acquiring STIs or HIV/AIDS. 
 
Infection with HIV remains an incurable condition (Division of HIV/AIDS Prevention, 2003; 
Frieden et al., 2005; Amet et al., 2008; Sing and Govender, 2009; Xu, 2009). For the 
foreseeable future the control of HIV/AIDS will depend on the prevention of infection and 
alleviation of the disease process in affected persons. HIV is transmitted through direct 
contact of the systemic circulation or mucous membranes with bodily fluids infected with 
HIV, such as blood, semen, vaginal fluid, pre-seminal fluid and breast milk (San Francisco 
AIDS Foundation, 2008). Transmission of HIV may occur during anal, vaginal or oral sex, 
contaminated blood transfusions, hypodermic needle pricks, exchange between mother 
and child during pregnancy, childbirth or breastfeeding. However, the highest rate of HIV 
transmission is through the exposure of the vaginal mucosal surface to HIV during sexual 
intercourse (San Francisco AIDS Foundation, 2008). To date, vaginal epithelial mucosal 
surfaces are the major route of HIV infection worldwide (Greenhead et al, 2000; Shattock, 
2001; Wira et al., 2004; Lackner and Veazey, 2007; Belyako and Ahlers, 2008). This 
mode of transmission is increasing in prevalence more rapidly than any other (Royce et 
al., 1997; Wortley and Flemming, 1997). The transmission of HIV is said to be either by 
selective penetration or selective amplification within the infected host (Verhofstede et al., 
2003). Interruption of cell-associated transmission requires an understanding of the 
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processes by which a virus moves from infected donor cells to cells of the recipient. The 
migration of HIV-infected cells and the movement of assembled virus particles out of the 
infected donor cell are critical to this process. Studies have shown that budding of HIV-1 
occurs selectively through lipid rafts on the epithelial cell surface (Nguyen and Hildreth, 
2000; Chazal and Gerlier, 2003; Herzberg et al., 2006). In addition, the ability of lipid rafts 
to act as adhesion platforms has been shown to facilitate cell-cell interactions and 
migration, which may be important for cell-to-cell transfer of the virus and for entry of 
infected cells through genital tract epithelia (Krauss and Altevogt., 1999). Therefore, 
understanding of the first critical events in genital mucosal transmission of HIV infection is 
important in developing strategies to block or limit such transmission.  
 
The majority of deaths from HIV/AIDS have occurred in sub-Saharan Africa where the 
prevalence rate for sexually active adults is greater than 35% (Pisani et al., 2003; Berger, 
2004; Malcolm et al., 2006). This culminates in causing the death of economically active 
adults with the accompanied macro-economic challenges. Much of the debates and the 
perpetual carnival of meetings addressing the HIV/AIDS epidemic that have taken place 
have ignored the truth about human sexual behavior which includes the sexual desire of 
women, but rather focuses on the ‘vulnerability of women’ and thus is an ‘incomplete” 
explanation for higher rates of HIV infection among women and girls (Berger, 2004). At 
present, the current use of ARV treatment reduces both the mortality and morbidity 
associated with HIV infection, but routine access to antiretroviral medication is not 
available in all countries. Furthermore, the stigma accompanying HIV/AIDS is more 
severe than that associated with other life-threatening conditions and extends even to 
healthcare providers and volunteers involved with the care of people living with the 
disease.  
 
Although the immunopathogenetic events that culminate in HIV transmission during 
unprotected sex are still poorly understood, it is now clear that STIs enhance both HIV 
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susceptibility and secondary transmission (Staff, 2002; Rebbapragada and Kaul, 2007 
Levinson et al., 2009). STIs may enhance HIV transmission through the following  
mechanisms: i) the impairment of innate mucosal defenses, including the integrity of the 
mucosal epithelium itself; ii) the local induction of pro-inflammatory cytokines that 
enhance HIV replication; iii) the recruitment of activated immune cells that might serve as 
targets for initial HIV infection and enhance local HIV replication; iv) enhanced 
susceptibility to other STIs and/or alterations in the normal vaginal microflora; and v) 
impairment of systemic HIV immune control with an increased viral load in both blood and 
the genital tract. STIs affect men and women of all backgrounds, with approximately two-
thirds of cases occurring in individuals less than 25 years of age (Brown et al., 1999; Drug 
Digest, 2004). Based on a WHO report that was last revised in 2007, 340 million new 
cases of curable STIs (syphilis, gonorrhoea, chlamydia and trichomoniasis) occur 
annually worldwide in adults aged 15-49 years (Reddy et al., 2002; Facts sheets, WHO, 
2007). The same report has indicated that STIs and their associated complications are 
among the top five disease categories for which adults seek health care (Facts sheets, 
WHO, 2007). According to WHO, STIs, excluding HIV, rank second to maternal factors as 
causes of disease and death in women of childbearing age in the developing countries 
(WHO, 2007).  
 
Practising of unsafe sex by individuals infected with HIV infection predisposes them to the 
risk of acquiring STIs. Such co-infection leads to both ulcerative and non-ulcerative STIs 
that ultimately promote HIV transmission by augmenting HIV infectivity and host 
susceptibility by a variety of biological mechanisms (Royce et al., 1997). Thus, regular 
screening and prompt treatment of STIs should be part of the routine care of HIV-positive 
patients. The management of some STIs such as Neisseria gonorrhoeae, Chlamydia 
trachomatis and Trichomonas vaginalis is normally the same for HIV-positive and 
negative individuals. However, many of the sexually transmitted pathogens result in more 
prolonged or severe infections in association with HIV/AIDS, and treatment may be 
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required for longer periods and may have a higher failure rate (Royce et al., 1997). For 
instance, infection with herpes simplex virus may require higher doses of antiviral therapy 
to suppress recurrences and resistance. Infection with human papillomavirus (HPV) 
causes genital warts that may respond less to treatment and may recur more frequently. 
The incidence of HPV-associated neoplasia such as anal cancer and cervical squamous 
intraepithelial lesions is also increased (Cohen, 2004). 
 
The management of syphilis in HIV-infected individuals can be a challenge (Butsashvili et 
al., 2001; Malow et al., 2009). Interpretation of serological tests for syphilis can be difficult, 
as titers can be unusually high, low, or fluctuating. False-negative results have also 
occurred (Baughn and Musher, 2005; Amy et al., 2007). HIV-infected patients may have a 
higher risk of neurological complications in early syphilis, therefore making it a necessity 
to have a cerebrospinal fluid examination before treatment. Although such patients may 
have a higher rate of treatment failure, this is likely to be minimal (Rolfs et al., 1997), thus 
allowing clinicians to recommend the same treatment for primary, secondary, and early 
latent syphilis regardless of HIV status. However, some clinicians prefer to treat all HIV-
infected patients with the regimen recommended for neurosyphilis (Thompson and 
Samuels, 2002; Goh, 2005).  In any case, regardless of the treatment regimen, careful 
long-term follow-up is essential. 
 
Despite the magnitude of the HIV pandemic, it is surprising that the probability of HIV 
transmission during a single episode of unprotected sex ranges from 0.1–1.0% only, 
irrespective of the type of sexual practice or biological factors in each partner (Royce et 
al., 1997). Furthermore, studies have shown that HIV acquisition and secondary 
transmission is highly influenced by the presence of genital tract co-infections in either 
partner, particularly STIs (Cohen, 2004; Kaul et al., 2008; Sheung et al, 2008; Spinillo et 
al., 2008). This may have accelerated spread of the HIV/AIDS epidemic worldwide and 
might serve to explain the profound regional and gender-based differences in HIV/AIDS 
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epidemics. Thus, there is a need to elucidate the immunopathogenetic events that 
underpin HIV sexual transmission at a mucosal level. Although studies on HIV 
immunopathogenesis have traditionally focused on systemic immune events, it is now 
evident that HIV transmission occurs mostly across the penile, oral, cervico-vaginal or 
rectal mucosa (Kaul et al., 2008). What is required is a better understanding of how HIV 
transmission occurs, and how it is influenced by genital co-infections and their effect on 
the mucosal micro-environment. This could contribute significantly in developing new 
technologies for HIV prevention modalities, such as HIV/STI microbicidal drug delivery 
systems.  
 
1.1.1 Current status of the HIV/AIDS treatment modalities 
The treatment of HIV/AIDS was revolutionized by the introduction of highly active anti-
retroviral therapy (HAART) in the 1990s (Glare, 2001; Greenberg, 2007). Use of HAART 
has resulted in a dramatic decrease in the incidence of HIV-associated morbidity and 
mortality (Palella et al., 1998; Farmer et al., 2001; Thirlwell et al., 2003; Battaglioli-
DeNero, 2007; Marin-Muller et al., 2009). However, cohort studies have found that 
regimens fail in many patients basically due to virological rebound or because initial 
suppression could not be achieved (Greub, et al., 2001, Fischer et al., 2003). A rise in 
plasma viral load indicates treatment failure which may be due to several reasons 
including low level of adherence to the therapy, emergence of drug resistance, suboptimal 
drug levels, and use of less potent regimens. The cluster of differentiation 4 (CD4) cell 
count is normally used as the main determinant in deciding when to start treatment since 
there is an increased mortality in patients with CD4 counts below 200/mm3 (WHO, 2006). 
Treatment is therefore indicated in all patients with a CD4 count <200/mm3 and in 
symptomatic patients (those with AIDS according to the 1993 Centers for Disease Control 
and Prevention classification as well as patients with wasting, thrush, or unexplained fever 
for >2 weeks) (Peritt et al., 1999). However, there is a lack of data to determine at which 
CD4 level antiretroviral therapies should be started for asymptomatic patients with CD4 
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counts >200/mm3. Quite often, an asymptomatic patient with a CD4 count >350/mm3 
presents with a high pre-treatment viral load (>50,000-100,000), which is another 
predictor of clinical progression (Bartlett, 2003; Kassaye and Katzenstein, 2003; Benson 
et al., 2004).  Therefore, the best option is to individualize treatment decisions by taking 
into account diverse factors such as the CD4 count and its rate of decline, viral load, 
patient interest and potential to adhere to therapy, individual risks of toxicity, drug 
interactions, as well as the risks and benefits of early versus late initiation of treatment. 
Adherence is a key determinant factor for any successful treatment regimen. 
 
To date, current treatment regimens have not been able to eradicate HIV and therefore 
the strategy is to: i) maximize inhibition of viral replication; ii) restore and/or preserve 
immunologic function; iii) improve quality of life; and iv) reduce HIV-related morbidity and 
mortality. This must also consider associated problems such as expensive regimens, pill 
burdens, complicated dosing schedules, drug-specific toxicities, drug interactions, viral 
resistance, and long-term complications, especially lipodystrophy and metabolic changes. 
Thus far, at least 19 antiretroviral (ARV) agents have been approved for the treatment of 
HIV infection (Pulido and Arribas, 2003; Marks and Gulick, 2004; Stanic and Grana, 
2009), some of them available through expanded-access programs to allow a large 
variety of potential combinations. However, no data exists to demonstrate the superiority 
of one regimen over another and therefore it is considered that the first regimen may 
afford the best opportunity for long term control of viral replication if administered and 
monitored properly (Vrijens and John 2005; WHO, 2006). Furthermore, the importance of 
individualization of therapy should always be emphasized. This is a complex clinical area 
which therefore requires proper management by experts in the field. 
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1.1.1.1 Combination therapy in HIV/AIDS 
It is now more than a decade since it became apparent that treatment of HIV infection 
with only one ARV agent is associated with rapid development of viral drug resistance 
(Richman et al., 1994; Brenner et al., 2002; Martinez-Picado and Wai, 2007; Marconi et 
al., 2008). Studies have shown that resistance is becoming more prevalent in ARV-naive 
patients and therefore ARV drug resistance testing is now an integral part of the 
management of the HIV-infected persons (Dam et al., 2001; Little et al., 2002). Clinical 
trials have shown that combining two antiretroviral agents leads to improved virological 
and immunological responses, when compared to the use of a single agent. A three-drug 
combination has proven to be even more effective than a two-drug combination 
(Bulgheroni et al., 2004: Youle et al., 2006; Greenberg, 2007). Therefore, ARV 
monotherapy is not recommended unless under special cases such as in pregnancy, to 
reduce perinatal transmission. Combination of two or more ARVs has now been adopted 
as standard treatment for maintaining viral suppression and minimizing the emergence of 
resistant strains, thereby reducing the risk of disease progression and death. The 
recommended three drug regimen of HAART usually include two Nucleoside Reverse 
Transcriptase Inhibitors (NRTIs) plus a Protease Inhibitor (PI), or a Non-nucleoside 
Reverse Transcriptase Inhibitor (NNRTI), or three NRTIs.  
PI drugs may be used singly or in combination with low-dose ritonavir as a boosted 
regimen that increases trough levels, minimizing opportunities for viral replication and 
potentially allowing for activity against moderately resistant strains of virus (Stanic, 2005; 
Lucas, 2008). Boosting also affords a more convenient regimen in terms of pill burden, 
scheduling, and elimination of food restrictions. Hepatotoxicity is the commonest adverse 
effect of PIs, especially ritonavir (Lucas, 2008). An NNRTI-based regimen can be as 
effective as a PI-based regimen with the additional advantage of reserving PIs for a later 
date. Hepatotoxicity may be caused by both, but the risk with nevirapine (an NNRTI), is 
twice that of efavirenz (also an NNRTI) after adjustment for PI use and hepatitis C virus 
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co-infection (Pulido and Torralba, 2002). An advantage of efavirenz is its once-daily 
dosing, but central nervous system side effects can cause hyperexcitability, vivid dreams, 
mood disturbances, and personality changes. Both may cause severe skin rashes (Pulido 
and Torralba, 2002). For triple NRTI regimens, the most promising are the ones 
containing abacavir (Kaufmann, and Cooper, 2000; Kessler, 2005; Dieterich, 2006). 
Advantages of NRTI regimens include a twice-daily schedule, low pill burden (i.e. 
available in a fixed-dose combination), relatively few adverse effects, and lack of 
undesirable pharmacokinetic interactions (Keiser, 2002; Sharma and Chakraborty, 2009). 
Furthermore, there is the advantage of reserving the other two classes of drugs which 
may be used at a later stage. It has been observed that hypersensitivity reactions to 
abacavir occur in 5% of patients subjected to this regimen (Hervey and Perry, 2000; 
Khanlou et al., 2005). A disadvantage of NRTI regimens is that they are considered 
ineffective in patients with high baseline viral loads or low CD4 counts (Khanlou et al., 
2005; Gallant, 2008). Studies have shown that despite the introduction of HAART, 
multiple treatment failures still occur (Ledergerber et al. 1999; Lucas et al., 1999; Moyle, 
2003; Flint et al., 2006; Wilcox and Saag, 2008). Many strategies have been proposed to 
deal with repeated treatment failures, but with dissapointing results (Lucas et al., 1999; 
Idemyor, 2004; Lemiale and Korokhov, 2009). Thus, despite the emergence of ARVs, HIV 
infection is still incurable. Therefore, the mainstay in the control of the pandemic remains 
primary prevention.   
1.1.2 Anatomy and physiology of the vagina in relation to drug delivery 
The human vagina is a tubular, fibromuscular organ that extends from the cervix of the 
uterus to the vaginal vestibule with a length of about 9 cm (das Neves and Bahia, 2006). 
The vagina wall is composed of 4 layers namely the stratified squamous epithelium, 
lamina propria, muscular layer, and tunica adventitia (Figure 1.1). The epithelial thickness 
is about 200–300μm, and it is not significantly affected by the reproductive cycle (Song et 
al., 2004). The epithelial layer forms a series of transverse folds called rugae which 
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dramatically increase its surface area. Vaginal ecology is normally influenced by factors 
such as the glycogen content of epithelial cells, glucose, pH, hormonal levels, trauma 
during sexual intercourse, birth-control method, age, antimicrobial treatment and child 
delivery (Budtz-jorgensen, 2000; Verman and Garg, 2000; Justin-Temu et al., 2004; 
Valenta, 2005). The vaginal flora is a dynamic system composed of facultative and 
obligate aerobes and anaerobes with Lactobacillus (Döderlein's bacilli) as the most 
prevalent organism (He et al., 2004). Lactobacilli produce sufficient lactic acid to acidify 
vaginal secretions (including the seminal fluid) to a pH of 3.5–5.5 which covers the pH 
range that keeps the vagina healthy (4.0-5.0) by inactivating HIV and other pathogens. 
Lactobacilli maintain this pH range by converting glycogen from exfoliated epithelial cells 
to lactic acid (Boskey et al., 2001). Thus, Lactobacilli play a vital role in maintaining the 
healthy vaginal acidic environment. Normally, vaginal pH changes with age, stages of the 
menstrual cycle, infections and sexual arousal. Therefore, in most women, a pH gradient 
exists in the vagina (Valenta, 2005). Possible causes of alterations in vaginal pH are 
various bacterial infections, yeast infections particularly of the Candida species type, 
STIs, premature rupture of fetal membranes, hormonal imbalance, postoperative infected 
wounds and excessive intimate care (Vitali et al., 2007). A disturbance in the micro-
ecological balance in the vagina (e.g. dysbiosis) is often connected with an increase in the 
pH level (Mastromarino et al., 2009). Semen, menstrual flow, cervical and uterine 
secretions act as alkalizing agents in the vagina changing the pH from acidic to near-
alkaline. (Desphande et al., 1992; Richardson and Illum, 1992). The vagina may also act 
as a site for drug absorption and action. The anterior and posterior vaginal fornixes are 
recesses (along with the other fornices) that exist due to the projection of the cervix to the 
vagina. If there is no cervix, there are no fornices. The deepest of these fornices is the 
posterior fornix, which is the most isolated from any activities. For instance, it is the only 
part of the vagina that is unlikely to be disturbed by sexual intercourse. It also happens to 
be out of the way of the menstrual flow, because it is behind and above the cervix. Thus, 
it is an ideal site for drug delivery application. Vaginal pH is an important parameter for 
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the efficacy of a drug delivery system (Ramsey et al., 2002). For instance, it may 
influence drug absorption and must therefore be considered during the development of 
any such drug delivery system. It has been observed that changes in hormonal levels 
(especially estrogen) during the menstrual cycle may lead to pH changes as well as 
alterations in the thickness of the epithelial cell layer, width of intercellular channels and 
secretions (Cajander and Rylander, 1988; Owen, 1975). Variations in enzyme activity 
(endopeptidases and aminopeptidases) with hormonal changes may further complicate 
the problem of achieving consistent drug delivery (Furuhjelm et al., 1980; Pschera et al., 
1989). During the post-menopausal period, women may experience progressive atrophy 
of the vaginal epithelium with elevation of the pH (6.0–7.5), and a decrease in the quantity 
of vaginal secretions (das Neves, 2006; Simon et al., 2008). These features may 
significantly impair the performance of a drug delivery system and therefore should be 
considered during development and evaluation of vaginal drug delivery systems. 
 
 
 
 
 
 
 
 
Figure 1.1: A schematic of the vaginal wall showing 1) capillary vessels, 2) artery and 3) 
vein, (Adapted: das Neves, 2006). 
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1.1.3 The vaginal mucus in relation to bioadhesion 
The target for the interaction of bioadhesive agents in the vagina is the mucus. Vaginal 
mucus is highly viscous and forms a protective coating over the lining of the vaginal 
epithelium in contact with external media. The vaginal mucus coating has several 
important physiological functions. It acts as a physical barrier to pathogenic organisms 
(Eggert-Kruse et al., 2000). It is a mixture of large glycoproteins (mucins), water, 
electrolytes, epithelial cells, enzymes, bacteria, bacterial products and various other 
materials depending on the source and location of the mucus (Junginger, 1990). Several 
mechanisms have been proposed to explain the interaction between a bioadhesive 
polymer and a biological surface, most being based on the structure of the mucin (Ch'ng 
et al., 1985; Lehr, 1995). The force and work of adhesion of a given bioadhesive system 
on a biological tissue is a good indicator of its bioadhesive capacity (Lejoyeux et al., 1989; 
Valenta et al., 2001). 
Vaginal secretions are a mixture of fluids produced from various sources (Stechever et 
al., 2002).  Although the vaginal epithelium is often considered to be a mucosal surface, it 
lacks goblet cells and therefore cannot release vaginal secretions such as mucin directly 
(Valenta, 2005). Vaginal mucus originates mostly from the endocervix, with small 
contributions from the endometrium and fallopian tubes. Vaginal discharge is comprised 
of a mixture of endocervical mucus, transudates through the epithelium, exfoliating 
epithelial cells, secretions of the Bartholin's glands, leukocytes, and endometrial and tubal 
fluids (Desphande et al., 1992).  
Studies have shown that contact of synthetic polymers that have ionic characteristics with 
the cervical mucus may cause significant changes in the structure of mucus gels (Willits 
and Saltzman, 2001; Espinosa et al., 2002; Valenta, 2005). Mucin is negatively charged 
due to the presence of sialic acid residues on its carbohydrate-rich regions (Valenta, 
2005). It has been observed that anionic {e.g. poly(acrylic acid) (PAA)}, non-ionic {e.g. 
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poly(ethylene)glycol} and cationic (e.g. polyvinyl pyridine) molecules may interact with the 
mucin gel to form regions with higher fiber density (Valenta, 2005). The fiber aggregation 
is mainly a result of electrostatic interactions between the polymer and the mucin. The 
ability to modify the structure of mucus gels by adding biocompatible synthetic polymers 
may provide new prevention measures for pathogenic organisms that infect the vaginal 
mucosa such as STI and HIV pathogens (Valenta, 2005; das Neves, 2006). Thus, the 
vagina has been targeted as a potential site for delivery of various drugs. The delivery of 
compounds is almost exclusively through the vaginal epithelium as described below. One 
of the most useful applications is the delivery of drugs that destroy or render dysfunctional 
spermatozoa and pathogens such as viruses and bacteria.  
1.1.4 The vagina as an application site for drug delivery  
The vagina, much as it has been proven to be a potential route for systemic drug delivery 
and uterine targeting, also has huge potential for the administration of drugs intended to 
confer a local effect, such as microbicides (Richardson and Illum, 1992; Jiménez-
castellanos et al., 1993; Vermani and Garg, 2000; Knox, 2004; Schiffman, 2004; Hussain 
and Ahsan, 2005; Valenta, 2005; das Neves and Bahia, 2006; Sitruk-Ware, 2007; das 
Iyer et al., 2008; das Neves et al., 2008; Nelson, 2008; Lai et al., 2009). The epithelium, 
normal flora, immune cells and acidic pH contribute to the vaginal defences which 
together with vaginal vascularity provide a potential route for local drug delivery (Li et al., 
2000; Vermani and Garg, 2000; Ogra et al., 2001; Valenta, 2005; Andrews et al., 2009). 
The vaginal commensals release organic acids, inorganic compounds and antimicrobial 
peptides into the milieu of the vaginal fluid which includes hydrogen peroxide, lysozyme, 
lactoferrin, bacteriocin-like substances, biosurfactants, secretory leukocyte protease 
inhibitor (SLPI), human neutrophil peptides (HNP-1, -2, and -3), and human ß-defensins 
(HBDs) which aid in killing pathogenic invaders (Wagner and Levin, 1978; Huggins and 
Preti, 1981; Cohen et al., 1984; Boris and Barbes, 2000; Valore et al., 2002; 
Venkataraman et al., 2005; Cole and Cole, 2007). Furthermore, it has been demonstrated 
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that the anatomical position of the vagina in humans, favors secure retention of vaginal 
formulations (Holmes, 2000; Iyer et al., 2008). Thus far, there has been considerable 
progress in the field of vaginal drug delivery in the recent years but with some challenges 
due to various factors (Merabet et al., 2005 Dobaria et al., 2007). To date, only a limited 
number of vaginal dosage forms are available, but increasing efforts are being made to 
make studies in this area of research. 
Apart from the novel drug-loaded inserts which are currently available on the market, 
there are also hydrogel drug delivery systems which may display higher retention times 
(Kumar et al., 2002; Lin and Metters, 2006). Most vaginal drug delivery systems are 
based on bioadhesive polymers since bioadhesitivity is an intrinsic pre-requisite for drug 
retention on the vaginal epithelium (Chang et al., 2002; Francois et al., 2003; Valenta, 
2005; Perioli et al., 2009). Bioadhesive polymers are able to swell while eroding slowly 
when exposed to an aqueous environment and therefore may well facilitate controlled 
drug release (Gavin et al., 2002; Kumar et al., 2002; Lin and Metters, 2006; Sudhakar et 
al., 2006). Significant efforts have been made to improve the adhesive properties of local 
drug delivery systems resulting in better retention and consequently improved availability 
and increased therapeutic efficacy (Gavin et al., 2002; Asane et al., 2008; Madhavlal 
and Manordas, 2009). 
Permeation of drugs through the vaginal epithelium is influenced by the physicochemical 
properties of the drug carrier and the tested drug, in terms of molecular weight, solubility, 
dissolution rates, lipophilicity, ionization, chemical stability, thermal stability, and also the 
characteristics of the membrane (Williams, 2003, Justin-Temu et al., 2004; Sandri et al., 
2004). In addition, physiological factors also play a role in the permeation process, for 
example cyclic changes in the thickness of the vaginal epithelium, fluid production 
volumes and composition as well as vaginal pH (Hussain and Ahsan, 2005). For instance, 
an increase of vaginal fluid volume may increase the absorption rate of poorly water-
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soluble drugs.  Changes in the vaginal pH may also have an influence on the release of 
pH-sensitive drugs from vaginal delivery systems (Hussain and Ahsan, 2005). Lipophilic 
molecules permeate faster than hydrophilic molecules (van Eyk and van der Bijl, 2005). 
Studies have shown that for the vaginal epithelium, the molecular weight cut-off points for 
permeation may be higher than those found in other epithelial surfaces (Williams, 2003, 
Justin-Temu et al., 2004). In addition, ionization may affect the permeation of drugs 
across the vaginal epithelium (Valenta, 2005; Nicolazzo and Finnin, 2008). Drugs that are 
in an unionized state penetrate epithelial membranes more freely (Williams, 2003, Justin-
Temu et al., 2004). Generally, chemical compounds cross the epithelial cell layers by two 
major pathways, namely the intercellular (paracellular) pathway where compounds pass 
between cells and the intracellular (transcellular) pathway where compounds pass 
through the cells. In both cases, drug permeation takes place either through passive 
diffusion, carrier-mediated transport or endocytosis (Meijer et al., 1990; Kapitza et al., 
2007). For mucosal delivery of most drugs, the intercellular route of diffusion 
predominates (Ghate and Edelhauser, 2006).  Furthermore, studies have shown that two 
types of pathways exist within the intercellular space (Wertz and Squier, 1991, Harris and 
Robinson, 1992; Williams, 2003). The first one is the hydrophobic pathway through the 
lipid bilayers while the second is the parallel hydrophilic pathway along the narrow 
aqueous regions that are associated with the polar head groups of the lipids. The 
penetration of the compound through the epithelial barrier increases as the hydrophobicity 
of a permeant molecule increases (Wertz and Squier, 1991, Harris and Robinson, 1992; 
Williams, 2003; van Eyk and van der Bijl., 2005). 
1.1.4.1 Advantages and disadvantages of vaginal drug delivery 
The vaginal route of drug administration offers advantages over other routes such as the 
avoidance of hepatic first-pass metabolism, reduction in the incidence and severity of side 
effects within the gastrointestinal tract (GIT), and reduction in hepatic side effects of 
steroids used in hormone replacement therapy or contraception (Patel, 1984; Cedars et 
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al., 1987; Vermesh et al., 1998; Dezarnaulds and Fraser, 2002). The vaginal route 
overcomes the inconvenience caused by pain, tissue damage and possible infection by 
parenteral routes. Furthemore, it has the potential for uterine targeting of active agents 
such as progesterone and danazol (Cicinelli et al., 1998, 2000; Einer-Jensen et al., 2002). 
Compared to the oral route, the vagina might prove better for the delivery of hormonal 
contraceptives due to a lack of drug interactions often encountered in the GIT. Another 
advantage is the possibility for self-administration of single-dose drug delivery systems 
that may suffice in releasing drugs over a period of weeks or months and simultaneously 
provide optimal drug pharmacokinetic profiles (Cohen et al., 1984; Woolfson et al., 2000; 
Benkop-Schnurch and Hornof, 2003; Iyer et al., 2008). 
Further advantages with vaginal administration include convenient access, prolonged 
retention of formulations, an extensive region for drug permeation, high vascularisation 
and relatively low enzymatic activity. Therefore, intravaginal drug delivery has exploitable 
advantages compared to other routes of administration in the area of bioavailability and 
controlled drug delivery (Carrington et al., 1944; Goldberger et al., 1947; Mishell et al., 
1972; Fried et al., 1973; Kirton et al., 1973; Nuwayser and Williams, 1974; Johansson et 
al., 1975; Verman and Garg, 2000; Valenta et al., 2001; Yoo et al., 2006; Bonferoni et al., 
2007; Wang and Tang, 2008). A contributing factor to the exploitable advantages 
conferred by the vaginal route of drug administration is the fact that the adult vaginal 
cavity has an extensive surface area (100-150cm2) that is adequately accessible for self-
administration purposes (Valenta, 2005). Furthermore, the vaginal route provides room for 
continuous programmed administration of drugs while simultaneously preventing the 
superfluous peaking of blood levels that is often seen with the use of oral drug delivery 
systems administered as discrete discontinuous doses (Valenta, 2005; das  Neves and 
Bahia, 2006).  
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The vaginal route is less preferable in terms of convenience depending on the type of 
dosage form. The influence of the estrogen concentration on the permeability of the 
vaginal membrane, which can influence the pharmacokinetics of drugs designed for 
systemic action, is yet another disadvantage (Okada et al., 1983; Acaturk and Robinson, 
1996). The quantity of vaginal fluid in the vagina of an adult woman is in the range of 2–
3g/24h (Müller, 1986). This quantity however decreases as the age increases. This 
volume of fluid may also affect the vaginal absorption of drugs. Furthermore, high quantity 
of vaginal fluid may lead to the expulsion of the dosage form. Studies have also shown 
that typical drug delivery systems such as foams, gels, and rings may be removed by the 
self cleansing action of the vaginal track (Vermani et al., 2002; Alam et al, 2007; Bilensoy 
et al., 2007; Romano et al., 2008). Since drugs must be in solution before they can be 
absorbed, the presence of a film of moisture might be an advantage but contrary to this, 
the presence of thick cervical mucus may also act as a barrier to drug absorption. This 
may however be an advantage for drugs administered for the purpose of exerting a local 
effect as is the case with microbicidal agents. In either case, for successful vaginal drug 
delivery, factors such as changing physiology of the cervix and vagina, the menstrual 
cycle, coitus, as well as leakage of the formulation from the vagina may grossly affect 
performance of an intravaginal drug delivery system. These factors must be recognised 
during design and development of an intravaginal drug delivery system (Garg et al., 
2003). 
 
1.2 Statement of the Problem 
Several therapeutic agents for curing HIV/AIDS have been developed, but, to date none 
has been proven to be ideally successful (Norris, 2008). Other than therapeutic agents 
use, other strategies proposed and adopted over the years to prevent sexually-acquired 
HIV infection include the promotion of abstinence, monogamy, condom use, reduction in 
the number of sexual partners and treatment of sexually-related infections. Yet, cultural, 
social and economic factors, particularly in the developing world, have resulted in these 
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strategies not being as successful as expected. Condom use has been the last and often 
preferred preventative measure advanced to combat the spread of HIV and STIs, but 
youth in particular do not respond appropriately to such initiatives (Fauci, 2005). When 
used consistently and correctly, male condoms can reduce the risk of pregnancy and 
many STIs, including HIV by about 80-90% (Weller and Davis; 2002; Hatcher,et al., 2004; 
Hearst and Chen, 2004; Holmes et al., 2004; Warner et al. 2004). Furthermore, condoms 
(including female condoms), are contraceptive methods that are substantially effective at 
reducing the risk of both STIs and pregnancy (USAID Health, 2009).  There is the 
perception that HIV and STIs only affect ‘others’ and despite the significant attempts to 
counter the belief that only certain groups are vulnerable and at risk of infection, studies 
show that some young men see HIV as a disease of atypical behavior associated with 
rape and commercial sex workers or as a result of excessive alcohol consumption 
(Pettifor et al., 2005). A Reproductive Health Research Unit study by Pettifor and co-
workers (2005) showed an extremely high percentage of respondents (93%), identified 
condom use as being an effective preventative measure but 67% did not use condoms 
consistently and as many as 31% had never used condoms. There is the belief that the 
way to protect ‘innocent victims’ is to stop only those who are infected from infecting 
others, perpetuating the view that their own conduct is unproblematic. As much of the 
research has failed to advance any explanation for the failure to transform knowledge into 
positive action, many of the crucial questions remain unasked and unanswered. In the 
wake of this denial, other effective female controlled measures that can protect both 
parties from exposure to this fatal disease are needed.  
 
The most compelling solution to HIV/AIDS is an effective vaccine. However, after 25 
years of research, development of an effective vaccine has remained unsuccessful due to 
various obstacles including inadequate resources, regulatory capacity concerns, 
intellectual property issues and mainly the scientific challenges (Malcolm et al., 2006; Lau 
et al., 2007; Gurunathan et al., 2009; Katsnelson, 2009). Despite major efforts and new 
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approaches, it is unlikely that an HIV vaccine will be available for human use in the near 
future (Weber et al., 2005; Hayden, 2009). This scenario, and the global estimate number 
of 5 million new cases of people suffering from HIV infection annually, coupled with the 
rising prevalence rate in women especially in resource-limited settings, identifies the core 
problem that this study seeks to address through a drug delivery perpective. 
 
1.3 Rationale and Motivation for this Study 
Given the devastating effects of the HIV/AIDS epidemic and the continuing difficulties in 
developing an effective HIV vaccine, there is a clear scientific rationale for developing 
alternative strategies to prevent STIs and the transmission of HIV infection. Thus, there is 
a need of searching for accessible, inexpensive and female-controlled pre-exposure 
prophylaxis strategies to prevent mucosal transmission of the virus. The most promising of 
these preventative approaches is the development of effective intravaginal microbicidal 
delivery systems (Uckun and D'Cruz, 1999; Bob, 2000; Best, 2000; van Damme, 2002a 
and b); Moore and Shattock, 2003; Balzarini and van Damme 2004; Malcolm et al., 2004;  
Uckun and D'Cruz, 2004, Mantell et al., 2005; Penttinen, 2005; Weber et al., 2005; 
Dhawan and Mayer, 2006; Balzarini and van Damme 2007; Eaton and Kalichman, 2007; 
Holmes, 2007; Nikolic et al., 2007; Brouwers et al., 2008; Kathambi, 2008; Klasse et al., 
2008; Ndesendo et al., 2008; Obioha 2008; Baloglu et al., 2009; Ndesendo et al., 2009). 
These are bioactive agents that when administered in the vagina prior to coitus, have the 
potential to either prevent or reduce HIV/AIDS and STI transmission through well 
established mechanisms (D'Cruz et al., 2003b; D'Cruz and Uckun, 2004; D'Cruz et al., 
2004a; Weber et al., 2005; Balzarini and Van Damme, 2007). 
  
A microbicide as a preventive strategy may thus function as follows: 
i) Maintenance and mobilization of normal physiological vaginal defence mechanisms in 
the cervicovaginal environment. A healthy, intact vaginal mucosa is an ideal natural 
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protective barrier against infection. This barrier may be supported by gel-forming 
agents that provide lubrication and an additional barrier to infectious organisms. 
ii) Enhancement of the natural vaginal defence mechanisms by maintaining an acidic pH 
environment, commensal vaginal microflora, antibodies and antimicrobial peptides. 
iii) Direct inactivation of sexually transmitted pathogens (HIV and STIs) by disrupting the 
pathogens’ protective membranes or envelopes.  
iv) Inhibition of early phases in the viral cycle of HIV and entry into the mucosal cells of 
the vaginal wall by specifically blocking surface proteins on the virus or by binding to 
receptors on human cells or by non-specifically coating the virus or human cells. 
v) Interruption of the viral life cycle at a post infection stage. ARVs already used for 
therapeutic use may also be employed as topical microbicides. These agents act by 
inhibiting viral replication or local spread of HIV infection.  
 
As opposed to the use of condoms, there may be greater potential for microbicidal drug 
delivery systems to empower women to protect themselves from HIV and STIs. An 
effective microbicide would be a valuable woman-controlled means to slow down the pace 
of the HIV/AIDS epidemic particularly in sub-Saharan Africa, where women aged between 
15 to 24 years are three times more likely to be infected with HIV-1 compared to the same 
age group of men (Fauci, 2005; Quinn and Overbaugh, 2005). To date, the development 
of an ideal microbicide (i.e. safe, effective, acceptable, affordable and accessible) has not 
been entirely successful (Weeks et al., 2004; Das Neves et al, 2006; Klasse et al., 2006; 
Balzarini and Van Damme 2007; Nuttall et al., 2007). Only a limited number of 
microbicidal drug delivery systems are available. The currently available vaginal delivery 
systems have several limitations which include leakage, messiness, low residence time 
and poor bioavailability, contributing greatly to poor compliance (Justin-Temu et al., 2004; 
Valenta, 2005; Biradar et al., 2009). Furthermore, the results of early clinical trials for the 
already developed microbicides have not been very encouraging (McCormack et al., 
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2001; Lazarus et al., 2008; Skoler-Karpoff et al., 2008). Therefore, efforts need to be 
directed at the development of novel microbicidal intravaginal drug delivery systems.  
 
The ultimate success of any intravaginal drug delivery system depends on the formulation 
and the bioactive agent. This requires consideration of several variables including the 
bioactive agent, vaginal physiology and the design of the delivery system. For these drug 
delivery systems, the challenge is to design a delivery system that provides a high drug 
concentration in the vagina over a prolonged period of time (Benkorp-Schnurch et al., 
2003). For controlled, zero-order release, sustained over prolonged periods (days 
extending to months), solid polymeric systems may be most suitable provided they are 
compatible with the physicochemical nature of the drug to be delivered and the body.  
 
To date, drug release durations for intravaginal delivery systems are either too rapid 
which ultimately requires the drug to be applied several times daily (typical of gels and 
tablets) (Gavin et al., 2002; El-Kamel et al., 2002; Wang and Lee, 2004; Bilensoy et al., 
2006) or the release period is adequate but they have been formulated for preventing HIV 
infection only, as is the case with vaginal rings (van Laarhoven et al., 2002; Malcolm and 
Woolfson., 2006). This research therefore proposes the development of a novel drug 
delivery system that will be active against both HIV and STIs with a controlled release 
effect of at least 1 month. This is a caplet-shaped device referred to as an “Intravaginal 
Bioadhesive Polymeric Device “(IBPD)” throughout this study. The delivery system will 
have desirable bioadhesive properties and will be capable of inducing an acidic pH 
environment in the vagina upon degradation, thus maintaining a wide spectrum of activity 
against pathogens. The main advantages of the developed IBPD are: i) it is easier and 
more convenient to apply a caplet than a gel or ring; ii) the developed bioadhesive caplet 
has desirable vaginal retention as opposed to poor retention conferred by gel formulations 
(Gavin et al., 2002); iii) controlled  release of the drug will mean less frequent application 
and therefore enhanced patient compliance; iv) the developed IBPD is non-messy and 
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can reside in the vagina long before coitus releasing drug gradually; the IBPD will be 
produced at low manufacturing costs and v) the IBPD can utilize more than one 
preventive mechanism of action unlike existing vaginal delivery systems which utilizes 
single mechanism of action. The IBPD has been designed to have a dual action by 
releasing an ARV and microbicide simultaneously. A formulation that simultaneously 
delivers an ARV and microbicide was sought because it has been suggested that a 
vaginal drug delivery system combining several mechanisms of prevention would be more 
effective or have less side effects than one with a single mechanism of action as is the 
case with preparations currently being researched (D’Cruz and Uckun, 2004; Ramjee, 
2006; Balzarini and Van Damme 2007; Cutler and Justman, 2008; Ndesendo et al., 2008, 
Gupta and Garg, 2009), partly due to inadequate attention to formulation, design and 
delivery technology development (Panttinen, 2005). The model microbicidal agent 
employed was Polystyrene sulfonate (PSS) (as a sodium salt) while the ARV agent was 
3'-azido-3'-deoxythymidine (AZT). The dimensions of the IBPD were 22×9×5mm for 
insertion into the posterior fornix of the vagina using an applicator (Figure 1.2). The 
posterior fornix location was purposely chosen to avoid any interference with the 
formulation during menses and sexual intercourse (Section 1.1.2). The anterior fornix was 
considered to be inappropriate for this purpose because it is right in the line of entry for a 
male sexual organ, and the in and out movement might disrupt the adhesion of the 
device. The formulation was designed in such a manner that a steady-state concentration 
of bioactive agents could be maintained locally (within the vaginal membrane and in the 
vaginal inner mucosal muscularated stratum). 
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Figure 1.2: A schematic of the upper vagina region depicting the posterior fornix as the 
site of the IBPD application. 
 
 
1.4 Aim and Objectives of this Study 
The aim of this study was to design and develop an IBPD for the potential prevention of 
STIs and HIV infection.  In order to achieve this aim, the following objectives have been 
outlined: 
1. To conduct extensive preformulation screening work on various biodegradable and 
biocompatible FDA-approved polymers for the selection of lead formulations that 
would ultimately provide an ideal bioadhesive polymeric set which is also capable of 
providing controlled drug delivery.  
2. To optimize the IBPD using the Artificial Neural Networks (ANN) approach. 
3. To assess the bioadhesivity of the drug-free IBPD that was developed from the blends 
of the selected polymers both in vitro and in vivo and optimize for bioadhesivity 
thereof.  
4. To perform in vitro and ex vivo analysis on the dug-loaded optimized IBPD in terms of 
physicomechanical and physicochemical properties, bioadhesivity, permeation and 
drug release characteristics.  
5. To perform computational and chemometric molecular structural modeling studies on 
the native polymers, drug-free IBPD and dug-loaded optimized IBPD. 
 
  
  
I   
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Anterior fornix 
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6. To conduct in vivo studies on the drug-loaded optimized IBPD in the pig model.  
          
1.5 Overview of this Thesis  
Chapter 1 provides the study protocol which contains the introduction, rationale, 
motivation for the study and objectives. The introduction provides a concise description of 
the current situation regarding the HIV/AIDS epidemic, proposing the way forward for 
which the enaction is taken care of by the highlighted aim and objectives. A clear 
description on the role played by STIs in enhancing both HIV susceptibility and secondary 
transmission is provided. An overview of the treatment modalities that have been 
employed in the management of HIV/AIDS is given. In addition, a description is provided 
on the anatomy and physiology of the vagina in relation to drug delivery, and the vagina 
as an application site for drug delivery, as well as the advantages and disadvantages of 
this route of adminstration. The characteristics of an ideal vaginal drug delivery system 
are described, and the concept of a microbicidal-Intravaginal Bioadhesive Polymeric 
Device is introduced. 
 
Chapter 2 provides a descriptive review of the current intravaginal drug delivery 
approaches that have been employed for the prophylaxis of HIV/AIDS and prevention of 
STIs. The current status of various microbicidal drug delivery systems, particularly in the 
context of their stage within clinical trials and their potential cervicovaginal defence 
successes are described. Furthermore, approaches that may lead to the successful 
design and development of more effective intravaginal microbicidal delivery systems for 
preventing the transmission of STIs and HIV are suggested. 
 
Chapter 3 explains thoroughly how various natural and synthetic biodegradable and 
biocompatible polymers with hydrophilic and hydrophobic properties were screened in an 
attempt to find suitable polymers for developing a novel intravaginal bioadhesive 
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polymeric device (i.e. IBPD). The key requirements for an intravaginal delivery system 
are: i) ease of manufacture; ii) low manufacturing costs; iii) ease of insertion; iv) high 
retention rate; v) minimal adverse effects such as damage to the vaginal epithelium; and 
vi) the potential for attaining controlled drug release and suitable lateral permeation (i.e. 
across the vaginal tissue). To satisfy all these requirements, it was necessary that the 
materials used for the development of such systems should have a multitude of essential 
properties. These include among others, biodegradability, biocompatibility, bioadhesivity, 
permeation capacity, compressibility and high matrix resilience. To achieve this goal, a 
One Variable at a Time (OVAT) approach was employed.  
  
Chapter 4 discusses how Artificial Neural Networks (ANNs) have been successfully 
employed in the optimization of the IBPD. For successful design and development of 
novel drug delivery systems careful selection and optimization of several formulation and 
process related variables is of paramount importance. This avoids wastage of materials 
and time, with the subsequent benefit of reducing the production costs. It is important to 
know exactly how preparation compositions determine the formulation characteristics and 
in particular how formulation factors and potential interactions between them affect the 
performance of a given delivery system. Generally, the impact of each variable can be 
assessed by varying one variable at a time while keeping others constant. The OVAT 
approach employed in Chapter 3 in the extensive investigational screening of the 
polymers has thus enabled the selection of the best 15 lead formulations from 62 
formulations. However, the OVAT approach cannot take into account interactions 
between the formulation factors. ANNs have been shown to be uselful in dealing 
efficiently with this difficulty and have therefore been used in this study.  
 
Chapter 5 provides an evaluation of the bioadhesive capacities of the various polymers 
that have been employed in this study for developing the IBPD.  For any given 
intravaginal drug delivery system, its retention to the vagina is an absolute requirement. 
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Good retention allows for the bioactives to be maintained at an optimal level locally and 
for extension of their residence time at the site of administration. To meet this 
requirement, an intravaginal device needs to be highly bioadhesive.  
 
Chapter 6 provides a thorough description of the evaluation of bioadhesivity, in vitro drug 
release, and permeation of the drugs from the IBPD. It also seeks to explain the 
physicochemical and physicomechanical properties of the developed drug delivery 
system. One of the main objectives of this study was to design and develop an 
intravaginal drug delivery system in which the formulation would initially swell in order to 
facilitate bioadhesion, and thereafter erode gradually to release the drug in a controlled 
manner, to finally permeate laterally into the vaginal tissue and provide the needed 
preventive effect against HIV and STIs.  
 
Chapter 7 describes the analysis of the drugs (AZT and PSS) in the vaginal tissue and 
plasma of a pig model admistered with an IBPD. It also provides a thorough 
histopathological toxicity evaluation of the IBPD in the pig model. This was in line with the 
ultimate goal of the study which required an intravaginal delivery system that could be 
retained in the vagina and release an ARV and microbicide simultaneously. Furthermore, 
the intention was that most of the released drugs would be retained in the vaginal tissue 
without causing toxicity. Assessment of the adherence, degradation and distribution 
patterns of the IBPD was also undertaken in this Chapter. 
 
Chapter 8 concludes the thesis, assimilating the significant issues addressed regarding 
the design and development of the novel controlled release IBPD, with recommendations 
for future investigations in terms of system applicability.  
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1.6 Concluding Remarks 
The current status of the HIV pandemic including the successes and failures of the 
therapeutic approaches which therefore identified the research problem has been well 
addressed. The aim and objectives of this study were pragmatically selected to realize the 
goal of developing a bioadhesive controlled release/prolonged release microbicidal drug 
delivery system. The synergy between STIs and HIV which enhances the susceptibility to 
secondary transmission of HIV have been elucidated and emphasized as being important 
entities to consider for the rational development of novel HIV prevention strategies. The 
anatomy and physiology of the vagina in relation to drug delivery has been addressed. 
Although the vagina exhibits a degree of dynamism, the benefit of exploiting it as a 
potential route for drug delivery still holds. Thus, the vagina still has its own place as a 
unique site for drug administration. Vaginal drug delivery can be engineered in such a 
way that maximum benefit is obtained as long as factors such as cyclic changes and 
physiological changes during menopause, are taken into consideration. Currently, the 
availability of microbicides is not a challenge as several are already in existence. The 
greatest challenge is finding the most effective way of delivering them to the required 
sites. It is anticipated that the design and methodological approach that has been 
undertaken in this study, will offer significant progress to this end, with the added benefit 
of the inclusion of an ARV into the formulation. 
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CHAPTER TWO 
 
L ITE R AT UR E  R E VIE W OF  C UR R E NT INTR AV AG INAL  DR UG  DE L IVE R Y  
AP P R OAC HE S  E MP L OY E D F OR  THE  P R OP HY L AXIS  OF  HIV/AIDS  AND 
P R E VE NTION OF  S E XUAL L Y  TR ANS MIT TE D INF E C TIONS  
 
2.1 Introduction 
Intravaginal drug delivery systems have traditionally been used to deliver contraceptives 
and drugs such as antibacterials, antifungals, antiprotozoals, antivirals, labor-inducing and 
spermicidal agents, prostaglandins, steroids, peptides and proteins to treat vaginal 
infections (Katz et al., 1997; Verman and Garg, 2000; Weber et al., 2005). Formulations 
have included pessaries and tablets designed after the advent of rectal suppositories. The 
first intravaginal controlled drug delivery system was developed in 1970, using a vaginal 
ring for the delivery of medroxyprogesterone acetate for contraception (Verman and Garg, 
2000). However, tablets, creams, and suppositories are now the most conventional 
formulations in vaginal drug delivery while vaginal rings are more commonly employed for 
long-term drug delivery.  
 
Recent advances have been made in the area of bioadhesive gels, microparticles and 
tablets, which show great promise for use as controlled intravaginal microbicide delivery 
systems (Tang et al., 2005; Valenta, 2005; Bonferoni et al., 2006; Al-Tahami and Singh, 
2007). Numerous hydrophilic polymers and hydrogels have been used in a number of 
vaginal products (Lew, 1994; Bogentoft and Carlsson, 1996; Robinson and Bologna, 
2002; Al-Tahami and Singh, 2007). Natural hydrogels include among others, starch, 
collagen, various proteins, gelatin and dextrans. Swollen cellulose derivatives such as 
hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC) and sodium 
carboxymethylcellulose (NaCMC) have also been used, especially in tablet formulations. 
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Among the standard synthetic hydrogels, poly(ethylene oxide) and poly(acrylic acid) have 
been used in vaginal microbicide delivery formulations (Lee et al., 2000). The thick 
cervical mucus in the vagina may assist in the bioadhesion of various delivery systems, at 
the same time serving as a diffusion barrier to subsequent microbicidal delivery (Lard-
Whiteford et al., 2004). Vaginal gels such as carageenan and PRO 2000™ Gel (Indevus 
Pharmaceuticals, Inc. Lexington, MA, USA) formulations when employed for the 
prevention of HIV and herpes virus transmission may be effective for up to one hour after 
sexual intercourse (Phillips and Maguire, 2002; Cadena, 2006; Rando et al., 2006; Brache 
et al., 2009).  
 
Thus, there is a need to develop affordable and easy to apply microbicidal delivery 
systems. Among potential intravaginal delivery systems about which researchers at the 
WHO, UNAIDS, and other organizations have expressed hope in terms of safety and 
effectiveness, are vaginal gel formulations such as BuffergelTM and CarraguardTM 
(Maguire, 2001; Thom, 2007). It is anticipated that future research will focus on the 
development of combination products capable of delivering microbicides that violate the 
HIV life-cycle at multiple steps, have increased efficacy and have limited cross-resistance 
and which can minimize microbicide-induced host toxicity (Penttinen, 2005). In the 
absence of an effective prophylactic anti-HIV vaccine or therapy, current efforts are aimed 
at developing topical intravaginal formulations of anti-HIV agents or microbicides to 
reduce vaginal and perinatal virus transmission and cure and prevent STIs which may 
enhance HIV transmission. Therefore the purpose of this Chapter is to provide an 
overview and description of recent developments in intravaginal delivery systems for 
microbicides employed for the prophylaxis of HIV/AIDS and prevention of STIs.  
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2.2 The Rationale for the Development of Intravaginal Microbicidal Delivery 
Systems  
Currently, much research on intravaginal drug delivery focuses on the prevention of HIV 
infection and STIs. Development of vaccines for the prevention of HIV transmission is still 
a challenge (Bourinbaiar et al., 2006; Lau et al., 2007; Hayden, 2009; Katsnelson, 2009). 
Microbicides circumvent many of the immunological difficulties associated with HIV 
vaccine development and make topical formulations such as gels a more realistic goal, 
especially in the short term. On the other hand, male condoms are not always accepted 
and correctly used. Unlike condoms, microbicidal delivery systems may be controlled by 
women, and do not require the cooperation, consent or even knowledge of the partner. 
Microbicidal delivery systems can provide an option to thousands of women who are at 
risk of contracting HIV and other STIs but are unable to negotiate condom use because of 
gender inequality, illiteracy, cultural resistance and poverty in many developing countries 
(Joshi et al., 2005). Thus, microbicidal delivery systems may be a solution to the 
prevention of STIs and sexual transmission of HIV infection (Moore et al., 2003; Malcolm 
et al., 2005). 
 
The potential for developing controlled release formulations for long-term intravaginal 
delivery of microbicides has recently gained momentum and may overcome challenges 
relating to compliance, acceptability and efficacy associated with current gel-based 
formulations (Woolfson et al., 2000; Moore et al., 2003; Nikolic et al., 2007; Klasse et al., 
2008; Obioha 2008; Baloglu et al., 2009). Furthermore, the emergence of resistant HIV 
strains and toxic side-effects of current ARVs require intravaginal delivery systems with 
superior safety profiles and potential for improved patient compliance. An intravaginal 
microbicidal delivery system combining several mechanisms of preventing the 
transmission of STIs and HIV would need to possess added effectiveness and less side-
effects than a delivery system having a single mechanism (Penttinen, 2005). Figure 2.1 
depicts various mechanisms of preventing the transmission of sexually transmitted 
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infections and HIV by employing microbicide delivery systems. The challenge is to design 
a delivery system that is able to provide high concentrations of the microbicidal compound 
in the vagina over a prolonged period of time (Benkorp-Schnurch et al., 2003). Studies 
have indicated that dosages in first-generation microbicides remain effective only for a 
few hours and therefore necessitate administration shortly before coitus (Kiser, 2006a). 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Schematic depicting the various mechanisms of preventing the transmission 
of sexually transmitted infections and HIV by employing microbicide delivery systems, 
(Adapted: Stone, 2002). 
 
 
2.3 Current Intravaginal Microbicide Delivery Approaches for Preventing the 
Transmission of STIs AND HIV 
The majority of microbicidal delivery systems for intravaginal administration that have 
been developed and evaluated in ongoing clinical trials are conventional semi-solid 
aqueous gels and vaginal ring formulations. These have been designed to provide a 
single dose of a microbicidal agent (Di Fabio et al., 2003; Herrewege et al., 2004; Alliance 
for Microbicide Development, 2005; Mitchel, 2006). Prior to widespread use, an 
intravaginal microbicide delivery system should meet several criteria (Table 2.1) in that 
the microbicide employed should be effective against a diversity of HIV strains.  
 
 
 
Gels or creams form 
physical barriers 
or lubrication 
Maintenance of  
normal vaginal 
microflora 
Prevention of other 
transmitted 
diseases 
Fusion/absorption  
inhibition onto cell  
co-receptors 
Inhibition by 
 non-nucleoside  
reverse transcriptase 
Inhibition of  
HIV uptake  
by dendritic cells 
Viral 
disruption 
prevents entry 
Vaginal  
Epithelium 
Stoma 
Layer 
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Table 2.1: Desirable criteria for ideal intravaginal microbicidal delivery systems 
 
i) Simple to manufacture, cost effective and easy to apply thus facilitating patient 
compliance. 
ii) Non-irritative and free from producing any physical discomfort. 
iii) Provide immediate and sustained protection by releasing the microbicide in a 
controlled manner over a prolonged period of time. 
iv) Have suitable vaginal retention and distribution. 
v) Be versatile against various pathogens encompassing STIs and HIV. 
 
 
 
Currently, the maximum duration of drug release for intravaginal microbicidal delivery 
systems is as follows: i) Vaginal gels (6 hours) (Wang and Lee, 2004; Bilensoy et al., 
2006), ii) vaginal tablets (8 hours) (El-Kamel et al., 2002; Gavin et al., 2002), and iii) 
vaginal rings (71 days) (van Laarhoven et al., 2002; Malcolm and Woolfson., 2006). 
Vaginal gels and tablets have rapid release rates which, for effective use, ultimately 
require administration several times a day. Vaginal rings have adequate release rates but 
have only been formulated for preventing the transmission of HIV and as a contraceptive. 
Several intravaginal delivery systems for microbicides have been formulated and 
traditionally include a large variety of pharmaceutical dosage forms such as semi-solids, 
tablets, capsules, pessaries, liquid preparations, vaginal films, vaginal rings, foams, and 
tampons. The most widely used semi-solid preparations for vaginal drug delivery include 
creams, ointments, and gels (Verman and Garg, 2000). These systems could be used to 
reverse the rising rates of STIs such as external genital warts, gonorrhea, chlamydia, and 
syphilis, which significantly predispose individuals to acquiring HIV (Penttinen. 2005; 
Kiser, 2006a) 
 
Over the past decade, there have been major advances in the field of microbicidal 
delivery with diverse types of delivery systems in various stages of development 
(Harrison, 2003). The ultimate success of an intravaginal microbicide delivery system 
requires consideration of variables including the microbicidal agent, vaginal physiology 
and the design of the delivery system. Targeting HIV entry into the body is a favored 
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preventative approach as it is the initial step in the process of infection. Several readily 
available anionic polymers interfere with the entry processes of HIV, and hence these 
polymers qualify as primary candidates for designing various microbicidal delivery 
formulations (Bernkop-Schnurch et al., 2003). However, few of these formulations have 
been tested in Phase I/II clinical trials, in HIV-uninfected, and HIV-infected populations 
(D’Cruz and Uckun, 2004). Current multi-center Phase I/II safety and Phase II/III efficacy 
studies are being conducted or planned in different geographical locations, by various 
groups which aim to design systems for rapid clinical applications (Bentley et al., 2002; 
Morin et al., 2008).   
 
2.4 Design of Intravaginal Microbicide Delivery Systems 
Intravaginal delivery may be formulated for administration of microbicides by using an 
applicator or specifically designed systems for intravaginal administration. In general, 
based on the delivery system or the microbicide used, drug absorption, distribution and 
residence time in the vagina may vary. Early studies by Johnson and Masters (1962) 
showed that the microbicide distribution in the vaginal tissue varies considerably with the 
nature of the delivery system. Solutions, suspensions and foams displayed greater 
superiority over oral dosage forms. Ideally, a vaginal delivery system that is intended for 
localized microbicidal delivery should distribute uniformly throughout the vaginal cavity. 
Thus, for a local effect to occur in the vagina, semi-solid, or fast dissolving solid systems 
are required. Bioadhesive delivery systems or intravaginal ring systems are more suited 
for topical effects. However, it has been difficult to measure the distribution of a 
microbicide after intravaginal administration (Di Fabio et al., 2003; Hussain and Ahsan, 
2005; Scorpio et al., 2008; Hendrix et al., 2009). Currently there is no data available 
regarding the bioavailability of most intravaginal microbicide delivery systems after 
extended vaginal exposure (D’Cruz and Uckun, 2004; Cutler and Justman, 2008; Hendrix 
et al., 2009). Furthermore, most of the intravaginal drug delivery systems for 
contraception and the prophylaxis against HIV lack efficacy (Katz et al., 1997). 
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Engineering and materials science may provide critical and new information to the 
process of designing and developing superior intravaginal microbicide delivery systems. 
First-generation microbicidal compounds that are currently under investigation are 
expected to be available within a few years. These systems may only be 50-60% effective 
in delivering microbicides (Kiser, 2006a), but even with this efficacy if they are used by 
only 20% of women, in 73 low-income countries, they may still lead to the prevention of 
2.5 million new infections during a three-year period (Penttinen. 2005; Kiser, 2006a).  
 
2.4.1 Creams and gels 
Although creams and gels are commonly used for the topical intravaginal delivery of 
microbicides (Bernkop-Schnürch and Hornof, 2003; Hardy et al., 2007), these systems 
are messy, uncomfortable and may not provide an exact dose due to non-uniform 
distribution and their leakage (DuBouchet, et al., 1998; Hussain and Ahsan, 2005). To 
evaluate the efficacy of a 3-day course of clindamycin vaginal cream in the treatment of 
bacterial vaginosis, some researchers performed a randomized, placebo controlled trial in 
pregnant women (Broumas and Basara, 2000; Lamont et al., 2003). They found that the 
clindamycin cream was well tolerated and more efficacious than placebo (Broumas and 
Basara, 2000; Lamont et al., 2003). Vaginal creams and gels are based on the principle of 
emulsion or hydrogel-based drug delivery. During the past few years, considerable work 
has been done on the development of hydrogel controlled release microbicide delivery 
systems (Owen, et al., 1999; Verman and Garg, 2000; Alvarez-Lorenzo and Concheiro, 
2002; Tang et al., 2005; Valenta, 2005; Bonferoni et al., 2006; das Neves and Bahia, 
2006; Al-Tahami and Singh 2007; Alvarez-Lorenzo and Concheiro, 2008). For example, a 
3% alginate gel of nonoxynol-9 has been investigated for intravaginal spermicidal activity 
(Owen et al., 1999). The study found that the spermicidal activity and the diffusion of the 
agent changed with the pH and osmolarity of the formulation. Recently, a gel 
microemulsion-based spermicide formulation, phenyl phosphate derivative of zidovudine, 
with anti-HIV effect, has been developed (Yiv, 2006; D’Cruz and Uckun, 2006a and b; 
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D’Cruz and Uckun, 2007). Multiple intravaginal applications of this drug as a 
microemulsion gel formulation did not cause any damage in the vaginal epithelium in the 
pig model (D’Cruz, 2003b; D’Cruz et al., 2004b; D’Cruz and Uckun, 2006a; Yiv, 2006; 
D’Cruz and Uckun, 2007).  
  
2.4.2 Tablets and suppositories 
Some authors use the terms pessaries and suppositories interchangeably and consider 
vaginal tablets as a separate dosage form. These formulations are designed to melt in the 
vaginal cavity and release the microbicide over several hours. Suppositories are most 
commonly used to administer drugs for cervical ripening prior to child birth and for local 
delivery of various drugs. Vaginal tablets may contain binders, disintegrants and other 
excipients that are used to prepare conventional oral tablets. Bioadhesive polymers are 
sometimes used in tablet formulations to increase the vaginal residence time of the 
microbicide been delivered. The presence of hydrophobic and release retarding materials 
may decrease the absorption of microbicides from a vaginal delivery system. Highly 
hydrophobic microbicides may not be suitable for vaginal tablets. The presence of 
penetration enhancers such as surfactants or bile salts can also significantly enhance 
systemic absorption if required. Other vaginal tablet-like formulations are extrapolations of 
silicone-based vaginal rings. Research groups have studied the release of microbicides 
from silicone matrices (Katz and Dunmire, 1993; Klavinskis, 1999). Release studies were 
performed in vitro for up to 1 year and in vivo in pigs for up to 52 days. Both in vitro and in 
vivo studies showed consistent release profiles over time, showing that microbicide 
delivery is controlled by diffusion from the silicone delivery device and was not limited by 
absorption through the vaginal epithelium. Further analysis of this diffusion process was 
performed by the development of a composite physical model. This involved the 
simultaneous receding boundary release of drug from a cylindrical silicone matrix delivery 
system, diffusion across an aqueous layer (vaginal fluid) and transport across the vaginal 
membrane by way of parallel lipoidal and aqueous pore pathways. The important 
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parameters in the analysis of this simulation are the solubility of the drugs in the silicone 
matrix, the solubility of the drugs in water, diffusion coefficients, silicone/water partition 
coefficients, and the permeability coefficient of the vaginal membrane to the microbicide.  
 
2.4.3 Vaginal rings 
Vaginal rings are circular ring-type drug delivery devices designed to release microbicides 
in a controlled manner after insertion, to prevent the transmission of STIs and HIV 
(Malcom et al., 2004 and 2006; Woolfson et al., 2006). The advantages of such a device 
are that they are controlled by the user; they do not interfere with coitus and they allow for 
the continuous delivery of microbicidal compounds. Vaginal rings are approximately 
5.5cm in diameter with a circular cross section diameter of 4–9mm. In simple vaginal 
rings, the microbicide is homogeneously dispersed within a polymeric ring with the 
surface of the ring releasing the microbicide faster than the inner layers. The key 
challenge in development of these systems is finding the optimum dose that will deliver 
the least amount of microbicide necessary to ensure protection. Advances have been 
made on the original two-layer ring system by adding a third, outer, rate controlling drug-
free elastomer layer (Washington, et al., 2001). This formulation design minimizes the 
drug concentration spike which was often observed during the first treatment cycle using 
a new ring. The rings are usually designed so that a new device is re-inserted at a time 
interval which is dependent upon the precise design of the delivery system and the 
microbicide being delivered. To obtain constant microbicide release from the vaginal ring, 
sandwich or reservoir-type rings have also been developed. Sandwich type devices 
consist of a narrow microbicide-loaded layer located below the surface of the ring and 
positioned between a central core and an outer band. In reservoir type ring systems, 
microbicides are dispersed in a centralized core, which is then encapsulated by a 
polymeric layer. In a single ring, it is possible to have several cores of different 
microbicidal compounds, thereby allowing administration of several microbicidal 
compounds from the same device. The rate of drug release can be modified by changing 
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the core diameter or thickness of the polymeric coating. Much of the vaginal ring literature 
relates to the commonly used polymer, poly(dimethylsiloxane) or silicone devices, 
although other elastomeric polymers such as ethylene vinyl acetate and styrene 
butandiene block copolymers have been tested (Roumen and Dieben, 1999; and van 
Laarhoven, et al., 2002; Airey et al., 2008; Hamid et al., 2008). The addition of vinyl 
acetate units in the polyethylene provides increased flexibility and greater adhesion. In a 
study by Roumen and Dieben (1999), evaluating the tolerability of ethylene vinyl acetate 
placebo vaginal rings of diameter 54mm, there was 91% acceptability among subjects 
involved in the study. The ring remained inserted for 21 consecutive days after insertion, 
with temporary removal during coitus (Roumen and Dieben, 1999). Most women judged 
the ring easy to insert and remove, and no side-effects were experienced among the test 
group during the study period (Roumen and Dieben, 1999; Ballagh, 2001; Harwood and 
Mishell, 2001; Dezarnaulds and Fraser, 2002; Novák, et al., 2003).  
  
2.5 Bioadhesive Intravaginal Systems 
Most conventional intravaginal formulations however are associated with disadvantages 
of low retention to the vaginal epithelium, leakage and messiness, thereby causing poor 
patient compliance. To circumvent these challenges, bioadhesive microbicidal delivery 
systems are being promoted. A bioadhesive polycarbophil gel, Replens® (One Nil Trade 
Ltd, Swanbridge, Caerphilly, UK), is currently available on the market, which is used to 
retain moisture and lubricate the vagina. The formulation remains in the vagina for 2–3 
days and maintains the vagina at a healthy acidic pH (Richardson and Armstrong, 1999). 
Bioadhesive polymers that have been used for intravaginal formulations include among 
others polycarbophil, hydroxypropylcellulose and PAA (Saettone et al., 2002; Hussain and 
Ahsan, 2005; Andrews et al., 2009). The first bioadhesive systems for vaginal drug 
delivery were in the form of tablets which could be placed on a diseased area for delivery 
of bleomycin, an anti-cancer agent (Hwang, et al., 1977; Brannon-Peppas, 1992). These 
tablets contained hydroxypropylcellulose and PAA (Carbopol® 934). Release rates in vitro 
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increased with increasing quantities of hydroxypropylcellulose and water absorption 
increased with increasing quantities of PAA. Studies in vivo showed that after 5 days of 
treatment with a total of 150mg of bleomycin, in some cases, cancerous lesions had 
necrosed and the normal mucosa was unaffected (Hwang, et al., 1977; Brannon-Peppas, 
1992). Bioadhesive tablets have been studied for the delivery of zinc sulphate as a model 
drug from compressed tablets of PAA and sodium carboxymethylcellulose, as 
bioadhesive polymers and cellulose (Avicel® PH102) (FMC BioPolymer, Philadelphia, 
USA) as a diluent (Sanders and Matthews, 1990). Experiments were performed in situ 
using bovine vaginal tissue. The force necessary to detach the tablets from bovine tissue 
was measured and correlated with the tablet composition. It was found that tablets 
containing only polyacrylic acid and zinc sulphate exhibited the optimal integrity. The 
presence of Avicel® in the formulations increased the tablet swelling in all cases but did 
not substantially decrease the force of detachment nor alter the drug release behavior. 
Increasing the quantity of polyacrylic acid increased the bioadhesion of the tablets to the 
vaginal epithelium (Woodley, 2001; Knuth, et al., 1993; Ceschel, et al., 2001). 
 
Attempts have also been made to deliver microbicides using bioadhesive microparticulate 
vaginal systems (Vasir et al., 2003; Hussain and Ahsan, 2005).  These systems may be a 
multi-phase liquid or a semi-solid, but they have been designed so as not to seep from the 
vagina like pessary formulations. The system is designed to provide controlled 
microbicidal delivery for at least 3 hours. The units of the release system have a lipoidal 
external phase and a non-lipoidal internal phase, providing bioadhesion when applied. A 
bioadhesive controlled release delivery system for nonoxynol-9 was reported by Lee and 
co-workers (1996) consisting of varying levels of nonoxynol-9 and ethylenediamine tetra-
acetic acid (EDTA), a chelating agent, formulated using the polymer Carbopol® 934P. 
Carbopol® 934P provided a high burst release of nonoxynol-9 in the first 2 minutes and 
controlled release for up to 6 hours (Lee et al., 1996). Ceschel and co-workers (2001) 
developed a new bioadhesive vaginal dosage form by incorporating bioadhesive polymers 
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namely polycarbophyl, hydroxypropylmethylcellulose and hyaluronic sodium salt, into 
pessaries made of semi-synthetic solid triglycerides. The authors of this study argued that 
these polymers hold the pessaries in the vagina for longer periods of time, without side-
effects, thereby prolonging the permanence of the drug on the vaginal epithelium. The 
presence of bioadhesive polymers largely modulated the behavior of pessaries in terms of 
adhesive force, liquefaction time and permanence of the drug in the simulated application 
site. However, their presence did not alter the release of the drug. The developed 
formulations showed good technological and adhesion properties and the ability to hold 
the delivery system at the application site.  
 
2.6 Compounds Delivered Intravaginally as Microbicides 
The numerous intravaginal compounds delivered intravaginally as microbicides are listed 
in Table 2.2 for which a concise description is provided hereafter. 
 
Table 2.2: Classification of the numerous intravaginal compounds delivered 
intravaginally. 
Classification                                                                          Compound 
Polymeric Compounds: Carageenan, Monocaprin, Polyacrylic Acid, 
Lactobacillus, Cellulose Acetate Phthalate, Cellulose 
Sulfate, Polystyrene Sulfonate, Naphthalene 
Sulfonate, Sulfated Polyvinyl Alcohol and Lactic Acid  
Non-Polymeric Compounds: Cetyl Betaine, Myristamine Oxide, Stampidine, 
Cyanovirin-N, Monoclonal Antibodies, Lyposomes, 
Thrombospondin-1, Lime Juice, Yoghurt, Tenofovir 
and Zidovudine 
Nano-Structured Compounds: Dendrimers, Thiourea, Silver, Polystyrene and 
Sodium Lauryl Sulfate 
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2.7 Dual-function Polymeric Gel-based Formulations Employed in the Design of 
Intravaginal Microbicide Delivery Systems: As Excipients with Potential 
Therapeutic Activity  
Microbicidal gel formulations are likely to be only partially effective, but can produce a 
significant difference in places such as Africa, where most gels can be produced at 
reasonable costs. The properties of the gel in which microbicides are included are known 
to affect the epithelial permeation rate of microbicides and their microbicidal properties 
(Wang and Lee, 2002; Geonnotti and Katz, 2006; Hendrix et al., 2009). A formulation 
comprising Carbopol® 974 (Noveon Inc, Cleveland, OH, USA) 1.0–1.5%w/w and HPMC 
1.0–1.5%w/w displayed a desirable gel-base intravaginal microbicide delivery system 
(Garg et al., 2001). Furthermore, the development of a “universal” placebo gel is required 
in order to assure that the placebo formulation does not distort either safety or efficacy 
assessments of microbicides. Recently, a hydroxyethylcellulose (HEC) placebo gel has 
been proposed as an adequate “universal” placebo, which is safe and sufficiently inactive 
for use in the clinical study of investigational microbicides (Wang and Lee, 2004a). 
 
Patient compliance is one of the main attributes that excipients should provide to gel-
based vaginal delivery systems for microbicides. Classes of excipients usually added to 
vaginal gels include gelling agents, humectants, preservatives and vehicles (Garg et al., 
2004b; Oshlack et al., 2009). Various polymers are also commonly used as gelling agents 
in the formulation of hydrophilic vaginal gels. By definition, excipients are usually chosen 
from among materials that are very nearly pharmaco-toxicologically inert, and they usually 
have no therapeutic activity. However, some sulphated polymers, such as the 
carageenans, that are usually used as gelling agents; present themselves as one of the 
most promising classes of potential microbicidal compounds (Perotti, et al 2003; Smit, 
2004; Buck et al., 2006; das  Neves and Bahia, 2006; Blakemore et al., 2008; Andrews et 
al., 2009).  
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2.7.1 Carageenan-based gel formulations 
Carageenan is a mixture of highly sulfated polysaccharides, comprised mainly of 
polygalactans such as gums, agar and fruit pectins. It is a hydrocolloid obtained from 
various members of the Gigartinaceae or Solieriaceae families or the red seaweed, 
Rhodophyceae. It is a yellow to white powder and is odorless and tasteless. The 
extracted product consists of three types of carageenan, known as iota, kappa or lambda 
(Table 2.3). Carageenan formulations may be effective against the spread of HIV infection 
because they appear to prevent the trafficking of HIV-infected mononuclear cells from 
vaginal fluids into the epithelium. These polymers form a negatively charged coat around 
HIV-infected mononuclear cells preventing their adhesion to the vaginal epithelial surface 
(Perotti et al., 2003). Data from a Phase I preliminary safety study indicates that a 
Carbopol® 974 Gel containing carageenans as microbicidal agents do not cause 
significant irritation to the female reproductive tract (Spencer et al., 2004). This may be an 
advantage over other microbicides or formulation excipients that are irritant to the vagina 
(Spencer et al., 2004). 
 
Before usage, excipients that are used to formulate vaginal drug delivery systems must 
prove their biocompatibility. These tests are usually performed in cell culture models. 
Biocompatibility can be determined by cell growth/cell viability assays, cell proliferation 
assays, cytotoxicity assays, nitrite assays, and by protein assays and identification. 
Carageenan has been classified as "Generally Recognized as Safe" (GRAS) material by 
the United States Food and Drug Administration (US FDA). Further extensive oral 
pharmacokinetic studies have been conducted in various animal models. These have 
shown that the breakdown of carageenans in the gastrointestinal tract is minimal and that 
absorption is virtually non-existent (Blakemore et al., 2008). Sulfated polysaccharides that 
are useful in inhibiting cell-to-cell transmission of HIV and thus the sexual transmission of 
HIV as well as STIs include iota carageenan, dextran sulfate, kappa carageenan, lambda 
carageenan, heparin mimetics, heparin sulfate, pentosan polysulfate, chondrotin sulfate, 
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lentinan sulfate, curdlan sulfate, de-N-sulfated heparin and fucoidan (Smit, 2004). It has 
been shown that certain carageenans, or permutations of various carageenans, possess 
specific physicochemical properties which enable them to provide a prolonged 
antimicrobial effect and inhibit or reduce the possibility of STIs. Carageenan is one of the 
most active microbicides among the sulfated polysaccharides (Pearce-Pratt and Phillips, 
1996). Iota carageenan is the most efficacious of the commercially available sulfated 
carageenans, in preventing HIV infection and in blocking chlamydia infection in vitro and 
in vivo (Blakemore et al., 2008). 
 
2.7.1.1 A carageenan vaginal gel formulation for HIV and HPV inhibition 
Carraguard™ (The Population Council Co., New York, USA) is a gel-like delivery system 
obtained from lambda and kappa carageenan that acts as an absorption inhibitor by 
coating the vagina. This may prevent HIV from entering the vaginal epithelium (Forbes 
and Harrison, 2000) (Table 2.3). The system forms a three-dimensional polymeric matrix 
with a high degree of physicochemical reticulation. Long, disordered chains are 
connected at specific points, but the connections are reversible. The molecular 
mechanisms of gelation are poorly understood, but researchers are attempting to design 
and enhance molecules with these properties. Carraguard™ has several advantages over 
other vaginal microbicide delivery systems such as a higher bioavailability, safety, 
versatility, and economic saving (Justin-Temu et al., 2004). There appears to be no effect 
on sperm motility (Coetzee et al., 2006; Fernandez-Romero et al., 2007). Furthermore, 
carageenan has shown the potential of being a potent inhibitor of sexually transmitted 
external genital warts. Certain sexually transmitted HPV types are causally associated 
with the development of cervical cancer (Perotti, et al., 2003; Smit, 2004; Buck et al., 
2006). Recent development of high-titer HPV pseudoviruses has made it possible to 
perform high-throughput in vitro screening to identify HPV infection inhibitors. Comparison 
of a variety of compounds has revealed that carageenan is an extremely potent infection 
inhibitor for a broad range of sexually transmitted HPVs and it acts primarily by preventing 
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the binding of HPV virions to cells (Buck et al., 2006). Clinical trials revealed that 
carageenan-based intravaginal microbicide delivery systems are effective against genital 
warts (Hartmann et al., 2006). However, phase 3 clinical trials did not show that 
Carraguard™ is effective in preventing HIV transmission during vaginal sex (Population 
council, 2009).  
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Table 2.3: Chemical structures of polymeric microbicide compounds 
Compound          Structure        Key Function                       Reference   
  
 Kappa 
Carageenan     
      Absorption inhibitor    (Forbes and Harrison, 2000) 
                                                                                                                            
                                                                       
 
 
 
   
 
Carbomer                                                                              Interruption of HIV      (D’Cruz and Uckun, 2004) 
              cell binding 
                               
                           
 
 
 
 
Cellulose  
Acetate                                                               Inactivates HIV and HSV      (Manson et al., 2000) 
Phthalate                                                                                                       
 
 
 
 
    
  
CapricAcid                                                                                Inactivates HIV and HSV             (Neyts et al., 2000) 
                                            
                                     
 
 
 
 
 
 
Polystyrene 
 Sulfonate Activity against HIV         (Simoes et al., 2002) 
                                        and HSV    
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2.7.1.2 A combinatory gel formulation of carageenan and a non-nucleoside reverse 
transcriptase inhibitor 
PC-815 gel is an intravaginal delivery system combining a microbicide containing 
carageenan with MIV-150. MIV-150 is a Non-Nucleoside Reverse Transcriptase Inhibitor 
(NNRTI) which binds to reverse transcriptase enzymes that in turn prevents HIV-infected 
cells from replicating. The safety and activity of carageenan against STIs has already 
been proven (Finley et al., 2006; Fernandez-Romero et al., 2007). Pre-clinical tests of 
MIV-150 have shown a significant increase in activity against HIV-1 primary isolates. 
Extensive pharmacological and toxicological profiles of MIV-150 have shown that the 
compound is non-toxic in vitro and in vivo (Fernandez-Romero et al., 2007). However, it 
has a low oral bioavailability which makes it an ideal compound for intravaginal delivery, 
since the chances of causing systemic side-effects become diminished (Fernandez-
Romero et al., 2007). In vitro pharmacological studies have indicated that the PC-815 
delivery system has significantly higher activity against HIV than that of the Carraguard™ 
system (Fernandez-Romero et al., 2007). MIV-150 and carageenan have different 
mechanisms of action, which when combined, have a synergistic effect. The anti-HIV 
activity of MIV-150 is not affected by the presence of seminal fluid or vaginal secretions 
and the activity of carageenan is not affected by the addition of MIV-150 to the 
formulation. 
 
2.7.1.3 A topical non-contraceptive carageenan gel formulation  
PC-515 gel is a topical gel formulation containing 3%w/w carageenan, benzyl alcohol as a 
preservative, and hydrochloric acid as pH adjuster. It is under development as a non-
contraceptive microbicidal delivery system that may offer disease protection while 
allowing women to conceive. Zacharopoulos and Phillips (1997) measured the protective 
properties of PC-515 in the vagina of mice inoculated with Herpes Simplex Virus (HSV), a 
standard model used to test microbicidal formulations. It was shown that PC-515 
protected against HSV, with an effect superior to many other microbicidal delivery 
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systems. Even at 100 times the lethal dose of HSV, 40% of mice were protected from 
infection. The protective effect was seen across a wide range of pH levels and lasted up 
to 18 hours (Zacharopoulos and Phillips, 1997). PC-515 has undergone developmental 
trials in humans to ascertain the overall performance of the formulation (Maria-Elisa et al., 
2003; Hart and Evans-Strickfaden, 2007; Ramjee, 2007).  
 
 2.7.2 A polyacrylic acid-based gel formulation  
A PAA polymeric gel (BufferGel™, ReProtect, LLC, Baltimore, MD, USA), was subjected 
to Phase II clinical trials as an intravaginal spermicidal delivery system for contraception 
and prevention of HIV in 2006 (Malcolm et al., 2006). Its principal mechanism of action 
involves maintaining the natural acidity of the vagina, even in the presence of semen, by 
buffering the vagina to a pH of less than 5 due to the presence of PAA which ensures the 
survival of lactobacilli (Boskey et al., 2000). Ideally vaginal delivery systems should not be 
detrimental to lactobacilli because they are responsible for producing lactic acid and 
hydrogen peroxide which inactivate many pathogens that cause STIs (Boskey et al., 
2000; Quayle, 2002; Lohr, 2007). The pH of a healthy human vagina ranges from 4-5 
(~pH 4.5), an environment too acidic for STI pathogens and HIV to survive (Forbes and 
Harrison 2000). However, semen is alkaline and therefore during intercourse the vaginal 
pH increases, allowing the survival of STI pathogens and HIV (Forbes and Harrison 
2000). The BufferGel™ system acidifies semen, thereby destroying sperm cells, HIV and 
a wide range of STI pathogens and keeps the vagina acidic even during sexual 
intercourse and thus creates a physical barrier that inhibits the passage of pathogens into 
the vaginal and cervical epithelium (Forbes and Harrison, 2000; Boskey et al., 2000 and 
2001; van de Wijgert, 2001; D’Cruz and Uckun, 2004). A similar system includes 
Acidform™ gel (CONRAD/CDC, Atlanta, Georgia, USA), an acid buffer anti-HIV vaginal 
gel formulation which is currently under Phase III clinical trials (Amarl et al., 2004; 
O'Brien, 2006; Mumper et al., 2009). However, recent clinical trials have revealed that 
BufferGel™ has no effect on HIV prevention (PENN Medicine News, 2009). 
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2.7.3 A Lactobacillus crispatus soft-gel capsule formulation   
A Lactobacillus crispatus (LC) microbicidal agent (Lactin Vaginal Capsules™, Gynelogix, 
Louisville, CO, USA) which acts by re-colonizing the vagina with hydrogen peroxide 
producing lactobacillus once released from the soft-gel capsule has been developed 
(Harrison et al., 2003). LC (Figure 2.2) is a normal commensal bacteria found in healthy 
vaginas (a sister species of lactobaccilli is found in yoghurt). LC assists in keeping the 
vagina free from infection by producing hydrogen peroxide, a substance that is weakly 
acidic. Normally, upon disturbing the ecology of the vagina either through infection, 
douching, or poor hygiene is when the vaginal pH rises above 4.5. This leads to the loss 
of lactobacilli resulting in the overgrowth of other bacteria and the proliferation of bacterial 
vaginosis which is a significant risk for pre-term labor, amnionitis, PID and HIV acquisition 
(Paavonen, 1983; Boskey et al., 2000; Forbes and Harrison, 2000). 
Maggi and co-workes (2000) conducted a study on ten strains of lactobacilli by evaluating 
their viability in restoring the normal indigenous flora for the treatment of urogenital tract 
infections (UTI) in women. The microorganisms were formulated in single- and double-
layer vaginal tablets. Each layer was characterized by different release properties. The 
first one was an effervescent composition that ensured a rapid and complete distribution 
of the active ingredient over the whole vaginal surface while the second one was a 
sustained release composition capable of releasing the lactobacilli over a longer period of 
time (Maggi et al., 2000). Three different retarding polymers were tested and all 
formulations were evaluated in terms of technological processability, bacterial viability and 
stability, and cell adhesion properties of the microorganisms. The results indicated that 
three out of ten strains appeared to be suitable for the application in the treatment of UTI. 
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Figure 2.2: Microscopic images of gram-stained vaginal smears depicting different 
categories of vaginal microflora. a) and b), grade 1a Lactobacillus crispatus cell types; c) 
and d), grade 1b non-L. crispatus cell types; e) and f), grade 1ab mixtures of L. crispatus 
and non-L. crispatus cell types; g) and h), grade 1-like Gram positive rods; i) and j), grade 
2 mixture of Lactobacillus cell types and bacterial vaginosis-associated bacteria cell 
types; k) and l), grade 3 bacterial vaginosis. (Source: Verhelst et al., 2005). 
 
 
2.7.4 Thermosensitive gel formulations  
Thermosensitive gels are systems that alter their physical characteristics with exposure to 
environmental changes within the vagina. This may be advantageous for intravaginal drug 
delivery due to the dynamic changes continually occurring in the vagina. These systems 
are capable of gelling in response to temperature changes, generally from ambient 
temperature to body temperature. Usually, the gelation temperatures have been 
considered suitable if they are in the range of 25–37ºC (Chang et al., 2002).  The thermo-
gelation mechanisms include partial crystallization, coil-to-helix transition, hydrophobic 
association, and micelle packing, which serve as reversible physical crosslinking points to 
form a gel (Jeong et al., 2002). The thermo-reversible properties of gels such as 
carageenan can be evaluated by rheological parameters such as the shear stress 
changes upon shear rates, sol–gel transition temperature, and viscoelasticity moduli 
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(Chang et al., 2002).  Commonly used thermosensitive polymers employed for 
intravaginal microbicide delivery include the polysaccharides, N-isopropylacrilamide 
copolymers, poloxamers and its copolymers, poly (ethylene oxide)/poly(D,L-lactic acid-co-
glycolic acid), and a few liposome-based systems. Poloxamer hydrogels perhaps 
represent the most extensively studied thermosensitive polymeric systems, while 
polysaccharides usually demonstrate good biocompatibility and/or biodegradability, with 
their solutions being thermosensitive at low polymeric concentrations (Ruel-Gariepy and 
Leroux, 2004). Chang and co-workers (2002) managed to produce thermosensitive 
vaginal gels containing clotrimazole. Results indicated that the gels were good potential 
candidates for safe, convenient, and effective intravaginal treatment. These gels, which 
also presented bioadhesive behavior, were prepared with mixtures of poloxamers and 
polycarbophil (Chang et al., 2002). 
 
2.7.5 Long-chain sulfated polysaccharides and sulfonated polymeric formulations 
A microbicidal delivery system that is a byproduct of non-cytotoxic poly(sodium 4-styrene 
sulfonate) (T-PSS) and cellulose sulfate (Ushercell™, Polydex Pharmaceuticals, Toronto, 
Canada) have reached Phase I and III clinical trials respectively (Bourne et al., 2003; 
Rohan and Sassi, 2009). UshercellTM is a long-chain sulfated polysaccharide ( 1,900 kDa) 
and T-PSS is a long-chain sulfonated polymer (Table 2.3). Both have broad-spectrum 
antimicrobial activity and act as adsorption inhibitors when released (Simoes et al., 2002).  
They are known to inhibit multiplication or activity of HIV, HPV, HSV-1, HSV-2, Chlamydia 
trachomatis, and Neisseria gonorrhea in vitro (Anderson et al., 2000; Herold et al., 2000; 
Christensen et al., 2001; Anderson et al., 2002; Simoes et al., 2002; Zanevelde et al., 
2002). T-PSS gel formulations have shown promising in vivo activity as topical 
microbicidal delivery systems. Gel formulations tested contained 5–10%w/w T-PSS, 
hydroxyethylcellulose, glycerine, propylene glycol, benzoic acid, methylparaben, and 
sodium hydroxide (Bourne et al., 1999). These systems do not inhibit Lactobacilli and 
have been proven safe in a variety of animal studies (Anderson et al., 2000; Anderson et 
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al., 2002; Zanevelde et al., 2002). As a result, the US FDA approved an Investigational 
New Drug (IND) application for both products. However, recently the Contraceptive 
Research and Development Program (CONRAD) reported that from interim data, from a 
trial where more than 1300 women in South Africa, Benin, Uganda and India that received 
UshercellTM, showed a greater prevalence of HIV infection compared to those who 
received the placebo gel (Highleyman, 2007; Thom, 2007). The Independent Data 
Monitoring Committee (IDMC, Rockville, MA, USA) overseeing this trial has agreed to 
conduct a detailed review of the data so as to better understand the findings and help 
determine their implications. Thus, these clinical trials have been halted pending the 
outcome of these investigations.   
 
Other, novel synthetic sulfated polymers, namely, sulfated polyvinyl alcohol (PVAS) and 
sulfated copolymers of acrylic acid with vinyl alcohol (PAVAS) have proved to be potent 
and selective inhibitors of HIV-1 and HIV-2 in vitro (Baba et al., 1990; Balzarini and van 
Damme, 2007). These polymers have been found to completely inhibit HIV-1-induced 
cytopathogenicity and HIV-1 antigen expression at a concentration of 0.8μg/mL and 
equally effective against HIV-2 replication (Baba et al., 1990). As is the case with other 
sulfated polysaccharide formulations, the mechanism of action of PAVAS and PVAS 
resides in the inhibition of virus entry into vaginal epithelial cells once released from the 
delivery system (Baba et al., 1990; De Clercq, 2004). 
 
2.7.6 A carbomer, lactic acid and naphthalene sulfonate gel formulation 
A water-based gel comprising a synthetic carbomer, a lactic-acid/lactate buffer system 
(pH 4.5) (Table 2.3), common preservatives and naphthalene sulfonate as an antiviral 
agent (PRO 2000™ Gel, Indevus Pharmaceuticals, Inc. Lexington, MA, USA) is an 
intravaginal microbicide delivery system currently under development for the prevention of 
STIs and HIV (Morrow et al., 2003; Dhawan and Mayer, 2006; Joshi et al., 2006). The gel 
is clear, with a slight yellow tint and has a viscosity twice that of KY® Jelly (Johnson and 
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Johnson, New Brunswick, NJ, USA). The mechanism of action of the microbicide 
released from the PRO 2000TM Gel formulation is by binding to the HIV virus, thereby 
disrupting any interaction of the virus with target cells. Similarly it is able to prevent 
chlamydia and HSV-2 infections (Forbes and Harrison, 2000). Results from in vivo animal 
studies have shown that PRO 2000™ Gel is safe and well tolerated (Ruscnis et al., 1996; 
Bourne et al., 1999; van Damme et al., 2000; Morrow et al., 2003; Smita et al., 2006). 
Currently it is under Phase III clinical trials where it has displayed promising results in low-
risk women (Mayer et al., 2003 and Smita et al., 2006; MTN microbicide trials network, 
2009). A recent clinical trial that involved more than 3,000 women in Southern Africa and 
USA has demonstrated for the first time the potential of PRO 2000™ gel for preventing 
HIV infection in women. According to the findings, PRO 2000™ Gel was found to be 30% 
effective (MTN microbicide trials network, 2009). However, additional evidence is required 
to thoroughly ensure the effectiveness of PRO 2000™ Gel. PRO 2000™ Gel is also 
compatible with the use of condoms, and therefore its further development may even 
prove to provide more benefits for women worldwide (Cadena, 2006).  
 
2.7.7 A micronized cellulose acetate phthalate gel formulation  
Cellulose Acetate Phthalate (CAP) has been used for several decades in the 
pharmaceutical industry for enteric coating of oral tablets and capsules (Table 2.3). 
Micronized CAP, is available commercially as an aquateric system, and contains 
excipients required for micronization and tablet coating. It has shown to adsorb and 
inactivate HIV-1, HSV and other STIs (Manson et al., 2000). Studies have indicated that a 
gel formulation of micronized CAP has the potential to be used for topical intravaginal 
delivery of microbicides for prevention of STIs and HIV (Neurath et al., 2003; Fichora et 
al., 2005). It is converted into a gel and therefore does not have to be removed following 
its application (Neurath et al., 2003). CAP is one of the potential anti-HIV vaginal gel 
formulations that are under Phase II clinical trials (Neurath et al., 2003; Fichora et al., 
2005). 
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2.7.8 A monocaprin-loaded hydrogel formulation  
Hydrogel formulations containing a 1-monoglyceride of capric acid (monocaprin) possess 
potent in vitro microbicidal activity against HIV, HSV, Chlamydia trachomatis and 
Neisseria gonorrhea (Thormar et al., 1999; Neyts et al., 2000) (Table 2.3). In vitro studies 
have shown that gels containing monocaprin, formulated using gel-forming agents such 
as either sodium carboxymethylcellulose and polyvinylpyrrolidone (pH 7.0) or carbomer 
and hydroxypropylmethylcellulose (pH 5.0), are highly virucidal to HSV-1 and less 
cytotoxic than nonoxynol-9 (Kristmundsdottir et al., 2000). In addition, the gels had 
spermicidal properties, and thus they may have potential contraceptive activity (Thormar 
et al., 1999). In vivo studies in mice showed that these gels were non-irritant and non-
toxic in the vagina (Neyts et al., 2000). The results from these studies also indicated that 
20mM monocaprin hydrogel could prevent HSV-2 infection and mortality in mice (Neyts et 
al., 2000). Hydrogel formulations of monocaprin could be further pursued in the 
development of intravaginal microbicide delivery systems for the prevention of STIs and 
HIV. 
 
2.7.9 Polystyrene sulfonate vaginal tablets 
Polystyrene Sulfonate (PSS) is also a microbicide that has been developed as an 
intravaginal tablet formulation (Garg et al., 2004a; Romano et al., 2008) (Table 2.3). 
When PSS intravaginal tablets were used as a microbicide delivery system they showed 
that they provided superior antimicrobial activity against HIV and HSV (Garg et al., 
2004a). This formulation did not immobilize sperm, was not cytotoxic and did not inhibit 
normal vaginal microflora. This demonstrates its potential as a safe and effective vaginal 
microbicide delivery system for the prevention STIs and HIV (Garg et al., 2004a; Romano 
et al., 2008). 
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2.8 Non-polymeric Intravaginal Microbicide Delivery Systems for Preventing the 
Transmission of STIs and HIV  
2.8.1 A cetyl betaine and myristamine oxide combinatory cream formulation 
C31G cream (Savvy™, Cellegy Pharmaceuticals, Inc, San Francisco, CA, USA) 
comprises a broad-spectrum antimicrobial and spermicidal agent with two surface-active 
compounds, cetyl betaine (a C16 alkyl betaine) and myristamine oxide (a C14 alkyl amino 
oxide) (Table 2.4). The formulation is an equimolar mixture of the two amphoteric, 
surface-active compounds and displays activity against gram-positive and gram-negative 
bacteria, fungi, yeasts, and enveloped viruses (Krebs et al., 2000). Savvy™ has shown 
activity against numerous micro-organisms that cause STIs, including chlamydia, HSV-1, 
HSV-2 and gonorrhea. These effects occur once the microbicidal agent diffuses through 
the cream, which is formulated with HEC and also acts as a surface-active microbicide. In 
Phase III clinical trials, the delivery system has shown the ability to prevent HIV-1 and 
HIV-2 transmission and also has a desirable contraceptive activity (van Damme et al., 
2002). Other studies have shown that Savvy™, when used alone, may also be 
approximately 85% effective in the prevention of pregnancy (van Damme et al., 2002; 
Dhawan and Mayer, 2006).  
 
2.8.2 A non-nucleoside reverse transcriptase inhibitor-loaded gel formulation 
UC781 (Cellegy Pharmaceuticals, Inc South San Fransisco, CA, USA) is a tight-binding 
Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) that is incorporated into gel 
formulations (Table 2.4). It has significant potential for use as an anti-HIV microbicide. 
Short pre-treatment of both isolated cells and human cervical tissue explants, with low 
concentrations of UC781 provided a strong barrier to subsequent virus infection by cell-
free or cell-associated HIV-1 (Gadi and Parniak, 2001; Kerr, 2007). UC781 is readily 
formulated as an appropriate carrier for vaginal application in the form of Replens® Gel 
(Anglian Pharma, Hertfordshire, UK). Furthemore, UC781 has shown to have a favorable 
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toxicity profile (Gadi and Parniak, 2001). UC781 warrants further clinical assessment for 
its use as a topical intravaginal delivery system for the prevention of STIs and HIV. 
 
Table 2.4: Structures of non-polymeric microbicide compounds 
Compound  Structure       Key Function                            Reference          
 
Cetyl Betaine                                  Broad-spectrum antimicrobial  
                          (Krebs et al., 2000) 
 
 
 
 
 
 
 
 
Myristamine                             Spermicidal agent                              
                         (Krebs et al., 2000) 
 
 
 
 
 
UC781                                Tight binding NNRTI   
                             (Kerr, 2007) 
 
 
 
 
 
 
Tenofovir Blocks HIV replication                         
                         (De Clercq, 2006) 
 
 
 
 
 
Stampidine      Broad-spectrum anti-HIV agent           
                             (D’Cruz, 2003a)  
 
 
 
 
 
Dapirivine                    Potent NNRTI  
                Malcolm and Woolfson, (2006) 
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2.8.3 A nucleotide analogue-loaded gel formulation 
PMPA Gel (Tenofovir™, Gilead Sciences, Foster City, CA, USA) is a microbicide delivery 
system that blocks HIV from replicating once it has entered cells (De Clercq, 2006). The 
hope is that Tenofovir™ could be absorbed by the vaginal epithelium to prohibit the 
replication and penetration of the virus in the outer cells of the vaginal wall (Table 2.4). 
Numerous ARVs initially explored for potential AIDS therapy were later abandoned due to 
inadequate delivery systems that provided poor systemic absorption. These may be 
suitable for re-formulation into newer effective intravaginal microbicide delivery systems 
(Forbes and Harrison, 2000). Preliminary results from studies of Tenofovir™ are 
encouraging and indicate that it may be a new microbicide delivery system to consider as 
part of a potent anti-HIV regimen. Tenofovir™ may require less frequent dosing than 
currently available therapies (only once daily) and appears to be active against resistant 
strains of HIV, including protease resistance (Forbes and Harrison, 2000). 
 
2.8.4 A novel synthetically derived aryl phosphate-loaded gel formulation  
Stampidine is a novel aryl phosphate derivative of stavudine (Table 2.4). It is a potent, 
broad-spectrum anti-HIV agent with potential to be used as a newer class of non-
spermicidal microbicides (D’Cruz, 2003a). A vaginal gel formulation of stampidine was 
tested for its potential to cause vaginal mucosal toxicity in New Zealand white pigs 
(D’Cruz, 2003a; D’Cruz et al., 2003a). Application of 0.5-2.0%w/w of this formulation, 
produced only minimal-to-mild vaginal irritation, of which is in an acceptable range for a 
clinical trial (total score <4 out of a possible 16). Repeated intravaginal treatment with 
stampidine gel was shown to cause no inflammation or hyperplasia in the vaginal 
epithelium and sub-epithelial tissue (D’Cruz et al., 2003a). Stampidine and its major 
metabolites were not detectable in the plasma of pigs after they received a 2%w/w 
stampidine-containing gel intravaginally. Thus, this finding coupled with the favorable 
toxicity profile of intravaginally administered stampidine-containing gel may provide the 
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foundation for its clinical development as a safe and effective broad-spectrum anti-HIV 
microbicide delivery system.  
 
2.8.5 A cyanovirin-N gel formulation for chemotherapeutic and immunoprophylactic 
prevention of HIV   
Cyanovirin-N (CV-N) is a novel protein, originally isolated from cultures of the 
cyanobacterium (blue-green algae) called Nostoc ellipsosporum that has generated 
interest as a natural product for the chemotherapy of HIV infection (Boyd et al., 1997; De 
Clercq, 2000). A possible combined chemotherapeutic and immunoprophylactic approach 
for preventing HIV may be based upon the concept that continuous exposure of HIV to 
gp120-binding agents from a gel formulation may diminish glycosylation sites, thus 
triggering the production of specific neutralizing antibodies to previously hidden gp120 
epitopes (Boyd et al., 1997; De Clercq, 2000). Both natural and recombinant CV-N are 
highly potent as virucidal agents (Boyd et al., 1997; De Clercq, 2000; Tsai et al., 2003; 
Balzarini, 2005; Xiaowen et al., 2006). CV-N inhibits the in vitro fusion of HIV-infected and 
non-infected cells as well as cell-to-cell transmission of HIV-1 infection. These effects 
make CV-N a promising candidate as a microbicide gel formulation for intravaginal 
delivery (Boyd et al., 1997; O’ Keefe, 2001). In cell cultures it is non-toxic, it is remarkably 
resistant to physical degradation and it is water-soluble and stable in solution with a shelf 
life of at least 6 months (Boyd et al., 1997).  
 
2.8.6 Sodium lauryl sulfate as an Invisible CondomTM gel-like formulation 
Sodium lauryl sulfate (SLS) which is an anionic surfactant that denatures membrane 
proteins of pathogens is currently under Phase II clinical trials and is classed as an entry 
fusion inhibitor (Malcolm et al., 2006). It is also called an Invisible CondomTM (Invisible 
CondomTM, Laval University, Infectious Diseases Research Center, Quebec City, QC, 
Canada). Ward and Ashley (1979) were the first to demonstrate that SLS at low 
concentrations is a potent inactivator of rotavirus and poliovirus. Previous in vitro studies 
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have demonstrated the ability of SLS to inhibit the infective capacity of different enveloped 
viruses such as HSV-1, HSV-2 and HIV-1 (Roy et al., 1999; Piret et al., 2000). SLS has 
also been reported to inhibit the infective capacity of non-enveloped bovine HIV and HPV 
(Howett et al., 1999). This suggested that SLS could be a candidate for use as an 
intravaginal microbicide gel formulation to prevent the sexual transmission of STIs and 
HIV. As previously mentioned, thermosensitive gels are recognized to allow 
advantageous application of active substances in the vagina. A thermoreversible gel 
composed of polyoxypropylene and polyoxyethylene in citrate buffer (pH 4.0) presents a 
phase transition temperature of 28ºC. This showed to be an ideal vehicle to deliver 
microbicidal substances, such as SLS or n-lauroylsarcosine, when applied in a murine 
model of HSV-2 (Roy et al., 1999). 
 
2.8.7 Dapivirine anti-HIV vaginal rings 
As mentioned earlier vaginal rings are suitable for the delivery of microbicides to prevent 
the transmission of STIs and HIV (Malcolm and Woolfson, 2006). While most research on 
microbicides has focused on single-dose and semi-solid topical gels, ring-based delivery 
systems could reduce the burden of patient compliance. These can provide long-term, 
controlled release of microbicides that may confer continuous protection against STIs and 
heterosexually transmitted HIV, and rule out the need for application of the intravaginal 
microbicide delivery system near the moment of sexual intercourse (Smith, 2006; 
Woolfson et al., 2006). Dapivirine, which is also known as TMC120, is a potent non-
nucleoside reverse transcriptase inhibitor and is the only vaginal ring system used as an 
intravaginal microbicide delivery system for preventing the transmission of STIs and HIV 
(Malcolm and Woolfson, 2006; Smith, 2006; Nutall et al., 2007) (Table 2.4). 
 
2.8.8 Polyherbal anti-HIV praneem-loaded vaginal tablets 
Praneem has been developed as an anti-HIV vaginal tablet formulation. Praneem 
contains purified extracts of Azadirachta indica also known as the Neem tree. Praneem 
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has preventative activity against STIs in vitro and therefore it has been developed as a 
possible intravaginal microbicide delivery system. Phase I safety studies on Praneem 
tablets, revealed that the formulation is safe for once daily intravaginal use, for 14 
consecutive days, in sexually active uninfected women (Joshi et al., 2005).  
 
2.9 Nanotechnology-based Intravaginal Microbicide Delivery Systems 
2.9.1 A Dendrimer-based microbicide formulation 
SPL7013 (VivaGel™, Starpharma Ltd., Melbourne, Victoria, Australia) is a dendrimer with 
a polyanionic outer surface that allows multiple interactions with target sites. It is the most 
advanced dendrimer-based microbicide delivery system in which the dendrimer is not a 
carrier but an active ingredient (Short, 2007). These substances are large highly branched 
macromolecules synthesized from a polyfunctional core (Bourne et al., 1999). SPL7013 
emerged as the most promising dendrimer after pre-clinical studies, and which was 
formulated as a gel that has been undergoing clinical trials (Jiang, et al., 2005; Nikolic et 
al., 2007). Bernstein and co-workers (2003) showed that a 5%w/w Carbopol® 974 Gel (pH 
4.5) can also be a suitable vehicle for the intravaginal administration of SPL7013. 
SPL7013 binds and blocks HIV-1, and chimeric simian/HIV-1 (SHIV) replication, thereby 
preventing STIs, including HIV and genital herpes (Okada, 1991; Highleyman, 2007; 
Short, 2007).  It works by making use of its branched structure to bind viral surface 
proteins thereby preventing attachment of the virus to human cells.  Gels containing 
different concentrations of SPL7013 were formerly used as intravaginal topical 
microbicide systems in female pigtailed macaques to study their ability to prevent vaginal 
transmission of SHIV. All untreated macaques (8/8) and seven (out of eight) macaques 
treated with a placebo gel formulation were infected with SHIV within 2 weeks after 
exposure. They showed a low plasma viremia and dramatic CD4+ cell decline within 4 
weeks (Short, 2007). Extrapolation from these results suggests that VivaGel™ may be a 
promising anti-HIV microbicide formulation. Phase I trials have shown that VivaGel™ is 
safe and well-tolerated (Rupp et al., 2007; Short, 2007; Fairley, 2009a). Further trials are 
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being conducted to test its efficacy against genital herpes and HIV (Highleyman, 2007; 
Short, 2007; Fairley, 2009b). 
 
2.9.2 Silver nanoparticles employed as microbicide delivery systems 
Various studies are currently investigating the production of a novel class of 
nanomaterials called protein-conjugated noble metal nanoparticles (Cho et al., 2005; 
Yacaman et al., 2006; Pal et al., 2007). The production involves direct conjugation of 
noble-metal nanoparticles with proteins that may be used in numerous forms including 
antiviral and antibacterial delivery systems. The process includes one or more targeting 
molecules (e.g. cytokines) that bind specifically to target cells expressing the cognate 
receptor for the cytokine. Researchers initially developed a method for synthesizing 
water-soluble noble metal nanoparticles, grown within and directly functionalized by 
bovine serum albumin (BSA), a globular protein, without the use of additional protecting or 
linking agents. Both gold and silver nanoparticles have been produced using this method, 
and the approach can easily be extended to other noble metals, such as the platinum 
group (Yacaman et al., 2006). Other globular proteins such as human serum albumin 
(HSA) may also be substituted for BSA and include, immunoglobulins, cytokines, 
receptors, lectins, glycoproteins, lipoproteins, toxins, toxoids, collagen, bacterial proteins, 
viral proteins, parasitic proteins, and fusion proteins (Richardson and Illum, 1992). The 
method of synthesis includes chemical reduction of an ionic metal precursor at room 
temperature in aqueous solution in the presence of a globular protein. Under certain pH 
conditions, disulfide bonds of the protein are available for direct bonding with the noble 
metal nanoparticles. The polypeptide backbone of the protein remains intact and the 
method does not affect the functional groups of the constituent amino acid residues. 
Silver nanoparticles take advantage of the microbicide properties of silver with different 
materials to produce effective microbicide delivery systems for preventing STIs and HIV 
transmission (Cho et al., 2005; Barbara et al., 2006; Yacaman et al., 2006). 
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2.9.3 Polystyrene nanospheres as microbicide delivery systems  
Mucosal secretory IgA may have an important role in the prevention of HIV-1 transmission 
during sexual intercourse. Therefore, substances that induce HIV-1-specific IgA 
antibodies in the genital tract have shown promise for use as prophylactic vaccines 
against HIV-1 infection. It has been reported that Concanavalin A-immobilized 
Polystyrene Nanospheres (Con A-NS) could efficiently capture HIV-1 particles and gp120 
antigens on their surface and that intravaginal immunization with these inactivated HIV-1-
capturing nanospheres (HIV-NS) induce vaginal anti-HIV-1 IgA antibodies in mice (Agaki 
et al., 2003). Thus, application of HIV-NS by intravaginal delivery is a practical approach 
to promote HIV-1-specific IgA responses as an effective immunization strategy. Likewise, 
lectin-immobilized polystyrene nanospheres have been synthesized and examined for 
their HIV-1 capturing abilities (Hayakawa et al., 1998). When Con-A is immobilized on the 
surface of polystyrene nanospheres (400nm in diameter) with polymethacrylic acid 
branches and incubated with HIV-1 suspensions at room temperature for 60min, the Con 
A-NS achieves greater reduction in viral infectivity of HIV-1 (IIIB strain) than does Con A-
free nanospheres (Hayakawa et al., 1998). The combination of Con A-NS treatment 
followed by in vitro filtration with a microporous membrane efficiently removes virion-free 
gp120 as well as infectious viral particles from HIV-1 suspensions. Electron microscopic 
examination has demonstrated that HIV-1 virions may be entrapped on the surface of Con 
A-NS (Hayakawa et al., 1998; Carmen and Angel, 2003). Thus, Con A-NS is able to 
capture HIV-1 virions and gp120 with a high affinity, and may potentially be an effective 
nanotechnology-based delivery system for the prevention of HIV-1 transmission 
(Hayakawa et al., 1998; Carmen and Angel, 2003). 
 
2.9.4 A gel-like molecular condom formulation as a barrier for STIs and HIV 
transmission 
The molecular condom is a recently developed anti-HIV vaginal gel (Kiser, 2006a and b). 
It is a polymeric construct designed, to incorporate controlled release characteristics, to 
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allow for enhanced tissue coating, to reduce viral transport and to allow for triggered 
release of anti-HIV bioactives by interacting with semen. The term “molecular condom” 
arises from the concept that the polymer construct is liquid at room temperature and, 
when applied intravaginally, spreads and converts to a gel that effectively coats the 
vaginal wall (Kiser, 2006a and b). The gel is designed to release the anti-HIV bioactives 
upon contact with semen during sexual intercourse. It is an aqueous-based gel or 
"hydrogel" sensitive to body temperature and pH, and serves as a "smart semen-triggered 
vaginal microbicide delivery vehicle." This system is nanotechnology-based and explores 
the use of bioresponsive drug delivery by tailoring the physiological and mechanical 
requirements essential for intravaginal application. This is a type of a prophylactic agent 
that women may use without relying on their partners. It is of particular interest in areas 
such as Sub-Saharan Africa and South Asia where HIV-infection rates are substantially 
high while use of condoms is not well accepted. It is believed that the bio-distribution and 
bioavailability of antiviral bioactives can be modulated to increase potency and allow for 
burst release of free HIV inhibitors at the initial onslaught of viral exposure. Thus far, in 
vitro studies have demonstrated that the substance converts from liquid to gel at body 
temperature and a vaginal pH of 4-5 and then reverts to liquid and releases bioactives, 
such as microbicides, when exposed to semen, with a pH of 7.5 (Kiser, 2006a and  b). 
The ultimate hope for this technology is to protect women and their unborn or nursing 
children from HIV. It is estimated that if all goes well, clinical trials in humans will start in 
three to five years, and the gel is expected to reach the market in several more years 
(Kiser, 2006a and b). The future plan is to incorporate an ARV into the gel so that it can 
cater both for blocking HIV movement and preventing the virus from replicating. 
 
2.10 Other Microbicidal Compounds Currently under Investigation 
2.10.1 A secretory leukocyte protease inhibitor  
Secretory leukocyte protease inhibitor (SLPI) is an endogenous antimicrobial agent found 
in mucosal tissue and saliva, most prominently in mucosal sites open to the external 
 62 
environment. Its original function is believed to be an anti-protease defense against 
neutrophils at the mucosal surfaces (Bob, 2000). In vitro laboratory studies have shown 
that SLPI can inhibit HIV entry into CD4+ cells by interacting with targeted cells and 
blocking access as a barrier function. This may provide a reason as to the low rate of HIV 
infection through oral sex (San Francisco AIDS Foundation, 2008) due to the presence of 
SLPI in saliva. Data from studies of various mucosal tissues such as the mouth, gut, 
rectum and endocervix, suggest an inverse relationship between infectious HIV and the 
presence of SLPI (Bob, 2000; Zuckerman et al., 2003; Campo et al., 2006; Odaka and 
Ding, 2009). In breast milk, levels of SLPI rise dramatically at birth and begin to drop two 
to three weeks later, to a point where they are not sufficient to inhibit HIV infections in 
infants (Bob, 2000; Cheshenko et al., 2004). Further studies of SLPI as "a natural 
endogenous product" need to be performed since it has been shown to have the potential 
to function as an effective microbicide (Bob, 2000; Cheshenko et al., 2004; Keller et al., 
2005).  
 
2.10.2 Thrombospondin-1 as a barrier to mucosal transmission of HIV-1 
During an investigation of the physiology of HIV inhibition by human saliva, laboratory 
studies identified thrombospondin-1 (TSP1) to have potential as a barrier agent against 
local mucosal transmission of HIV-1 (Crombie et al., 1998, 2000, 2001). TSP1 is a 
trimeric-sulfated glycoprotein that belongs to a family of five distinct extracellular matrix 
adhesion molecules (Bornstein, 1995; Adams, 1997; Crombie, 2000). Unlike other 
multifunctional extracellular matrix glycoproteins, TSP1 is found in lower concentrations in 
plasma and most body fluids (Mosher, 1990) (Figure 2.3) but not in saliva (Crombie et al., 
1998). Since TSP1 is a high molecular mass compound, difficult to purify, and labile in the 
presence of tissue proteases, it is an impractical candidate to be formulated as a localized 
intravaginal delivery system. Investigations have therefore focused on the activity of 
peptides prepared from different regions of this molecule for which the attention has been 
on type 1 properdin/malaria-like repeat sequence (Crombie et al., 1998, 2000, 2001). 
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Characterization of alternative TSP1 peptide modifications currently under design may 
identify conformations that are more potent and stable and thus better for localized 
intravaginal therapy (Crombie et al., 2001). 
 
2.10.3 Short interfering RNA as potential liposomal microbicide delivery systems 
Short interfering RNA (siRNA) is a type of microbicide based on RNA interference (RNAi), 
a natural selective process for turning off genes, which holds great potential in its ability to 
treat disease at the genetic level (Dykxhoorn and Lieberman, 2006; Palliser et al., 2006; 
Soifer et al., 2007). In contrast to other classes of therapeutics, such as proteins, 
antibodies and small molecules, RNAi do not require either "drugable" domains on the 
molecular target, or specific locations at the cell membrane nor an extracellular site for 
their effective action. RNAi is triggered by siRNA molecules that engage a group of 
cellular proteins, known as RNA-induced silencing complexes (RISC). RISC guides the 
siRNA to its target mRNA (messenger RNA) by complementary base pairing and splits it 
in a selective fashion, thus halting protein expression or viral replication (Roumeliotis, 
2006). Currently, in vitro vaginal tissue culture systems have been investigated and work 
continues with in vivo vaginal xenograft models to determine the optimum dose required 
for maximum down-regulation of virus replication. In vitro tests utilizing fluorescent tagged 
siRNA in liposomal delivery systems indicate that siRNAs are absorbed throughout the 
vaginal tissue (Cristofaro and Ramratnam, 2005; Holmes, 2007).  
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Figure 2.3: Schematic of the trimeric-sulphated glycoprotein Thrombospondin-1 with five 
distinct extracellular matrix adhesion molecules, (Adapted: Mosher, 1990). 
 
 
2.10.4 Thiophen-Thiourea: A non-nucleoside reverse transcriptase inhibitor 
PHI-443 (N′-[2-(2-thiophene) ethyl]-N′-[2-(5-bromopyridyl)] thiourea) is a rationally 
designed novel thiophene-thiourea NNRTI with potent activity against the wild-type and 
drug-resistant primary clinical HIV-1 isolates (D’cruz et al., 2004a; D’cruz and Uckun, 
2005c) (Table 2.5). Its potential as a non-spermicidal microbicide for preventing the 
sexual transmission of HIV has been examined by testing its effect on in vitro sperm 
function where it has shown to inactivate viruses in human cells. It completely prevents 
the vaginal transmission of a genotypically and phenotypically drug-resistant HIV-1 isolate 
in the humanized severe combined immunodeficient mouse model of sexually transmitted 
HIV (D’cruz et al., 2004a). Exposure of human sperm to PHI-443 at doses 30,000 times 
greater than those that yield effective concentrations against HIV has shown that PHI-443 
has no effects on sperm motility, kinematics, cervical mucus penetrability, or the viability 
of vaginal and cervical epithelial cells. Exposure of pig semen to PHI-443 either ex vivo or 
in vivo resulted in no side-effects on the in vivo fertilizing ability. Repeated intravaginal 
administration of 0.5– 2%w/w of PHI-443 as a gel has been found to be safe in pigs 
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(D’cruz et al., 2004a). Thus, PHI-443 has potential as a prophylactic broad-spectrum anti-
HIV microbicide without contraceptive activity. 
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Table 2.5: Chemical structures of other novel microbicide compounds 
Compound  Structure             Key Function                           Reference              
 
    
Thiophen- 
Thiourea            NNRTI  
                                        against drug resistant HIV             (D’Cruz et al., 2004a) 
                                                      
                                  
                                 
 
 
 
 
 
 
 
 
 
Monoclonal 
Antibodies                                                              Passive immunization           (Cairns, 2007) 
        
                            
 
 
 
 
 
 
 
 
  
Lime 
Juice                                                     Retards HIV transmission (Hemmerling et al., 2007) 
            
                                  
 
 
 
 
 
Yoghurt      
                                 Inhibits transmission of HIV (Turpin, 2006; Ramratnam, 2006) 
                                     
 
 
 
 
 
 
 
 
O
OH
OH
OH
OH
OH
n-1
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2.10.5 Monoclonal antibodies as microbicides 
Monoclonal antibodies are Y-shaped molecules synthesized by the immune system as 
‘mirror images’ of foreign substances (Cairns, 2007). A long-range goal in vaginal 
protection is to develop monoclonal human antibodies in a microbicidal gel for protecting 
genital skin and epithelia against infections by topical passive immunization. Mucus 
secretions contain large quantities of antibodies that are highly specific and potent agents 
for preventing the entry of pathogens (Workman, 2003) (Table 2.5). Secreted mucosal 
antibodies also help maintain healthy bacterial flora on mucosal surfaces. Mucosal 
antibodies are polyvalent and hence bind with high affinity to pathogens. Monoclonal 
synthetic antibodies against sperm, HIV, and other STI pathogens can be applied directly 
to genital skin and epithelia for protection (Cone and Whaley, 1994; Sherwood et al., 
1996). This may closely mimic the normal function of antibodies in the mucosal immune 
system, e.g. antibodies in breast milk help protect the surfaces of the mouth, nose, eyes, 
and digestive tract of the baby. To date, the results of studies performed indicate that 
monoclonal antibodies delivered to the vagina may help prevent pregnancy as well as 
sexual transmission of genital herpes and HIV (Castle et al., 1997; Zeitlin, et al., 1999; 
Castle 2002; Perotti et al., 2003; Whaley and Zeitlin, 2005). Topical application of these 
synthetic antibodies protects mice from HSV infection (Briggs and Zeitlin, 2000; Yim et al., 
2005; Pedras-Vasconcelos et al., 2006). The end objective is to develop a protective 
topical gel containing these synthetic antibodies for human use (Briggs and Zeitlin, 2000).  
 
2.10.6 Lime juice as a microbicide 
Lime juice has been known for long in history as a contraceptive and vaginal douche 
(Thaineua et al 2003; Clarke et al., 2006; Hemmerling et al., 2007) (Table 2.5). In vitro 
studies that were conducted by Potts and co-workers (2004) demonstrated that 
lemon/lime juice is an effective microbicide and in in vivo primate studies, repeated use of 
lime juice did not damage the vagina. Hemmerling and co-workers (2007) further 
conducted a study on lime juice that involved twenty five sexually abstinent women. Tests 
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for genital infections, measurement of inflammatory biomarkers and a colposcopy were 
conducted, before and after treatment. Results indicated that no participant showed 
severe vaginal irritation. The reported side effects were mostly singular, mild and transient 
events. Thus, lime juice up to 20% concentration proved to have an acceptable safety 
profile for vaginal use (Potts et al., 2004; Hemmerling et al., 2007). Recent in vitro 
research has shown that, for effective prevention of HIV transmission the concentration of 
lime juice should be at least 50% which is associated with some toxicity uncertainties 
(Hemmerling et al., 2007).  Therefore, there is an urgent need for a systematic study to 
determine the best ways of delivering lime juice effectively without any toxicity risks. If the 
use of lime juice can retard HIV transmission, then lime juice could prove to be a life- 
saving microbicide. If the effect is modest, lime juice might still prove to be a 'gold 
standard' microbicide with which artificial microbicides could be compared, short circuiting 
the need for time-consuming expensive placebo controlled trials (Potts et al., 2004). 
However, thorough research still needs to be conducted on the efficacy of lime juice as an 
inexpensive and ubiquitous intravaginal microbicide drug delivery system.  
 
2.10.7 Yoghurt as a microbicide 
It has been shown that yoghurt may soon be enlisted in the battle against HIV/AIDS 
(Turpin, 2006) (Table 2.5). Lactobacillus which is a harmless bacterium that helps to turn 
milk into yoghurt has been engineered to produce HIV-fighting microbicides (Turpin, 
2006). Consuming yoghurt containing Lactobacillus may provide a way for women to fend 
off HIV if no other means are available (Turpin, 2006). Apart from being present in 
yoghurt, lactobacillus is a natural inhabitant of the human vagina. It survives the passage 
through the gastrointestinal tract and can easily cross from the anus to the vagina and 
colonize there. Once in the vagina, the bioengineered bacteria can produce compounds 
that inhibit transmission of HIV and maintain a normal vaginal pH, thus helping prevent 
HIV and STIs infection (Turpin, 2006). Similarly, Ramratnam (2006) showed that it was 
possible to genetically manipulate bacteria present in yoghurt to release an anti-HIV drug. 
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This could successfully alter the genetic constitution of Lactobacillus lactis to enable it to 
release cyanovirin which has already been found to confer protection against HIV 
infection in monkeys and human cells. Although successful results (followed by clinical 
trials) are yet to be obtained, there is optimism that yoghurt may eventually pave a way for 
the development of cost-effective microbicide delivery systems (Ramratnam, 2006).   .  
 
2.11 Concluding Remarks 
Intravaginal microbicide delivery systems are providing a new option for preventing the 
transmission of STIs and HIV. This could have considerable public health and economic 
impact especially in resource-poor countries. As described in this Chapter, numerous safe 
and effective anti-HIV intravaginal microbicide delivery systems are currently being 
evaluated at various stages in clinical trials that include the dual-function polymeric 
compounds, non-polymeric compounds and nano-structured compounds. To date, none 
of the delivery systems described, which comprise mainly gel formulations, have been 
found to be fully effective at preventing the transmission of STIs and HIV. Several clinical 
trials have demonstrated that intravaginal microbicide delivery systems have the ability to 
protect against the transmission of STIs and HIV but numerous challenges still remain 
before these systems are used commercially. These challenges include: i) the need for 
the development of newer and innovative intravaginal microbicide delivery technologies 
that can completely prevent the transmission of STIs and HIV; ii) securing a cost-effective 
and efficient production and distribution of these compounds and systems; iii) securing 
wide access to these compounds and systems that takes into account cultural sensitivities 
of the most affected countries; and iv) securing extensive education in the use of the 
intravaginal microbicidal delivery system. It is thus anticipated that future research will 
focus on the design and development of more effective intravaginal microbicidal delivery 
systems for preventing the transmission of STIs and HIV employing a wide variety of 
dosage forms with multiple mechanisms of action and microbicidal delivery. 
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CHAPTER THREE 
 
P R E F OR MUL ATION INVE S TIG AT IONS  F OR  THE  DE VE L OP ME NT OF  L E AD 
INTR AV AG INAL  B IOADHE S IVE  P OL Y ME R IC  DE VIC E S  
 
3.1 Introduction 
Major efforts have been directed towards designing intravaginal drug delivery systems 
that can deliver drugs to the vagina at a desired rate to maximize drug efficacy while 
minimizing side effects (Garg and Tambwekar, 2003; das  Neves and Bahia, 2006; D'Cruz 
and Uckun, 2006a; Andrews et al., 2009). However, successful design of intravaginal 
drug delivery systems still poses numerous challenges (Justin-Temu et al., 2004; 
Ndesendo et al., 2008; Rohan and Sassi, 2009). It is imperative that the type and 
properties of the drug and the drug carrier (e.g. polymer) be thoroughly understood if 
successful intravaginal delivery is to be achieved. In the case of a polymer as the carrier 
agent, appropriate selection is of paramount importance. The polymer employed can be 
either degradable or non-degradable. Biodegradable polymers that are biocompatible to 
the body are most frequently chosen for the design of intravaginal drug delivery systems. 
Their value is attributed to the fact that they do not require to be removed from the body 
after application. The type, physicochemical and physicomechanical properties, 
proportions of the polymers in the formulation, as well as the degree of swelling and /or 
erosion for the polymers employed in formulating an intravaginal delivery system, play an 
important role in matrix integrity and retention capacity. These are the determinant factors 
for bioadhesion and release characteristics of a given system (Vueba et al., 2004; Ravi et 
al., 2008). Figure 3.1 depicts a biometric simulation undertaken in our laboratories on 
ACD/I-Lab, V5.11 (Add-on) software (Advanced Chemistry Development Inc., Toronto, 
Canada, 2000), indicating the different levels of coiling that polymers may undergo to 
produce the highest degree of matrix integrity. A polymer’s physicochemical and 
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physicomechanical properties contribute substantially to  diffusion, swelling, degradation 
and erosion dynamics, which play an important role in terms of drug release kinetics 
(Siepmann and Peppas, 2001; Avgoustakis, 2004; Arifin et al., 2006).  Other phenomena 
such as osmotic, magnetic or electric effects may also be involved. The chemical nature 
of polymers commonly used for pharmaceutical purposes differs significantly. Some are 
freely water-soluble, while others are completely water-insoluble. Thus, they vary in the 
rate and extent of swelling, bioerosion/biodegradation and their potential to interact with 
the drug. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: A computationally-derived model predicted in our laboratories depicting the 
polymer coiling stages a) polymer strands, b) identification of molecular sites, c) initial 
stages of coiling, d) secondary and tertiary coiling randomizations and patterns where (C-
1)-(C-7) is non-breaded non-rope coiling and (C-8)-(C-12) is breaded rope coiling. The 
number of coil arm may vary in (C-1)-(C-5). R1, R2 and R3 are functional groups. The lines 
represent polymeric strains while the blocks represent polymer strain interactions. 
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In the current study, both natural and synthetic biodegradable and biocompatible 
polymers have been employed, some with hydrophilic properties, others with hydrophobic 
properties and yet others with bioadhesion properties. Hydrophilic polymers can control 
drug release because of their compressibility and swelling properties, as well as the ability 
to accommodate high levels of drugs (Pinto et al., 2004; Hiremath and Saha, 2008; Jin et 
al., 2008). However, hydrophilic matrix systems generally result in nearly first-order 
release profiles (Hassan et al., 2003; Chopra et al., 2007; Rahman et al., 2009). For this 
reason, use of both hydrophilic and hydrophobic polymers have been considered to be an 
absolute necessity in this study since the ultimate aim was to achieve zero-order delivery 
(Einmahl et al., 2001; Breton et al., 2008; Barakat et al., 2009). Studies have shown that 
an increase in hydrophobicity may substantially alter the release kinetics of a drug 
delivery system (Nirmal, 2006; Khoee et al., 2007; Wu and Jin, 2008; Smith et al., 2009). 
This is attributable to its ability to hinder the penetration of the solvent molecules into the 
polymer matrix thereby leading to a reduction in the drug release rate (Sanchez-Lafuente 
et al., 2002; Sant et al., 2008; Yu et al., 2009). Furthermore, an increase in hydrophobicity 
often assists to control the rate of polymer disentanglement (Khoee et al., 2007; Smith et 
al., 2009). This occurs through various mechanisms, but mostly through a decreased 
tendency for the polymer to undergo hydrolysis due to decreased exposure to water (Liu 
et al., 2001; Khoee et al., 2007; Wu and Jin, 2008; Smith et al., 2009). In addition, 
hydrophobilic polymers may also provide several advantages, ranging from differing 
stability at varying pH and moisture levels, to well-established safe applications (Tiwari et 
al., 2003). 
 
In this study a novel caplet-shaped device was considered to be the most appropriate 
based on the route of application. Conventional vaginal delivery systems including 
solutions, semi-solids (ointments, creams, gels), tablets and pessaries suffer in one way 
or another from the problems of retention, spreadability and drug release control (Garg 
and Tambwekar, 2003; das  Neves and Bahia, 2006; Garg et al., 2007). Semi-solids in 
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particular are perceived as messy in use and prone to leakage (Justin-Temu et al., 2004; 
Valenta, 2005). Furthermore, the conventional vaginal drug delivery systems do not 
provide sufficient design flexibility in the control of drug release over periods extending 
from days to months. In this regard, there is then a great need for designing more specific 
formulations that can circumvent the problems associated with the conventional vaginal 
drug delivery systems. 
 
Polymer swelling is one of the factors that determines the matrix stability and 
subsequently the   drug release kinetics from polymer matrices (Patel and Patel, 2007; 
Barakat et al., 2008; Sibeko et al., 2009). Normally in swellable polymer matrices, polymer 
relaxation and erosion mechanisms may coexist (Bettini et al., 2001). Swelling and 
erosion front domains specifically define the gel layer thickness, which is considered to be 
the key factor in drug release kinetics and in most cases occur simultaneously (Christ et 
al., 1998; Bettini et al., 2001; Al-Taani and Tashtoush, 2003). Thus, the extent of polymer 
swelling, relative mobilities of dissolution medium and drug, and matrix erosion dictate the 
kinetics as well as mechanism of drug release from polymeric matrices (Dahlberg et al., 
2007). Generally, swelling–controlled release systems consist of a drug, which is 
molecularly dispersed in a polymeric matrix. Swelling occurs with subsequent formation of 
a thin gel layer as soon as water begins to penetrate the polymer matrix. In addition, it has 
been shown that the porosity of a polymeric system is another dominant factor that may 
control the swelling behavior (Mehta et al., 2000; Vlachou et al., 2001). Increased porosity 
leads to fast initial rates of water uptake and therefore high extent of swelling equilibrium. 
For a better outcome in terms of matrix stability and therefore optimal drug release 
kinetics, low swelling and slow erosion are the most desirable features. 
 
The aim of this Chapter was therefore to screen various polymers through an extensive 
preformulation investigation so as to ultimately obtain polymer combinations for the 
design of lead Intravaginal Bioadhesive Polymeric Devices (IBPDs). A one-dimensional 
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search with successive variation in variables i.e. OVAT approach was employed.  
Although it is practically impossible for a one-dimensional search to accomplish an 
appropriate optimum in a finite number of experiments (Haltrich et a., 1994; He et al., 
2005), it does successfully provide a lead formulation/s upon which mathematical 
optimization can be used for further refinement. 
 
3.2 Materials and Methods 
3.2.1 Materials 
The following polymers were employed in this study: Modified polyamide 6,10 (mPA 6,10) 
was synthesized using hexamethylenediamine, sebacoyl chloride, anhydrous n-hexane 
and cyclohexane, all purchased from Sigma-Aldrich Chemie (Sigma-Aldrich Chemie, 
Steinheim, Germany). The remainder of the polymers employed were commercially 
available. These were poly(acrylic acid) (Carbopol® 734 and 974) (Noveon Inc Cleveland, 
OH, USA), carageenan (Type one-kappa and alpha),  ethylcellulose (Ethocel-10), xanthan 
gum, tragacanth, bovine serum albumin (BSA) (Sigma-Aldrich Chemie, Steinheim, 
Germany); poly(ethylene oxide) (Union Carbide Corporation, Danbury, CT, USA); 
poly(lactic-co-glycolic) acid (Resomer® RG504; Boehringer Ingelheim, Ingelheim, 
Germany); poly(vinyl alcohol), polyvinyl povidone (Merck-Schuchardt, Hohenbrunn, 
Germany); gelatin, beeswax (Saarchem (Pty) Ltd., Krugersdorp, South Africa); 
methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylymethylce- 
llulose (Merck-Schuchardt®, Hohenbrunn, Germany); poly(ethyl acrylate, methyl-
methacrylate, and chlorotrimethyl-ammoniumethylmethacrilate) S 100 (Eudragit® S-100) 
and poly(ethyl acrylate, methyl-methacrylate, and chlorotrimethyl-ammoniumethylmetha- 
crilate) RS 100 (Eudragit® RS-100) (Rohm & Co., Pharma Polymers, Darmstadt, 
Germany); calcium hydroxide, glycerol, acetic acid (Associated Chemical Enterprises 
(Pty) Ltd., Southdale, South Africa). All other reagents used were of analytical grade and 
employed as received. 
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3.2.1.1 Synthesis of modified polyamide 6,10 
The modified polyamide 6,10 (mPA 6,10) was synthesized in our laboratory using a 
method developed by Kolawole and co-workers (2007) employing hexamethylenediamine 
(HMD), sebacoyl chloride (SC), hexane (HXN), cyclohexane (C-HXN), sodium hydroxide 
(NaOH) and deionized water (DW). The overall chemical reaction is illustrated in Figure 
3.2. These researchers focused on exploring the effect of volume ratio, stoichiometric 
variations and the addition of solvent phase modifiers such as sodium hydroxide and 
cyclohexane on the physicochemical and physicomechanical properties of the mPA 6,10. 
In the present study, it is only the optimized mPA 6,10 that was synthesized. Briefly two 
sets of solutions were prepared. The first solution comprised SC dissolved in a mixture of 
HXN and C-HXN while the second solution comprised of specific quantities HMD and 
NaOH dissolved in DW. The optimized formulation comprised of HMD (1.5g), SC (0.63), 
HXN 40 (mL), C-HXN (40mL), NaOH (0.1g) and DW 10 (mL). 
 
The first solution was gradually added to the second to form two immiscible phases which 
resulted in a polymeric film being formed at the interface (i.e. by an interfacial 
polymerization process). The polymeric film was collected as a mass by slowly rotating a 
glass rod at the interface. Upon collection of the polymeric mass, it was thoroughly 
washed, with HXN to remove any unreacted SC and then with DW (3×300mL) to remove 
any un-reacted NaOH. The polymeric mass was then lightly rolled on filter paper 
(diameter 110mm, pore size 20µm) to remove any excess solvent and dried to a constant 
weight at 40°C over 48 hours. 
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Figure 3.2: Synthesis of modified polyamide 6,10 by interfacial polymerization. 
 
3.2.2 Methods 
3.2.2.1 Selection of formulation components 
In polymeric drug delivery systems, controlled drug delivery occurs when a polymer, 
whether natural or synthetic, is combined with a drug or other bioactive agent in such a 
manner that the bioactive agent is released from the polymeric material in a pre-
determined manner. Initially 18 polymers were investigated. These were modified 
polyamide 6,10 (mPA 6,10), poly(lactic-co-glycolic acid) (PLGA), polyethylene oxide 
(PEO), poly(acrylic acid) (PAA), carrageenan (CG), ethycellulose (EC), polyvinylalcohol 
(PVA), polyvinyly polidone (PVP), tragacanth (TG), xanthan gum (XG), gelatin (GL), 
methylcellulose (MC), Hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), 
hydroxypropymethylcellulose (HPMC), beeswax (BWX), poly(ethyl acrylate, methyl-
methacrylate, and chlorotrimethyl-ammoniumethylmethacrilate) S 100 (Eudragit® S100) 
(ED-S100) and poly(ethyl acrylate, methyl-methacrylate, and chlorotrimethyl-
ammoniumethylmethacrilate) RS 100 (Eudragit® RS 100) (ED-RS100). Out of the 18 
polymers, 5 of them namely modified polyamide 6,10 (mPA 6,10), poly(lactic-co-glycolic 
acid) (PLGA), ethycellulose (EC), polyvinylalcohol (PVA) and poly(acrylic acid) (PAA) 
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have finally been employed to encapsulate PSS and AZT (Figure 3.3) with the purpose of 
attaining controlled release within the vagina (see Chapter 6 later). These polymers have 
their own inherent properties when used alone. However, this study has aimed at using 
their combination, a move that is expected to provide superior physicochemical and 
physicomechanical properties suitable for development of the IBPD. Furthermore, these 
polymeric materials are FDA approved and are biocompatible and biodegradable. Table 
3.1 depicts the polymer type, properties and the rationale for selection of each polymer.  
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Table 3.1: Polymers, properties and rationale for selection 
Polymer Properties Rationale for selection 
mPA 6,10 • High matrix 
      resilience 
• Abrasion resistance 
• Chemical inertness 
• High modulus 
• Thermoplasticity 
• To control drug release  
• To control permeation 
• To intensify the robustness of the 
IBPD  
   
PLGA  • Highly hydrophobic  
•     Degrades into two  
            acidic units namely 
        lactic acid and 
        glycolic acid 
• To produce an acidic pH environment 
within the vagina upon degrading into 
lactic and glycolic acid. 
• Acidic pH maintains the normal 
vaginal ecology by favoring the growth 
of Lactobacilli-containing microflora 
      which prevents bacterial vaginosis.  
• To control drug release  
   
EC • Highly hydrophobic 
• Easily compressible 
 
• To control drug release  
• To control permeation 
   
PVA • Hydrophilic  
• Compressible  
• Mildly bioadhesive 
• To control drug release 
• To foster bioadhesivity 
   
PAA • Hydrophilic  
• Possesses 
            hydrogen bonds  
            and strong anionic/ 
            cationic charges  
• High molecular  
      mass and chain 
      flexibility  
• Surface energy 
      interactions    
      favoring 
      spreading onto 
      mucus 
 
• Confers bioadhesiveness to the IBPD, 
thus favoring extension of drug 
      residence time in the vagina     
• To control drug release 
• To control permeation 
 
 
For an intravaginal drug delivery system to be effective as an anti-HIV microbicidal agent, 
the drug employed should be able to inactivate HIV replication in lymphocytes, epithelial 
cells and sperm cells (D’Cruz and Uckun, 2002). Given the fact that the passage of HIV-
infected mononuclear cells in semen contributes to the sexual transmission of HIV (Zhang 
et al., 1998; D’Cruz and Uckun, 2002), the anti-HIV microbicide should be metabolized 
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with equal efficiency by both the seminal cells and the epithelial cells of the cervico-
vaginal region (D’Cruz and Uckun, 2002). AZT (Figure 3.3a) is one such a compound and 
therefore the reason for being employed in this study. It undergoes intracellular hydrolysis 
yielding monophosphate derivatives which further become phosphorylated by thymidylate 
kinase to produce a bioactive triphosphate derivative. PSS (Figure 3.3b) is a microbicidal 
polymer which is also homogenous and viscous, and forms bioadhesive dispersion itself, 
thus facilitating its retention in the vagina for prolonged periods of time (Garg et al., 
2004a). Furthermore, It has been FDA approved as an alternative vaginal topical 
microbicide following the drawbacks found with the Nonoxynolol-9 when it was once used 
as a spermicidal and contraceptive (i.e. it potentiated bacterial vaginosis as well as HIV 
transmission) (Richardson et al., 1998; Rosenstein et al., 1998; Anderson et al., 2000; 
Simoes et al., 2002). In addition, PSS has been shown to possess some ARV effect 
(Simoes et al., 2002), and it has gelling properties which may help in preventing HIV 
transmission by acting as a physical barrier 
 
 
Figure 3.3: a) 3'-azido-3'-deoxythymidine (AZT), molecular weight 267.24 and a solubility 
20.1 mg/mL, b) Polystyrene Sulfonate (PSS) molecular weight 70,000, water soluble. 
 
 
3.2.2.2 Preparation of preliminary lead intravaginal bioadhesive polymeric devices 
In the search for a suitable combination of polymers which will finally have the suitable 
bioadhesivity, matrix integrity and controlled release effect for the development of a novel 
controlled release intravaginal bioadhesive device, vast in vitro preformulation work was 
HN
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carried out on 18 different polymers as mentioned above (Section 3.2.2.1). From these 
polymers, 62 different formulations weighing 800mg each were obtained through different 
polymer combinations at varying quantities of each polymer (Table 3.2). All polymer 
combinations were thoroughly blended using an Erweka cube blender (Erweka 
Apparatebau, Heusenstamm, Germany) and then directly compressed into caplet devices 
using a Carver Press (Carver Inc. Hydraulic Laboratory Press, Wabash, IN, USA) at a 
force of 5 tons. Each device was subjected to in-process validation tests that involved 
longitudinal crushing force, friability and mass uniformity analysis to ensure manufacturing 
reproducibility. A sample of 10 devices from each formulation was used for each test. 
Longitudinal crushing force test was conducted on a Hardness Tester (Pharma Test, 
Hainburg, Germany) while friability was conducted on a Friabilator (Erweka D-63150, 
Heusenstamm, Germany) at 25rpm for 4 minutes with 1% set as the upper limit of 
acceptability. The weight of each device was determined using an electronic balance 
(Mettler, Model AE 240, Griefensee, Switzerland) with readings recorded to 2 decimal 
places. 
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Table 3.2: The sixty two formulations obtained from different polymer combinations 
F: Formulatio number; P6: Modified polyamide 6,10; PL: Poly(lactic-co-glycolic acid); PE: Polyethylene oxide PA: Polyacrylic 
acid; CG: Carrageenan; EC: Ethycellulose; PV: Polyvinylalcohol; XG: Xanthan gum; GL: gelatin; ML: Methylcellulose; HE: 
Hydroxyethylcellulose; HP: Hydroxypropylcellulose; BW: beeswax; ES: Eudragit S100; ER: Eudragit RS 100; MA, MB, MC, 
MD, ME, MF:Mixture of two polymers among gelatin, beeswax, xanthan gum and Eudragit S 100 25mg each; MG, MH, MI: 
Mixture of three  polymers among gelatin, beeswax, xanthan gum and Eudragit S 100 25mg each; WT: Weight 
 
Polymeric Composition (mg) 
F P6 PL PE PA CG EC PV XG GL ML HE HP BW ES ER MA MB MC MD ME MF MG MH MI WT 
1 150 150 100 200 200 - - - - - - - - - - - - - - - - - - - 800 
2 100 150 150 200 100 - - - - - - - - - - - - - - - - - - - 800 
3 100 100 200 250 150 - - - - - - - - - - - - - - - - - - - 800 
4 130 155 170 205 140 - - - - - - - - - - - - - - - - - - - 800 
5 120 180 160 210 130 - - - - - - - - - - - - - - - - - - - 800 
6 200 150 150 200 100 - - - - - - - - - - - - - - - - - - - 800 
7 105 155 105 205 195 - - - - - - - - - - - - - - - - - - - 800 
8 110 165 120 230 175 - - - - - - - - - - - - - - - - - - - 800 
9 140 160 110 240 150 - - - - - - - - - - - - - - - - - - - 800 
10 230 120 100 110 240 - - - - - - - - - - - - - - - - - - - 800 
11 210 105 130 205 250 - - - - - - - - - - - - - - - - - - - 800 
12 205 150 145 200 100 - - - - - - - - - - - - - - - - - - - 800 
13 150 300 150 200 - - - - - - - - - - - - - - - - - - - - 800 
14 250 200 150 200 - - - - - - - - - - - - - - - - - - - - 800 
15 50 300 125 125 - 200 - - - - - - - - - - - - - - - - - - 800 
16 50 200 125 125 - 300 - - - - - - - - - - - - - - - - - - 800 
17 50 150 125 125 - 350 - - - - - - - - - - - - - - - - - - 800 
18 50 100 125 125 - 400 - - - - - - - - - - - - - - - - - - 800 
19 150 250 - 125 - 275 - - - - - - - - - - - - - - - - - - 800 
20 150 225 - 175 - 250 - - - - - - - - - - - - - - - - - - 800 
21 150 200 - 225 - 225 - - - - - - - - - - - - - - - - - - 800 
22 160 250 - 190 - 200 - - - - - - - - - - - - - - - - - - 800 
23 170 250 - 205 - 175 - - - - - - - - - - - - - - - - - - 800 
24 180 250 - 220 - 150 - - - - - - - - - - - - - - - - - - 800 
25 190 250 - 235 - 125 - - - - - - - - - - - - - - - - - - 800 
26 195 250 - 225 - 100 - - - - - - - - - - - - - - - - - - 800 
27 200 250 - 25 - 300 25 - - - - - - - - - - - - - - - - - 800 
28 175 250 - 25 - 300 50 - - - - - - - - - - - - - - - - - 800 
29 150 250 - 25 - 300 75 - - - - - - - - - - - - - - - - - 800 
30 125 250 - 25 - 300 100 - - - - - - - - - - - - - - - - - 800 
31 100 250 - 25 - 300 125 - - - - - - - - - - - - - - - - - 800 
32 220 275 - 25 - 250 25 5 - - - - - - - - - - - - - - - - 800 
33 215 275 - 25 - 250 25 10 - - - - - - - - - - - - - - - - 800 
34 210 275 - 25 - 250 25 15 - - - - - - - - - - - - - - - - 800 
35 205 275 - 25 - 250 25 20 - - - - - - - - - - - - - - - - 800 
36 200 275 - 25 - 250 25 25 - - - - - - - - - - - - - - - - 800 
37 195 275 - 25 - 250 25 30 - - - - - - - - - - - - - - - - 800 
38 190 275 - 25 - 250 25 35 - - - - - - - - - - - - - - - - 800 
39 185 275 - 25 - 250 25 40 - - - - - - - - - - - - - - - - 800 
40 180 275 - 25 - 250 25 45 - - - - - - - - - - - - - - - - 800 
41 175 275 - 25 - 250 25 50 - - - - - - - - - - - - - - - - 800 
42 195 300 - 25 - 250 25 - 5 - - - - - - - - - - - - - - - 800 
43 185 300 - 25 - 250 25 - 15 - - - - - - - - - - - - - - - 800 
44 175 300 - 25 - 250 25 - 25 - - - - - - - - - - - - - - - 800 
45 165 300 - 25 - 250 25 - 35 - - - - - - - - - - - - - - - 800 
46 155 300 - 25 - 250 25 - 45 - - - - - - - - - - - - - - - 800 
47 175 300 - 25 - 250 25 - - 25 - - - - - - - - - - - - - - 800 
48 175 300 - 25 - 250 25 - - - 25 - - - - - - - - - - - - - 800 
49 175 300 - 25 - 250 25 - - - - 25 - - - - - - - - - - - - 800 
50 175 300 - 25 - 250 25 - - - - - 25 - - - - - - - - - - - 800 
 
51 175 300 - 25 - 250 25 - - - - - - 25 - - - - - - - - - - 800 
52 175 300 - 25 - 250 25 - - - - - - - 25 - - - - - - - - - 800 
53 150 400 - 25 - 150 25 - - - - - - - - 50 - - - - - - - - 800 
54 150 400 - 25 - 150 25 - - - - - - - - - 50 - - - - - - - 800 
55 150 400 - 25 - 150 25 - - - - - - - - - - 50 - - - - - - 800 
56 150 400 - 25 - 150 25 - - - - - - - - - - - 50 - - - - - 800 
57 150 400 - 25 - 150 25 - - - - - - - - - - - - 50 - - - - 800 
58 150 400 - 25 - 150 25 - - - - - - - - - - - - - 50 - - - 800 
59 75 400 - 25 - 200 25 - - - - - - - - - - - - - - 75 - - 800 
60 75 400 - 25 - 200 25 - - - - - - - - - - - - - - - 75 - 800 
61 75 400 - 25 - 200 25 - - - - - - - - - - - - - - - - 75 800 
62 150 400 - 25 - 200 25 - - - - - - - - - - - - - - - - - 800 
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For the mixture of two polymers, MA was GL+ES; MB: GL+BW; MC: ES+BW; MD: 
ES+XG; ME: BW+XG and MF: GL+XG while for the mixture of three polymers, MG was 
GL+ES+BW; MH: GL+BW+XG and MI: ES+BW+XG. 
 
3.2.2.3 Equilibrium swelling studies conducted on the preliminary formulations as a 
critical indicator of the formulation’s matrix stability 
A polymer combination selected as the working formulation onto which the OVAT 
approach was applied in an attempt to find lead IBPDs was: mPA 6,10 (50mg), PLGA 
(300mg), PEO (125mg), PAA (125mg) and CG (200mg). A series of swelling tests were 
conducted on various sets of the formulations shown in Table 3.2 to investigate which 
device would have the optimal swelling at both human and pig vaginal pH (i.e. ~4.5) and 
human/pig seminal pH (i.e. ~7.4) by employing the OVAT approach. Due to the 
physiological similarity between the human and pig (Buddhikot et al. 1999; Quintanar-
Guerrero et al., 2001; Sandri et al., 2004; D’cruz et al., 2005b), simulated human vaginal 
and seminal fluids (Owen and Katz, 1999, 2005) prepared as indicated in Table 3.3, were 
employed for the tests. Each of the tested devices was weighed, immersed into both 
simulated fluids and then placed in an orbital shaking incubator (MRC Laboratory 
Instruments Ltd., Hahistadrut, Holon, Israel), maintained at 20rpm and a temperature of 
37ºC for 24 hours. After 24 hours each device was removed from the orbital shaking 
incubator, gently blotted on a filter paper and then re-weighed. The swelling behavior was 
determined in terms of the equilibrium swelling ratio (ESR) which was calculated using 
Equation 3.1. The ESR (after 24 hours) which was the critical indicator of the formulation’s 
matrix stability (i.e. the degree of matrix robustness), was used as a screening parameter 
for each formulation.  
 W
WWESR
o
ot −=
                                                                       Equation 3.1 
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where ESR is the equilibrium swelling ratio, Wo is the initial weight of the device and Wt is 
the weight of the device after 24 hours. 
Table 3.3: Constituents used to prepare the simulated human vaginal and seminal fluids  
SHVF1 SHSF2 
Component Quantity(g/L) Component Quantity(g/L) 
 
NaCl 
 
3.510 
 
NaH2PO4·H2O 
 
16.974 
KOH 1.400 Na2HPO4 17.466 
Ca(OH)2 0.222 Na3C3H5O(CO2)3   8.130 
Bovine serum albumin 0.018 KCl   0.908 
Lactic acid 2.000 KOH   0.881 
Acetic acid 1.000 CaCl2   1.010 
Glycerol 0.160 MgCl2   0.920 
Urea 0.400 ZnCl2   0.344 
Glucose 5.000 Glucose   1.020 
  Fructose   2.720 
  Urea   0.450 
  Lactic acid   0.620 
  Bovine serum albumin 50.400 
 1Simulated human vaginal fluid according to Owen and Katz, (1999) 
2Simulated human seminal fluid according to Owen and Katz, (2005) 
 
 
3.2.2.4 Effect of changing the formulation components of the IBPD on the 
equilibrium swelling ratio 
The formulations components of the IBPD were changed sequentially (changes 
highlighted in grey color) to see the effect on equilibrium swelling ratio. 
 
3.2.2.4.1 Effect of the elimination of carrageenan 
Carrageenan is a highly hydrophilic compound which is substantially water-soluble with 
the capacity to transform into a gel that presents with a high degree of swelling in an 
alkaline pH (Campo et al., 2009). It was thus eliminated to see the effect in terms of the 
composite swelling of the devices. After elimination of the carrageenan an adjustment of 
the quantities of the remaining polymers was undertaken to maintain a constant weight of 
800mg (Table 3.4). 
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Table 3.4: Formulations without carrageenan 
Polymeric Composition (mg) 
F # mPA 6,10 PLGA PAA PEO 
1 50.0 400.0 250.0 100 
2 100.0 350.0 250.0 100 
3 200.0 250.0 250.0 100 
4 250.0 200.0 250.0 100 
5 300.0 150.0 250.0 100 
6 350 100.0 250.0 100 
 
 
3.2.2.4.2 Effect of the addition of ethylcellulose  
Due to its hydrophobic nature and high compressibility, EC was employed to replace CG. 
The quantities of PAA and PEO were substantially reduced as they enhanced matrix 
swelling, due to their high degree of hydrophilicity. The quantities of EC employed ranged 
from 240mg-460mg as shown in Table 3.5. 
 
Table 3.5: Formulations in which carrageenan was substituted with ethylcellulose     
Polymeric Composition (mg) 
F # mPA 6,10 PLGA PEO PAA EC 
1 90.0 340.0 65 65.0 240.0 
2 90.0 240.0 65 65.0 340.0 
3 90.0 190.0 65 65.0 390.0 
4 90.0 140.0 65 65.0 440.0 
5 90.0 130.0 65 65.0 450.0 
6 90.0 120.0 65 65.0 460.0 
                          
 
3.2.2.4.3 Effect of the elimination of polyethylene oxide 
PEO is a hydrophilic polymer with a high tendency to undergoing swelling (Varma et al., 
2004). PEO as a bioadhesive and a rate-controlling polymer was removed to reduce the 
number of hydrophilic polymers so as to reduce the extent of swelling of the devices. 
However, PAA remained included throughout all formulations due to its substantial 
bioadhesive imparting (Table 3.6). 
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Table 3.6: Formulations without polyethylene oxide 
Polymeric Composition (mg) 
F # mPA 6,10 PLGA PAA EC 
1 100 300.0 75.0 325 
2 100 300.0 100 300 
3 100 300.0 150 250 
4 100 300.0 200.0 200 
5 100 300.0 250.0 150 
6 100 300.0 300.0 100 
 
3.2.2.4.4. Effect of the addition of polyvinyl alcohol 
PVA has high tensile strength and flexibility, as well as adhesive and high oxygen barrier 
properties (Yan et al., 2006; Yang et al., 2008; Mukherjee, 2009). It is also an atactic 
material but exhibits crystallinity as the hydroxyl groups are small enough to fit into the 
lattice without disrupting it. It was therefore incorporated into the formulation to enhance 
the control of drug release as well as the bioadhesivity of the devices. Quantities ranging 
from 25mg-150mg were employed in formulations to produce a total weight of 
800mg/device while keeping the quantities of PLGA, EC and PAA constant (Table 3.7). 
 
Table 3.7: Formulations containing polyvinyl alcohol 
Polymeric Composition (mg) 
F# mPA 6,10 PLGA EC PAA PVA 
1 200.0 250.0 300.0 25.0 25.0 
2 175.0 250.0 300.0 25.0 50.0 
3 150.0 250.0 300.0 25.0 75.0 
4 125.0 250.0 300.0 25.0 100.0 
5 100.0 250.0 300.0 25.0 125.0 
6 75.0 250.0 300.0 25.0 150.0 
 
 
3.2.2.4.5 Effect of the addition of polyvinyl povidone 
PVP is a water-soluble material with a Newtonian-type viscosity. When dry it is a light 
flaky powder, capable of readily absorbing up to 40% of its weight in atmospheric water. 
In solution, it has excellent wetting properties and readily forms films which make it a 
good coating agent.  It was therefore added to the formulations ranging from 25-150mg 
with the intention of fostering the bioadhesivity of the devices. The quantities of PLGA, EC 
and PAA were kept constant as shown in Table 3.8. 
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Table 3.8: Formulations containing polyvinyl povidone 
Polymeric Composition (mg) 
F # mPA 6,10 PLGA EC PAA PVP 
1 200.0 250.0 300.0 25.0 25.0 
2 175.0 250.0 300.0 25.0 50.0 
3 150.0 250.0 300.0 25.0 75.0 
4 125.0 250.0 300.0 25.0 100.0 
5 100.0 250.0 300.0 25.0 125.0 
6 50.0 250.0 300.0 25.0 150.0 
 
 
3.2.2.4.6 Effect of the addition of xanthan gum 
XG is a water-soluble polysaccharide produced by Xanthomonas campestris. It forms a 
single or double-stranded helix in dilute solution that transforms into molecular 
assemblages which show liquid crystallinity in the presence of water (Rodd et al., 2000; 
Iseki et al., 2001). XG can form hydrogels upon annealing its solution in the sol state and 
then cooling (Quinn et al., 1994; Song et al., 2006). XG was therefore added to the 
formulations due to its gel-forming and viscosity-enhancing properties in an attempt to 
facilitate adhesion of the device to the vaginal epithelium. The quantities added ranged 
from 5-50mg. The quantities of PLGA, EC, PAA and PVA were kept constant (Table 3.9). 
 
Table 3.9: Formulations containing xanthan gum 
Polymeric Composition (mg) 
F # mPA 6,10 PLGA EC PAA PVA XG 
1 220.0 275.0 250.0 25.0 25.0 5.0 
2 210.0 275.0 250.0 25.0 25.0 15.0 
3 200.0 275.0 250.0 25.0 25.0 25.0 
4 190.0 275.0 250.0 25.0 25.0 35.0 
5 180.0 275.0 250.0 25.0 25.0 45.0 
6 175.0 275.0 250.0 25.0 25.0 50.0 
 
 
3.2.2.4.7 Effect of the addition of guar gum 
GG is a polysaccharide comprising galactose and mannose. In water it is nonionic and 
hydrocolloidal and remains stable in solution over a pH range of 5-7. Guar gum presents 
with high low-shear viscosity but is strongly shear-thinning. It is very thixotropic above 
1%w/v with a low degree of thixotropy below a concentration of 0.3%w/v (Soukoulis et al., 
2007).  It shows viscosity synergy with xanthan gum. Guar gum has almost eight times 
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the water-thickening potency of other thickening agents such as starch, and therefore can 
be used in the preparation of various multi-phase formulations (Billa et al., 2000). It was 
therefore added to the current formulations so as to enhance the bioadhesivity. The 
quantities added ranged from 5-50mg (Table 3.10). 
 
Table 3.10: Formulations containing guar gum 
Polymeric Composition (mg) 
F # mPA 6,10 PLGA EC PAA PVA GG 
1 220.0 275.0 250.0 25.0 25.0 5.0 
2 210.0 275.0 250.0 25.0 25.0 15.0 
3 200.0 275.0 250.0 25.0 25.0 25.0 
4 190.0 275.0 250.0 25.0 25.0 35.0 
5 180.0 275.0 250.0 25.0 25.0 45.0 
6 175.0 275.0 250.0 25.0 25.0 50.0 
 
3.2.2.4.8 Effect of the addition of gelatin  
GL is a translucent, brittle, solid substance derived from the collagen obtained from skin 
and bones of animals. It forms a solution of high viscosity in water, which sets to a gel on 
cooling. Gelatin solutions present with viscoelastic flow and streaming birefringence 
(Ward and Courts, 1977). It qualifies as a binder, and therefore was used to substitute 
xanthan gum in an attempt to improve the bioadhesivity of the devices. The quantities 
added ranged from 5-50mg while the quantities of the other polymers remained constant 
(Table 3.11). 
 
Table 3.11: Formulations in which xanthan gum was substituted with gelatin 
Polymeric Composition (mg) 
F # mPA 6,10 PLGA EC PAA PVA GL 
1 195.0 300.0 250.0 25.0 25.0 5 
2 185.0 300.0 250.0 25.0 25.0 15 
3 175.0 300.0 250.0 25.0 25.0 25 
4 165.0 300.0 250.0 25.0 25.0 35 
5 155.0 300.0 250.0 25.0 25.0 45 
6 150.0 300.0 250.0 25.0 25.0 50 
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3.2.2.4.9 Effect of the addition of beeswax 
Beeswax is comprised of a mixture of many organic compounds, including hydrocarbons, 
wax esters, and fatty acids. It has emollient, soothing and softening properties. 
Furthermore, it is very stable over prolonged periods. It is resistant to hydrolysis and 
natural oxidization and is completely insoluble in water. Thus, beeswax was added to the 
formulations ranging from 5-50mg (Table 3.12) so as to increase the matrix stability of the 
devices.  
 
Table 3.12: Formulations in which gelatin was substituted with beeswax 
Polymeric Composition (mg) 
F # mPA 6,10 PLGA EC PAA PVA BW 
1 195.0 300.0 250.0 25.0 25.0 5 
2 185.0 300.0 250.0 25.0 25.0 15 
3 175.0 300.0 250.0 25.0 25.0 25 
4 165.0 300.0 250.0 25.0 25.0 35 
5 155.0 300.0 250.0 25.0 25.0 45 
6 150.0 300.0 250.0 25.0 25.0 50 
 
 
3.2.2.4.10 Effect of the addition of tragacanth 
Tragacanth is a translucent and horny fracture short material. It swells in water forming 
smooth nearly uniform stiff opalescent mucilage that is free of cellular fragments. It 
imparts great viscidity to water, a property that renders it useful for the suspension of 
heavy insoluble powders. Pharmaceutically, it is has good applications particularly in 
imparting consistence to troches and emulsions. It was added to the formulations for its 
effect on the matrix stability. The quantities added ranged from 5-50mg (Table 3.13). 
 
Table 3.13: Formulations containing tragacanth 
Polymeric Composition (mg) 
F # mPA 6,10 PLGA EC PAA PVA TG 
1 195.0 300.0 250.0 25.0 25.0 5 
2 185.0 300.0 250.0 25.0 25.0 15 
3 175.0 300.0 250.0 25.0 25.0 25 
4 165.0 300.0 250.0 25.0 25.0 35 
5 155.0 300.0 250.0 25.0 25.0 45 
6 150.0 300.0 250.0 25.0 25.0 50 
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3.2.2.4.11 Effect of the addition of methylcellulose, hydroxyethylcellulose, hydroxyl- 
propylcellulose, hydroxypropylmethylcellulose, Eudragit® S100 and Eudragit® RS 
100 as substitutes for gelatin 
MC, HEC, HPC and HPMC are cellulose ethers that differ in their type and degree of 
substitution. These polymers are hydrophilic in nature with pharmaceutical attributable 
properties that favor their use in the preparation of controlled release formulations. They 
are also used as bulking agents in the tabletting process. When exposed to aqueous 
media, they swell forming a gel layer around the tablet core (Baumgartner et al., 2002). 
Chain dissolution may take place at the gel surface depending on the type of cellulose 
ester. These polymers were added to the formulations to investigate their effect on the 
equilibrium swelling ratio of the devices with the intention of finally employing them to 
control drug release. 
ED-S100 and ED-RS100 are poly(ethyl acrylate, methyl-methacrylate, and 
chlorotrimethyl-ammoniumethylmethacrilate) co-polymers. They are insoluble at 
physiological pH but undergo swelling in water (Pignatello et al., 2002). ED-S100 and ED-
RS100 are commonly employed for the enteric coating of tablets and in the preparation of 
controlled release formulations. Both are good materials for the dispersion of drugs and 
have been used successfully to obtain appropriate controlled release matrix formulations 
(Ndesendo et al., 1996; Wong et al., 1999; Trapani et al., 2007). They were therefore 
added to the formulations for the purpose of modulating the release kinetics. The quantity 
of each polymer added to the formulations was 25mg. The quantities of the other 
polymers were kept constant (Table 3.14). 
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Table 3.14: Formulations containing methylcellulose, hydroxyethlycellulose, hydroxyl- 
propylcellulose, hydroxypropylmethylcellulose, Eudragit® S100 and Eudragit® RS100 
Polymeric Composition (mg) 
F # mPA 6,10 PLGA EC PAA PVA Additional polymer 
1 175.0 250.0 300.0 25.0 25.0 25 (MC) 
2 175.0 250.0 300.0 25.0 25.0 25 (HEC) 
3 175.0 250.0 300.0 25.0 25.0 25 (HPC) 
4 175.0 250.0 300.0 25.0 25.0 25 (HPMC) 
5 175.0 250.0 300.0 25.0 25.0 25(ED-S100) 
6 175.0 250.0 300.0 25.0 25.0 25 (ED-RS100) 
 
 
3.2.4.12 Effect of the addition of a binary polymer combination to the formulation 
Combinations of 2 polymers in equal quantities of 25mg each (1:1), from among gelatin, 
beeswax, xanthan gum and ED-S100 were added to the formulations to investigate their 
effect on the matrix stability. The quantities of the other polymers were kept constant 
(Table 3.15). 
 
Table 3.15: Formulations with a binary polymer combination among gelatin, beeswax, 
xanthan gum and Eudragit® S100 
Polymeric Composition (mg) 
F # mPA 6,10 PLGA EC PAA PVA Combination of  2 polymers 
1 150.0 400.0 150.0 25.0 25.0 50 (GL+ED-S100) 
2 150.0 400.0 150.0 25.0 25.0 50 (GL+BWX)  
3 150.0 400.0 150.0 25.0 25.0 50 (ED-S100+BWX) 
4 150.0 400.0 150.0 25.0 25.0 50 (ED-S100+XG) 
5 150.0 400.0 150.0 25.0 25.0 50 (BWX+XG) 
6 150.0 400.0 150.0 25.0 25.0 50 (GL+XG) 
 
 
3.2.2.4.13 Effect of the addition of a tertiary polymer combination to the formulation 
Combinations of 3 polymers in equal quantities of 25mg each (1:1:1), from among gelatin, 
beeswax, xanthan gum and ED-S100 were added to the formulations to investigate the 
effect on the matrix stability of the devices. The quantities of the other polymers were kept 
constant (Table 3.16). 
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Table 3.16: Formulations with a tertiary polymer combination among gelatin, beeswax, 
xanthan gum and Eudragit® S100 
Polymeric Composition (mg) 
F 
# 
mPA 6,10 PLGA EC PAA PVA Combination of 3 polymers 
1 75.0 400.0 200.0 25.0 25.0 75(GL+ED-S100+BWX ) 
2 75.0 400.0 200.0 25.0 25.0 75 (GL+BWX+XG) 
3 75.0 400.0 200.0 25.0 25.0 75 (ED-S100+BWX+XG) 
 
 
3.3 Results and Discussion 
3.3.1 Physical properties of mPA 6,10 and in-process validation tests 
The mPA 6,10 product synthesized presented as a firm white crystalline spherical 
compact. The unrefined mPA 6,10 powder was subsequently sieved through an aperture 
size of 1mm in keeping with the other polymeric components of the caplet matrix to obtain 
a particle size ranging from 0.8-1.2mm which facilitated desirable powder compression 
properties. The compressed caplets (Figure 3.4) were sufficiently strong and robust (i.e. 
sturdy and with high resilience) with an average longitudinal crushing force of 286±0.03N, 
a uniformity mass of 800±0.48mg and average friability of 0.31±0.04% which was within 
the set limits (Table 3.17).  
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Figure: 3.4: The intravaginal bioadhesive polymeric devices (IBPDs) a) Planar view, b) 
Side view, c) Oblique view and d) Longitudinal view. 
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Table 3.17: Mass, friability and longitudinal crushing force of the sixty two caplet 
formulations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F# 
 
 
Mass (mg) 
 
 
±SD 
 
 
% Friability 
 
 
±SD 
Longitudinal  
Crushing  
Force (N) 
 
 
±SD 
1 789.22 3.633 0.39 0.018 284.81 1.311 
2 803.65 4.109 0.41 0.019 285.76 1.317 
3 788.11 2.998 0.44 0.020 284.28 1.309 
4 799.06 3.678 0.42 0.019 284.82 1.313 
5 800.09 4.003 0.40 0.018 284.92 1.315 
6 801.89 4.006 0.40 0.018 285.61 1.318 
7 798.09 3.593 0.42 0.019 285.90 1.319 
8 788.72 3.701 0.41 0.020 285.82 1.317 
9 804.29 4.015 0.39 0.017 285.09 1.312 
10 803.22 4.012 0.39 0.015 284.41 1.308 
11 804.21 4.018 0.46 0.024 280.63 1.309 
12 790.32 3.456 0.37 0.013 285.71 1.326 
13 800.33 4.009 0.35 0.011 285.92 1.328 
14 803.43 4.013 0.36 0.013 286.03 1.330 
15 805.21 4.127 0.33 0.010 286.41 1.338 
16 802.44 4.018 0.32 0.010 286.65 1.339 
17 801.29 4.003 0.32 0.012 286.91 1.400 
18 801.29 4.003 0.30 0.009 287.25 1.403 
19 803.64 4.012 0.29 0.009 287.07 1.401 
20 789.08 3.987 0.28 0.007 287.38 1.328 
21 789.00 3.967 0.26 0.005 286.82 1.330 
22 805.78 4.134 0.27 0.006 286.71 1.338 
23 788.99 3.556 0.31 0.011 286.52 1.339 
24 801.98 4.007 0.33 0.013 286.33 1.400 
25 800.37 4.001 0.32 0.013 287.18 1.403 
26 789.98 3.897 0.30 0.010 288.97 1.401 
27 810.02 5.004 0.24 0.005 289.36 1.428 
28 801.99 4.120 0.29 0.009 287.66 1.429 
29 788.89 3.898 0.30 0.010 287.94 1.407 
30 802.77 4.108 0.31 0.010 286.84 1.330 
31 807.22 4.130 0.32 0.012 286.62 1.338 
32 789.69 3.789 0.34 0.012 285.51 1.339 
33 803.11 4.015 0.37 0.015 285.42 1.400 
34 801.25 4.001 0.35 0.014 285.08 1.403 
35 800.66 4.002 0,33 0.013 284.93 1.381 
36 798.76 3.972 0.30 0.009 287.19 1.328 
37 792.53 3.864 0.32 0.010 287.28 1.330 
38 801.48 3.999 0.33 0.013 287.39 1.338 
39 790.98 3.870 0.26 0.010 288.14 1.429 
40 808.79 4.137 0.29 0.010 287.66 1.400 
41 789.98 2.987 0.27 0.012 288.49 1.403 
42 803.44 4.121 0.35 0.009 285.65 1.401 
43 802.00 4.002 0.36 0.009 285.23 1.428 
44 788.89 2.998 0.29 0.007 287.09 1.429 
45 801.66 4.006 0.33 0.005 285.25 1.407 
46 787.98 2.999 0.37 0.006 285.73 1.326 
47 799.86 3.003 0.39 0.011 284.93 1.328 
48 808.00 4.985 0,36 0.013 285.06 1.330 
49 803.33 4.006 0.38 0.013 285.34 1.338 
50 800.30 4.000 0.31 0.010 286.78 1.339 
 
 
51 803.01 3.998 0.24 0.005 289.02 1.423 
52 808.22 5.000 0.25 0.005 288.77 1.328 
53 789.56 3.979 0.32 0.012 285.88 1.330 
54 809.29 5.001 0.29 0.010 286.23 1.338 
55 804.44 4.110 0.33 0.010 285.56 1.429 
56 789.79 3.961 0.30 0.012 285.68 1.400 
57 800.67 3.998 0.30 0.012 286.05 1.403 
58 804.58 4.029 0.34 0.015 285.83 1.301 
59 798.98 4.001 0.37 0.014 285.07 1.328 
60 802.44 4.008 0.32 0.013 285.41 1.329 
61 789.88 3.989 0.31 0.009 285.90 1.307 
62 800.45 4.007 0.23 0.006 289.69 1.425 
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3.3.2 The influence of different polymeric composition on the equilibrium swelling 
ratio 
3.3.2.1 The influence of carageenan, polyethylene oxide and ethylcellulose on the 
matrix stability 
The formulations prepared with CG and PEO (F1- F12) (Table 3.2) presented with the 
highest level of matrix swelling as shown by their ESR values (0.55-0.76) (Table 3.18). 
The highest ESR was observed in F11 (ESR=0.76; Table 3.18). This was most likely due 
to the hydrophilic nature of CG and PEO. These polymers, being highly hydrophilic, 
rapidly absorbed water which led to a high degree of swelling. A similar trend was 
apparent in F3 (ESR=0.71) though to a lesser extent, due to relatively lower quantity of 
CG. The elimination of PEO and substitution of CG with EC resulted in a marked negative 
impact on matrix swelling in that a formulation with an ESR as low as 0.12 (F 19; Table 
3.18) was obtained. This was due to the hydrophobic nature of EC. 
 
3.3.2.2 The influence of guar gum, polyvinyl povidone, tragacanth and polyvinyl 
alcohol on matrix stability 
GG produced matrix swelling to a large extent after 12 hours. PVP and TG were found to 
induce initial swelling and subsequent erosion of the formulation after 24 hours. PVA 
resulted in formulations with minimal matrix swelling (Table 3.18; F27; ESR=0.02) and 
therefore was considered to have the most favorable matrix stability among the entire 
group. 
 
3.3.2.3 The influence of xanthan gum, beeswax and gelatin on the matrix stability 
Xanthan gum provided substantially swollen formulations which remained intact (no 
evidence of erosion), in addition to being highly bioadhesive. Overall, XG, BWX and GL at 
low quantities (25mg each) (Table 3.18) resulted in formulations with minimal ESR (0.02-
0.16). This may be due to the ability of XG, BWX and GL to form gel-like microstructure 
(Gimeno et al., 2003) which interspersed itself throughout. 
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3.3.2.4 The influence of the addition of methylcellulose, hydroxethylcellulose, 
hydroxypropylcellulose and hydroxylpropylmethylcellulose in the formulations, on 
matrix stability 
The MC-containing formulations underwent initial massive swelling and thereafter erosion 
after 24 hours (formulations completely collapsed). HEC, HPC and HPMC-containing 
formulations remained stable for at least 72 hours. This finding may be attributed to the 
fact that these polymers are non-ionic and hydrophilic with water retention properties.  
 
3.3.2.5 The influence of Eudragit® S100 and Eudragit® RS 100 on matrix stability 
ED-S100 and ED-RS100 are random copolymers of methacrylic acid and ethyl acrylate, 
which are insoluble at acidic pH but become increasingly soluble in a neutral to weakly 
alkaline solution by forming salts (Guoqiang et al., 1995; Arasaratnam et al., 2000). Thus, 
the ED-S100- and ED-RS100-containing formulations presented with minimal swelling 
tendency (ESR=0.02 and 0.03) in simulated vaginal fluid (pH 4.5) (Table 3.18; F51 and 
F52).  
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Table 3.18: The equilibrium swelling ratios for the sixty two formulations that were 
subjected to screening using the OVAT approach 
 
 
F# ESR ±SD 
32 0.13 0.006 
33 0.14 0.006 
34 0.15 0.007 
35 0.16 0.007 
36 0.06 0.003 
37 0.08 0.004 
38 0.08 0.004 
39 0.04 0.002 
40 0.05 0.002 
41 0.04 0.002 
42 0.14 0.006 
43 0.16 0.007 
44 0.06 0.003 
45 0.13 0.006 
46 0.15 0.007 
47 0.53 0.025 
48 0.49 0.023 
49 0.56 0.026 
50 0.07 0.003 
51 0.02 0.001 
52 0.03 0.001 
53 0.12 0.006 
54 0.09 0.004 
55 0.14 0.006 
56 0.12 0.006 
57 0.11 0.005 
58 0.13 0.006 
59 0.15 0.007 
60 0.14 0.006 
61 0.12 0.006 
62 0.01 0.001 
F# ESR ±SD 
1 0.63 0.029 
2 0.58 0.027 
3 0.71 0.033 
4 0.65 0.030 
5 0.60 0.028 
6 0.58 0.027 
7 0.60 0.028 
8 0.61 0.028 
9 0.59 0.027 
10 0.68 0.032 
11 0.76 0.035 
12 0.55 0.026 
13 0.53 0.025 
14 0.50 0.023 
15 0.47 0.022 
16 0.45 0.021 
17 0.42 0.020 
18 0.11 0.005 
19 0.12 0.006 
20 0.11 0.005 
21 0.08 0.004 
22 0.09 0.004 
23 0.10 0.005 
24 0.12 0.006 
25 0.08 0.004 
26 0.06 0.003 
27 0.02 0.001 
28 0.05 0.002 
29 0.07 0.003 
30 0.09 0.004 
31 0.08 0.004  
 
 
3.3.2.6 Equilibrium swelling ratios of the selected fifteen lead formulations 
screened through the OVAT approach  
The ESRs for the selected 15 lead formulations are summarized in Table 3.19. 
Depending on the polymer combination and hydrophilic/hydrophobic proportions, all 
devices demonstrated a different swelling equilibrium as depicted by their ESR values 
(Table 3.19). Swelling ratio describes the amount of water that was contained within the 
device at equilibrium and is a function of the proportion between hydrophilicity and 
hydrophobicity in the device network structure. Ionization of the polymer functional 
groups, crosslinking density, charge density, and simulated vaginal fluid ionic strength, 
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may have played a role as well in this regard. The higher the hydrophobicity the lower the 
ESR and the higher the hydrophilicity the higher the ESR. The opposite holds true in both 
cases. Low ESR is an indication of low swelling rate and therefore high matrix stability 
and vice versa (Baumgartner et al., 2000; Girish et al, 2008; Wen et al., 2008). Among the 
15 lead formulations, F62 presented with the lowest ESR (0.011). These findings may be 
associated with the presence of a high quantity of PLGA (400mg) in the formulation which 
prevented the influx of water into the IBPD matrix due to its high hydrophobicity. The 
presence of EC in the formulation at a relatively high quantity (200mg) may have as well 
attributed to the obtained results since EC is also a polymer with high degree of 
hydrophobicity. Most certainly, minimal quantities of the hydrophilic polymers PAA and 
PVA coupled the superior matrix resilience of mPA 6,10 contributed as well to the small 
ESR value of F62. ED-S100 and ED-RS100 are both pH-dependent polymer materials 
that are only soluble at pH above 6.0 (Ohmura et al., 1991). Thus, at the simulated 
vaginal fluid pH (4.5), these polymers were insoluble indicating that they may have played 
a role in preventing the entrance of water molecules to the IBPD matrix, therefore leading 
to the low ESR values obtained in F51 (ESR=0.023) and F52  (ESR=0.033) respectively 
(Table 3.19).  
 
The high tendency GL, BWX and XG to form a non-collapsible networked-structure may 
have improved the veracity of the IBPD matrix and therefore the relatively low values of 
ESR values obtained in the formulations containing these polymers (Table 3.19).The ESR 
for the best 15 formulations was in the following order F62>F27>F51>F52>F41>F39> F28 
>F40>F44> F36>F29>F50> F37> F38>F31 (i.e. lowest to the highest) (Table 3.19). 
Overall, the high degree of hydrophobicity in the polymers constituting these formulations, 
prevented rapid penetration of water molecules into the IBPD matrix resulting in a low 
swelling tendency (Table 3.19) and therefore lower ESR values when compared to the 
rest of the tested formulations (Table 3.18). 
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Table 3.19: The selected fifteen lead formulations screened through the OVAT approach 
Polymeric Composition (mg) 
F# P6 PL PA EC PV XG GL BW ES ER ESR 
62 150 400 25 200 25 - - - - - 0.011 
27 200 250 25 300 25 - - - - - 0.020 
51 175 300 25 250 25 - - - 25 - 0.023 
52 175 300 25 250 25 - - - - 25 0.033 
41 175 300 25 250 25 - 25 - - - 0.041 
39 185 275 25 250 25 40 - - - - 0.044 
28 175 250 25 300 50 - - - - - 0.050 
40 180 275 25 250 25 45 - - - - 0.053 
44 175 275 25 250 25 50 - - - - 0.060 
36 200 275 25 250 25 25 - - - - 0.064 
29 150 250 25 300 100 - - - - - 0.071 
50 175 300 25 250 25 - - 25 - - 0.073 
37 195 275 25 250 25 30 - - - - 0.080 
38 190 275 25 250 25 35 - - - - 0.082 
31 100 250 25 300 125 - - - - - 0.084 
 
P6: Modified polyamide 6,10; PL: Poly(lactic-co-glycolic acid); PE: Polyethylene oxide PA: 
Polyacrylic acid; CG: Carrageenan; EC: Ethycellulose; PV: Polyvinylalcohol; XG: Xanthan gum; 
GL: gelatin; BW: beeswax; ES: Eudragit S100; ER: Eudragit RS 100; ESR: Equilibrium swelling 
ratio 
 
 
3.4 Concluding Remarks 
Through extensive screening of the developmental formulations using an OVAT 
approach, robust caplets with substantial matrix integrity were produced, as evidenced by 
the Equilibrium Swelling Ratios. Fifteen lead formulations with minimal swelling 
tendencies were obtained. F62 which is composed of mPA 6,10 (150mg), PLGA (400mg), 
EC (200mg), PVA (25mg) and PAA (25mg) appeared to be the most suited in terms of 
minimal swelling capacity and highest matrix stability. Optimization was further conducted 
on the fifteen lead formulation employing ANN in Chapter 4.  
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CHAPTER FOUR 
 
AP P L IC AT ION OF  AR TIF IC IAL  NE UR AL  NE TWOR K S  F OR  THE  E L UC IDAT ION OF  
AN OP TIMIZE D S Y NE R G IS TIC  P OL Y ME R  C OMB INATION F OR  E F F E C TIVE  
P E R F OR MANC E  OF  THE  INTR AV AG INAL  B IOADHE S IVE  P OL Y ME R IC  DE VIC E  
 
4.1 Introduction 
Successful delivery of drugs to the human vagina is mainly dependent on the residence 
time as well as the ability of the delivery system to contain and release the drug in a 
controlled manner (Justin-Temu et a., 2004; Grassi et al., 2005; Andrews et al., 2009; 
Rohan and Sassi, 2009; Serra et al., 2009). Therefore, the selection of polymers to 
achieve good matrix integrity that will subsequently lead to the control of drug release is a 
vital goal in formulation optimization of an intravaginal drug delivery system. Conducting a 
comparative analysis of polymers for developing a specific drug delivery system is of 
paramount importance if the appropriate matrix integrity and controlled release effect is to 
be achieved. Comparative studies of polymers would also facilitate the process of 
formulation optimization. In addition, matrix integrity evaluation may enable identification 
of the physicochemical and physicomechanical properties of a polymeric delivery system 
which may be used to predict the in vivo behavior and therefore its suitability for 
intravaginal drug delivery.  
 
Reproducibility of experimental procedures during formulation development is frequently 
hindered by numerous factors. In solving such problems, several techniques have been 
employed in attempting to discover the rules, patterns and relationships in a given data 
set. Software-based computational techniques namely Artificial Neural Networks (ANNs) 
are able to simulate the neurological processing ability of the human brain through 
mathematical modeling of its functional unit (Hopfied and Tank 1985; Achanta et al., 
 100 
1995; Arulsudar et al., 2005; Parojčić et al., 2007; Patel et al., 2007; Hassanien et al., 
2008; Lee et al., 2008; Munasur et al., 2008; Lancashire et al., 2009). Essentially ANNs 
are networks of adaptable nodes, which store experimental knowledge through the 
learning process from the given samples (Yang et al., 2005; Lancashire et al., 2009). 
They can also be applied in establishing a non-linear relationship between causal factors 
and the required efficacy (Chen et al., 2002; Sun et al., 2003; Rizkalla and Hildgen 2005; 
Agatonovic-Kustrin et al., 2008; Najah et al., 2009).  Thus, an ANN may be considered as 
an advanced non-linear regression model that can be used to assess the association of 
variables by means of iterative training of data obtained from a designed experiment 
(Takayama et al., 1999). Thus far, ANNs have successfully been used to solve various 
problems in pharmaceutical research, including pharmaceutical process optimization 
(Takahara et al., 1997; Peh et al., 2000), product development (Leane et al., 2003; 
Parojčić et al., 2007), predicting drug release patterns (Brier et al., 1995; Peh et a., 2000; 
Sun et al., 2003; Reis et al., 2004; Mendyk and Jachowicz, 2005; Fogel, 2008), predicting 
diffusion dynamics (Jha et al., 1995; Yuzgec et al., 2008; Lee et al., 2008), predicting the 
mechanism of action of drugs (Nair et al., 1994; Leane et al., 2003; Gunther et al. 2003; 
Ghaffari et al., 2006), predicting pharmacokinetic parameters, and pharmaceutical product 
coefficients (Weinstein et al., 1992; Hussain et al., 1993; Brier et al., 1995; Smith and 
Brier, 1996; Peh et al., 2000; Fu et al., 2003; Leane et al., 2003).  Furthermore, ANNs are 
more accurate than conventional linear correlation techniques in identifying specific input 
variables such as the type of polymers that may substantially affect the performance of a 
formulation (Bourquin et al., 1998; Chen et al, 2002; Caputo and Pelagagge 2008). ANNs 
are also capable of generating non-linear input-output mappings for use in producing 
accurate confirmation or predictions of previous results within shortest periods and with 
highest computational precision (Agatonovic-Kustrin and Beresford 2000; Lee et al., 
2008). 
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The aim of this Chapter was therefore to assess the matrix integrity of the initial selected 
15 lead formulations derived from the OVAT-based developmental screening approach 
(Chapter 3), in terms of matrix erosion. ANN was used to optimize the erosion kinetics of 
the 15 lead formulations to generate an optimized formulation with the best erosion 
properties. Furthermore, to achieve ideal matrix erosion, ANN was employed to undertake 
sensitivity testing on the polymers that constituted the 15 lead formulations (Chapter 3; 
Section 3.3.2.6; Table 3.19) so as to optimize a selection of polymers that would 
ultimately lead to the achievement of this objective. 
4.2. Materials and Methods 
4.2.1 Materials 
Materials employed are the same as in Chapter 3; Section 3.2.1.  
 
4.2.2 Methods 
4.2.2.1 Preparation of the intravaginal bioadhesive polymeric device 
The polymers employed in this study were modified polyamide 6,10 (mPA 6,10), 
poly(lactic-co-glycolic acid) (PLGA), polyacrylic acid (PAA 974), polyvinly alcohol (PVA), 
ethylcellulose (EC), polyethlene oxide (PEO), carageenan (CG) gelatin (GL), xanthan 
gum (XG), beeswax (BWX), Eudragit S-100 (ES100) and Eudragit RS-100 (ERS100). 
Different combinations and quantities of these polymers (Table 4.1), derived from the 
preliminary screening experiments that were conducted in Chapter 3, were blended by 
using a cube blender (Erweka® GmbH, Heusenstamm, Germany). The powder blends 
were then compressed at a pressure of 5 tons into caplet-shaped intravaginal bioadhesive 
polymeric devices (IBPDs) on a Manesty D3B 16 station tableting press equipped with 
D3B oblong tooling of 22×9mm in dimension (Manesty D3B L249Q, Liverpool, England).  
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Table 4.1: The Polymer combinations employed in the production of the intravaginal 
bioadhesive polymeric devices 
Polymeric Composition (mg) 
F# P6 PG PA EC PV XG GL BW ES ER WT 
62 150 400 25 200 25 - - - - - 800 
27 200 250 25 300 25 - - - - - 800 
51 175 300 25 250 25 - - - 25 - 800 
52 175 300 25 250 25 - - - - 25 800 
41 175 300 25 250 25 - 25 - - - 800 
39 185 275 25 250 25 40 - - - - 800 
28 175 250 25 300 50 - - - - - 800 
40 180 275 25 250 25 45 - - - - 800 
44 175 275 25 250 25 50 - - - - 800 
36 200 275 25 250 25 25 - - - - 800 
29 150 250 25 300 100 - - - - - 800 
50 175 300 25 250 25 - - 25 - - 800 
37 195 275 25 250 25 30 - - - - 800 
38 190 275 25 250 25 35 - - - - 800 
31 100 250 25 300 125 - - - - - 800 
 
P6: Modified polyamide 6,10; PL: Poly(lactic-co-glycolic acid); PE: Polyethylene oxide PA: 
Polyacrylic acid; CG: Carrageenan; EC: Ethycellulose; PV: Polyvinylalcohol; XG: Xanthan gum; 
GL: gelatin; BW: beeswax; ES: Eudragit S100; ER: Eudragit RS 100; WT: Weight 
 
 
4.2.3. In-process validation tests 
In-process validation tests involving indentation hardness, mass uniformity and friability 
analysis were performed to ensure the reproducibility of the matrices. Indentation 
hardness was represented by the Brinell Hardness Number (BHN) derived through the 
textural profiling analysis. A sample of 10 caplets from each formulation batch was tested 
for mass uniformity and friability using the same instruments, parameters and limits as 
described in Chapter 3, Section 3.2.2.2.  
 
4.2.3.1 Determination of the Brinell hardness number  
The BHN (N/mm2) was computed for each set of devices using the ball probe approach. A 
calibrated Texture Analyzer (TA.XTplus, Stable Micro Systems, Surrey, UK) fixed with a 
ball probe indenter of diameter 3.125mm, indentation depth set at 1.5625mm and 5kg 
load cell for all readings was employed. The textural settings used to calculate the BHN 
values are depicted in Table 4.2. The typical force-distance profiles generated for the 
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calculation of the BHN value are illustrated in Figure 4.1. Each analysis was conducted in 
triplicate. The indentation hardness was represented by a conversion to the Brinell 
Hardness Number (BHN) (Equation 4.1). 
 
 
Equation 4.1  
                                                                                                   
       
where F= force generated from indentation (N), D= diameter of ball probe indenter 
(3.125mm) and d= indentation depth (1.5625mm). 
 
Table 4.2: Textural settings employed for BHN value calculations 
Parameters        Settings 
 
Pre-test speed                1.000 mm/sec 
Test speed                 0.500 mm/sec 
Post-test speed                   1.000 mm/sec 
Compressive distance               1.563 mm 
Trigger force                 0.050 N  
 
 
 

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Figure 4.1: Typical force-distance profiles employed in the determination of matrix 
indentation hardness of the IBPD. 
 
4.2.4 In vitro matrix erosion of the intravaginal bioadhesive polymeric device 
Each formulation was subjected to in vitro matrix erosion studies. Formulations  were 
immersed in 100mL of simulated vaginal fluid (pH 4.5; 37°C) using a sealable glass 
vessel (150mL) and then placed in an orbital shaking incubator (LM-530-2, MRC 
Laboratory Instruments Ltd., Hahistadrut, Holon, Israel) maintained at 20rpm.  After 24 
hours, each formulation was removed from the medium, blotted on filter paper (diameter 
110mm and pore size 20µm) and dried to constant weight at 40±0.5°C in an oven. All 
determinations were conducted in triplicate. The mathematical expression stated in 
Equation 4.2 was employed to determine the percentage matrix erosion (ME) (i.e. %w/w) of 
each formulation. 
 
100x
OM
RMOM
(%)ME
−
=                                                               Equation 4.2       
where ME is the matrix erosion, OM original mass, and RM the residual mass. 
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4.2.5 Optimization by ANN for the best polymer combination selection 
Optimization was conducted by employing the feedback Multilayer Perceptron (MLP) 
neural network to train the empirical input matrix erosion data with static back 
propagation. Figure 4.2 illustrates the typical construction of the MLP network while Table 
4.3 shows the input matrix erosion data (obtained from the matrix erosion studies) that 
was trained. The main advantage of these networks is that they can approximate any 
input/output map.   
 
Figure 4.2: Constructed multilayer perceptron network.  
 
 
A genetic algorithm with a Sigmoid Axon transfer function and Conjugated Gradient 
learning rule was employed for the hidden input and output layers. Figure 4.4 shows the 
network topology for the hidden input and output layers.  
 
 
Figure 4.3: Network topology depicting the hidden input and output layers. 
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Table 4.3: The input matrix erosion data that was trained by the Multilayer Perception 
Network  
Polymeric Composition 
F# P6 PG PA EC PV XG GL BW ES ER ME% 
62 150 400 25 200 25 - - - - - 1.21 
27 200 250 25 300 25 - - - - - 1.43 
51 175 300 25 250 25 - - - 25 - 2.89 
52 175 300 25 250 25 - - - - 25 3.26 
41 175 300 25 250 25 - 25 - - - 3.58 
39 185 275 25 250 25 40 - - - - 3.81 
28 175 250 25 300 50 - - - - - 3.83 
40 180 275 25 250 25 45 - - - - 4.37 
44 175 275 25 250 25 50 - - - - 4.45 
36 200 275 25 250 25 25 - - - - 5.57 
29 150 250 25 300 100 - - - - - 6.31 
50 175 300 25 250 25 - - 25 - - 6.48 
37 195 275 25 250 25 30 - - - - 7.20 
38 190 275 25 250 25 35 - - - - 7.53 
31 100 250 25 300 125 - - - - - 7.68 
 
P6: Modified polyamide 6,10; PL: Poly(lactic-co-glycolic acid); PE: Polyethylene oxide PA: 
Polyacrylic acid; CG: Carrageenan; EC: Ethycellulose; PV: Polyvinylalcohol; XG: Xanthan gum; 
GL: gelatin; BW: beeswax; ES: Eudragit S100; ER: Eudragit RS 100; ME%: Matrix erosion 
percentage 
 
A maximum of 10,000 epochs were run on NeuroSolutions Version 5.0 (NeuroDimension 
Inc., Gainsville, Florida) for ensuring optimal training of data. Sensitivity analysis was 
used for extracting the cause and effect relationship between the inputs and the outputs 
of the network. This could provide feedback pertaining to the input variable that was the 
most significant by testing the network with regard to its sensitivity about the matrix 
erosion for each formulation, thus elucidating the polymer combination type that was most 
significant. The parameters used to construct the neural network are as shown in Table 
4.4 
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Table 4.4: Artificial neural network construction parameters employing a neural builder 
Parameter Setting 
Hidden layer 2 
Exemplars 17 
Output Processing element 1 
Transfer function SigmoidAxon:sigmoid (0/1) 
Learning rule ConjugateGradient: second order method 
 for gradient 
Maximum Epochs  10,000: Supervised Learning Control 
Termination at Mean Square Error; Load 
Best Weights Approach 
Probe Configuration Quantitative-MatrixViewer, MatrixEditor;  
Qualitative-MegaScope, Hinton 
 
 
4.3. Results and Discussion 
4.3.1 In-process validation tests 
 
The devices were uniform in mass (800±0.48mg). Textural analysis confirmed BHN 
values ranging from 2.687-4.981N/mm2 while friability was at an average of 0.21% (Table 
4.5), demonstrating desirable matrix compatibility and compressibility. F15 presented with 
the highest BHN value (4.981N/mm2) while F1 presented with the lowest BHN value 
(2.687N/mm2). The high compressibility of PLGA and EC coupled with the ability of GL, 
BWX and XG to form a gel-like macrostructure may have contributed to the good friability 
and BHN values obtained. In addition, GL, BWX and XG resulted in non-collapsible 
formulations with a swelling tendency which improved the veracity of the matrix 
networked-structure, which contributed to the highest matrix integrity and thus the high 
BHN values obtained. 
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Table 4.5: Brinell hardness number, mass, and friability of the intravaginal bioadhesive 
polymeric device 
F# BHN (N/mm2) ±SD Mass (mg) ±SD %Friability ±SD 
1 2.687 0.109 801.23 4.459 0.369 0.015 
2 2.745 0.110 800.22 4.013 0.350 0.024 
3 2.778 0.100 799.45 4.127 0.312 0.013 
4 2.884 0.115 802.02 4.018 0.298 0.011 
5 2.922 0.121 798.79 3.933 0.274 0.013 
6 2.989 0.120 800.98 4.003 0.231 0.012 
7 3.063 0.132 802.00 4.012 0.227 0.012 
8 3.340 0.138 799.32 3.987 0.217 0.010 
9 3.521 0.139 801.79 3.967 0.201 0.009 
10 3.894 0.141 800.38 4.134 0.131 0.014 
11 4.367 0.140 797.97 3.556 0.108 0.007 
12 3.708 0.129 800.33 4.009 0.138 0.017 
13 4.703 0.148 800.58 4.013 0.103 0.006 
14 3.988 0.140 797.98 4.018 0.123 0.011 
15 3.897 0.138 800.23 4.127 0.326 0.017 
 
 
4.3.2 Matrix erosion evaluation  
Matrix erosion, polymer swelling and drug dissolution are the important factors that 
determine drug release from polymer matrices (Colombo et al., 1996; Gao and Meury, 
1996). Disolution systems can provide a means of overcoming the well-known advantage 
of a purely diffusion control system (Kim and Fassihi, 2000; Dürig and Fassihi, 2002; Al-
Taani and Tashtoush, 2003; Lopes et al., 2007; Sriamornsak et al., 2007; Efentakis and 
Peponaki, 2008; Malik et al., 2008). Furthermore, synchronization between erosion and 
diffusion fronts may produce zero-order drug release kinetics (Lee, 1980; Pillay and 
Fassihi, 2000; Pillay and Danckwerts, 2002; Pillay et al., 2005; Al-Taani and Tashtoush, 
2003). Normally in polymer matrices, polymer relaxation and erosion mechanisms may 
coexist (Christ et al., 1998; Bettini et al., 2001). The results of the matrix integrity as 
determined in terms of the matrix erosion percentage for the fifteen lead formulations are 
as shown in Table 4.3. Depending on the polymer combination and proportions of 
hydrophilic/hydrophobic polymer, all devices demonstrated different degrees of erosion as 
depicted in Table 4.3. F1 presented with the least matrix erosion (1.21%) while 
Formulation F31 presented with the highest matrix erosion (7.68%) (Table 4.3). Generally, 
the rate of matrix erosion from the IBPDs appeared to depend mainly on the networking 
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level of their hydrophilic and hydrophobic polymer-based microstructure. Matrix erosion in 
a polymer matrix is usually determined by the rate at which the polymer undergoes 
hydration and swelling (Roy et al., 2002; Khamanga and Walker, 2006; Sriamornsak et 
al., 2007; Choonara et al., 2008). Therefore, matrix erosion from the IBPDs depended on 
the relative magnitude of polymer hydration at the moving rubbery/glassy front within the 
IBPDs. F1 contained the highest content of PLGA (400mg) and a relativey high quantity of 
EC (200mg) (Table 4.3). These polymers are highly hydrophobic with high compressibility 
properties. The presence of relatively low quantities of the hydrophilic polymers in this 
formulation (mPA 6,10: 150mg; PAA: 25mg; PVA 25mg) coupled with the hydrophobic 
nature of PLGA and EC are certainly the reasons for the minimal matrix erosion observed. 
The same reason holds for the rest of the formulations which apparently were the best 
formulations from the OVAT-based screening that was undertaken in Chapter 3. Thus, the 
high degree of hydrophobicity prevented rapid penetration of water molecules into the 
polymer matrices, leading to less hydration, swelling and erosion and therefore the lowest 
degree of matrix erosion.  
 
PAA has played the leading role in fostering the bioadhesivity of the IBPD (see Chapter 5 
later), but it had to be applied in minimal quantities due its high swelling properties. PAA 
in water swells up to 1000 times its original volume (Bonacucina et al., 2004), which 
permits the ionization of its carboxylic groups, that facilitate the formation of adhesive 
bonds with either the protein or glycoprotein of the vaginal epithelium (Figure 4.4). A 
chemometric structural model developed in our laboratories showed that the protein and 
polymer bonding at the cell surface of the vaginal epithelium, via the embedded glyco-
protein and other surface proteins plays a key role in linking the incoming polymer or 
other smaller units. The saccharide part in the glycol-protein binds to the inherent surface 
protein and available functional groups in the protein and to some extent the glyco-
proteins saccharide units are extended in binding to the polymer (i.e. PAA) (Figure 4.4).  
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Figure 4.4: A chemometric structural model developed in our laboratories for a glyco-
protein structure showing attachment of cellular surface protein (red) bound to the 
saccharide part of the glyco-protein (blue) and both (surface) protein and glyco-protein 
(green) bound to the polymer (here PAA) (white) for non-evenly distributed applied force 
during adhesion, with non-smooth and unevenly contacted two interacting surfaces with 
non-evenly distributed and non-constant, non-steadily (applied) force for the adhesion 
shown in a 3D optimized state with ball model. The coiling loop distortions for both protein 
and glycoprotein are also shown.  
 
 
4.3.3 Selection of polymer combinations as per ANN optimization 
For the 12 polymers that were employed in the study, the MLP network was able to 
accurately confirm that mPA 6,10, PLGA, EC, PVA and PAA were the most significant 
input variables in terms of matrix integrity of the IBPD based on the empirical data. The 
approach followed in this work required prior assumption for the selection of a 
mathematical model before applying the ANN models so as to be able to confirm the 
sensitivity coefficients of the various polymer types as input variables that significantly 
contributed to characterizing the matrix integrity. In order to obtain accuracy and 
maximum degree of precision, the training was done twice (i.e. primary and secondary 
training). For the primary training, the three run outcomes are as shown in Figure 4.5a. 
Run # 2 gave the lowest level of the mean square error (MSE). The gradual leveling of the 
MSE with standard deviation (SD) boundaries for the training runs indicated a sequential 
PAA 
Glyco-protein 
Surface protein 
Surface protein and 
glycol-protein 
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improvement of data modeling as illustrated in Figure 4.5b. Table 4.6 depicts the average 
of the MSE values for the three runs of the primary training, the best network run out 
10,000 epochs, and the overall efficiency and performance of the neural network during 
the data training.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: a) MSE for the primary ANN training, b) Average MSE for the primary ANN 
trains with standard deviations for 10,000 epochs.   
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Table 4.6: Neural network indicators characterizing the efficiency and performance of 
data in the primary training as per ANN 
Best Network Training  Performance ME (%) 
Epoch # 10,000 MSE 0.768 
Minimum MSE 0.001 NMSE 0.010 
Final MSE 0.002 MAE 0.519 
- - Min Abs Error 0.002 
- - Max Abs Error 2.512 
R2 - - 0.99 
MSE: Mean square error 
NMSE: Normalized mean square error 
MAE: Mean absolute error 
Min Abs Error:  Minimum absolute error 
Max Abs Error:  Maximum absolute error  
 
Basing on the obtained results, it is evident that the employed training model was highly 
efficient (MSE=0.001). Results revealed a highly satisfactory fit for the input variables (R2 
= 0.99). The performance criterion employed to assess the closeness and correlation 
between the desired and the actual network output for matrix erosion of each formulation 
is listed in Table 4.7 and illustrated in Figure 4.6. The sensitivity coefficient of each 
polymer type (input variables) is depicted in Figure 4.7. 
 
 
Table 4.7: Actual and desired network performance criterion data from the primary 
training 
Desired output: ME (%) Actual network output (%) 
1.21 1.19905708 
1.43 1.73679249 
2.89 3.27070479 
3.26 3.27070479 
3.58 3.27070479 
3.81 4.75966199 
3.83 3.48203039 
4.37 4.02684657 
4.45 4.48380486 
5.57 5.98735234 
6.31 6.08292899 
6.48 6.48950281 
7.2 7.01026921 
7.53 6.66716927 
7.68 7.91356107 
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Figure 4.6: A profile depicting the a) desired and b) actual network output. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: A typical bar chart graph depicting the sensitivity coefficients of each polymer 
type against the matrix erosion following the primary training.  
 
 
From the primary ANN training it was apparent that 6 among 10 polymer types had the 
highest sensitivity against matrix erosion. These were mPA 6,10, PLGA, EC, PEO PVA 
and PAA (Figure 4.7). Thus, a second (secondary) ANN training was run to explore the 
potential of these polymers to constitute an optimal formulation for developing the IBPD. 
The MSE for the secondary training is shown in Figure 4.8a. As can be noted, the 
secondary training resulted in highly reduced MSE values. For the primary training the 
 
Polymer Type
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MSE ranged between 0.02-9.02 (Figure 4.5a) while for the secondary training the MSE 
ranged between 0.01-0.92 (i.e. less than 1) (Figure 4.8a). The gradual leveling of the 
MSE with standard deviation (SD) boundaries for the secondary training exhibited a 
sequential improvement of data modeling in that the average MSE decreased from values 
that were almost close to 10 (for primary training) (Figure 4.5) to values less than 1 as 
shown in Figure 4.8b. Overall these results depict a high degree of sensitivity for this set 
of polymers when compared to the rest. 
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Figure 4.8: a) MSE for the secondary ANN training, b) Average MSE for the secondary 
training with standard deviations for 10,000 epochs.   
 
 
As was the case with the primary training, the MSE for the secondary training was 0.001 
with an excellent fit for the input variables as well (i.e. R2 = 0.99). The sensitivity 
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coefficient of each polymer type against matrix erosion is as shown in Figure 4.9. EC 
presented with the highest sensitivity against matrix erosion followed by PLGA (Figure 
4.9). This depicts their high capacity in controlling matrix erosion. This behavior may be 
attributed to their high degree of hydrophobicity. The sequence of the other remainng 
polymers in terms of sensivity against matrix erosion was PVA, PAA and mPA 6,10. The 
results observed with PVA is a reflection of the results obtained earlier in matrix swelling 
tests where it had presented with minimal swelling (Chapter 3; Section 3.3.2.2). The low 
sensitivity against matrix erosion shown by PAA and PA 6,10 (Figure 4.9), may be 
associated with their hydrophilic nature. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: A typical bar chart graph showing the sensitivity coefficients of each polymer 
type against the matrix erosion following the secondary training.  
 
 
The desirable matrix integrity exhibited by formulations with markedly reduced quantities 
of PAA is reflected in the formulation containing mPA 6,10 (150mg), PLGA (400mg), EC 
(200mg), PVA (25mg) and PAA (25mg). This formulation was able to provide a matrix 
erosion value which was as low as 1.21% (Section 4.2.5; Table 4.3). These results are 
supported by the relationship between the matrix erosion and the varied input polymer 
quantity (Figure 4.10). PAA, which was mainly employed due to its bioadhesivity potential, 
showed a markedly high influence on matrix erosion in that even at quantities as low as 
25mg, it could result in a static impact on matrix erosion (Figure 10). This is certainly due 
Polymer Type
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to its high degree of hydrophilicity. PVA which was mainly used for the purpose of 
enhancing bioadhesivity and controlled release to the IBPD, portrayed a substantially high 
positive sensitivity for matrix erosion (Figure 10) and therefore the reason why it was also 
used in minimal quantities (25mg). mPA 6,10 which was employed for the purpose of 
achieving desirable controlled drug release, presented with a relatively low sensivity to 
matrix erosion compared to the other hydrophilic polymers i.e PAA and PVA. PLGA and 
EC which are highly hydrophobic polymers, presented with a markedly high degree of 
negative sensitivity for matrix erosion (Figure 4.10). The substantially high matrix integrity 
of this formulation, may therefore be attributed to the high degree of hydrophobicity in 
PLGA and EC, good matrix resilience of mPA 6,10, and the hydrophilic nature of PAA and 
PVA which allowed formation of the networked microstructure in the IBPD polymer matrix. 
The bioadhesivity capacity of the optimized formulation is assessed later in Chapter 5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: Correlation between matrix erosion and polymer quantity. 
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4.4. Concluding Remarks 
A comprehensive analysis of several polymers for the development of the IBPD was 
conducted in terms of matrix erosion. The results of this study have highlighted polymeric 
effects on the matrix erosion of the IBPD. The high sensitivity against matrix erosion 
shown by the best 5 polymers (Figure 4.7 and 4.9) in both primary and seconadary ANN 
training was an indication of their suitability in formulating a stable IBPD. The ANN 
approach confirmed that mPA 6,10 (150mg), PLGA (400mg), EC (200mg), PVA (25mg) 
and PAA (25mg) could lead to the development of an optimized intravaginal bioadhesive 
polymeric drug delivery device.  
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CHAPTER FIVE 
 
IN VITRO AND EX VIVO BIOADHESIVITY ANALYSIS ON THE OPTIMIZED 
INTRAVAGINAL BIOADHESIVE POLYMERIC DEVICE COMPOSED OF DIFFERENT 
CROSSLINKED POLYACRYLIC ACIDS 
 
5.1 Introduction 
The development of bioadhesive intravaginal drug delivery systems allows for therapeutic 
levels of bioactive to be maintained locally, extends the bioactive residence time within 
the vagina and reduces the dosing frequency and quantity of bioactive administered 
(Mathowitz and Jacob, 1999; Ugwoke et al., 1999; Ceschel et al., 2001). Thus, the 
therapeutic efficacy of locally-acting bioactives may be improved due to the increased 
availability at the vaginal epithelium afforded through bioadhesion (Elson et al., 2000; 
Genc et al., 2000; Mandal, 2000). Currently, the majority of bioadhesive polymers include 
polyacrylic acid and cellulose derivatives (Repka and McGinity 2001), 
poly(vinylpyrrolidone) (PVP), poly(vinylalcohol) (PVA), chitosan and various gum-based 
polymers such as xanthan gum (XG) (Tambwekar et al., 2002). Multifunctional polymers 
exhibiting bioadhesive and/or gelling properties such as the thiolated polyacrylates and 
poloxamers represent a useful framework for the design of intravaginal drug delivery 
systems (Bogentoft et al., 1996; Remuñán-López et al., 1998; Lee et al., 2000; Lehr, 
2000;Valenta et al., 2001; Kast et al., 2002; Robinson and Bologna, 2002; Valenta et al., 
2002; Tang et al., 2005 ; Bonferoni et al., 2006; Al-Tahami and Singh, 2007;  Trapani et 
al., 2009).  
Bioadhesivity is essentially defined as the interfacial force between the polymeric drug 
delivery system and the mucus layer coating an epithelium (Peppas and Buri, 1985). 
Bioadhesion may occur in three distinct phases namely wetting, interpenetration and 
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subsequent mechanical interlocking between mucin and the polymer (Longer and 
Robinson, 1986; Jast et al., 2003). Bioadhesion is thus thought to be a result of the 
presence of hydrogen bonding groups, strong anionic/cationic charges, high molecular 
mass, chain flexibility and surface energy interactions which favor spreading onto the 
vaginal tissue. Basic theories such as electronic, adsorption, wetting and diffusion 
phenomena have been described and associated with the mechanisms by which 
bioadhesion occurs (Helfand and Tagami, 1972; Kaelble, 1977; Deryaguin et al., 1997). 
Each of the steps involved in bioadhesion may be facilitated by the polymeric composition 
of the drug delivery system and the mode of application (Hussain, 2000). Several 
techniques for the in vitro assessment of bioadhesion have been explored and include 
adhesion mass methods (Smart and Kellaway, 1982), fluorescent probe methods (Park 
and Robinson, 1984), shear stress testing (Smart et al., 1984), flow channel techniques 
(Mikos and Peppas, 1986), tensile testing (Park and Robinson, 1987), colloidal gold 
staining methods (Park, 1989), averted sac technique and the CAHN microbalance 
(Santos, 1999). However, these techniques lack sufficient sensitivity.  
Therefore the aim of this Chapter was to investigate the use of a comprehensive multi-
dimensional approach including chemometrical molecular modeling and pertinent 
mathematical descriptors to assess the polymeric bioadhesivity to vaginal tissue. The 
Area Under the Force-Distance Curve (AUCFD) under a global locale was computed for all 
data points iterated during bioadhesion testing of optimized polyacrylic acid (PAA)-based 
intravaginal matrices generated through an Extreme Vertices Mixture Experimental 
Design template. Bioadhesivity testing was conducted on both simulated vaginal 
membrane and freshly excised pig vaginal tissue. The ideal polymers obtained through 
the optmization by ANN approach i.e. modified polyamide 6,10, (mPA 6,10), poly (lactic 
co-glycolic acid (PLGA), ethylcelloluse (EC), polyvinyl alcohol (PVA) and polyacrylic acid 
(PAA) were employed for the study. Apart from the ensured matrix integrity, these 
polymers also have the potential for controlling drug release, ensuring desirable 
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erodability, homeostatic control of the vaginal environment and bioadhesive potential. 
Studies have shown that PAA is a highly bioadhesive polymer (Semalty et al., 2006; 
Semalty and Semalty, 2008). Therefore, for the purpose of achieving optimal 
bioadhesivity, this study explored two combinatory matrices comprising PAA, namely allyl 
sucrose-crosslinked PAA (AS-PAA) and allyl penta erythritol-crosslinked PAA (APE-PAA). 
  
5.2 Materials and Methods 
5.2.1 Materials 
The simulated vaginal membranes employed were dialysis flat sheet membranes of 
Mw=12,000-14,000g/mol purchased from Spectrum Laboratories Inc. (Rancho 
Dominguez, CA, USA). Allyl sucrose-crosslinked PAA (AS-PAA) and allyl penta erythritol-
crosslinked PAA (APE-PAA) were purchased from Noveon Inc Cleveland, OH, USA. Pig 
vaginal tissue was excised from euthanized pigs obtained from the University of the 
Witwatersrand Central Animal Services Unit. The modified PA 6,10 was synthesized as 
per the  method described in Chapter 3, Section 3.2.1.1. The rest of the materials used 
were as described in Chapter 3. 
 
5.2.2 Methods 
5.2.2.1 Preparation of the intravaginal bioadhesive polymeric device caplets 
composed of allyl sucrose and allyl penta erythritol-crosslinked PAA  
An Extreme Vertices Mixture Design template was generated employing Minitab® V15 
(Minitab® Inc., PA, USA) statistical software to produce various caplet formulations 
comprising 11 polymer combinations (Table 5.1). Each formulation had an equivalent 
mass of 800mg. Formulation response optimization was performed using an inherent D-
optimal technique by combining mixture components and processing factors to converge 
to pre-optimal settings prior to achieving a global optimized solution with the desirable 
polymeric proportions for the AS-PAA and APE-PAA caplets that were subsequently 
prepared and further tested. 
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Table 5.1: Extreme Vertices Mixture Formulation Template for caplet preparation 
F # mPA 6,10 (mg) PLGA(mg) EC (mg) PVA (mg) PAAa (mg) PAAb 
(mg) 
1 150 50 100 100 200 200 
2 100 50 100 150 250 200 
3 100 50 100 100 205 250 
4 130 55 105 105 205 205 
5 105 80 105 105 200 205 
6 100 100 100 100 205 200 
7 105 55 130 105 230 205 
8 105 55 105 105 210 230 
9 110 60 110 110 200 210 
10 100 50 150 100 205 200 
11 105 55 105 130 200 205 
 aAS-PAA: allyl sucrose-crosslinked PAA 
 bAPE-PAA: allyl penta erythritol-crosslinked PAA 
 
PLGA, mPA 6,10, EC, PVA and the two crosslinked PAA variants were weighed in 
triplicate and subsequently blended using a cube blender (Erweka Apparatebau, 
Heusenstamm, Germany). Two sets of blends were prepared in each case, one 
containing AS-PAA and the other APE-PAA. The polymer blends were then compressed 
into IBPD caplets using a Manesty D3B 16 station tableting press (Manesty D3B L249LQ, 
Liverpool, England) equipped with D3B oblong tooling of 22×9mm in dimension at a 
compression pressure of 5 tons. 
 
5.2.2.2 In-process validation tests  
Diametric hardness, mass uniformity and friability analysis were conducted on the IBPD 
caplets to ensure adequate manufacturing reproducibility. A sample of 10 caplets from 
each formulation batch was tested for diametric hardness, mass uniformity and friability 
using the same instruments, parameters and limits as described in Chapter 3, Section 
3.2.2.  
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5.2.2.3 In vitro and ex vivo bioadhesivity analysis 
Bioadhesivity testing was performed on all experimental formulation batches and both 
sets of optimized caplets (i.e. the AS-PAA and APE-PAA caplet formulations) using a 
highly sensitive Texture Analyzer (TA.XTplus, Stable Microsystems, UK). This approach 
was employed to principally measure the bioadhesiveness using a cylindrical probe that 
was robotically guided to make contact and induce a test force onto the non-deformed 
substrate surface comprising either a simulated vaginal membrane or freshly excised pig 
vaginal tissue and thereafter disengage in order to simultaneously measure the force 
required to detach the probe containing the vaginal tissue from the hydrated caplet. The 
maximum force required to detach the simulated vaginal tissue attached to the cylindrical 
probe from the secured caplet on the platen was obtained from the Peak Adhesive Force 
(PAF) and also computed from the Area Under Force-Distance Curves (AUCFD.) 
representing the Work of Adhesion. In each case, the simulated vaginal membrane and 
the caplets were hydrated for 30 minutes in simulated vaginal fluid (pH 4.5; 37°C) 
(Chapter 3, Section 3.2.2.3, Table 3.3) prior to testing (N=3). For further method and 
formulation validation bioadhesivity testing was also conducted using freshly excised 
vaginal tissue obtained from a pig model on the APE-PAA and AS-PAA caplets. The 
textural analysis parameter settings employed were pre-test and test speeds = 2.0mms-1, 
a post test speed = 10mms-1, a trigger force = 0.5N and a contact time of 5s. 
 
5.2.2.4 Removal of vaginal tissue from the pig model for bioadhesivity testing 
A Large White female pig (84kg) was euthanized with 40mL of sodium pentobarbitone 
(200mg/mL) administered intravenously. The pelvic canal of the pig was opened by 
dissecting through the symphysis pubis and then exposing the intra-abdominal vaginal 
tract. The external vaginal tract was carefully dissected from the surrounding tissues 
before removing the vaginal tissue (Figure 5.1). An incision was made through the vaginal 
canal to expose the inner lining of the tissue, which was then placed in an airtight 
specimen jar and immediately subjected to bioadhesivity testing. 
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Figure 5.1: The dissection process to remove the vaginal tissue from the pig.  
 
The freshly excised vaginal tissue was secured onto a cylindrical textural probe of a 
Texture Analyzer (TA.XTplus, Stable Microsystems, UK). An optimized APE-PAA caplet 
was fixed onto the textural platen after exposure to simulated vaginal fluid (pH 4.5; 37°C) 
for 30 minutes. Bioadhesive testing was then conducted immediately by measuring the 
maximum force (N) required to detach the vaginal tissue from the hydrated APE-PAA 
caplet matrix. Data was represented as the Peak Adhesion Force (PAF) and the work of 
adhesion (AUCFD.) (Figure 5.2). The work of adhesion per unit area (wA αβδ), was 
characterized by the work executed on the matrices when the two contact phases i.e. the 
vaginal tissue (α) and the caplet matrix (β), formed an interface of unit area which were 
subsequently separated reversibly to form unit areas of each of the αδ- and βδ- interfaces. 
This relationship is mathematically described by Equation 1.  
 
wAαβδ = γ α δ + γ β δ − γ αβ            Equation 5.1 
 
Where, γ αβ, γ αδ and γ βδ are the surface tensions between the two bulk phases 
comprising the vaginal tissue and the APE-PAA IBPD caplets , α, β; α, δ and β, 
δ respectively. 
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Figure 5.2: Textural analysis method employed to generate Force-Distance profiles for 
assessing the caplet bioadhesivity to freshly excised pig vaginal tissue indicating a) blue 
paint design, b) actual process. 
 
5.2.2.5 Rheological analysis of hydrated AS-PAA and APE-PAA polymers 
The ability of PAA to partially hydrate within the IBPD matrix ultimately results in wetting 
and volumetric distension of the system which facilitates the intimate contact and 
interaction with the simulated vaginal membrane and freshly excised pig vaginal tissue. 
Rotational rheological analysis was therefore performed to generate flow curves for 
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analyzing relationships between the viscosity and shear stress as a function of shear rate 
using a Modular Advanced Rheometer system (ThermoHaake MARS Rheometer, 
Thermo Fischer Scientific, Karlsuhe, Germany) equipped with a T-type spindle sensor 
(C35/1oTi) set at a sample gap of 1mm and a Thermocontroller (UTC-MARS II). The AS-
PAA and APE-PAA polymers were dissolved in simulated vaginal fluid at a concentration 
of 2%w/v, vortexed for 2 minutes, and then assessed for their rheological behavior at 
25±1.0oC with a test time of 200s and a controlled rate starting at 5.00s-1 decreasing to 
0.001s-1 and a shear rate ranging from 0 to 500s-1.  
 
5.2.2.6 Mechanistic postulation of caplet bioadhesion employing chemometric and 
molecular modeling and associated interactive energy paradigms 
Cellular adhesion will play a critical role toward the mechanisms of achieving superior 
bioadhesion. While a number of computational models and experimental studies have 
addressed the issue of cell adhesion to surfaces, no model or theory has adequately 
addressed cell adhesion at the molecular level employing freshly excised pig vaginal 
tissue as the bioadhesive substrate (King, 2001; Yang and Zaman, 2007). Computational 
and molecular structural modeling was performed in our laboratories to deduce the 
transient mechanisms of bioadhesivity, chemical interactions and inter-polymeric 
interfacing during caplet adhesion to the freshly excised pig vaginal tissue as the 
adhesive substrate. This approach led to predictive findings solely based on the chemical 
interactions underlying the bioadhesion of the caplet to the vaginal tissue substrate. Semi-
empirical quantum mechanics was used to generate molecular interactions and 
computational energy paradigms of the caplet components based on inherent interfacial 
phenomena underlying the mechanisms of bioadhesion provided by the inter-polymeric 
blended caplet. Models and graphics supported on the step-wise molecular caplet-tissue 
interaction, polymeric interconversion and bioadhesion as envisioned by the molecular 
behavior and stability of the hydrated caplet network were generated on  ACD/I-Lab, 
V5.11 (Add-on) software (Advanced Chemistry Development Inc., Toronto, Canada, 
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2000). The energy distribution curves assumed a componential progression of 
bioadhesion stability, a spatially uniform distribution of polymers within the caplet, and an 
irreversible gelation process (Schroeder et al., 1998; Yu et al., 1998; Picout et al., 2000a 
and b; Kalugin et al., 2001; Gilsenan et al., 2003a, b, c).  
 
A comprehensive chemometric molecular understanding of the mechanisms by which 
certain macromolecules adhere to the vaginal tissue epithelium is not yet available (Mikos 
and Peppas, 1990; Valenta, 2005). Therefore a thermodynamic model that addresses 
receptor-mediated cell adhesion at the molecular level was explored. By incorporating the 
entropic, conformational, solvation, and long- and short-range interactive components of 
receptors and the extracellular matrix molecules, adhesive free energy as a function of a 
number of key variables such as surface coverage, interaction distance, molecule size, 
and solvent conditions were predicted. This allows the computation of the free energy of 
adhesion in a multi-component system in order to simultaneously elucidate adhesion 
receptors and ligands of different sizes, chemical identities, and conformational 
properties. This approach not only provides a fundamental understanding of adhesion at 
the molecular level but may also aid in identifying possible strategies for designing novel 
biomaterials to improve bioadhesion of the caplet to the pig vaginal tissue substrate.  
 
5.3 Results and Discussion 
5.3.1 Assessment of caplet bioadhesivity 
Work of adhesion values for the APE-PAA caplets were significantly higher (P<0.05) than 
those of AS-PAA caplets. The difference in work of adhesion was 94.1% (Figure 5.3). 
This clearly indicated that the APE-PAA caplets had superior bioadhesivity than the AS-
PAA caplets. The difference in bioadhesivity may be due to the difference in percentage 
crosslinking of allyl sucrose and allyl penta erythritol to PAA. Allyl sucrose is 1.5% 
crosslinked (Corring, 1992) while penta erythritol is 2.0% crosslinked (Wilber et al., 2003). 
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This slightly higher density of crosslinking in APE-PAA may therefore have translated into 
an intense hydrated network capable of facilitating superior bioadhesion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: A comparison of work of adhesion (AUCFD) (J) between the AS-PAA and 
APE-PAA caplets (N=3; SD<0.03). 
 
5.3.2 Response optimization via textural analysis outputs from the optimized AS-
PAA and APE-PAA caplets 
Response optimization of the AS-PAA and APE-PAA caplets using Minitab® V15 (Minitab® 
Inc., PA, USA) software revealed the optimum level for each polymer (mPA 6,10, PEO, 
PLGA, CG and PAA) within the caplets in order to provide the most desirable relative 
bioadhesivity (Figure 5.4).  The bioadhesivity values for the in vitro test were significantly 
higher compared to the in vivo test (P<0.01) (Table 5.2). The reason is mainly based on 
the nature of the surfaces with which the caplets made contact with to establish the 
bioadhesive force. The in vitro test employed artificial simulated vaginal membrane 
whereas the in vivo test employed freshly excised vaginal membrane. The mucus present 
on the surface of the freshly excised vaginal membrane underwent a constant turn-over 
with the old layer being replaced by a new one. This process interrupted the 
establishment of hydrogen bonds and van der Waal forces between the caplet and the 
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vaginal membrane thereby resulting in low bioadhesion. With articial membrane, there 
was no turn-over effect and therefore once a bond formed, it remained intact (i.e. the 
interaction holds) which may thus be the reason for the higher bioadhesivity observed. 
Furthermore, mucus degrades while artificial membranes do not and therefore the 
biodhesive forces established in the later, remained intact and undisturbed. The 
difference in bioadhesivity between the AS-PAA and APE-PAA caplets was 46.7% (Figure 
5.5). The desirability (D) values were 0.98 and 0.92 respectively indicating the sufficient 
convergence of data toward an optimized global solution. 
 
 
 
 
 
Figure 5.3: A typical response optimization plot for the AS-PAA and APE-PAA caplets 
Figure 5.4: A typical response optimization plot for the AS-PAA and APE-PAA caplets. 
 
 
 
Table 5.2: Comparative in vitro and ex vivo bioadhesivity results for the optimized caplets 
 
Textural parameters 
 
Predicted 
(x10-3) 
Experimental 
(x10-3) 
In vitro analysis of optimized AS-PAA and APE-PAA caplets 
Force of adhesion (N) 
AS-PAA caplet 1300.00 1168.10 ± 93.270 
APE-PAA caplet 2000.00 1671.60 ± 23.221 
 
Work of adhesion (J) 
AS-PAA caplet 0.50 0.32 ± 0.13 
APE-PAA caplet 0.90 0.60 ± 0.21 
 
Ex vivo analysis of the optimized APE-PAA caplet 
Force of adhesion (N) 1000.00 883.00 ± 82.73 
Work of adhesion (J) 0.35 0.30 ± 0.035 
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5.3.3 Ex vivo bioadhesivity analysis of the optimized APE-PAA caplets on freshly 
excised vaginal tissue 
The PAF value obtained was 0.883±0.08273N while the work of adhesion (AUCFD) was 
0.0003±3.53553 X10-5J. The results portrayed a direct correlation between the PAF and 
the work of adhesion (Table 5.2 and Figure 5.6). The optimized caplet matrices with 
desirability (D) values close to 1 depicted excellent correlation (R2=0.99) between the 
predicted and the experimental results (Table 5.2).  
 
 
Figure 5.5: Typical textural profiles elucidating the peak adhesive force (PAF) (N) and 
work of adhesion (AUCFD) (J) for the optimized composed of: a) AS-PAA, and b) APE-
PAA. 
 
a) b) 
Force (N) Force (N) 
Distance (m) Distance (m) 
2 2 
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Figure 5.6: Typical textural profile elucidating the force (N) and work of adhesion (AUCFD) 
(J) for the optimized APE-PAA caplets on freshly excised vaginal tissue. 
 
5.3.4 Rheological analysis of the hydrated AS-PAA and APE-PAA polymer solutions 
AS-PAA and APE-PAA are polymers that are able to produce mucilages with short 
rheological flow properties that can be associated with the high degree of crosslinking in 
both polymers. In terms of rheological properties, APE-PAA was found to be highly 
viscous (900x10-3mPas) in comparison to AS-PAA (80x10-3mPas) with a subsequent 
higher shear stress (180Pa vs. 58Pa) (Figure 5.6). Justifiably, this rheological observation 
may explain the superior bioadhesivity of the APE-PAA caplets over the AS-PAA caplets. 
In both cases the viscosity decreased as the shear rate increased (Figure 5.7). 
 
 
 
 
 
 
 
 
 
 
 
Force (N) 
Distance (m) 
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Figure 5.7: Rheological behavior of 2%w/v AS-PAA and APE-PAA solutions at a shear 
rate between 0-500s-1. 
 
The bioadhesivity behavior of the caplets to the freshly excised pig vaginal tissue is a 
typical reflection of the fact that the polymer combination employed for matrix formation 
typically possesses different structural deformation mechanisms due to their backbone, 
molecular mass, polymeric concentration, chain flexibility, spacial conformation, pH of 
volumetric distention at the polymer-substrate interface, the associated forces, the initial 
contact time and the extent of mucin turn-over. This may be a result of their variation in 
moduli and rheological deformation energies. Hence deformation or flow at the polymer-
vaginal tissue substrate interface occurred within the polymeric matrix with subsequent 
failure at the interface to induce and control the degree of bioadhesion between the caplet 
and the freshly excised vaginal tissue.  
5.3.5 Postulative chemometric and molecular modeling of the mechanisms of caplet 
bioadhesion and the associated interactive energy paradigms 
Results obtained from chemometric and computational analysis of the associated energy 
paradigms have revealed that the caplet bioadhesivity to the freshly excised pig vaginal 
tissue substrate may be explained in terms of the Differential Adhesion Hypothesis (DAH) 
 
0
20
40
60
80
100
120
140
160
180
0
100
200
300
400
500
0
200
400
600
800
Sh
ea
r S
tr
es
s 
(P
a)
Sh
ea
r R
at
e (
1/s
)
Viscosity (X10 -3 mPa)
AS-PAA matrix
APE-PAA matrix
 133 
theory of cell adhesion (Steinberg, 1996; Brodland, 2003; Foty and Steinberg, 2005; 
Steinberg, 2007; Katsamba et al., 2009). The pig vaginal tissue substrate acted as a 
viscoelastic flexible semi-solid with a tissue surface tension corresponding to a mutual 
classification behavior occupying an internal position relative to the gelled caplet with a 
lower surface tension during interaction. Quantitative energy variations in homo-and 
hetero-typic bioadhesion were sufficient to account for the phenomenon without the need 
to postulate cell-type specific bioadhesion. The caplet bioadhesion occurred in a stepwise 
mechanism involving weak inter-atomic and inter-molecular physical forces that interplay 
at the outset (Figure 5.8).  
 
During initial contact of the caplet with the freshly excised pig vaginal tissue substrate 
mechanical bioadhesion occurred with all surface voids between the caplet and tissue 
substrate filled and therefore resulted in surface interlocking. As the caplet hydrated a 
more unyielding chemically adhesive interaction progressed between the hydrated inter-
polymeric blend of the caplet to form a bioadhesive compound at the interface either 
through ionic or covalent bonding prior to caplet dispersion. In the dispersive phase of 
bioadhesion the hydrated caplet and vaginal tissue substrate were bound by van der 
Waals forces as a result of polymeric ionic species generated due to disentanglement and 
volumetric distention of the constituent polymers. In the simplest case, molecules during 
this phase of bioadhesion were polar with respect to the average charge density and may 
be due to Keesom forces or a transient effect of London forces. Once the caplet and 
vaginal tissue substrate diffusively merged, both interfaces were miscible through a 
sintering-like mechanism. The strength of bioadhesion depended on a hybrid between the 
dispersive and diffusive phases as well as the contact surface area. Polymers such as the 
AS-PAA and APE-PAA were able to significantly wet during sol-gel interconversion and 
therefore provided a reduced contact angle facilitating bioadhesion.  
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Figure 5.8: A chemometric structural model developed in our laboratories depicting caplet 
bioadhesion to freshly excised pig vaginal tissue with muco-epithelial cell secretions and 
surface bio-molecule interactions. 
 
Figure 5.9a-d depicts the energy estimates for bioadhesion representing the physical 
forces, ionic and chemical interactions as well as ion-exchanges during bioadhesion. This 
involved electron donations and sharing of covalent bonds between the xenobiotic 
polymers of the caplet and cellular proteins of the vaginal tissue substrate. Interactions 
with collagen in the substrate surface with polymer-protein interactions were also present. 
The extent of hydration also played a significant role in hydration of the caplet resulting in 
ionic interaction pockets that contributed towards bioadhesion. Structural deformities of 
the caplet and proteins occurred with proteins transitioning into coiling at primary, 
secondary, tertiary and quaternary structure levels that participated in bonding to the 
polymers and facilitated bioadhesion.   
 
The energy barrier between the compartmental interactions determined the extent of 
bioadhesion as a factor of energy (Figure 5.9a-d). The protein and polymer bonding at the 
cell surface via the embedded glyco-protein and other surface proteins played a role in 
linking the polymer. The saccharide component of the glyco-proteins bonded to the 
inherent surface protein and available functional groups and to some extent also bonded 
to the AS-PAA and APE-PAA polymers within the caplet. The energy differences and 
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level played a rate-limiting factor in the proposed bioadhesion phenomenon. Helical 
structural transitions and distortions within the polymer were predicted by molecular 
modeling and also affected by stereo-orientation though no effects on the coiling or helical 
turns of the protein were observed. The embedded glyco-proteins were least affected and 
provided the anchoring groups for polymer-substrate bioadhesion.   
 
 
Figure 5.9: Energy estimates for the mechanism of bioadhesion developed in our 
laboratories: a) compartment A=interactions at physical forces levels, B=ionic interactions 
and ion-exchanges producing bioadhesion, C= chemical interaction involving covalent 
bonding between the xenobiotic polymer and cellular protein, D=interaction with surface 
collagen in the tissue substrate includes polymer-protein-collagen interactions.  
 
Hydration also played a role and facilitated polymeric gelling and induction of ionic 
interaction pockets that contributed towards bioadhesion. Furthermore, collagen was 
dissolved from the fibrils by proteases and structurally adjusted to the requirements of 
bioadhesion as a result of polymer-protein and polymer-collagen interactions. Generally, 
the barriers to break weak physical bonds do not usually exceed 10–20 times the thermal 
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energy, kT (where k is the Boltzmann constant and T is the absolute temperature). The 
lifetime of these bonds can vary from microseconds to seconds. Hence, polymers form 
and break these weak physical bonds numerous times during the course of bioadhesion.  
 
The caplets comprised two types of polymeric chain molecules arising from the AS-PAA 
and APE-PAA within the matrices. In order to predict the mechanisms of cell-matrix 
bioadhesion it was assumed that both surfaces (i.e. the caplet and vaginal tissue 
substrate) were two dimensional parallel planar impenetrable surfaces. In addition to 
polymeric chain molecules, the residual voids between the two surfaces were assumed to 
be filled with simulated vaginal fluid. To simulate protein interactions with the polymers, 
“generic” amino acids were employed and conformations chosen randomly from sterically 
allowable regions using dihedral angles. The polymer molecules were simulated with a 
similar strategy. Bioadhesive mechanisms were modeled to capture the essential features 
of polymer-protein interactions. Increasing the number of sampled conformations did not 
significantly alter the results and for simplicity only interactions between polymer-protein, 
collagen-polymer and polymer-protein-collagen were considered with self-interaction 
terms ignored. All interaction terms contained attractive and repulsive phases with an 
incompressibility condition or volume-filling constraint introduced to account for repulsive 
interactions. Under this assumption, no two segments could occupy the same volume 
which was the result of repulsive interactions. 
 
5.4 Concluding Remarks 
The polymer-based caplets adhered to the simulated vaginal membranes and the freshly 
excised pig vaginal tissue revealing the potential for application in intravaginal drug 
delivery. Chemometrical and molecular structural modeling deduced that the potential 
mechanisms of bioadhesivity are a combination of mechanical, chemical, dispersive and 
diffusive bioadhesive phenomena. Rheological analysis revealed that AS-PAA and APE-
PAA displayed varying rheological behavior contributing to bioadhesion to the in vitro and 
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ex vivo substrates evaluated. Furthermore, the results demonstrated that APE-PAA 
caplets were more bioadhesive than the AS-PAA caplets and therefore capable of 
providing an optimized IBPD formulation. The bioadhesivity testing approach employed 
using freshly excised pig vaginal tissue suggests that the method developed may be 
useful for measuring the bioadhesivity of other intravaginal drug delivery systems on 
vaginal tissue substrates. Rational design of future bioadhesive intravaginal drug delivery 
systems should focus on the polymer properties that conform to vaginal retention to target 
bioactives more appropriately.  
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CHAPTER SIX 
 
INVE S TIG AT ION OF  THE  P HY S IC OC HE MIC AL  AND P HY S IC OME C HANIC AL  
P R OP E R TIE S  OF  THE  OP TIMIZE D INTR AV AG INAL  B OADHE S IVE  P OL Y ME R IC  
DE VIC E  
 
6.1 Introduction 
The thermodynamic behavior of polymers is known to have a significant impact on the 
physicomechanical properties and therefore their final performance (Pillay and Fassihi, 
1999; Liu et al., 2003; Parija, et al., 2004). Therefore, accurate thermal analysis of 
polymer blends employing temperature modulated differential scanning calorimetry 
(TMDSC) is critical during formulation design (Ribeiro and Grolier, 1999). TMDSC 
provides a clearer interpretation of thermal transitions on analyzed samples due to the 
improved sensitivity and resolution, coupled with the ability to separate reversible glass 
transitions that have diminutive transitions in heat capacity from overlapping non-
reversible relaxation endotherms. TMDSC is also used to reveal thermal transitions at 
sub-zero temperatures that cannot be detected by conventional DSC due to poor 
equilibrium of the heat flow baseline below 0°C (Pijpers et al., 2000). Thus, the 
development of multi-polymeric intravaginal drug delivery systems requires a 
comprehensive understanding of the thermodynamic stability of the polymeric 
constituents used in designing the system.  
 
The natural and most important protection against potential infections in the vagina is the 
presence of a normal, healthy vaginal flora (Vitali et al., 2007; Obiero et al., 2008; 
Mastromarino et al., 2009). An acidic vaginal pH value ranging from 4-5 is a crucial 
requirement for the optimal functioning of the body's natural protective system in the 
vagina. Thus, maintenance of this pH range in the vagina is important as it can effectively 
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avoid colonization by pathogens which may lead to gynecological problems since most of 
the pathogens cannot thrive under acidic conditions (Boskey et al., 2001; Ramsey 2002; 
Mastromarino
 
 et al., 2009). There are numerous factors that regulate the composition and 
dynamics of the vaginal microbial ecosystem and that maintain the natural protective 
functions of the vagina. The most important one, however, is the breakdown of glycogen 
(released from the upper vaginal epithelium), which is then metabolised to glucose, and 
finally lactic acid by Lactobacilli (Boskey et al., 2001). This results in an ideal acidic 
environment in the vagina, thus providing effective protection against infection.  Generally, 
drug permeation rates correlate with partition coefficients and are inversely proportional to 
the molecular mass of the drug (Iyer et al., 2008). Thus, successful development of an 
intravaginal drug delivery system should consider permeation characteristics as a result of 
the formulation design, the therapeutic agent and vaginal physiology (Verman and Garg, 
2000; Iyer et al., 2008; Ndesendo et al., 2008).   
Therefore the aim of this Chapter was to design, develop and evaluate the bioadhesivity, 
permeability, thermal stability and the in vitro drug release of a novel drug-loaded 
intravaginal bioadhesive polymeric device (IBPD) for the prevention of HIV and other STIs 
employing model drugs AZT and PSS. The device should provide controlled drug release 
over an experimental period of at least one month when inserted into the posterior fornix 
of the vaginal cavity. Pig vaginal tissue was employed for permeation analysis due to the 
fact that the pig vaginal mucosa is very similar in many respects to human vaginal 
mucosa (Kremer et al., 2001; Thomson et al., 2001; Davis et al., 2003; Squier et al., 
2008). Both types of mucosa consist of stratified squamous epithelium that is supported 
by connective tissue and lamina propria with lipid compositions that are comparable (van 
Kremer et al., 2001; Thomson et al., 2001). The specific polymers expressly selected in 
formulating the device included combinations of modified polyamide 6,10 (mPA 6,10), 
poly(lactide-co-glycolide) (PLGA), allyl penta erythritol-crosslinked PAA (APE-PAA), 
polyvinyl alcohol (PVA) and ethylcellulose (EC) that were primarily employed for 
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controlling the release of AZT and PSS from the IBPD. PSS played a dual role as a 
polymer matrix and a bioactive (Garg et al., 2004a; Chu et al., 2007) (Chapter 3, Section 
3.2.1.1). PAA was used as both polymer matrix constituent as well as a coating agent for 
the purpose of achieving extended bioadhesivity within the posterior fornix of the vagina 
(Bonacucina et al., 2006; Ndesendo et al., 2009).  
 
The acidic environment in the vagina may be influenced by the changes in pH and ionic 
concentrations as a result of PLGA degradation into lactic and glycolic acid through 
cleavage by enzymatic or non-enzymatic hydrolysis (Park et al., 2005; Yasukawa et al., 
2006; Kulkarni et al., 2007). Thus, since PLGA was one of the polymers selected for 
formulating the IBPD, it was important to determine the changes in micro-environmental 
pH the simulated vaginal fluid when exposed to the degradating constituents of the IBPD. 
A specific X-ray imaging approach employing radiopaque barium sulfate (BaSO4) was 
developed for detecting and determining the retention and sequential biodegradation 
pattern of the IBPD device within the vagina of the Large White pig. In addition to having 
radiopaque properties, BaSO4 (which is biocompatible) was employed as a polymer 
matrix stabilizer for the purpose of enhancing matrix integrity (Bailey and Swett, 2007).
 
 
Furthemore, since chemometric and molecular modeling approaches can precisely 
explicate various interactive mechanisms of drug release and permeation dynamics that 
occur from a drug delivery system, a model was developed in our laboratories to elucidate 
these mechanisms at a molecular level. 
6.2 Materials and Methods 
6.2.1 Materials 
The two model drugs were AZT (Evershine Ind., Naejar Malad, Mumbai, India) and PSS 
(Omega (Pty) Ltd., Montreal, Canada). Methylparaben (Merck (Pty) Ltd., Darmstadt, 
Germany), shellac (Roeper GmbH, Hamburg, Germany), castor oil (Jayant Oils and 
Derivatives Ltd., Mumbai, India), barium sulphate (BaSO4) (Merck-Schuchardt, 
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Hohenbrunn, Germany), pentobarbitone, ketamine (Bayer (Pty) Ltd, Wrenchwerg, Isando, 
South Africa), midazolam (Roche Products (Pty) Ltd, Isando, Gauteng, South Africa) and 
isoflurane (Safe Line Pharmaceuticals (Pty) Ltd, Florida, South Africa) were utilized to 
facilitate the in vivo studies. The mobile phase solvents comprising acetonitrile (99.9%) 
and methanol (99.9%) were purchased from Romil-SpS™ (Cambridge, UK). All other 
materials employed were the same as in Chapter 3. 
 
6.2.2 Methods 
6.2.2.1 Preparation of the intravaginal bioadhesive polymeric device 
Biodegradable and biocompatible polymers namely mPA 6,10 (150mg), PLGA (400mg), 
APE-PAA (25mg), PVA (25mg) and EC (200mg) were blended with model drugs AZT and 
PSS (separately and in combination) as well as radio-opaque barium sulfate (BaSO4), 
using a cube blender (Erweka® GmbH, Heusenstamm, Germany), and then compressed 
into robust devices on a tableting press. One set of devices was coated with 2%w/v
 
 APE-
PAA while another set remained uncoated. In process validation tests were performed to 
ensure that the IBPD device had desirable quality attributes in terms of diametric 
hardness, uniformity in mass and friability.  
6.2.2.2 Pan coating of the intravaginal bioadhesive polymeric device  
A dual coating process using the Thai Coater® (Pharmaceutical and Medical Supply 
Limited Partinership, Yannawa, Bankok, Thailand) was employed with a protective 
undercoat comprising shellac and thereafter a mixture of XG and APE-PAA as an 
overcoat in order to prevent any irritation to the vaginal tissue during device insertion. The 
addition of APE-PAA was to facilitate bioadhesion of the IBPD to the posterior fornix of 
the vagina. The process involved firstly undercoating the IBPD with a combination of 
shellac (4mg/device), cold pressed castor oil (3mg/device) and ethanol (96%). This was 
followed by an overcoat of XG (2%w/v) and APE-PAA (2%w/v). XG was used for its 
viscoelastic non-collapsible swellability in order to facilitate bioadhesion of the IBPD in 
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conjunction with APE-PAA that was employed as a biodhesive polymer (Iseki et al., 2001; 
Gimeno et al., 20003; Verhoeven et al., 2006). The processing conditions utilized for 
effective coating of the IBPDs are listed in Table 6.1. A non-coating period of 30 minutes 
was allowed after each coating phase to effect a reduction in pan temperature and avoid 
sticking or fracture of the undercoat or overcoat seal. The increase in weight after coating 
the IBPD was determined using an electronic balance (Mettler, Model AE 240, 
Griefensee, Switzerland) while the increase in thickness was determined using a digital 
vernier caliper (Taizhou hangyu tools gauge and blades Co., Ltd, Wenqiao, Zhejiang, 
China) with a sensitivity of 0.01. 
 
Table 6.1: Parameters and settings employed for coating the intravaginal bioadhesive 
polymeric device 
Parameter Settings 
Temperature 
 
50-56°C 
Relative humidity 23-28% 
Warming-up period 10min 
Pan rotation  2-3rpm 
Spray rate 4g/min 
Volume of coating  2L 
Number of caplets coated  2000 
Undercoating duration 30min 
Over-coating duration 
 
60min 
 
 
 
6.2.2.3 Influence of the intravaginal bioadhesive polymeric device on the micro-
environmental pH of the vagina 
The changes in micro-environmental pH within simulated vaginal fluid due to the presence 
of the IBPD were assessed by incubation of 3mL simulated vaginal fluid (containing the 
IBPD) in a Multi-Purpose Titrator (MPT-2) equipped with a rapid response, liquid filled 
glass pH micro-electrode supported on a vertical puller (Malvern Instruments Ltd., 
Worcestershire, UK). The changes in pH were evaluated from a pH-time profile over 30 
days. The electrode calibration standards were adjusted to cover the buffer range from pH 
3.5-5.5 with a linear Nernstian response maintained.   
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6.2.2.4 Thermal analysis of the polymeric composition and the coated intravaginal 
bioadhesive polymeric device  
TMDSC was performed on the constituent polymers (mPA 6,10, PLGA, APE-PAA, PVA, 
and EC) as well as the unhydrated and hydrated physical mixtures of the polymers and 
the IBPD (Mettler Toledo, DSC1, STARe System, Schwerzenback, Switzerland). The 
thermal events were explicated in terms of the glass transition (Tg) measured as the 
reversible heat flow (∆H) due to changes in the magnitude of the C p-complex values 
(∆Cp), melting (Tm) and crystallization (Tc) temperature peaks which are consequences of 
irreversible and reversible ∆H values corresponding to the total heat flow. The 
temperature calibration was accomplished with the melting transition of indium. The 
transitions of the individual polymers and their physical mixtures were compared with the 
transition of the composite IBPD matrix. Samples were weighed (5mg) on perforated 40μL 
aluminum pans, crimped and then ramped from -35-230°C under a nitrogen (Afrox, 
Germiston, Gauteng, South Africa) atmosphere in order to diminish oxidation at a rate of 
1°C/min. The instrument parameters and settings employed are listed in Table 6.2. 
 
Table 6.2: Temperature modulated differential scanning calorimetry settings employed for 
thermal analysis of the intravaginal bioadhesive polymeric device and its formulation 
components 
Segment Type Parameter Setting 
 
SINE PHASEa                                                                    
Start 
 
 
-35°C 
Heating rate 1°C/min 
Amplitude 0.8°C 
Period  
 
LOOP PHASEb   
To segment  
Increment  
End  
Count 
0.8°C 
 
 
1 
0.8°C 
230°C 
436 
 
aSinusoidal oscillations 
bOscillation period 
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6.2.2.5 Ex vivo bioadhesivity testing of the coated drug-loaded intravaginal 
bioadhesive polymeric device 
The excision of vaginal tissue from the pig model for bioadhesivity testing was undertaken 
following the method described in (Chapter 5, Section 5.2.2.4). 
 
6.2.2.6 Textural profiling analysis to determine the bioadhesivity of the intravaginal 
bioadhesive polymeric device  
Bioadhesivity of the IBPD was determined using a method described in one of our recent 
publications (Ndesendo et al., 2009). Briefly, the freshly excised pig vaginal tissue was 
secured on the textural probe and the IBPD was fixed onto the heated textural platen after 
exposure to simulated vaginal fluid (pH 4.5, 37°C) (Chapter 3, Section 3.2.2.3, Table 3.3) 
for 30 minutes. Testing was then conducted by measuring the maximum force (N) 
required to detach the vaginal tissue from the fixed device. This was determined by 
measuring the Peak Adhesive Force (PAF) or the Work of Adhesion that was computed 
as the area under the curve of a Force-Distance textural profile (AUCFD).  
 
6.2.2.7 Insertion of the intravaginal bioadhesive polymeric device into the vagina of 
the pig 
Three Large White pigs each weighing 35kg were anaesthetized with midazolam 
(0.3mg/kg I.M.) and ketamine (11mg/kg I.M.). 2% isoflurane in 100% oxygen was 
administered via a face mask to maintain anesthesia. The IBPD was then deeply inserted 
into the posterior fornix of the vagina of each pig with the aid of an applicator and a 
speculum as shown in Figure 6.1a and b. 
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Figure 6.1: Digital images depicting a) insertion of the IBPD into the vagina of the pig and 
b) tracking the location of the IBPD in the vagina using a speculum. 
 
 
6.2.2.7.1 X-ray imaging of the pig for detection of the intravaginal bioadhesive 
polymeric device 
To detect the presence and position of the IBPD in the pig vagina after insertion, animals 
were X-rayed (Siemens AG, Medical Engineering Group, Erlangen, Germany) directly 
after device insertion and thereafter three times weekly for 2 weeks, then twice weekly for 
a further 2 weeks to confirm the retention of the IBPD in the vagina and to qualitatively 
analyze its swellability and bioerosion dynamics. 
 
6.2.2.8 In vitro drug release from the coated and uncoated intravaginal bioadhesive 
polymeric device 
In vitro drug release evaluation was conducted on the APE-PAA coated and uncoated 
AZT-loaded IBPDs and coated AZT-and PSS-loaded IBPDs  
 
6.2.2.8.1 Analysis of the effect of device coating on the drug release 
To assess the effect of coating on drug release, analysis was conducted on IBPDs 
(coated and uncoated) containing AZT as a representative drug model due to its 
hydrophilicity. An IBPD was immersed in a 100mL (Umamaheshwari et al., 2004; Charde 
et al., 2008) simulated vaginal fluid (pH 4.5; 37°C) (Chapter 3, Section 3.2.2.3, Table 3.3) 
using a sealable glass vessel (150mL) and placed in an orbital shaking incubator (LM-
530-2, MRC Laboratory Instruments Ltd., Hahistadrut, Holon, Israel) maintained at 20rpm 
and a temperature of 37ºC. For the determination of AZTconcentration, 3mL samples 
a) b) 
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were withdrawn at predetermined time intervals over a period of 30 days and subjected to 
Ultra Performance Liquid Chromatography (UPLC) analysis. An equivalent volume of 
drug-free simulated vaginal fluid was replaced into the release medium to maintain sink 
conditions. The analysis was conducted in triplicate.  A correction factor was appropriately 
applied in all cases where dilution of samples was required.  
 
6.2.2.8.2 Analysis of the drug release from the coated devices containing AZT and 
PSS separately and in combination 
For the analysis of the drug release from the coated devices containing AZT and PSS 
separately and in combination, the same procedure as in Section 6.2.2.8.1 was employed 
the only difference being that in this case samples for analysis were withdrawn over a 
period of 72 days.   
 
6.2.2.8.3 Chromatographic conditions for the analysis of AZT and PSS 
concentration 
Quantitative analysis was performed using a Waters® Acquity Ultra Performance Liquid 
Chromatographic (UPLC) system (Waters Corp., Milford, MA, USA), equipped with a 
photodiode array (PDA) detector and interchangeable columns, namely, a UPLC® BEH 
phenyl column (1.7µm; 2.1×50mm) for AZT separation, and a UPLC® BEH C18 column 
(1.7µm; 2.1×100mm) for PSS separation. The binary mobile phases were composed of 
water/acetonitrile (60:40v/v) and methanol/water (50:50v/v) for AZT and PSS respectively. 
All solutions were filtered using a 0.22µm membrane filter (Millipore Corp., Bedford, 
Massachusetts, USA) prior to injection onto the UPLC column. A gradient assay method 
was used for AZT separation with a column temperature set at 25°C, injection volume of 
2µL and a UV detection wavelength of 267nm. The gradient settings for the assay method 
are shown in Table 6.3. An isocratic assay method was used for PSS separation 
employing methanol/water (50:50v/v) as the mobile phase, a flow rate of 0.2mL/min, a 
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column temperature of 25°C, an injection volume of 1.7µL and a UV detection wavelength 
of 244nm. 
 
Table 6.3: Chromatographic mobile phase gradient settings used for the separation of 
AZT 
Separation 
events 
Time  
(min) 
Flow Rate 
(mL/min) 
% A 
 (Water) 
% B 
(Acetonitrile) 
 
1 
 
0.00 
 
0.500 
 
60.0 
 
40.0 
2 1.00 0.500 5.0 95.0 
3 2.60 0.500 5.0 95.0 
4 3.50 0.500 60.0 40.0 
 
 
6.2.2.8.4 Preparation of standard solutions and calibration curves 
The internal standard employed for both model drugs was methylparaben (MP). Standard 
solutions of AZT, PSS and MP (internal standard) were separately prepared by mixing 
specific quantities in water/acetonitrile (60:40v/v) for AZT and methanol/water (50:50v/v) for 
PSS to yield a concentration of 0.1mg/mL in each case. The standard solutions employed 
in preparing the calibration curve of the test drug and internal standard were obtained by 
further serial dilutions with a final concentration range of 25-10,000ng/mL. The internal 
standard solution was prepared at a concentration of 5000ng/mL and was added to all 
samples prepared for UPLC analysis. Calibration curves were developed using blank 
simulated vaginal fluid (pH 4.5) and computed as a ratio of the Area Under the Curve 
(AUC) of AZT and PSS chromatographic peaks to that of the internal standard MP against 
the corresponding standard concentrations of AZT and PSS (Figure 6.2a and b).  
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Figure 6.2: a) Calibration curves for: a) AZT in simulated vaginal fluid 267nm (N=3, 
SD<0.001 in all cases); b) PSS in simulated vaginal fluid 244nm (N=3, SD<0.003 in all 
cases).  
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6.2.2.8.5 The solid phase extraction procedure employed in the extraction of the 
drugs from simulated vaginal fluid samples for UPLC analysis 
This was carried out by using single use Water Oasis® HLB 3cc (60mg) extraction 
cartridge (Waters Corporation, Milford, Massachusetts, USA) adapting a method 
developed by Notari and co-workers (2006). The Solid Phase Extraction (SPE) cartridge 
was conditioned with 1.0mL methanol followed by 1.0mL water Milli-Q. For AZT sample 
preparation, 1mL of sample was mixed with 1mL of acetonitrile vortexed for 1 minute and 
centrifuged (Nison Instrument (Shangai) Limited, Shangai, China) at 13,000rpm for 6 
minutes at 24oC. 650μL of the supernatant was diluted by adding water Milli-Q (1mL) and 
loaded in the cartridge. Thereafter, the cartridges were washed with 1.0mL of 5%v/v 
methanol in water Milli-Q. Analytes were eluted by washing cartridges with 550μL 0.01M 
KH2PO4 followed by 2mL methanol. The eluate was evaporated to dryness in a slow 
stream of high purity nitrogen gas (Afrox, Germiston, Gauteng, South Africa). The 
extracted sample was re-constituted with 100μL absolute methanol, mixed with 400μL of 
MP, and then filtered into the injection vials using 0.22μm syringe-driven filter units 
(Millipore Corporation, Bedford, Massachusetts, USA) for UPLC analysis. The same 
procedure was followed for PSS samples. However, methanol was used as the mobile 
phase. 
 
6.2.2.9 Ex vivo drug permeation studies through pig vaginal tissue from the 
intravaginal bioadhesive polymeric device using the Franz Diffusion Cell Apparatus 
The permeation studies to assess the extent of drug permeation across pig vaginal tissue 
were performed using a Franz Diffusion Cell (FDC) apparatus (PermeGear Inc. 
Bethlehem, PA, USA) equipped with a 12mL receptor compartment, clamp and stirrer-bar. 
Freshly excised pig vaginal tissue obtained from the euthanized Large White pig 
described above was placed between the donor and receptor compartments of the FDC 
apparatus (Figure 6.3). 10mL simulated plasma (pH 7.4; 37°C) (Giannola et al., 2007) 
(Table 6.4) was used in the receptor compartment and continuously agitated. IBPD device 
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containing AZT and PSS was dissolved in 50mL simulated vaginal fluid (pH 4.5; 37°C) 
(Chapter 3; Section 3.2.2.3; Table 3.3), by crashing and triturating it into a powder form 
and then solubilising the powder by the aid of a sonicator (SB 5200D, Ultrasonic, Ningbo 
Scientists Biotechnology Co Ltd, Ningbo, China). The solutions were then assessed for 
the permeation of the drug across the pig vaginal tissue (thickness=1.5±0.06mm; 
permeation area=2.0±0.01cm2) and into the simulated plasma in the receptor 
compartment. Samples (2mL) were withdrawn from the receptor compartment, at 
predetermined intervals over a period of 24 hours, and subjected to quantitative drug 
analysis using UPLC. An equivalent volume of drug-free simulated plasma was replaced 
into the receptor compartment to maintain sink conditions throughout the permeation 
study. The analyses were conducted in triplicate. A correction factor was appropriately 
applied in all cases where dilution of samples was required.  
The extent of permeation of AZT and PSS across the pig vaginal tissue was determined 
in terms of drug flux. The flux (mg.cm−2.hr−1) of drug across the vaginal tissue was 
calculated at steady-state per unit area by linear regression analysis of permeation data 
using Equation 6.1.  
tA
rQ
sJ ×
=                                                                                                   Equation 6.1   
where, Js is the flux (mg.cm−2.hrg−1), Qr (mg) is the quantity of AZT or PSS that diffused 
through the pig vaginal tissue into the receptor compartment, A (cm−2) is the effective 
cross-sectional area available for drug permeationand t (h) is the time of drug exposure to 
the vaginal tissue. 
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Figure 6.3: Permeation studies of AZT and PSS across pig vaginal tissue using a Franz 
Diffusion Cell apparatus. 
 
 
Table 6.4: Constituents used to prepare the simulated plasma fluid  
Simulated Plasma 
Component Quantity (g/L) 
                             KH2PO4                                0.144 
Na2HPO4 0.795 
NaCl 9.000 
(Giannola et al., 2007) 
 
6.2.2.9.1 Chromatographic conditions for the analysis of AZT and PSS 
concentration 
The chromatographic conditions for the analysis of AZT and PSS concentration in the 
simulated plasma fluid were the same as described in Section 6.2.2.8.3.  
 
6.2.2.9.2 Preparation of standard solutions and calibration curves 
This was conducted in the same way as described in Section 6.2.2.8.4, the only 
difference being that calibration curves were developed using blank simulated plasma 
fluid (pH 4.5) (Section 6.2.2.9, Table 6.4) instead of simulated vaginal fluid. The 
constructed calibration curves are as shown in Figure 6.4a and b.  
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Figure 6.4: a) Calibration curves for: a) AZT in simulated plasma fluid 267nm (N=3, 
SD<0.001 in all cases); b) PSS in simulated plasma fluid 244nm (N=3, SD<0.003 in all 
cases).  
 
 
6.2.2.9.3 The solid phase extraction procedure employed in the extraction of the 
drugs from simulated plasma fluid samples for UPLC analysis 
The solid phase extraction procedure employed in the extraction of the drugs from 
simulated plasma fluid samples was the same as described in Section 6.2.2.8.5.  
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6.2.2.10 Postulated mechanism of the drug permeation and dissolution dynamics 
from the intravaginal bioadhesive polymeric device employing chemometric and 
molecular modeling 
Chemometric and molecular structural modeling was used to deduce the transient 
mechanisms of diffusion and dissolution, chemical interactions and inter-polymeric 
interfacing during the dissolution of the IBPD device and the permeation of AZT and PSS 
across the vaginal tissue. This approach allowed us to make predictive findings based on 
the chemical and physical interactions underlying the dissolution of the IBPD and the 
diffusion of AZT/PSS from the IBPD (contained in the simulated vaginal fluid) and finally 
the permeation of these drugs to simulated plasma fluid across the pig vaginal tissue. In 
addition, semi-empirical quantum mechanics were employed to generate molecular 
interactions and computational energy paradigms of the IBPD components based on 
inherent interfacial phenomena underlying the mechanisms of dissolution and diffusion as 
provided by the inter-polymeric blended IBPD. Models and graphics supported on the 
step-wise molecular IBPD-simulated fluids and IBPD-tissue interactions, polymeric 
interconversion, dissolution and diffusion as envisioned by the molecular behavior and 
stability of the gelled IBPD network were generated on  ACD/I-Lab, V5.11 (Add-on) 
software (Advanced Chemistry Development Inc., Toronto, Canada, 2000).  
 
6.3 Results and Discussion 
6.3.1 Coating of the intravaginal bioadhesive polymeric device 
Uniformly coated IBPDs were produced. The final mass for the coated caplets was 
1278±0.04mg while the uncoated caplets weighed 1200±0.01mg. Thus, the increase in 
weight was 6.5±0.02%w/w for which the thickness of the coat was 0.520±0.005mm. 
 
6.3.2 Micro-environmental pH variation analysis within the simulated vaginal fluid 
It was generally observed that the superficial simulated vaginal fluid immediately adjacent 
to the immersed IBPD exhibited higher pH values than the simulated vaginal fluid 
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immediately surrounding the device. The initial pH, measured as close as possible to the 
device, upon insertion of the IBPD into the titration system (MPT-2) was 4.5±0.01 (N=3). 
The pH electrode was inserted using a Narashige micro-manipulator and was submerged 
towards the IBPD by careful hydraulic micro-movements to avoid creating any 
unnecessary turbulent hydrodynamic flow. A slight drop in pH was routinely recorded as 
the electrode passed in proximity to the IBPD with a slightly more acid pH than the entire 
simulated vaginal fluid (pH 4.48±0.02) around a superficial surface diameter of 5mm. The 
pH, measured away from the superficial layer was 4.58±0.03 (N=3). The relatively higher 
pH at the superficial layer may have been due to the extruding OH- ions from mPA 6,10, 
EC, PAA or PVA. The relatively lower pH observed at the IBPD proximity (micro-
environmental pH) could most certainly have been due to the break down of PLGA into 
lactic and glycolic acids. This biphasic response in pH was observed over an 
experimental period of 30 days. A profile depicting this sequence is shown in Figure 6.5. 
 
Attempts were made to perturb the inherent pH of the simulated vaginal fluid by adding 
incremental volumes of simulated seminal fluid of pH 7.4 (a significantly > volume than 
would be produced on degradation of the PLGA-based IBPD in the simulated vaginal 
fluid). After the addition of simulated seminal fluid, the pH recorded within the simulated 
vaginal fluid was 4.58+0.02 (N=3) and not significantly different from the resting pH of 
4.50 (P<0.01). Upon further addition of simulated seminal fluid into the MPT-2, the 
inherent pH was reduced to 4.52±0.03 (N=3) indicating that the simulated vaginal fluid 
was able to maintain its internal pH close to a value of 4.50 in the presence of a more 
alkaline medium (e.g. seminal fluid). Overall the results portrayed the potential of the 
IBPD to control and buffer the pH range of 3.5-5.5 in the simulated vaginal fluid by the 
virtue of the degradation of PLGA to lactic and glycolic acids. This pH range is the same 
as that produced by Lactobacilli species (Boskey et al., 2001) which plays a vital role in 
keeping the vagina healthy. It also covers the average pH range of a normal healthy 
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human vagina which is 4-5 (Smith, 1993; Ferris et al., 2006; WebMD, 2008) indicating the 
suitability of the IBPD for the intended purpose. 
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Figure 6.5: Micro-environmental pH variation in the simulated vaginal fluid containing the 
IBPD (N=3). 
 
 
6.3.3 Thermal analysis of the polymer constituents of the intravaginal bioadhesive 
polymeric device  
The thermal stability of the constituent polymers as well as the composite unhydrated 
IBPD was investigated by TMDSC at a temperature range from -35-230°C. The 
corresponding TMDSC thermograms are shown in Figures 6.6 to 6.13. The polymers 
displayed multi-transitional thermal behaviors with multiple Tg, Tm and Tc values (Table 
6.5) that were attributed to the existence of reversing and non-reversing endothermic 
signals arising from the transient melting of molecules within each polymer.  
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Table 6.5: Critical thermal events evidenced by diverse temperature inflection peaks for 
the polymer constituents of the intravaginal bioadhesive polymeric device 
Sample Analyzed 
Critical temperature transition points (°C) 
Tg Tc Tm 
 
mPA 6,10 163 120; 200 65; 140 
PLGA 45-55; 210 230 22; 220 
APE-PAA 90 60 30; 130-170 
PVA 22; 115 163; 215 30; 180 
EC 100 130 170 
Hydrated polymer 
blend 70; 160 210 22; 163; 200 
Unhydrated 
polymer blend 170 220 200 
Hydrated IBPD  83; 163 160 -10; 38; 85 
Unhydrated IBPD  
 
  
150 
 
 
140; 220 
 
 
222 
 
 
Tg=Glass transition temperature 
Tc=Crystallization temperature  
Tm=Melting temperature 
 
 
6.3.3.1 Thermal characterization of the native unhydrated polymer constituents of 
the intravaginal bioadhesive polymeric device 
 
6.3.3.1.1 Ethylcellulose (EC) 
EC was characterized by a Tg at 100°C and an exothermic Tc at 130°C (Figure 6.6). The 
Tm of EC occurred at 170°C which was relatively high compared to the other polymers 
employed. This revealed the superior thermodynamic stability of the polysaccharide 
subunits of EC.  
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Figure 6.6: TMDSC thermogram for the unhydrated ethylcellulose.  
 
6.3.3.1.2 Modified polyamide 6,10 (mPA 6,10) 
The mPA 6,10 had a distinct Tg at 163oC and two endothermic Tm values at 65°C and 
140°C. In addition, the exothermic Tc peaks observed at 120°C and 200°C followed this 
melting phases. This suggested partial decomposition of mPA 6,10 that may be related to 
matrix erosion (Figure 6.7) and the fact that the aliphatic polyamides inherently have a 
high heat of fusion and low entropy of fusion dependent on the collective dissociation 
energy of intramolecular H-bonds before any macroscopic dimensional changes can be 
realized (de Candia et al., 1998; Murthy, 2006).  
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Figure 6.7: TMDSC thermogram for the unhydrated polyamide 6,10 (PA 6,10). 
 
6.3.3.1.3 Poly(lactic-co-glycolic acid)  
PLGA was characterized by two Tg values (Figure 6.18). The first Tg peak appeared during 
the initial heating scan in which an enthalpy of relaxation peak superimposed the Tg 
between 20-30°C. The second Tg value at 210°C was also noted as PLGA is a quench 
cooled amorphous material (Teixeira et al., 2005; Mainardes et al., 2006; Rouse et al., 
2007). Furthermore, thermograms representing the total heat flow depicted a transient 
endothermic Tm peak at 22°C which was a recovery of heat loss. As heating proceeded, 
the Tg and the temperature at the apex of the overheating peak shifted to higher 
temperatures (Tg=210°C; Tm=220°C) due to the formation of a percolated network 
structure resulting from the quench cooling properties of PLGA. 
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Figure 6.8: TMDSC thermogram for the unhydrated poly (lactic-co-glycolic acid).  
 
6.3.3.1.4 Polyvinyl alcohol  
PVA is a semi-crystalline polymer in which high physical polymeric chain interactions exist 
due to H-bonding between the OH- groups. Thermograms for PVA revealed two Tg values 
at 22°C and 115°C and two endothermic Tm peaks at 30°C and 180°C (Figure 6.9) due to 
the thermal decomposition of the ordered PVA elements. Physical interactions between 
the polymer chains such as H-bonding contributed to the high enthalpy of fusion and Tm 
values observed for PVA. Thermodynamic analysis of PVA isotherms and crystallite 
growth rates has shown that crystallization of PVA (163°C; 215°C) is one-dimensional 
(Peppas and Hansen, 2003). Thus, due to the absence of water or other swelling agents, 
kinetic hindrances predominated as a result of interactions between the OH- groups of 
PVA. 
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Figure 6.9: TMDSC thermogram for the unhydrated polyvinyl alcohol.  
 
6.3.3.1.5 Allyl penta erythritol-crosslinked poly(acrylic acid)   
The salient thermal events for APE-PAA are shown in Figure 6.10 and Table 6.5. The 
broad endothermic peak (130-170°C) resulted from conformational changes in the 
macromolecules of APE-PAA related to the magnitude of crosslinking interactions 
between the proton-donating pendent COOH- groups and polar OH- groups of APE-PAA 
during synthesis (Sugama et al., 2007). The presence of COOH- groups favored the 
bioadhesiveness of APE-PAA within the pig vaginal tissue when used as a coating agent 
for the IBPD device.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10: TMDSC thermogram for the unhydrated allyl penta erythritol-crosslinked 
poly(acrylic acid).    
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6.3.3.2 Thermal characterization of the unhydrated intravaginal bioadhesive 
polymeric device 
Thermal analysis of the unhydrated IBPD revealed a Tg at 150°C, two Tc peaks at 140°C 
and 220°C and a Tm peak at 220°C (Figure 6.11). The presence of transient Tm peaks in 
the total TMDSC signals for the unhydrated IBPD indicated that the polymers were 
dispersed within the device matrix. In addition, diminutive exothermic events were 
observed at the corresponding Tc ranges for the constituent polymers indicating a high 
degree of crystallinity within the matrix structure. The deconvolution of the total TMDSC 
signals for the unhydrated IBPD in terms of reversing and non-reversing events reflected 
the average of the equivalent signals for each polymer. However, for the unhydrated IBPD 
the Tm appeared to be predominantly reversing due to the concurrent re-crystallization 
and melting phenomena that offset one another. This indicated that solid-solid phase 
transitions may have occurred within the unhydrated IBPD due to polymeric compression, 
and subsequently contributed to the prolongation and control of drug from the device. 
Thus, the thermodynamic stability of polymer blends may affect the drug release process 
and can therefore be used to predict the drug release behavior based on unequivocally 
defined thermodynamic events. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11: TMDSC thermogram for the unhydrated IBPD. 
 
 
 
  
   
Standard DSC Curve   
Total heat flow   
Non - reversing curve   
Reversing curve   
 
 162 
6.3.3.3 Thermal characterization of unhydrated and hydrated physical polymer 
blends as well as hydrated intravaginal bioadhesive polymeric device 
TMDSC analysis was also performed on hydrated and unhydrated physical blends of the 
constituent polymers of the IBPD as well as the hydrated IBPD in order to determine the 
effect of compression on the polymer blend. Thermograms obtained on the hydrated and 
unhydrated physical polymer blends as well as the hydrated and unhydrated IBPD are 
depicted in Figures 6.12 and 6.13 and in Table 6.5. Overall, there was a distinct similarity 
between thermal events of the hydrated physical polymer blend and the hydrated IBPD 
(Figures 6.16a and b). Thermograms presented with regions associated with very low 
temperatures (-10°C and -15°C) for the hydrated samples of the physical polymer blend 
and the IBPD while dehydration was complete at 200°C (Figure 6.16a and b). For the 
hydrated physical polymer blend (Figure 6.15a), the onset of the low-temperature 
endothermic Tm peak (22°C) was attributed to the high moisture content in the physical 
polymer blend while the apparent Tm peaks (163°C and 200°C) resulted from the loss of 
residual water as heating proceeded. The Tm endotherms were distinctly separated from 
the total heat flow in the non-reversing signal. 
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Figure 6.12: TMDSC thermogram for a) the hydrated physical polymer blend, b) the 
hydrated IBPD. 
 
The thermal behavior for the unhydrated physical polymer blend was markedly different 
from that of the unhydrated IBPD (Figure 6.13a and b). This was attributed primarily to the 
effect of polymer compression on the physical polymer blend to produce the device. 
Contrary to the hydrated physical polymer blend, the unhydrated polymer blend showed 
fewer thermal events (Figure 6.13a). A single Tg at 170°C and a Tm peak at 200°C were 
observed (Figure 6.13a). Furthermore, the Tg and Tm peaks that appeared for the 
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hydrated physical polymer blend prior to 170°C, were absent in the unhydrated polymer 
blend (Figure 6.13a). This may be associated with a baseline transition at ±170°C in the 
reversing heat flow signal. Overall, the hydrated physical polymer blend presented with 
lower Tm peaks (22°C and 163°C). These observations were consistent with previous 
results reported by Frushour (2004), where upon hydrating a physical polymer blend, the 
Tm peak was reduced well below the onset temperature. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13: TMDSC thermogram for a) the unhydrated physical polymer blend, b) the 
unhydrated IBPD. 
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6.3.4 Analysis of the drug release behavior from the coated and uncoated optimized 
drug-loaded intravaginal bioadhesive polymeric device 
 
6.3.4.1 Chromatographic separation of 3'-azido-3'-deoxythymidine and polystyrene 
sulphonate with methyparaben as an internal standard 
A UPLC assay method was used for quantifying the concentration of AZT and PSS 
released from the IBPD. The 3 dimensional chromatographic analysis of blank simulated 
vaginal fluid revealed complete separation with no interfering peaks at the retention times 
within the UV wavelength range of 200-400 (AZT/PSS and MP) as shown by the typical 
representative 3D UPLC profile in Figure 6.14. Chromatograms depicting the retention 
times for MP (internal standard), AZT and PSS in simulated vaginal fluid are as shown in 
Figure 6.15a and b. 
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Figure 6.14: A typical 3D UPLC profile showing a complete separation between AZT and 
MP (internal standard). 
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Figure 6.15: UPLC chromatograms depicting the separation of a) AZT and MP (internal 
standard) and b) PSS and MP (internal standard) in simulated vaginal fluid (pH 4.5; 
37°C). 
 
 
6.3.4.2 Assessment of the effect of coating on the drug release from the 
intravaginal bioadhesive polymeric device 
The shellac/APE-PAA-coated IBPD containing only one of the model hydrophilic drugs, 
AZT, demonstrated extended drug release when compared to the uncoated devices (28 
vs 20 days) (Figure 6.16a and b). This was due to the shielding effect of the initial shellac 
undercoat and APE-PAA overcoat applied. Once the APE-PAA coating was hydrated the 
shellac gradually solubilised in a manner that diffusion channels formed within the coating 
layer. This facilitated the drug diffusion from the IBPD. Furthermore, shellac (used as an 
undercoat) shielded the device against the ingress of release medium due to its wax-like 
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properties (Sinha, 2003). This may be attributed to its inherent moisture protecting 
properties, as well as its ability to act as a plasticizer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.16: A typical profile showing the effect of coating on the model hydrophilic drug  
AZT from a) uncoated IBPD and b) shellac/APE-PAA-coated IBPD in simulated vaginal 
fluid (pH 4.5; 37°C) (N=3; SD<0.18 in all cases). 
 
6.3.4.3 Analysis of the drug release behavior from the optimized coated intravaginal 
bioadhesive polymeric device containg AZT and PSS separately and in combination 
The substantial matrix integrity imparted by the polymers used to formulate the IBPD 
resulted in the minimization of the rate of matrix disentanglement and consequently 
prolonged and controlled the release of AZT and PSS from the IBPD. Controlled drug 
release representing zero-order was realized consistently over 40 days for AZT and 72 
days for PSS (Figure 6.17). These results can be attributed to the hydrophobic nature and 
high compressibility of EC, PLGA and PSS, coupled with the superior matrix resilience of 
mPA 6,10. The electrolytic nature of BaSO4 may have also contributed to the prolongation 
and control of drug release. The PSS-loaded IBPD achieved superior drug release 
behavior with consistent and controlled release over a period of 72 days (Figure 6.17d). 
For the IBPD loaded with both PSS and AZT, the release of PSS occurred over 56 days 
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compared to 40 days for AZT (Figure 6.17b and c). However this was still diminutive in 
comparison to the 72 days achieved from the PSS-only loaded IBPD (Figure 6.17d). 
Conversely, the period of AZT release from the IBPD was more prolonged than from the 
AZT-only loaded IBPD device (i.e. 40 vs 28 days) (Figure 6.17a and b). This was clear 
that the inclusion of PSS had a significant role in controlling the release of AZT from the 
IBPD due to the hydrophobicity of PSS and electrostatic properties (as a sodium salt) 
arising from its polymeric segmental charge density (Singh et al., 1995). Studies have 
shown that charge density of polyelectrolytes such as PSS enhance binding interactions 
and favors oppositely charged compounds, culminating in the lowering of the rate of 
desorption and diffusion thereby slowing the drug release rate from the polyelectrolyte 
compound (Singh et al., 1995; Vishalakshi, 1995, Pu et al., 2004). The hydrophobicity of 
PSS results from the presence of strong electrostatic charges and internal linkages (H- 
and S-bonds) in the residual un-sulfonated aromatic moieties of the PSS molecule (Jiang 
et al., 2003; Bonifazi et al., 2007). In addition, previous studies conducted on 
polyelectrolytes such as PSS have shown that the higher the osmotic coefficient and 
radius of gyration, the greater the ability to control the rate of drug release (Alvarez-
Lorenzo et al., 1999; Griffiths et al., 2004; Le Cer et al., 2004; Sen et al., 2007; Thapa et 
al., 2009; Viridén et al., 2009). 
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Figure 6.17: Drug release profiles of a) AZT (AZT-loaded IBPD), b) AZT (AZT/PSS-
loaded IBPD), c) PSS (AZT/PSS-loaded IBPD) and d) PSS (PSS-loaded IBPD), in 
simulated vagina fluid (pH 4.5; 37°C) (N=3; SD<0.38 in all cases). 
 
6.3.5 Assessment of drug permeation across the pig vaginal tissue   
The flux of AZT and PSS across the pig vaginal tissue over time is shown in Figure 6.18. 
A relatively constant increase in the rate of flux occurred over the initial 12 hours and 
thereafter a steady-state was achieved up to 24 hours (Figure 6.18). This suggests that 
the mechanism of passive drug transport across the pig vaginal tissue became saturated 
with drug. The lower flux of PSS reflects its high degree of hydrophobicity coupled with 
the presence of strong intermolecular charges in the polymer (Knudsen et al., 2004; Pu et 
al., 2004; Chu et al., 2007). This may therefore have contributed to controlling the 
permeation of the drug across the vaginal tissue. Overall, it can therefore be proposed 
that most of the drug was retained within the vaginal tissue.  
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Figure 6.18: Profiles showing the flux of AZT and PSS across pig vaginal tissue over a 
period of 24 hours (N=3, SD<0.23 in all cases). 
 
 
6.3.6 Ex vivo bioadhesivity analysis of the intravaginal bioadhesive polymeric 
device 
The devices that were produced were strongly bioadhesive. Textural profile analysis 
indicated that the uncoated devices had the lowest bioadhesivity (PAF=1.1976±0.150N; 
AUCFD=0.0019±0.0001J) compared to the PAA-coated devices (PAF=3.699±0.0.464N; 
AUCFD=0.0098±0.0004J) (Figure 6.19a and b). This indicates the superiority of APE-PAA 
as a bioadhesive coating as may be attributed to its hydrophilicity, H-bonding capacity, 
the high molecular mass and the surface tension properties of the polymer. APE-PAA 
controlled the extent of interpenetration between the polymer and the vaginal 
mucosal/epithelial surface. The high hydrophilicity of APE-PAA enabled the formation of 
strong bioadhesive bonds due to the high water content within the mucosal layer of the 
pig vaginal tissue. The presence of OH- and COOH- groups in APE-PAA may have 
favored the formation of H-bonds between the entangled APE-PAA chains and the pig 
vaginal tissue that ultimately resulted in bioadhesion (Chapter 4; Section 4.3.2; Figure 
4.4). In addition, the desirable surface tension of PAA facilitated spreading over the 
epithelial surface of the vaginal mucosal layer thereby enhancing bioadhesion.  
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Figure 6.19: Typical Force-Distance textural profiles used for computing the Peak 
Adhesion Force (PAF) and Work of Adhesion (AUCFD) for a) uncoated devices and b) 
PAA-coated devices on freshly excised pig vaginal tissue. 
 
 
6.3.7 Retention of the intravaginal bioadhesive polymeric device within the pig 
vagina 
Analysis of X-ray images (Figure 6.20) revealed that the devices were maintained in the 
posterior fornix of the pig vagina for the experimental period up to 30 days. The devices 
underwent swelling and gradually eroded over time as shown in Figures 6.20a, b and c 
which is in accordance with the stipulated design in which the formulation is expected to 
initially swell in order to facilitate bioadhesion and thereafter gradually erode and release 
the drug over the vaginal tissue for the required clinical preventative effect. 
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Figure 6.20: X-ray images depicting the presence of the intravaginal bioadhesive 
polymeric device at a) day 1, b) day 14, and c) day 30 after insertion into the posterior 
fornix of the pig vagina. 
 
 
 
 
a) 
b) 
c) 
 174 
6.3.8 Chemometric and molecular modeling of the intravaginal bioadhesive 
polymeric device drug dissolution and diffusion  
 
6.3.8.1 Postulation of dissolution dynamics and subsequent effect on drug release 
Chemometric and computational analysis conducted in our laboratories revealed that 
polymer-polymer and polymer-drug ratios, as well as the ratio between the coating 
polymers and components of the dissolution medium contributed substantially to drug 
dissolution kinetics obtained. Figure 6.21 depicts a step-wise model of the IBPD 
undergoing dissolution. 
 
inner core
shellac & castor oil layering
outer PAA layer
dissolution
AZT
PSS
Polymer strands
Medium & its ingredients
Hydrophilic areas
Hydrophobic areas
Hydrogen bondings & other ionic and molecular 
associations
Water intakeCaplet
ruptures
Figure 6.21: Molecular model mechanistically depicting the IBPD dissolution process with 
lesser H-bond formation due to the excessive of simulated vaginal fluid providing more 
freedom to polymeric strands to disentangle. 
 
Regarding the physicochemical associations of the polymers, AZT and PSS, all 
components were homogenized to produce a characteristic even distribution within the 
IBPD matrix. The hydrophile-hydrophobe properties, molecular interactive sites and 
functional groups in the mass and stoichiometry of the matrix was in a 2:3 ratio as 
depicted in Figures 6.22a-c for a typical IBPD matrix. The core of the IBPD was a 
heterogenous matrix medium in the active solid-state and molecular properties of the 
polymers and excipients were in a dormant solid-state. The dissolution medium provided 
the induction phase for the dormant properties to become activated. With the presence of 
excess dissolution medium and subsequent complete dissolution of the IBPD, this 
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weakened the interactions and physicochemical associations with no further channel 
formations that may not be conclusive for channelized diffusion of drug. The hydrophilic 
and hydrophobic areas of certain polymeric components within the matrix and their 
association provided the flexible hydration sites. The hydrophilic sites were located within 
the outer regions of the matrix and the hydrophobic sites were confined to fewer 
interactive regions at the center of the IBPD matrix. AZT was confined near hydrophilic 
regions of the matrix while PSS consolidated the inner core as well as areas associated 
with other hydrophobic polymeric interactions such as PLGA and EC. This segregated 
hydrophile-hydrophobe clusters within the IBPD matrix was primarily responsible for 
modulating the diffusion path of drug molecules through the matrix and subsequently 
controlling drug release. Figure 6.22 depicts the IBPD matrix in a solid and 
heterogeneous form as well as the inter-polymeric entanglements that involved the 
polymer-polymer, polymer-drug associations and other componential interactions. 
 
                                                                        
           A                                B                                   C                                  D 
Figure 6.22: A 3D model representing the IBPD matrix under dissolution along with drug 
associations: a) the polymer matrix, b) fluid interactions producing hydrophilic pockets and 
swelling of the device, c) generation of hydrophobic areas in the matrix due to critical 
formulation excipients and d) the drug molecule (AZT) in association at hydrophilic sites 
prior to release. 
 
The chemometric and molecular modeling revealed that, remarkably, the rate of transport 
for the hydrophilic drug AZT compared to the hydrophobic PSS was found to be in a ratio 
of 3:2 indicating that AZT diffused at a rate that was 1.5 times faster than PSS. This 
explains the longer controlled release effect obtained when PSS was incorporated into the 
IBPD device. Through chemometric modeling, it was also ascertained that the difference 
in molecular mass between AZT and PSS was not solely responsible for this behavior and 
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that the high degree of charge density in PSS, the ionic interactions between the cationic 
PSS and the polymer constituents as well as the high osmotic coefficient and radius of 
gyration of PSS, were the primary contributing factors. Figure 6.23 depicts the polymeric 
strands in the dissolution medium, the free floating AZT in the simulated vaginal fluid and 
PSS occupying the inner core regions of the matrix, in comparison to the 
interactions/entanglement in the solid/semi-solid/gel state at the onset of the dissolution 
process when the IBPD device was not fully dissolved. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.23: Chemometric models depicting a) dissoluted polymeric strands and b) AZT 
molecules (grey-colored circles) and PSS (white-colored circles) in the free float and 
associated forms with the loosely interacting polymeric strands in the dissolution medium.  
 
 
6.3.8.2 Diffusion kinetics depicting the drug flux mechanism during ex vivo studies 
The presence of excess simulated vaginal fluid, led to complete dissolution of the caplet 
in the donor compartment of the Franz Diffusion Cell apparatus during the ex vivo vaginal 
tissue permeation studies weakening the interactions and physicochemical associations. 
It was observed that approximately 21% of AZT and 14% of PSS permeated across the 
pig vaginal tissue in 24 hours. Thus, the actual transport of the drugs (considering that 
16.67% of both drugs i.e. 200mg each in a 1200mg IBPD matrix) from the donor 
compartment to the receptor compartment was 42mg and 28mg for AZT and PSS 
respectively. This finding substantiates the results obtained in Section 6.3.5 for which it 
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was proposed that most of the drug remained in the vaginal tissue. A chemometric model 
depicting the step-wise process of generating diffusion/transport channels perpendicularly 
to a polymer-strand localized in the IBPD is depicted in Figure 6.24. 
 
 
 
 
 
 
 
 
 
            A                                                                B                                          C                   
Figure 6.24: Chemometric model depicting the development of a diffusion channel with a) 
a single polymer strand P, situated perpendicularly to a forming pore C, b) a group of 
strands also denoted collectively as P giving rise to the channel C which is formed 
perpendicular to the polymer strands backbone with F=the direction of flow from the 
starting point S to form a a networked 3D channel and c) a polymeric strand with the 
generated diffusion channel. 
 
With regard to the diffusion kinetics of the IBPD device, the pH of the simulated vaginal 
fluid had a contributory effect on the transport of drug across the pig vaginal tissue. An 
osmotic gradient mediated transport across the vaginal tissue based on the higher 
concentration of drugs, ions and other molecular entities in the 2mL donor compartment 
of the Franz Diffusion Cells. The permeation of drug was also inversely proportional to the 
molecular mass and almost all components i.e. ions, drugs, polymeric strands, protein, 
salts and acids as well as urea from the donor cell permeated though in varying 
concentrations. Figure 6.25 shows the actual events that occurred during the generation 
of diffusion/transport channels within the IBPD matrix. 
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  A                B                       C                       D                             E                            F        
Figure 6.25: 3D models depicting the generation of diffusion channels with the IBPD 
matrix with a) polymeric strands, b) inter-strand physicochemical interactions, c) stereo-
orientation within a group of associated polymeric strands generating an inter-polymeric 
cavity d) the cavity formed, e) associations between different polymeric strands and f) the 
blocked cavity due to excessive associative networking at various localized sites 
incorporating other components such as drug in different associative settings.  
 
The considerable energy paradigms were governed by the solvation of the dissolution 
medium and osmotic flux. The qualitative status of energy paradigms and energy-time 
relationships for the IBPD matrix is as shown in Figure 6.26a-c. A simple energy status is 
depicted as a qualitative energy-time relationship for the IBPD matrix as clearly portrayed 
in Figure 6.26b.  
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        a)                                              b)                                                              c) 
Figure 6.26: Qualitative status of energy paradigms and energy-time relationship for the 
IBPD matrix with a) stable energy status as a solid matrix, b) energy change following 
dissolution and c) energy transaction and changes for the drug permeation across the pig 
vaginal tissue with the static energy status at equilibrium without flux also shown.    
 
 
6.4 Concluding remarks 
Robust polymeric devices were produced that confirmed the ability of the polymer blend 
selected (PA 6,10, PLGA, PVA, PAA and EC) to control the release of the model drugs 
AZT and PSS over a period of 72 days (PSS). The thermodynamic stability of the native 
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polymers and device was substantiated by TMDSC thermograms. Ex vivo bioadhesion 
and permeation studies revealed that the APE-PAA-coated devices were desirably 
bioadhesive and a relatively substantial fraction of the drug-load was confined within the 
vaginal tissue. The produced IBPDs showed the potential of maintaining the acidic 
microenvironmental pH of the simulated vaginal fluid upon degrading which is a desirable 
feature in the vagina. The chemometric and molecular structural modeling approach 
qualitatively supported the deduction of the IBPD rate of dissolution and has shown that 
the drug release rate was dependant on the stoichiometric parameters between the 
polymers, drugs and the simulated vaginal fluid. Furthermore, it was mechanistically 
deduced that the permeation of drug across the pig vaginal tissue during ex vivo studies 
was based on an osmotic gradient and depended on the degree of ionization as well as 
the size and molecular mass of the drug molecules. Thus, the developed IBPD may be 
suitable for use as a localized intravaginal drug delivery system for the potential treatment 
and prevention of HIV infection and STIs. 
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CHAPTER SEVEN 
 
IN VIVO DRUG CONTENT ANALYSIS AND HISTOPATHOLOGICAL EVALUATION OF 
THE INTRAVAGINAL BIOADHESIVE POLYMERIC DEVICE 
 
7.1 Introduction 
Prevention of sexual transmission of HIV at the vaginal mucosal epithelial level is a critical 
global health priority because of the devastating impacts of HIV/AIDS on women, young 
adults and infants (Keller et al., 2005). Studies using cervical organ culture as a model of 
primary infection, have demonstrated that HIV-infected cells mostly reside within 
subepithelial mucosa (Miller et al., 1992; Nuovo et al., 1993; Padian et al., 1997). This 
indicates that the establishment of HIV infection requires transepithelial penetration and 
therefore blocking this step may assist to prevent the HIV infection. HIV pathogens cross 
the mucosal surface either by: a) direct HIV infection of epithelial cells; b) transcytosis of 
HIV through epithelial cells; c) epithelial transmigration of HIV-infected donor cells; d) 
uptake of HIV by intraepithelial dendritic cells (e.g. Langerhans cells) and e) 
circumvention of the epithelial barrier through physical breaches (Ibata et al., 1997; 
Shattock, 2001, Saïdi et al., 2009). Furthermore, it has been shown that penetration of the 
mucosal surface by HIV to reach the submucosal target cells (macrophages, lymphocytes 
and dendritic cells) may be modulated by: a) supraepithelial factors, such as seminal 
complement components (opsonized HIV); b) epithelial factors released in the 
submucosal microenvironment, such as antimicrobial soluble factors, cytokines and 
chemokines; and c) by the potent intraepithelial and submucosal innate immunity 
(Kozlowski and Neutra, 2003; Saïdi et al., 2009).  
 
Following the translocation across the mucosal epithelium, HIV-1 finds potential target 
cells in the dense lymphocyte and macrophage populations of the lamina propria. Cervical 
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mucosa, lamina propria and CD4+ T lymphocytes are early target cells for HIV-1 and 
Simian Immunodeficiency Virus (SIV) in humans and support viral replication (Spira et al., 
1996; Zhang et al., 1999; Collins et al., 2000; Greenhead et al, 2000; Gupta et al., 2002; 
Moore et al., 2004; Shen et al., 2009). Thus, the trajectory of anti-HIV microbicide delivery 
system development approach should preferably be towards agents that can block 
specific virus–host cell interactions at the vaginal mucosal epithelial level. Targeting HIV 
entry has been a favored approach because it is the first step in the process of HIV 
infection (D’Cruz and Uckun, 2004; Cutler and Justman, 2008). An anti-HIV microbicide 
delivery system that can block transmission of HIV at the vaginal mucosal epithelial level 
may provide a realistic method of intervention worldwide. 
 
The strong epidemiological association of inflammatory ulcerative venereal disease with 
HIV transmission and the observation that mucosal SIV transmission may be enhanced 
following thinning of vaginal epithelium by steroids such as progesterone implants 
suggests an important barrier role of the genital epithelium (Marx et al., 1996; Royce et 
al., 1997). Thus, following any study in the vagina that involves administration of a foreign 
body (tablet, caplet, ring etc), it is imperative to undertake histopathological and 
histomorphological evaluation on the vaginal epithelium since it plays a vital role, both as 
a physical and as an immunological barrier, in preventing entry of bacterial and viral 
pathogens into host tissues (Catalone et al., 2005; Hirbod and Broliden 2007; 
Rebbapragada and Kaul, 2007; Levinson et al., 2009). Disruption of this barrier and the 
presence of genital tract inflammation are risk factors for HIV infection as well as other 
STIs (Coombs et al., 2003; Catalone et al., 2005; Dhawan and Mayer, 2006; Sundstrom 
et al., 2007; Brenchley and Douek 2008; Kaul et al., 2008; Sheung et al., 2008; Broliden 
et al., 2009; Hendrix et al, 2009; Shafir et al., 2009). Therefore, it is important for a vaginal 
delivery system to not only target STI pathogens but also to have negligible or no toxic 
effects on the vaginal epithelium (Levine et al., 1998; Stafford et al., 1998; Greenhead et 
al, 2000; Miller and Shattock, 2003; Shen and Iwasaki, 2006; Iijima et al., 2008).  
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The aim of this Chapter therefore, was to report on the in vivo study that was conducted in 
a pig model administered with AZT and PSS-loaded IBPD with the following purposes: i) 
to analyze the drug content contained in plasma (if any) as well in the vaginal tissues after 
sacrificing the animals; and ii) to conduct a thorough toxicity study that involved 
histopathological evaluation on the vaginal tissues exposed to drug-containing IBPDs and 
placebo in comparison to a control. In each case, the IBPDs (properly coated to avoid 
irritation to the vaginal tissue as well as to facilitate easy insertion) were inserted into the 
vagina using a special applicator designed in our laboratories. A pig model was selected 
because of many similarities with the human vagina, particularly in genital tract physiology 
and histology. (Pond and Houpt, 1988; D’Cruz et al., 2005b; Wang et al., 2009).  
 
7.2 Materials and Methods 
7.2.1 Materials 
For anesthesia, ketamine was purchased from Bayer (Pty) Ltd (Bayer Pty Ltd, Isando, 
Gauteng, South Africa., midazolam from Roche products (Pty) Ltd (Roche products (Pty) 
Ltd, Isando, Gauteng, South Africa) and  isoflurane from Safeline Pharmaceuticals (Pty) 
Ltd (Safeline Pharmaceuticals (Pty) Ltd, Florida, South Africa). The digestive enzyme for 
the vaginal tissues was subtilisin which was purchased from Merck Co. Ltd (Merck-
Schuchardt®, Hohenbrunn, Germany). The rest of the materials employed were the same 
as in Chapter 6.  
 
7.2.2 Methods 
7.2.2.1 In vivo studies in the pig model using the drug-loaded intravaginal 
bioadhesive polymeric device 
The study involved 20 female, healthy Large White pigs (35kg) divided into 4 groups of 5 
each. Group 1 was a control group in which no IBPDs were inserted. Groups 2 and 3 
were used for testing the model drugs, and therefore IBPDs with drugs were inserted. 
Group 4 was used as a placebo group in which IBPDs with no drug (i.e. formulated with 
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native polymers) were inserted. The study period for each group was 1 month spanning 
across a total of 4 months in staggered manner. In Group 2 and Group 3, IBPDs 
containing AZT and PSS respectively were inserted after anaesthetizing the pigs. X-ray 
imaging was done three times a week (1st, 3rd and 5th day) for two weeks and then twice a 
week (1st and 5th day) for another two weeks, each time under anesthesia. Furthermore, 
blood samples (10mL) were withdrawn from the jugular vein of each pig on days 1, 3, 5, 
7, 14 and 28 while the pigs were still under anesthesia. In Group 4, placebo IBPDs were 
inserted and then subjected to the same procedure as above. Group 1 was subjected to 
blood sampling procedures on the scheduled days. On the 28th day, each pig was 
euthanized, followed by dissection of the vaginal tissue for drug content analysis using 
UPLC, and toxicity studies. The toxicity studies involved histological examination for 
inflammation, exocytosis, hyperplasia, hypoplasia, epithelial exudate, ulceration, 
polymorphonuclear infiltration and any evidence of infection. A summary of the in vivo 
study is shown in Figure 7.1. 
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Figure 7.1: Summary of the in vivo study. 
 
7.2.2.2 Anesthesia, X-ray imaging and blood sampling  
Each group of pigs was anesthetized with ketamine (11mg/kg I.M.) and midazolam, 
(0.3mg/kg I.M.). The pigs were then intubated and anesthesia was maintained with 2% 
isoflurane in 100% oxygen. X-ray imaging of the pelvic region was performed (Figure 
7.2a), and blood samples were taken following the procedure stipulated in Section 7.2.2.1 
(Figure 7.2b). All blood samples were immediately transferred into heparinised 
vacutainers (BD Vacutainer®, Plymouth, BD Beliver Industrial State, UK) and then stored 
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in a refrigerator at 4oC for one hour. The blood was then centrifuged (Nison Instrument 
(Shangai) Limited, Shangai, China) at 15,000rpm for 10 minutes and the supernatant was 
pipetted as blank plasma using an adjustable volume micropipette (Boeco Gmbh, 
Hamburg, Germany). The blank plasma was stored in a refrigerator at -70oC for the 
quantitative drug analysis using UPLC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2: a) X-Ray imaging process and b) blood sampling procedure from the jugular 
vein of the pig. 
 
 
 
a) 
b) 
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 7.2.2.3 Vaginal tissue removal for drug analysis and histopathological studies 
On 28th day, each pig (weighing between 80-85kg) was euthanized and then dissecting 
out the vaginal tract following the procedure described in Chapter 5, Section 5.2.2.4, 
Figure 5.1. Transverse cuts of tissues (at the anterior, middle and posterior part of the 
vagina) with a cross-sectional size 1.5×3.0cm were made through the vaginal wall. Half of 
the tissues were kept in 100mL of 10% formalin and then subjected to histopathological 
studies (including toxicity evaluation). The remaining tissue was immediately frozen using 
liquid nitrogen, and then stored in a refrigerator at -70oC for quantitative drug analysis.  
 
7.2.2.4 Quantitative analysis of AZT and PSS in the blood and the vaginal tissue of 
the pig. 
7.2.2.4.1 Preparation of standard solutions and calibration curves 
The same procedure as previously described under Chapter 6, Section 6.2.2.8.4, was 
used except that in this case calibration curves were developed using blank pig plasma 
instead of simulated vaginal fluid. The constructed calibration curves are as shown in 
Figures 7.3a and b.  
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Figure 7.3: a) Calibration curves for: a) AZT in blank plasma 267nm (N=5, SD<0.001 in 
all cases); b) PSS in blank plasma 244nm (N=5, SD<0.009 in all cases).  
 
7.2.2.4.2 The drug extraction method from the plasma samples for UPLC analysis 
This was conducted employing a single use Water Oasis® HLB 3cc (60mg) extraction 
cartridge (Waters Corporation, Milford, Massachusetts, USA) adapting a method 
Y=0.0291+0.0029x
R2=0.99
Concentration of AZT (ng/mL)
0 2000 4000 6000 8000 10000
Ar
ea
 (P
D
A:
 2
67
nm
 A
ZT
)
0
5
10
15
20
25
30
AZT Linear Regression Curve
95% Confidence Band 
95% Prediction Band 
a) 
Y=0.1437+0.0039x
R2=0.99
Concentration of PSS (ng/mL)
0 2000 4000 6000 8000 10000
A
re
a 
(P
D
A
: 2
44
nm
 P
SS
)
0
10
20
30
40
PSS Linear Regression Curve
95% Confidence Band 
95% Prediction Band 
b) 
 188 
developed by Notari and co-workers (2006). The Solid Phase Extraction (SPE) cartridge 
was conditioned with 1.0mL methanol followed by 1.0mL ultra pure water Milli-Q. 1mL of 
acetonitrile (for AZT) was added to 600μL of pig plasma. The solution was vortexed for 1 
minute and then centrifuged (Nison Instrument (Shangai) Limited, Shangai, China) at 
15,000 rpm for 6 minutes at 24oC. 650μL of the supernatant was diluted by adding ultra 
pure water Milli-Q (1mL) and loaded in the cartridge. Thereafter, the cartridges were 
washed with 1.0mL of 5%v/v methanol in ultra pure water Milli-Q. Analytes were eluted by 
washing cartridges with 550μL 0.01M KH2PO4 followed by 2mL methanol. The eluate was 
evaporated to dryness in a slow stream of high purity nitrogen gas (Afrox, Germiston, 
Gauteng, South Africa). The extracted sample was re-constituted with 100μL absolute 
methanol, mixed with 400μL of MP, and then filtered into the injection vials using 0.22μm 
syringe-driven filter units (Millipore Corporation, Bedford, Massachusetts, USA) for UPLC 
analysis. The same procedure was followed for PSS but substituting acetonitrile with 
methanol as a mobile phase.  
 
7.2.2.4.3 Drug extraction from the vaginal tissue for UPLC analysis 
To extract the drug from the tissues, a method developed by Wang and co-workers 
(2009) was adapted but with some modifications. Briefly, each tissue sample (8g each) 
was homogenized in 16mL of simulated plasma (pH 7.4). The homogenized sample was 
digested by incubating it with 10 mg of subtilisin (Merck-Schuchardt®, Hohenbrunn, 
Germany), vortexed for 1 minute, and then placed in a thermostatic bath for 1 hour at 
56°C while mixing after every 10 minutes to ensure complete degradation of the tissue. 
After enzymatic digestion, the sample was centrifuged at 10,000rpm for 15 minutes. For 
the AZT sample preparation, 1mL of the supernatant was withdrawn, mixed with 1mL of 
acetonitrile and then pipetted into the centrifuge tubes into which 550μL of 0.01M KH2PO4 
was added as an extracting medium. The tubes were vortexed for 1 minute and then 
centrifuged at 13,000 rpm for 6 minutes at 24oC. 650μL of the supernatant was diluted by 
adding ultra pure water Milli-Q (1mL) followed by the addition of 2mL absolute methanol. 
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The supernatant was placed into sample vials and then evaporated to dryness in a slow 
stream of high purity nitrogen gas (Afrox, Germiston, Gauteng, South Africa). The 
samples were re-constituted with 100μL absolute methanol mixed with 400μL of MP, then 
filtered into the injection vials using 0.22μm syringe-driven filter units (Millipore 
Corporation, Bedford, Massachusetts, USA). The same procedure was followed for the 
PSS sample preparation but substituting acetonitrile with methanol as the mobile phase.  
 
7.2.2.4.4 Instrumentation and chromatographic conditions for the quantitative 
analysis of AZT and PSS from plasma and vaginal tissue samples 
Quantitative analysis was performed using the Waters Acquity Ultra Performance Liquid 
Chromatographic (UPLC) system (Waters Corporation, Milford, Massachusetts, USA), 
equipped with the Acquity Photodiode Array (PDA) and Evaporative Light Scattering 
(ELS) detectors. The columns employed were Acquity UPLC® BEH Phenyl 1.7µm, 
2.1×50mm column and Acquity UPLC® BEH C18, 1.7µm, 2.1×100mm for AZT and PSS 
analysis respectively. The mobile phases were composed of water/acetonitrile (60/40v/v) 
and methanol/water (50/50v/v) for AZT and PSS respectively. The wash solutions used, 
namely strong and weak washes were composed of 90/10 acetonitrile/water, 10/90 
water/acetonitrile, and 100% ultra pure water Milli-Q, respectively. All prepared solutions 
were filtered using 0.22µm membrane filters (Millipore Corporation, Bedford, 
Massachusetts, USA) under vacuum and degassed before their use. For AZT analysis, a 
gradient method was used at a column temperature of 25°C, injection volume was 2µL 
and UV detection wavelength of 267nm. The employed gradient settings were as shown 
in Table 7.1. For PSS analysis, an isocratic method was employed using methanol/water 
(50/50v/v) as a mobile phase, flow rate 0.2mL/minute, column temperature 25°C, total run 
time of analysis was 3 minutes, injection volume was 1.7µL and UV detection wavelength 
of 244nm. 
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Table 7.1: Parameter settings for the AZT gradient method. 
Separation 
events 
Time 
(min)  
Flow (mL/min) % A (Water) % B (Acetonitrile) 
1 0.00 0.500 60.0 40.0 
2 1.00 0.500 5.0 95.0 
3 2.60 0.500 5.0 95.0 
4 3.50 0.500 60.0 40.0 
 
 
7.2.2.4.5 Histopathological evaluation of the vaginal mucosa 
The vaginal tissue specimens obtained were cut into three tissue blocks containing the 
anterior, middle and posterior sections. These blocks were processed with routine 
histological methodology in an automated tissue processor. They were then sectioned at 
5µm, placed on slides and stained with haematoxylin and eosin in an automated stainer 
(Rankin Biomedical Corporation, Michigan, USA) and finally subjected to thorough 
histological evaluation. The evaluation was divided into three parts. The first was an 
evaluation on epithelial histological lesions; the second one was an assessment of the 
lamina propria and the third was an evaluation on the subepithelial tissues and vaginal 
wall. The evaluation of epithelial histological lesions encompassed: i) hyperplasia which is 
an increase in epithelial cell layers which finally results in acanthosis and thickening of the 
epithelium; ii) exocytosis which refers to transepithelial leukocyte migration of 
inflammatory cells; iii) exudate on the epithelial surface; and iv) ulceration. In the lamina 
propria, mononuclear inflammation, polymorphonuclear infiltration and foreign body 
inflammation were assessed. The evaluation of subepethelial tissues and vaginal wall 
was mainly concerned with a search for perivascular inflammation. 
 
7.3. Results and Discussion 
7.3.1 Chromatographic separation and retention times of AZT and PSS from 
methylparaben (MP) (Internal Standard) 
AZT/PSS and MP were eluted at 1.701±0.43 and 1.184±0.18 for AZT and 0.583±0.15 and 
1.275±0.13 for PSS after extraction from pig plasma (Figures 7.4a and b). Assay method 
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validation analysis revealed that the intra-and inter-day precision and accuracy were 
satisfactory (R2=0.9987 for AZT; R2=0.9998 for PSS). The signal to noise ratio at the 
lower limit of quantification (25ng/mL) was >10.8 in both cases. For the validation testing 
of the linear regression model, the weighting factors were selected to be proportional to 
the reciprocal of the standard deviations which was optimal under the least squares 
estimation with R2>0.99. The three dimensional chromatographic analysis of blank 
plasma revealed no interfering peaks at the retention times within the UV wavelength 
range of 200-400 (AZT/PSS and MP). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4: UPLC chromatograms depicting the retention times for the standard solutions 
of a) AZT, b) PSS and MP as an internal standard in blank plasma. 
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7.3.2 AZT and PSS concentrations in the blood and vaginal tissue of the pig model 
The drug concentration in the plasma from day 1-28 ranged between 0.012-0.332mg/mL 
(AZT) and 0.009-0.256mg/mL (PSS) (N=5) (Figure 7.5a). This indicates that only a 
minimal quantity of the AZT and PSS crossed into the systemic circulation. This may be 
attributed to the hydrophobicity and high matrix resilience of the polymers employed. A 
steady-state concentration of AZT/PSS was observed from day 14 through day 28 
indicating that no further drug crossed into systemic circulation. The lower concentration 
value of PSS may be due to the presence of strong intermolecular forces in the polymer 
that reduced the rate of permeation of the drug into blood compartment (Pu et al., 2004; 
Chu et al., 2007). The mean drug concentration in the vaginal tissue at day 28 was 
1.2148±0.062mg/mL (N=5) for AZT and 1.4004±0.071mg/mL (N=5) for PSS, while the 
plasma concentration was 0.332±0.014mg/mL (N=5) for AZT and 0.256±0.013mg/mL 
(N=5) for PSS (7.5b).  This is an indication that the majority of the drug was retained in 
the vaginal tissue. For each pig, the vaginal tissue drug concentration at three vaginal 
sites (namely anterior, middle and posterior) was approximately the same (P>0.05). On 
average, PSS presented with the highest vaginal tissue drug concentration at the 28th day 
(Figure 7.5b). This indicates that PSS was better retained in the vaginal tissue than AZT. 
This may be attributed to the high degree of hydrophobicity coupled with the presence of 
strong intermolecular charges in PSS. Figure 7.6 depicts a typical profile for the PSS 
content in the vaginal tissue. The finding corresponds well with the earlier results of drug 
flux analysis (Chapter 6, Section 6.3.5) whereby PSS had lower flux values, indicating 
that its permeation rate across the vaginal tissue was slower compared to AZT. Likewise, 
the results of the analysis of drug concentration in the plasma revealed that a lower 
concentration of PSS crossed into the blood compared to AZT. Overall, the results 
portrayed a direct correlation (R2 = 0.99) between the drug concentration in the blood and 
in the vaginal tissue (Figures 7.7a and b).  
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Figure 7.5: a) AZT and PSS plasma concentration profiles (N=5, SD<0.01), b) AZT and 
PSS mean vaginal tissue and plasma concentration values on day 28 (N=5, SD<0.014 in 
all cases). 
 
 
 
 
 
 
 
 
 
Figure 7.6: A typical profile depicting the content of PSS in the vaginal tissue. 
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Figure 7.7: Correlation between a) AZT, b) PSS concentrations in the blood plasma and 
vaginal tissue for the 5 pigs tested at the 28th day. 
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role played by the components forming the vaginal epithelium and the polymers of the 
IBPD as depicted in Figure 7.8. However, the IBPD was found to have broken into several 
parts (close to the cervix) and most of it had eroded (Figure 7.9). A gel-like soft matrix 
was also observed at the vaginal epithelial lining. This is an indication that the IBPD was 
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degrading slowly into a gel-like matrix that adhered to the vaginal walls. These findings 
correlate well with the objectives of the study whereby the IBPDs were supposed to 
degrade, adhere to the vaginal walls and release the ARV and microbicide 
simultaneously.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.8: A schematic modeled in our laboratories depicting the mechanistic approach 
of adhesion between a polymer and the vaginal epithelium. Figure generated on ACD/I-
Lab, V5.11 (Add-on) software (Advanced Chemistry Development Inc., Toronto, Canada, 
2000). 
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Figure 7.9: Intravaginal Bioadhesive Polymeric Device (IBPD) as observed in the excised 
pig vagina on the 28th day. 
 
 
7.3.3 Histopathological evaluation of the vaginal tissue 
In this study, negative to mild epithelial hyperplasia was observed (Figure 7.10a) except 
for pig number 3, 9 and 14 which presented with moderate to severe hyperplasia (Table 
7.2). This was noted from an increase in the epithelial rete ridges (Figure 7.10b). The 
controls showed no epithelial hyperplasia thus showing normal vaginal epithelium (Figure 
7.10c) (Table 7.2). The reason for the moderate to severe hyperplasia observed in pig 
number 3, 9 and 14 may have been due to the small vaginas of these pigs. In these pigs, 
the insertion of the IBPD was achieved with some difficulty resulting in a relatively higher 
degree of inflammation. Some irritation from the polymeric device was most likely 
responsible for the hyperplastic epithelial response. Regarding exocytosis, neutrophils 
were detected in intercellular spaces in the vaginal epithelium, in the process of migrating 
to the vaginal lumen. The exocytosis varied among the different test groups as well as the 
placebo, but was not found in the control animals.  
 
The exudate attached to the mucosal surface followed the transepithelial migration and 
exocytosis of neutrophils into the lumen. This was found in only one of the animals 
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receiving PSS and two that received AZT (Figure 7.10d). However it was not observed in 
the placebo and control pigs. Ulceration in the vagina refers to the complete loss of 
superficial epithelium due to an underlying submucosal inflammatory process and was 
confirmed only in a few animals from the AZT group (Table 7.2), and more so in pig 
number 9 which again may have been caused by the epithelial damage or necrosis during 
the insertion process due to the small size of the vagina. Mononuclear inflammatory cells 
(lymphocytes and plasma cells) were observed in the lamina propria and stromal tissue 
directly underneath the vaginal epithelium (Figure 7.10e). As shown in Table 7.2, (Figure 
7.10e), moderate mononuclear inflammation was recorded in PSS (N=1) and AZT-
containing IBPDs (N=2) as well as placebo animals (N=1), but was not visible in the 
controls. Polymorphonuclear cells (eosinophils and neutrophils), were found in the 
submucosa as well as in the superficial exudate. These cells originated from the 
circulation and migrated into the tissues from the blood vessels and also by exocytosis 
into the lumen of the vagina. The mononuclear and polymorphonuclear inflammation 
indicates that there was mild to moderate chemotaxis of polymorphonuclear cells as well 
as an antigenic stimulation of mononuclear leukocytes arising from the polymeric devices. 
This is normal for any foreign object introduced onto an epithelium.  
 
In pig number 9, a foreign body granuloma and inflammation was observed in the focal 
area of the vaginal epithelium. The foreign material appeared as homogenous 
eosinophilic staining and was surrounded by numerous macrophages, epithelioid cells 
and multinucleated foreign body giant cells. This reaction was also associated with 
ulceration in the epithelium. Possibly the foreign body reaction was related to the 
traumatic insertion process in this pig. The perivascular inflammatory infiltrates consisted 
mainly of mononuclear cells with few polymorphonuclear infiltrates dispersed among the 
mononuclear cells in the submucosa and the wall of the vagina (Figure 7.10f) (Table 7.2). 
It was negative to mild and could be demonstrated in just few individual pigs (PSS: N=1; 
AZT: N=2; placebo: N=1).  
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Figure 7.10: Histological images of haematoxylin and eosin stained pig vaginal tissue 
samples depicting a) Epithelial hyperplasia of the vagina x 40, b) Epithelial hyperplasia, 
exocytosis and superficial exudate x 40, c) Lamina propria with no inflammatory cells and 
normal vagial epithelium x 20, d) Hyperplastic epithelium with exocytosis x 40, e) 
Mononuclear cell infiltrates in the lamina propria and f) Perivascular inflammation in the 
submucosal wall x 40. 
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Table 7.2: Histopathological findings in the vaginal tissue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.4 Concluding Remarks 
The results of the drug content analysis in the blood and vaginal tissue revealed that only 
0.332mg/mL (16.78%) of AZT and 0.256mg/mL (12.94%) of PSS crossed into the 
systemic circulation, indicating that the majority of the drugs was not absorbed and was 
thus in the vaginal lumen and possibly the tissues. This shows the superior ability of the 
employed polymers in retaining the drugs within the vaginal tissue. The observed gradual 
erosion of the IBPD and the subsequent adherence of its byproducts to the vagina is a 
clear indication that the developed IBPDs had the required matrix integrity attributes and 
were also substantially bioadhesive. The microscopical examination of the vaginal tissue 
following the termination of the pigs revealed that the histopathological changes (e.g. 
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inflammation, ulceration) were either negative, mild or moderate, which was pathologically 
or clinically a sign of non-toxicity. The developed microbicide-ARV delivery system meets 
most of the essential requirements of an ideal microbicidal delivery system with 
characteristics that are defined as desirable in that they have shown substantial retention 
to the vaginal epithelium with very low systemic absorption and high permeation of the 
drug within the vaginal tissue.  
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CHAPTER EIGHT 
 
C ONC L US IONS  AND R E C OMME NDAT IONS  
 
8.1 Conclusions 
An effective anti-HIV intravaginal microbicide delivery system represents a practical and 
accessible means of reducing male to female sexual transmission of HIV. However, 
successful design and development of such a system brings with it a multitude of 
challenges, evidenced by a need for efficacy, acceptability, accessibility and affordability. 
Thus, exhaustive efforts have been made during the design and development of an IBPD 
in this study to address these challenges, leading to the successful achievements of the 
aim and objectives. The current status of the treatment modalities of HIV/AIDS has been 
well described. Factors such as vaginal physiology, vaginal pH, the type and the intrinsic 
properties of the polymer vehicles as well as the drugs employed have been well 
addressed. 
 
Numerous safe and effective HIV vaginal microbicide delivery systems are still being 
evaluated at various stages in clinical trials, meaning that this research has been 
conducted at a period when the successful development of an effective anti-HIV 
intravaginal microbicide delivery system is still an ongoing agenda. Polymeric biomaterials 
appear to have great potential for intravaginal drug delivery development because of their 
peculiar physicochemical and physicomechanical properties which allow delivery and 
maximization of the drug concentration at the required site, ultimately resulting in 
improved efficacy of drug therapy. Striking a balance between the hydrophobicity and 
hydrophilicity was an essential criterion upon which polymer selection was based using 
the equilibrium swelling ratio. The polymeric materials employed after undergoing a 
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thorough screening have resulted in the development of a delivery system that 
demonstrated the potential for providing controlled release over a period of 72 days. This 
is a significant achievement in the current research. 
  
The major prerequisite for the developed IBPD was proper matrix integrity which would 
eventually ensure highly controlled drug release and substantial bioadhesion (retention) to 
the vaginal epithelium. To attain these goals, this research utilized multifunctional 
polymers with intrinsic properties that could lead to the development of a delivery system 
with a high degree of matrix integrity and subsequently controlled drug release. 
Successful optimization mainly based on polymer matrix erosion as a measure of matrix 
integrity, and was carried out using the most recent highly-enabled, mathematically-based 
technology of Artificial Neural Networks.   
 
Extensive bioadhesivity testing on the employed polymers on both a simulated artificial 
membrane and on freshly exercised pig vaginal tissue under conditions simulating the 
vaginal fluid pH demonstrated the bioadhesivity capacity of the developed intravaginal 
drug delivery system. Deduction of the transient mechanisms of bioadhesivity and the 
associated interactive energy paradigms during caplet adhesion to the freshly excised pig 
vaginal tissue was successfully carried out using computational and structural modeling 
techniques. 
 
Economic and social conditions as well as patient’s preference are prime factors that 
needed to be considered during the design and development of the IBPD. Acceptability 
depends on affordability, ease of use and minimal side-effects. Failure in this regard 
would result in non-compliance and non-adherence, amounting to no progress with the 
intended mission. Thus, it was absolutely important to conduct a thorough scientific 
evaluation of the physicochemical and physicomechanical properties of the IBPDs. The 
benefit of this evaluation, attested to by the good matrix hardness, matrix integrity, 
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thermal stability and acceptable friability of the IBPD, also ensured safety, functionality 
and efficacy and therefore its suitability as a microbicide-ARV delivery system. 
Furthermore, the highly controlled release pattern shown by the IBPD, the permeation 
dynamics obtained and the fact that the IBPD could adhere to the vaginal epithelium, 
satisfied the formulation requirements. This entailed, among other things, the ability of the 
IBPD to maintain a steady-state concentration of the bioactives within the vaginal tissue. 
 
 Numerous challenges are currently faced by the pharmaceutical industry. Therefore, 
there is a pressing need for new and innovative technology in drug delivery, for preventing 
HIV/AIDS and STIs. For this reason, novel techniques and appropriate materials were 
employed in this study which produced a robust IBPD with the following important 
attributes: a) the IBPD could remain stable in simulated human vaginal fluid (pH 4.5) and 
in simulated human seminal fluid (pH 7.4) for more than 30 days; b) the IBPD was 
substantially vaginally bioadhesive both ex vivo and in vivo; c) the IBPD could provide 
controlled release rate of the microbicide-ARV ensuring the potential for prolonged 
protection in women; and d) the IBPD was non-toxic. Thus, the novel developed 
controlled release microbicide-ARV loaded IBPD may significantly contribute in solving 
the problems currently faced in drug delivery  technology  development and may lead to 
the following: i) provide an alternative preventive measure in the transmission of 
HIV/AIDS; ii) reduce the burden of HIV/AIDS; iii) improve the quality of life with 
subsequent macroeconomic benefits; iv) reduce the cost of medication; v) develop 
products locally; vi) create intellectual property; vii) overcome the challenges of current 
intravaginal drug delivery systems; and viii) a versatile IBPD may be suitable for the 
treatment of other diseases burdening developed and developing countries. 
 
8.2 Recommendations 
Although prevention of HIV infection is an overwhelming task, a human, female-controlled 
anti-HIV intravaginal microbicide delivery system points to promising future for success in 
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the fight against HIV-1 with the eventual eradication of the HIV pandemic. The 
development of an ideal anti-HIV intravaginal microbicide delivery system that will pass 
through all clinical trial phases will be achieved through focused and endeavored scientific 
efforts. The work presented in this thesis provides a significant contribution towards this 
goal. 
 
Local delivery of an anti-HIV intravaginal microbicide to the vaginal compartment at the 
correct time and concentration is a key requirement, and this presents a formidable 
challenge to overcome if the potential for microbicides in preventing HIV infection is to be 
realized. This research has identified priority challenges and opportunities for pre-
competitive research in intravaginal anti-HIV microbicide delivery for the prevention of 
STIs and HIV infection. Much needed further research should gain greater interactive-
based understanding of the physicochemical and physicomechanical properties of 
biomaterials (in addition to polymers), microbicidal agents and anti-HIV drugs. Such 
studies will discover how these properties can be modified within the human vaginal 
biological environment so as to determine how optimal efficiency towards prevention of 
STIs and HIV infection can be achieved. It will also be of great importance to conduct in 
vivo human-oriented clinical trials to validate and compare the stability, viability and 
efficacy of the IBPD. 
 
The developed IBPD may be applied not only for preventing STIs and HIV but also in 
other areas like hormone replacement therapy, contraception, infections, infertility, and 
other female-related conditions, as an alternative to oral or parenteral administration. One 
such example is the everlasting problem that has been incurred so far in the treatment of 
Candidiasis (from Candida albicans) due to resistance complications. The great stability 
of the IBPD in the vagina, its high bioadhesivity and therefore unquestionable substantial 
retention, and the superior ability to control drug release rate over a prolonged period may 
make it a gold standard in this endeavor. Needed at this point in time is to streamline the 
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developed IBPD by undertaking more directed studies aimed at realizing its best clinical 
applicability. Such attempts should involve a study on irritation potential of this device 
which goes beyond the histology work but also involves looking at the liberation of any 
cytokines like IL-1, alpha IL-6 and IL-8 in the skin tissue. Furthermore, it may be 
necessary to look for pharmacodynamic disease models to which this device can be 
applied in order to finally assess the benefit of this approach which will be a very good 
preclinical model.  
 
Finally, this study does not only provide encouraging results for the delivery of PSS and 
AZT but also provides a novel systematic approach for the development of delivery 
systems for other microbicide-ARVs. It is therefore highly recommended that the 
approach employed in this study for the development of a microbicide-ARV delivery 
system for the prevention of STIs and HIV infections be adopted as a design tool for other 
similar bioactive systems. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 206 
REFERENCES 
 
 
Acaturk F. and. Robinson, J.R., (1996). Effect of the spermicide, nonoxynol 9, on vaginal     
permeability in normal and ovariectomized pigs, Pharmaceutical Research, 13, 950–951. 
 
Achanta, A.S., Kowalski, J.G., James K.W. and Rhodes, C.T., (1995).  Artificial neural 
network: implications for pharmaceutical sciences, Drug Development and Industrial 
Pharmacy, 21,119–155. 
 
Adams, J.C., (1997). Thrombospondin-1. The International Journal of Biochemistry & Cell 
Biology,  29, 861-865.  
Agatonovic-Kustrin, S. and Beresford, R., (2000). Basic concepts of artificial neural 
network (ANN) modeling and its application in pharmaceutical research. Journal of 
Pharmaceutical and Biomedical Analysis, 22, 717-727. 
Agatonovic-Kustrin, S. Turner, J.V. and Glass, B.D., (2008). Molecular structural 
characteristics as determinants of estrogen receptor selectivity. Journal of Pharmaceutical 
and Biomedical Analysis, 48, 369-375.  
Airey, G.D., Mohammed, M.H. and Fichter C., (2008).  Rheological characteristics of 
synthetic road binders. Fuel, 87, 1763-1775.  
 
Akagi, T., Kawamura, M., Ueno, M., Hiraishi, K., Adachi, M., Serizawa, T., Akashi M. and 
Baba, M., (2003). Mucosal immunization with inactivated HIV-1-capturing nanospheres 
induces a significant HIV-1-specific vaginal antibody response in mice. Journal of Medical 
Virology, 69, 163-172. 
 207 
Alam, M.A., Ahmad, F.J., Khan, Z.I., Khar, R.K. and Ali, M., (2007). Development and 
Evaluation of Acid-buffering Bioadhesive Vaginal Tablet for Mixed Vaginal Infections. 
AAPS Pharmaceutical Sciences and Technology. 8, 229-236. 
 
Alliance for Microbicide Development. Microbicide Research and Development Database, 
2005.http://secure.microbicide.org/NetReports/ClinicalTrialsOngoingByProduct.aspx 
[Accessed July 21, 2007]. 
Al-Taani, B.M. and Tashtoush, B.M., (2003). Effect of Microenvironment pH of Swellable 
and Erodable Buffered Matrices on the Release Characteristics of Diclofenac Sodium. 
AAPS Pharmaceutical Sciences and Technology, 4, 1-6. 
Al-Tahami, K. and Singh, J., (2007). Smart polymer based delivery systems for peptides 
and proteins. Recent Patents on Drug Delivery and Formulation, 1, 65-71. 
 
Alvarez-Lorenzo C, Gomez-Amoza JL., Martinez-Pacheco, R. and Souto, C., (1999).  
Microviscosity of hydroxypropylcellulose gel as a basis for prediction of drug diffusion 
rates. International Journal of Pharmaceutics, 180, 91-103. 
Alvarez-Lorenzo, C., Concheiro, A., Gomez-Amoza, J.L., Souto C. and Martinez-
Pacheco, R., (2002). Effect of microcrystalline cellulose grade and process variables on 
pellets prepared by extrusion-spheronisation, Drug Development and Industrial 
Pharmacy, 28, 451–456. 
Alvarez-Lorenzo, C. and Concheiro, A., (2008). Intelligent Drug Delivery Systems: 
Polymeric Micelles and Hydrogels. Mini Reviews in Medicinal Chemistry, 8, 1065-1074.  
 
 208 
Amarl, E., Perdigao, A., Souza, M.H., Mauck, C., Waller, D., Zaneveld, L. and Faundes, 
A., (2004). Postcoital testing after the use of acid buffering gel (ACIDFORM) and a 2% 
nonoxynol-9 product. Contraception, 70, 492-7. 
 
Ambrose, Z., Compton, L. and Piatak Jr., M., (2008). Incomplete Protection against 
Simian Immunodeficiency Virus Vaginal Transmission in Rhesus Macaques by a Topical 
Antiviral Agent Revealed by Repeat Challenges. Journal of Virology, 82, 6591-6599.  
 
Amet, T., Nonaka, M., Dewan M., Saitoh, Y., Xi, X., Ichinose, S., Yamamoto, N and 
Yamaoka, S., (2008). Statin-induced inhibition of HIV-1 release from latently infected U1 
cells reveals a critical role for protein prenylation in HIV-1 replication. Microbes and 
Infection, 10, 471-480.  
 
Amy, E., Rachel, L. and Amy, M., (2007). HIV Revisited: The Global Impact of the 
HIV/AIDS Epidemic. SKINmed: Dermatology for the Clinician, 3, 149 – 156. 
 
Anderson, R.A., Feathergill X., Diao M., Cooper, R., Kirkipatrick, P., Spear, D.P., Waller, 
C., Chany, G.F., Doncel, F., Herold, B. and Zaneveld, L.J.D., (2000). Evaluation of poly 
(styrene-4-sulfonate) as a preventive agent for conception and sexually transmitted 
diseases, Journal of Andrology, 21, 862-875.  
 
Anderson, R.A., Feathergill, K.A.,  Diao, X.H., Cooper, M.D., Kirkpatrick, R., Rencher, 
W.F., Waller, D.P., Chany, C.J., Doncel, G.F., Herold, B.C. and Zaneveld, L.J.D., (2002). 
Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive 
antimicrobial agent. Journal of Andrology, 23, 426-438. 
 209 
Andrews, G.P., Laverty, T.P. and Jones D.S., (2009). Bioadhesive polymeric platforms for 
controlled Drug Delivery. European Journal of Pharmaceutics and Biopharmaceutics, 71, 
505-518.  
Arasaratnam, V., Galaev I. Y., and Mattiasson, B., (2000). Reversibly soluble biocatalyst: 
optimization of trypsin coupling to Eudragit S-100 and biocatalyst activity in soluble and 
precipitated forms. Enzyme and Microbial Technology, 27, 254-263.  
Arifin, D.Y., Lee L.Y. and Wang C., (2006). Mathematical modeling and simulation of drug 
release from microspheres: Implications to Drug Delivery systems. Advanced Drug 
Delivery Reviews, 58, 1274-1325. 
Arulsudar, N., Subramanian N. and Murthy, R.S.R., (2005). Comparison of artificial neural 
network and multiple linear regression in the optimization of formulation parameters of 
leuprolide acetate loaded liposomes Journal of Pharmacy and Pharmaceutical Sciences, 
8, 243-258. 
Asane, G.S., Nirmal, S. A. and  Rasal, K. B. Naik, A.A. Mahadik, M.S., and Rao Y.M., 
(2008). Polymers for Mucoadhesive Drug Delivery System: A Current Status. Drug 
Development and Industrial Pharmacy, 34, 1246 – 1266.  
 
Avgoustakis, K., (2004). Pegylated poly(lactide) and poly (lactide-co-glycolide) 
nanoparticles: Preparation, properties and possible applications in Drug Delivery. Current 
Drug Delivery, 1, 321-333. 
 
Baba, M., Schols, D., De Clercq, E. Pauwels, R., Nagy, M., Györgyi-Edelényi, J., Löw, M. 
and Görög, S., (1990). Novel sulfated polymers as highly potent and selective inhibitors of 
human immunodeficiency virus replication and giant cell formation. Antimicrobial Agents 
and Chemotherapy, 34, 134-138. 
 210 
Bailey, M.L and Swett, J.E., (2007). Radiopaque compositions, articles and methods of 
making and using same. US Patent 20070270691. 
http://www.freshpatents.com/Radiopaque-compositions-articles-and-methods-of-making-
and-using-same-dt20071122ptan20070270691.php [Accessed 05 April 2009]. 
 
Ballagh, S.A., (2001). Vaginal ring hormone delivery systems in contraception and 
menopause, Clinical Obstetrics and Gynecology, 44, 106–113. 
 
Baloglu E., Senyigit, Z.A., Karavana, S.Y., and Bernkop-Schnürch, A., (2009). Strategies 
to Prolong the Intravaginal Residence Time of Drug Delivery Systems. Journal of 
Pharmaceutical Sciences, 12, 312 – 336. 
 
Balzarini, J. and van Damme, L., (2007). Microbicide drug candidates to prevent HIV 
infection. Lancet, 369, 787-797. 
 
Balzarini, J., Hatse, S., Vermeire, K., Princen, K., Aquaro, S., Perno, C.F. De Clercq, E., 
Egberink, H., Mooter, G.V., Peumans, W.,   van Damme, E. and Schols D., (2004). 
Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient 
microbicides for prevention of human immunodeficiency virus infection. Antimicrobial 
Agents and Chemotherapy, 48, 3858-3870. 
 
Balzarini, J., (2005). Targeting the glycans of gp120: a novel approach aimed at the 
achilles heel of HIV. Lancet infectious diseases, 5, 726-731. 
 
Barakat, N.S.  Elbagory, I.M. and Almurshedi A.S., (2009). Controlled-Release 
Carbamazepine Matrix Granules and Tablets Comprising Lipophilic and Hydrophilic 
Components. Drug Delivery, 16, 57–65. 
 211 
Barakat, N.S.  Elbagory, I.M. and Almurshedi, A.S., (2008). Controlled-Release 
Carbamazepine Granules and Tablets Comprising Lipophilic and Hydrophilic Matrix 
Components. AAPS Pharmaceutical Sciences and Technology, 9, 1054-1062.  
Barbara, E., Valeria, F., Fabrizio, E., (2006). Candidate HIV -1 tat vaccine development 
frombasic science to clinical trials. AIDS, 20, 2245-2261. 
 
Bartlett, J.G., (2003). The Hopkins HIV report. The Johns Hopkins University AIDS 
Service, 15, 1-16. 
 
Bártolo, I., Rocha, C., Bartolomeu J. Gama, A., Marcelino, R., Fonseca, M., Mendes, A., 
Epalanga, M, Silva, P.C. and Taveira, N., (2009). Highly divergent subtypes and new 
recombinant forms prevail in the HIV/AIDS epidemic in Angola: New insights into the 
origins of the AIDS pandemic. Infection, Genetics and Evolution, 9,  672-682.  
Battaglioli-DeNero, A., (2007). Strategies for Improving Patient Adherence to Therapy and 
Long-Term Patient Outcomes. Journal of the Association of Nurses in AIDS care, 18, 
S17-S22. 
 
Baughn, R.E. and Musher D.M.(2005). Secondary Syphilitic Lesions. Clinical Microbiology 
Reviews, 18, 205-216. 
 
Baumgartner, S., Kristl, J. and Peppas, N.A., (2002). Network structure of cellulose ethers 
used in pharmaceutical applications during swelling and at equilibrium. Pharmaceutical 
Research, 19, 1084-1090. 
 
 212 
Baumgartner, S., Kristl J., Vrecer F., Vodopivec, P. and Zorko, B., (2000). Optimisation of 
floating matrix tablets and evaluation of their gastric residence time. International Journal 
of Pharmaceutics. 195, 125-135. 
Becker, J.U., Theodosis, C., and Kulkarini, R., (2008). HIV/AIDS, conflict and security in 
Africa: rethinking relationships. Journal of the International AIDS Society, 11, 1-7. 
Belyakov, I.M. and Ahlers J.D., (2008). Functional CD8+ CTLs in mucosal sites and HIV 
infection: moving forward toward a mucosal AIDS vaccine. Trends in Immunology, 29, 
574-585. 
 
Benson, C.A.,  Kaplan, J.E. and  Masur, H., (2004). Treating opportunistic infections 
among HIV-infected adults and adolescents. Centers for Disease Control and Prevention, 
53, 1-112. 
 
Bentley, M.E., Marrow, K.M., Fullem A., Chesney M., Horton D. S., Zosenberg Z. and 
Mayer H. K., (2002). Acceptability of a novel vaginal microbicide during safety trial among 
low-risk women, Family Planning Perspective, 32, 184.  
 
Berger, J., (2004). Re-sexualizing the Epidemic: Desire, risk and HIV prevention. 
Development Update, 5, 45-67. 
 
Bernkop-Schnurch, A., (2005). Mucoadhesive Polymers: Strategies, Achievements and 
Future Challenge. Advanced Drug Delivery Reviews, 57, 1553-1555. 
 
Bernkop-Schnürch, A. and Hornof, M., (2003). Intravaginal Drug Delivery systems: 
Design, challenges, and solutions. American Journal of Drug Delivery, 1, 241-254. 
 
 213 
Bernstein, D.I., Stanberry, L.R., Sacks, S. Ayisi, N. K., Gong, Y. H.,  Ireland, J., Mumper, 
R. J.,  Holan, G.,  Matthews, B.,  McCarthy, T. and Bourne, N., (2003). Evaluations of 
unformulated and formulated dendrimer-based microbicide candidates in mouse and 
guinea pig models of genital herpes. Antimicrobial Agents and Chemotherapy, 47, 3784–
3788. 
 
Best, K., (2000). Microbicide products enter human trials. FHI’s Prevention Trials 
Network. 20, 1-12. 
Bettini, R., Catellani, P. L., Santi, P., Massimo, G, Peppas, N.A. and Colombo, P., (2001). 
Translocation of drug particles in HPMC matrix gel layer: effect of drug solubility and 
influence on release rate. Journal of Controlled Release,  70,  383-391.  
Bilensoy, E., Cirpanli, Y. and Sen, M., (2007). Thermosensitive mucoadheisive gel 
formulation loaded with 5-Fu: cyclodextrin complex for HPV-induced cervical cancer. 
Journal of Inclusion Phenomena and Macrocyclic Chemistry, DOI 10.1007/s 10847-006-
9259-y, 1-8. 
 
Bilensoy, E., Rouf, A.M, Vural, I., Sen, M. and Hincal, A.A., (2006). Mucoadhesive, 
thermosensitive, prolonged-release vaginal gel for clotrimazole cyclodextrin complex. 
AAPS Pharmaceutical Sciences and Technology, 7, 1-13. 
Billa, N. and Yuen, K.H., (2000). Formulation Variables Affecting Drug Release From 
Xanthan Gum Matrices at Laboratory Scale and Pilot Scale. AAPS Pharmaceutical 
Sciences and Technology, 1, 1-8.  
Biradar,S.V.,  Dhumal, R.S., Shah,M.H., Paradkar, A.R. and Yamamura, S., (2009). 
Preparation of Multiparticulate Vaginal Tablet Using Glyceryl Monooleate for Sustained 
Progesterone Delivery. Pharmaceutical Development and Technology, 14, 41-52  
 214 
Blakemore, W.R., Ballard, A.D, Sewall, C.J., Modliszewski, J.J. and Bubnis, W.A., (2008).  
Carageenan based antimicrobial compositions. US Patent 0161551. 
http://www.freshpatents.com/Carrageenan-based-antimicrobial-compositions-
dt20080703ptan20080161551.php [Accessed June 23, 2009]. 
 
Bob, R., (2000). Microbicide. Fashioning new tools to deter HIV transmission 
International Association of Physicians in AIDS Care, 6, 157. 
 
Bogentoft, C. and Carlsson., A., (1996). Gel forming liquid carrier composition. US Patent 
5492937. http://www.patentstorm.us/patents/5492937/claims.html [Accessed June 2, 
2007]. 
 
Bonacucina, G., Martelli, S. and Palmieri G.F., (2004). Rheological, mucoadhesive and 
release properties of Carbopol gels in hydrophilic cosolvents. International Journal of 
Pharmaceutics, 282, 115-130.  
 
Bonacucina, G., Cespi, M., Misici-Falzi, M. and Palmieri, G.F., (2006). Rheological, 
adhesive and release characterisation of semisolid Carbopol/tetraglycol systems. 
International Journal of Pharmaceutics, 307, 129-140.   
 
Bonferoni, M.C., Sandri, G., Rossi, S., Ferrari, F., Gibin, S. and Caramella, C., (2007). 
Chitosan citrate as multifunctional polymer for vaginal delivery: Evaluation of penetration 
enhancement and peptidase inhibition properties. European Journal of Pharmaceutical 
Sciences, 33, 166-176.  
 
Bonferoni, M.C., Giunchedi, P., Scalia, S. Rossi, S., Sandri, G. and Caramella, C., (2006). 
Chitosan gels for the vaginal delivery of lactic acid: Relevance of formulation parameters 
 215 
to mucoadhesion and release mechanisms. AAPS Pharmaceutical Sciences and 
Technology, 7, E1-E8. 
 
Boris, S. and Barbés, C., (2000). Role played by lactobacilli in controlling the population of 
vaginal pathogens, Microbes Infect. 2, 543–546. 
 
Bonifazi, D., Enger, O and  Diederich F., (2007). Supramolecular [60]fullerene chemistry 
on surfaces, Chemical Society Reviews, 36, 390-414. 
Bornstein, P., (1995). Diversity of function is inherent in matricellular proteins: an 
appraisal of thrombospondin-1. Journal of Cell Biology, 130, 503-506. 
 
Boskey, E. A., Jansen, M., Merski, I.K., Whaley, I.T., Moench, T. and Cone, R., (2000).  
BufferGelTM favors in vitro growth of lactobacilli while inhibiting BV-associated organisms 
Johns Hopkins University and ReProtect, Inc. Abstract A07. 
http://curezone.com/blogs/fm.asp?i=974816 [Accessed November 18, 2007]. 
 
Boskey, E.R. and Cone, R.A., (2001). Whaley KJ and Moench TR. Origin of vaginal 
acidity: High D/L lactate ratio is consistent with bacteria being the primary source. Human 
Reproduction, 16, 1809-1813.  
 
Bourinbaiar, A.S., Root-Bernstein, R.S., Abulafia-Lapid, R., Rytik, P.G., Kanev, A.N., 
Jirathitikal, V. and Orlovsky, V.G., (2006). Therapeutic AIDS vaccines. Current 
Pharmaceutical Design, 12, 2017-2030. 
 
Bourne, N., Bernstein, D.L., Ireland, J., Sonderfan, A.J., Profy, A.T. and Stanberry, L.R., 
(1999). The topical microbicides PRO 2000 protects against genital herpes infection in a 
mouse model. Journal of infectious Diseases, 180, 203-205. 
 216 
Bourne, N., Zanevelde, L.J.D., Ward, J.A., Ireland, J.P. and Stanberry, L.R., (2003). Poly 
(sodium 4-sulfonate): Evaluation of a topical microbicide gel against herpes simplex virus 
type 2 and Chlamydia trachomatis infection in mice. Clinical Microbiology Infections, 9, 
816-822.  
 
Bourquin, J., Schmidli, H., van Hoogevest, P. and Leuenberger, H., (1998). Advantages of 
artificial neural networks (ANN) as alternative modelling technique for data sets showing 
non-linear relationship using data from a galenical study on a solid dosage form. 
European Journal of Pharmaceutical Sciences, 7, 5-16. 
 
Boyd, M.R., Gustfson, K.R., Mc Mahon, J.B. Shoemaker, R.H., O'Keefe, B.R., Mori, T., 
Gulakowski, R.J., Wu, L.,  Rivera, M.I., Laurencot, C.M.,  Currens, M.J., Cardellina, J.H., 
Buckheit, R.W., Nara, P.L., Pannell, L.K., Sowder, R.C. and Henderson, L.E., (1997). 
Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that 
binds viral surface envelope glycoprotein gp 120: potential application to microbicide 
development. Antimicrobial Agents and Chemotherapy, 41, 1521-1530. 
 
Brache, V., Croxatto, H., Kumar, N., Sitruk-Ware, R., Cochón, L., Schiappacasse, V., 
Sivin, I., Muñoz, C., Maguire, R. and Faundes A., (2009). Effect of sexual intercourse on 
the absorption of levonorgestrel after vaginal administration of 0.75 mg in Carraguard® 
gel: a randomized, cross-over, pharmacokinetic study. Contraception, 79, 150-154.  
 
Brannon-Peppas, L., (1992). Novel vaginal drug release applications. Advanced Drug 
Delivery Reviews, 11, 169–177. 
Brenchley, J.M. and Douek D.C., (2008). HIV infection and the gastrointestinal immune 
system. Mucosal Immunology, 1, 23–30.  
 217 
Brenner, B.G., Wainberg, M.A. and Turner, D., (2002). HIV-1 drug resistance: can we 
overcome? Expert Opinion on Biological Therapy, 2, 751-761. 
 
Breton, P., Larras V., Roy, D., Segodira, S., Limal, D., Bonnafous, D., Colin, N, Bru, N, 
Fattal, E. and Couvreur, P., (2008). Biocompatible poly(methylidene malonate)-made 
materials for pharmaceutical and biomedical applications. European Journal of 
Pharmaceutics and Biopharmaceutics, 68, 479-495.  
 
Brier, M.E. Zurada J.M. and Aronoff, G.R. (1995). Neural network predicted peak and 
trough gentamicin concentrations, Pharmaceutical Research, 12, 406–412. 
 
Briggs, K. and  Zeitlin, L., (2000). An anti-HSV antibody produced in transgenic rice plants 
prevents HSV-2 infection in mice. AIDS, 15, S19-S20. 
Brodland, G.W., (2003). New information from cell aggregate compression tests and its 
implications for theories of cell sorting. Biorheology, 40, 1-3, 273-277. 
 
Broliden, K., Haase, A. T., Ahuja, S. K., Shearer, G.M. and Andersson, J., (2009). Back to 
basics: mucosal immunity and novel HIV vaccine concepts. Journal of Internal Medicine, 
265, 5-17.  
 
Broumas, A.C. and Basara, L.A., (2000). Potential patient preference for three day 
treatment of bacterial vaginosis: Responses to a new suppository form of clindamycin, 
Advances in Urethrane Science and Technology, 17, 159-166. 
Brouwers, J., Vermeire, K., Schols, D. and Augustijns P., (2008). Development and in 
vitro evaluation of chloroquine gels as microbicides against HIV-1 infection. Virology, 378,  
306-310.   
 218 
Brown, T.J., Yen-Moore, A. and Trying, S.K., (1999). An overview of sexually transmitted 
diseases. Part 1. Journal of American Academy of Dermatology, 41, 511-532. 
 
Buck, B.C., Thompson, C.D., Roberts, J.N., Müller, M., Lowy D.R. and Schiller J.T., 
(2006). Carageenan is a potent inhibitor of papillomavirus infection. PloS Pathogens, 2, 
0671-0680. 
Buddhikot, M., Falkenstein, E., Wehling M. and Meizel, S., (1999). Recognition of a 
human sperm surface protein involved in the progesterone-initiated acrosome reaction by 
antisera against an endomembrane progesterone binding protein from porcine liver. 
Molecular and Cellular Endocrinology. 158, 187-193  
Budtz-jorgensen, E., (2000). Ecology of candida-associated denture stomatitis. Microbial 
Ecology in Health and Disease, 12, 170-185. 
Bulgheroni, E., Citterio, P., Croce, F. Cicero, M.L., Viganò, O., Soster, F., Chou, T., Galli 
M. and Rusconi S., (2004).Analysis of protease inhibitor combinations in vitro: activity of 
lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant 
isolates. Journal of Antimicrobial Chemotherapy, 53, 464-468. 
 
Butsashvili, M., Tsertsvadze, T., McNutt, L.A. Kamkamidze, G., Gvetadze, R. and 
Badridze N., (2001). Prevalence of hepatitis B, hepatitis C, syphilis and HIV in Georgian 
blood donors. European Journal of Epidemiology, 17, 693–695. 
 
Cadena, C., A., (2006). HIV Vaginal Gel: An overview of PRO. http://www.associatedcont 
ent.com/article/92443/HIV_vaginal_gel_an_overview_of_pro.html [ Accessed March 24, 
2007]. 
 
 
 219 
Cairns, G., (2007). Microbicides trials get London start. Prevention. 
 http://www.guscairns.com/ [Accessed July 23, 2007]. 
 
Cajander, S.S. and Rylander, E., (1988). Morphometric characteristics of the vaginal 
epithelium during the menstrual cycle. Gynecologic and Obstetric Investigation, 26, 136–
144. 
 
Campo, J., Perea, M.A., del Romero, J., (2006). Oral transmission of HIV, reality or 
fiction? An update. Oral diseases, 12, 3219 – 228.  
Campo, V. L., Daniel Fábio Kawano, D.F., da Silva D.B. and Carvalho I., 
(2009).Carrageenans: Biological properties, chemical modifications and structural 
analysis – A review. Carbohydrate Polymers,  77, 167-180.   
Caputo, A.C. and Pelagagge, P.M., (2008). Parametric and neural methods for cost 
estimation of process vessels. International Journal of Production Economics. 112,  934-
954.  
Carmen, A. and Angel, C., (2003). Effects of surfactants on gel Behavior: Design 
implications for Drug Delivery systems. American Journal of Drug Delivery, 1, 77-101. 
 
Carrington, G.L, Rohrer, T., Jones, E., Moore, P., (1944). Sulfanilamide absorption via the 
rectum and vagina. Surgery, Gynecology and Obstetrics, 78, 333-334. 
 
Castle, P.E., Whaley, K.J., Hoen, T.E., Moench, T.R. and Cone, R.A., (1997). 
Contraceptive effect of sperm-agglutinating monoclonal antibodies in pigs. Biolology of 
Reproduction, 56, 53-159. 
 
 220 
Castle, P.E., (2002). Human monoclonal antibody stability and activity at vaginal pH 
Journal of Reproductive Immunology, 56, 61-76.  
 
Catalone, B.J., Kish-Catalone, T.M., Neely, E.B., Budgeon, L.R. Ferguson, M.L., Stiller, 
C., Miller, S.R., Malamud D., Krebs, F.C., Howett, M.K. and Wigdahl B., (2005). 
Comparative Safety Evaluation of the Candidate Vaginal Microbicide C31G. Antimicrobial 
Agents and Chemotherapy, 49, 1509–1520. 
Cavalcanti, O.A., Petenuci, B., Bedin, A.C., Pineda, E.A.G and Hechenleitner, A.A.W., 
(2004). Characterisation of ethylcellulose films containing natural polysaccharides by 
thermal analysis and FTIR spectroscopy. Latin American Journal of Pharmacy, 23, 53-57.  
Cedars, M.I. and Judd, H.L. (1987). Nonoral routes of estrogen administration. Obstetrics 
& Gynecology Clinics of North America, 14, 269–298. 
 
Ceschel, G.C., Maffei, P., Lombardi, B.S., Ronchi, C., and  Rossi, S., 2001. Development 
of a mucoadhesive dosage form for vaginal administration.  Drug Development and 
Industrial Pharmacy, 6, 541-547.  
Chakraborty, R., (2008). Update on HIV-1 infection in children. Paediatrics and Child 
Health, 18, 496-501.  
Chang, J.Y., Oh, Y. and Choi, H. Kim, Y.B. Kim, C.K., (2002). Rheological evaluation of 
thermosensitive and mucoadhesive vaginal gels in physiological conditions. International 
Journal of Pharmaceutics. 241, 155-163.  
 
Charde, S., Mudgal, M., Kumar, L. and Saha, R., (2008). Development and Evaluation of 
Buccoadhesive Controlled Release Tablets of Lercanidipine. AAPS Pharmaceutical 
Sciences and Technology, 9, 182-190.  
 221 
 
Chazal, N. and Gerlier, D., (2003).  Virus Entry, Assembly, Budding, and Membrane Rafts. 
Microbiology and Molecular Biology Reviews, 67, 226–237.  
 
Chen, X., Galeski, A. and Michler, G.H., (2006). Morphological alteration and strength of 
polyamide 6 subjected to high plane–strain compression. Polymer, 47, 3171-3185. 
 
Chen, Y. Jiao, T.  McCall, T.W.  Baichwal A.R. and Meyer, M.C., (2002). Comparison of 
four artificial neural network software programs used to predict the in vitro dissolution of 
controlled- release tablets.  Pharmaceutical Development and Technology, 7, 373–379. 
 
Cheshenko, N., Keller, M.J. and MasCasullo, V., (2004). Candidate topical microbicides 
bind herpes simplex virus B and prevent viral entry and cell-to-cell spread. Antimicrobial 
Agents and Chemotherapy, 48, 2025-2036. 
 
Ch'ng, H.S.  Park, H. Kelly, P. and Robinson, R., (1985). Bioadhesive polymers as 
platforms for oral controlled drug delivery: II. Synthesis and evaluation of some swelling 
water insoluble bioadhesive polymers. Journal of Pharmaceutical Sciences, 74, 399–405. 
 
Cho, K., Park, J., Osaka, T. and Park, S., (2005). The study of antimicrobial activity and 
preservative effects of nanosilver ingredient. Electrochimica Acta, 51, 956-960. 
Choonara, Y.E., Pillay, V., Singh, N., Khan, R.A. and Ndesendo, V.M.K., (2008). 
Chemometric, physicomechanical and rheological analysis of the sol-gel dynamics and 
degree of crosslinking of glycosidic poymers. Biomedical Materials, 3, 1-15.  
 222 
Chopra, S., Patil, G.V. and Motwani, S.K., (2007). Release modulating hydrophilic matrix 
systems of losartan potassium: Optimization of formulation using statistical experimental 
design. European Journal of Pharmaceutics and Biopharmaceutics, 66,  73-82.  
Choudhry, M. and Choudhry, V. P., (2003).  Prevention and control of HIV/AIDS. Indian 
Journal of Pediatrics, 70, 975-981. 
Christ, K.A., Zessin, G. and Cobet, U., (1998). The use of ultrasound and penentrometer 
to characterize the advancement of swelling and eroding fronts in HPMC matrices. 
International Journal of Pharmaceutics, 163, 123–131. 
Christensen, N.D., Reed, C.A., Culp, T.D., Hermonat, P.L., Howett, M.K., Anderson, R.A. 
and Zaneveld L.J.D., (2001). Papillomavirus microbicidal activities of high-molecular-
weight cellulose sulfate, dextran sulfate, and polystyrene sulfonate. Antimicrobial Agents 
and Chemotherapy, 45, 3427-3432. 
 
Chu, H., Yeo, Y., Chuang, K.S., (2007). Entry in emulsion polymerization using a mixture 
of sodium polystyrene sulfonate and sodium dodecyl sulfate as the surfactant. Polymer, 
48, 2298-2305.  
 
Cicinelli, E., Cignarelli, M., Sabatelli, S. Romano, F., Schonauer, L..M., Padovano, R. and 
Einer-jensen, N., (1998). Plasma concentrations of progesterone are higher in the uterine 
artery than in the radial artery after vaginal administration of micronized progesterone in 
an oil-based solution to postmenopausal women. Fertility and Sterility, 69, 471–473. 
 
Cicinelli, E., de Ziegler D., Bulletti, C., Matteo, M.G., Schonauer L.M. and  Galantino P., 
(2000). Direct transport of progesterone from vagina to uterus. Obstetrics and 
Gynecology, 95, 403–406. 
 
 223 
Clarke, G., McCoombe, S. and Short, R., (2006). Sperm immobilizing properties of lemon 
juice. Fertility and Sterility, 85, 1529-1530. 
 
Coetzee, N., Hoosen, A., Blanchard, K., de Kock, A., Sebda, H., Friedland, B., Ellerton, 
C., Nkompela, N., Altin, L., Ndlovu, G. and Tweedy, K., (2006).  Safety of lambda 
carageenan microbicides (Carraguard™) in South Africa. University of Cape Town, 
Medical University of Southern Africa, Population Council and Family Health International. 
http://www.itg.be/micro2002/downloads/presentations/2Monday_May_13_2002/Track_B_
sessions/Nicol_Coetzee.pdf [Accessed October 17, 2007].  
 
Cohen, M.S. (2004). HIV and sexually transmitted diseases: lethal synergy, Topics in HIV 
Medicine, 12 104–107. 
Cohen, M.S., Black J.R., Proctor R.A., Sparling P.F., (1984). Host defences and the 
vaginal mucosa: a re-evaluation. Scandinavian Journal of Urology and Nephrology, 86, 
(Suppl.), 13-22.  
 
Cole, A.M. and Cole. A.L., (2007).  Antimicrobial polypeptides are key anti-HIV-1 effector 
molecules of cervicovaginal host defense. American Journal of Reproductive 
Immunology,  59, 27–34. 
 
Collins, K. B., Patterson, B. K., Naus, G. J., Landers, D. V. and Gupta, P., (2000). 
Development of an in vitro organ culture model to study transmission of HIV-1 in the 
female genital tract. Nature Medicine, 6, 475-479. 
 
Colombo, P., Bettini, R., Santi, P., De Ascentiis A. and Peppas, N.A., (1996).  Analysis of 
the swelling and release mechanisms from Drug Delivery systems with emphasis on drug 
solubility and water transport. Journal of Controlled Release, 39, 231–237.  
 
 224 
Cone, R.A. and Whaley, K.J., (1994). Monoclonal antibodies for reproductive health: 
Preventing sexual transmission of disease and pregnancy with topically applied 
antibodies. American Journal of Reproductive Immunology, 32, 114-131. 
 
Coombs, R.W.,Reichelderfer, P.S. anf Landay, A.L., (2003). Recent observations on HIV 
type-1 infection in the genital tract of men and women. AIDS, 17, 455-480. 
  
Corring, R., (1992). Gel detergent compositions containing a clay and a cross-linked 
polycarboxylic polymer.  US Patent 5160448. http://www.freepatentsonline.com/5160448 
[Accessed August 28, 2000]. 
 
Cristofaro, P. and Ramratnam, B., (2005). Prevention Strategies: Vaccines and 
Microbicides. 12th conference on retrovirus and opportunistic infections, Boston, USA. 22-
25. 
 
Crombie, R. and Silverstein, R.L., (1998). Lysosomal integral membrane protein LIMP II 
binds thrombospondin-1: structure-function homology with the cell adhesion molecule 
CD36 defines a conserved recognition motif. Journal of Biological Chemistry, 273, 4855-
66. 
 
Crombie, R., (2000). Mechanism of thrombospondin-1 anti-HIV-1 activity. AIDS Patient 
Care and STDs, 14, 211-214. 
 
Crombie, R., Kawasaki, K., Hojo, K. and Laurence, J., (2001). Peptides derived from 
salivary thrombospondin-1 replicate its anti-HIV effect: Potential role in microbicide 
development. Journal of Acquired Immune Deficiency Syndromes, 27, 91-93. 
 
 225 
Cutler, B. and Justman, J., (2008). Vaginal microbicides and the prevention of HIV 
transmission. Lancet Infectious Diseases, 8, 685–697.  
Dahlberg, C., Fureby, A., Schuleit, M., Dvinskikh, S.V. and Furo, I., (2007). Polymer 
mobilization and drug release during tablet swelling. A 1H NMR and NMR microimaging 
study. Journal of Controlled Release, 122, 199-205.  
Dam, E., Clavel, F., Calvex, V. Salmon, D., Pellegrin, J.L., Mamet, J.P., Antoun, Z. and 
Vauthier, J.M., (2001). Comparison of HIV-1 resistance phenotypes obtained by two 
different assay systems. Antiviral Therapy, 6, 122. 
 
das Neves, J. and Bahia, M.F., (2006). Gels as vaginal drug delivery systems. 
International Journal of Pharmaceutics, 318, 1-14.  
 
das Neves, J., Santos, B., Teixeira, B. Dias, G., Cunha, T. and Brochado, J., (2008). 
Vaginal drug administration in the hospital setting. American Journal of Health-System 
Pharmacy, 65, 254-259. 
 
Davis, C.C.  Kremer, M.J.  Schlievert P.M. and Squier, C.A., (2003).  Penetration of toxic 
shock syndrome toxin-1 across porcine vaginal mucosa ex vivo: permeability 
characteristics, toxin distribution, and tissue damage, American Journal of Obstetrics and 
Gynecology. 189, 1785–1791. 
D’Cruz, O.J. and Uckun, F.M., (2002).  Pre-clinical safety evaluation of novel nucleoside 
analogue-based dual-function microbicides (WHI-05 and WHI-07). Journal of 
Antimicrobial Chemotherapy, 50, 793-803.  
 
D’Cruz, O.J., (2003a). Stampidine is a potential nonspermicidal broad-spectrum anti-
human immunodeficiency virus microbicides. Fertility and Sterility, 81, 831-841. 
 226 
 
D’Cruz, O.J., (2003b). Contraceptive activity of a spermicidal aryl phosphate derivative of 
bromo-methoxy-zidovudine (compound WHI-07) in pigs. Fertility and Sterility, 79, 864-
872.  
 
D'Cruz, O.J., Samuel, P., Waurzyniak, B. and Uckun, F.M., (2003a). In vivo evaluation of 
a gel formulation of stampidine, a novel non-spermicidal broad-spectrum anti-HIV 
microbicide. American Journal of Drug Delivery, 1, 275-285. 
 
D'Cruz, O.J. Samuel, P., Waurzyniak, B., and Uckun F.M., (2003b). Development and 
evaluation of a thermoreversible ovule formulation of stampidine. a novel nonspermicidal 
broad-spectrum anti-human immunodeficiency virus microbicide. Biology of Reproduction, 
69, 1843–1851.  
D’Cruz, O.J. and UcKun, F.M., (2004). Clinical development of microbicides for the 
prevention of HIV infection. Current Pharmaceutical Design, 10, 315-335.  
D'Cruz, O.J., Samuel, P. and Uckun, F.M., (2004a). PHI-443: A novel noncontraceptive 
broad-spectrum anti-human immunodeficiency virus microbicide, Biology of Reproduction, 
71, 2037-2047. 
 
D'Cruz, O.J., Samuel, P. and Uckun, F.M., (2004b). Antiretroviral Spermicide WHI-07 
Prevents Vaginal and Rectal Transmission of Feline Immunodeficiency Virus in Domestic 
Cats. Antimicrobial Agents and Chemotherapy, 48, 1082-1088. 
 
D'Cruz, O.J., Samuel, P. and Uckun, F.M., (2005a). Conceival, a novel non-contraceptive 
vaginal vehicle for lipophilic microbicides. AAPS Pharmaceutical Sciences and 
Technology, 6, E56-E64. 
 227 
 
D’cruz, O.J., Erbeck, D. and Uckun F.M., (2005b). A Study of the potential of the pig as a 
model for the vaginal irritancy of benzalkonium chloride in comparison to the nonirritant 
microbicide PHI-443 and the spermicide vanadocene dithiocarbamate. Toxicologic 
Pathology, 33, 465-476.  
 
D'Cruz, O.J. and Uckun, F.M., (2005c). Discovery of 2,5-dimethoxy-substituted 5-
bromopyridyl thiourea (PHI-236) as a potent broad-spectrum anti-human 
immunodeficiency virus microbicide. Molecular Human Reproduction, 11, 767-777. 
 
D’Cruz, O.J. and Uckun, F.M., (2006a). Influence of long-term stability conditions on 
microbicidal nucleoside prodrug (WHI-07)-loaded gel-microemulsion. AAPS 
Pharmaceutical Sciences and Technology, 7, 1530-9932.  
 
D'Cruz, O.J.D. and Uckun, F.M., (2006b). Dawn of non-nucleoside inhibitor-based anti-
HIV microbicides. Journal of Antimicrobial Chemotherapy, 57, 411-423.  
D'Cruz, O.J. and Fatih, Uckun, F.M., (2007). Preclinical Evaluation of a Dual-Acting 
Microbicidal Prodrug WHI-07 in Combination with Vanadocene Dithiocarbamate in the 
Female Reproductive Tract of Pig, Pig, and Cat. Toxicologic Pathology, 35, 910-927. 
 
De Clercq, E., (2000). Current lead natural products for the chemotherapy of human 
immunodeficiency virus (HIV) infection. Medical Care Research and Review, 20, 323-349. 
 
De Clercq, E., (2004). New anti-HIV agents in preclinical and clinical development. 
Frontiers in Medicinal Chemistry, 1, 543-579. 
 
 228 
De Clercq, E., (2006). The role of tenofovir in the prevention of HIV infections. AIDS, 20, 
1990-1991. 
 
de Candia, F,   Maglio, G,  Palumbo, R and Sirletti, M., (1998). Synthesis and physical 
behavior of polyamide 6,10-poly(butadiene-co-acrylonitrile) segmented block copolymers. 
Colloid and Polymer Science, 267, 9-15.  
 
Deryaguin, B.V., Toporov, Y.P., Mueler, V.M. and Aleinikova, I.N., (1997). On the 
relationship between the electrostatic and molecular component of the adhesion of elastic 
particles to a solid surface, Journal of. Colloid and Interface Science, 58, 528-533. 
 
Desphande, A., Rhodes, C.T., and Danish M., (1992). Intravaginal drug delivery. Drug 
Development and Industrial Pharmacy, 18, 1225-1279.  
 
Dezarnaulds, G., and Fraser, I.S., (2002). Vaginal ring delivery of hormone replacement 
therapy—a review. Expert Opinion on Pharmacotherapy, 4, 201–212. 
 
Dhawan, D. and Mayer, K.H., (2006). Microbicides to Prevent HIV Transmission: 
Overcoming Obstacles to Chemical Barrier Protection. The Journal of Infectious 
Diseases, 193, 36–44. 
 
Di Fabio, S., Van Roey, J., Giannini, G. van den Mooter, G., Spada, M., Binelli, A., Pirillo, 
M.F., Germinario, E., Belardelli, F., de Bethune, M. and Vella, S., (2003). Inhibition of 
vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse 
transcriptase inhibitor TMC120 in a gel formulation. AIDS, 17, 1597–1604. 
 
 229 
Dieterich, D.T., (2006). Disease management–constructing optimal NRTI-based 
combinations: Past, Present, and Future. Medscape General Medicine, 8, 16. 
 
Division of HIV/AIDS Prevention, (2003). HIV and its transmission. Center for Disease 
Control and Prevention (CDC). https://www.cdc.gov/hiv/pubs/facts/transmission.htm 
[Accessed May 23, 2006]. 
 
Dobaria, N., Mashru, R. and Vadia, N.H., (2007).Vaginal drug delivery systems: A Review 
Current Status. East and Central African Journal of Pharmaceutical Studies, 10, 3-13. 
 
Drug Digest, (2004). Sexually transmitted infections (STIs). http://www.drugdigest.org/DD/ 
Printab-lePages/HealthConditions/1,20041,550367,00.html [Accessed April 20, 2007]. 
 
DuBouchet, L, McGregor, J.A., Ismail, M. and McCormack, W.M., (1998). A pilot study of 
metronidazole vaginal gel versus oral metronidazole for the treatment of trichomonas 
vaginalis vaginitis. Sexually Transmitted Diseases, 25, 176–179. 
 
Dürig, T. and Fassihi, R., (2002). Guar-based monolithic matrix systems: effect of 
ionizable and non-ionizable substances and excipients on gel dynamics and release 
kinetics. Journal of Controlled Release, 80, 45-56 
 
Dykxhoorn, D.M. and Lieberman, J., (2006). Silencing Viral Infection. PLoS Medicine, 3, 
e242. 
 230 
Eaton L.A. and Kalichman S.C., (2007). Risk compensation in HIV prevention: 
Implications for vaccines, microbicides, and other biomedical HIV prevention 
technologies. Current HIV/AIDS Reports, 4, 165-172. 
Efentakis M. and Peponaki C., (2008). Formulation Study and Evaluation of Matrix and 
Three-layer Tablet Sustained Drug Delivery Systems Based on Carbopols with Isosorbite 
Mononitrate. AAPS Pharmaceutical Sciences and Technology, 9, 917-923. 
 
Eggert-Kruse, W., Botz, I., Pohl, S., Rohr, G. and Thomas Strowitzki, T., (2000). 
Antimicrobial activity of human cervical mucus. Human Reproduction, 15, 778-784 
 
 
Einer-Jensen, N., Cicinelli, E., Galantino, P., Pinto V. and Barba B., (2002).  Uterine first 
pass effect in postmenopausal women, Human Reproduction, 17, 3060–3064. 
Einmahl, S., Capancioni, S. Schwach-Abdellaoui, K., Moleller, M., Behar-Cohen, F. and 
Gurny, R., (2001). Therapeutic applications of viscous and injectable poly(ortho esters). 
Advanced Drug Delivery Reviews,  53, 45-73.  
El-Kamel A., Soker M., Naggar V. and Al Gamal S., (2002). Chitosan and sodium 
alginate-based bioadhesive vaginal tablets, AAPS Pharmaceutical Sciences and 
Technology, 4, 1-8. 
  
Elson, C., Milne, A., Curran, D. and Kydonieus, A. N., (2000). O-Carboxymethylchitosan 
as a mucoadhesive for vaginal delivery of levonorgestrel, Proceedings of International 
Symposium on Controlled Release of  Bioactive Materials, 27, 7201-7202.  
 231 
Espinosa, M. Noé, G., Troncoso, C. Ho, S.B. and Villalón M., (2002). Acidic pH and 
increasing [Ca2+] reduce the swelling of mucins in primary cultures of human cervical 
cells. Human Reproduction, 17, 1964-1972.  
 
Fairley, J., (2009a). Completes Patient Testing In Retention Of VivaGel Antiviral Activity 
Study. Starpharma Holdings Limited (ASX:SPL). http://www.ecplaza.net/news/0/22998/ 
starpharma _holdings_limited.html [Accessed July 5, 2009].  
 
Fairley, J., (2009b). VivaGel New Clinical Trial Commences. Starpharma Holdings Limited 
(ASX:SPL).  http://www.femail.com.au/vivagel-new-clinical-trial-commences.htm 
[Accessed August 20, 2009]. 
 
Farmer, P., Le´andre, F., Mukherjee, J., Gupta, R., Tarter, L. and Kim, J.Y., (2001). 
Community-based treatment of advanced HIVdisease: introducing DOT-HAART (directly 
observedtherapy with highly active antiretroviral therapy). Bulletin of the World Health 
Organization, 79, 1145–1151. 
 
Fauci, A.S., (2005). International Trial Of Two Microbicides Begins, Science Daily. 
http://www.sciencedaily.com/releases/2005/02/050213135251.htm [Accessed May 22, 
2009]. 
 
Ferris, D.G., Francis, S.L., Dickman, E.D. Miler-Miles, K., Waller, J.L. and McClendon N., 
(2006). Variability of Vaginal pH Determination by Patients and Clinicians. The Journal of 
the American Board of Family Medicine, 19, 368-373.  
Fernández-Romero, J.A., Thorn, M., Turville, S.G., Titchen, K., Sudol, K., Li, J., Miller, T., 
Robbiani, M., Maguire, R.A., Buckheit, R.W. Jr, Hartman, T.L. and Phillips, D,M., (2007). 
 232 
Carrageenan/MIV-150 (PC- 815), a combination microbicide.  Sexually Transmitted 
Diseases, 34, 9–14. 
 
Fichora, R.N., Zhou, F., Ratnan, V., Atanassova, V., Giang, S., Strick, N. and Neurath, 
A.R., (2005). Anti-human immunodeficiency virus type I microbicides cellulose acetate 
1,2-benzene dicarbxylate in a human in vitro model of vaginal inflammation. Antimicrobial 
Agents and chemotherapy, 49, 323-325. 
 
Finley, B.M., Plescia, C.J., Harrison, P.F. and Vignes, F.N., (2006). An analytical overview 
of the microbicide preclinical and clinical pipeline. AIDS Conference. Toronto Canada; 
Abstract No. TuPE0438 [Accessed November 18, 2007].  
Fischer, M., Hafner, R., Schneider, C., Trkola, A., Joos, B., Joller, H., Hirschel, B., Weber, 
R. and Gunthard, H., (2003). HIV RNA in plasma rebounds within days during structured 
treatment interruptions. AIDS, 17, 195-199. 
Flint, S.R., Tappuni, A., Leigh, J., Schmidt-Westhausen, A.M. and MacPhail L., (2006). 
(B3) Markers of Immunodeficiency and Mechanisms of HAART Therapy on Oral Lesions. 
Advances in Dental Research. 19, 146-151. 
 
Fogel, G.B., (2008). Computational intelligence approaches for pattern discovery in 
biological systems. Briefings in Bioinformatics, 9, 307-316. 
 
Forbes, A. and Harrison, P., (2000). Microbicides. Aids Community Research Initiative of 
America. http://www.thebody.com/content/art14112.html [Accessed November 15, 2007]. 
 
Foty R.A. and Steinberg M.S., (2005). The differential adhesion hypothesis: a direct 
evaluation. Developmental Biology, 278, 255-263. 
 233 
Francois, M., Snoeckx, E., Putteman, P. et al., (2003).A Mucoadhesive, cyclodextrin-
based vaginal cream formulation of itraconazole. American Association of Pharmaceutical 
Scientists, 5, 1-5. 
Fried, N.D., Tredway, D.R. and Mishell, D.R., (1973). Termination of early pregnancy with 
prostaglandin E2 vaginal suppositories. Contraception. 8, 255-263.  
 
Frieden, T.R., Das-Douglas, M., Kellerman, S.E. and Henning, K.J., (2005).  Applying 
Public Health Principles to the HIV Epidemic. The New England Journal of Medicine, 353, 
2397-2402. 
 
Frushour, B.G., (2004). A new thermal analytical technique for acrylic polymers. Polymer 
Bulletin, 4, 305-314.  
Fu, X.C., Wang, G.P., Gao, J.Q. Zhan, S.Y. and Liang W.Q., (2003). Prediction of plasma 
protein binding of cephalosporins using an artificial neural network. Pharmazie, 62, 157-
158. 
Furuhjelm, M., Karlgren, C. and Carlstrom, K., (1980). Intravaginal administration of 
conjugated estrogens in postmenopausal women. International Journal of Gynecology 
and Obstetrics, 17, 335-339.   
 
Gadi, B. and Parniak, M.A., (2001). Anti-HIV-1 microbicide potential of the tight-binding 
non-nucleoside reverse transcriptase inhibitor UC781. AIDScience, 1, 12. 
Galeski, A., (2003). Strength and toughness of crystalline polymer systems. Progress in 
Polymer Science, 28, 1643-1699.  
 234 
Gallant, J.E., (2008). Initial regimen. Johns Hopkins poc-IT Center. http://www.hopkins-
hivguide.org/management/antiretroviral_therapy/full_initial_regimen.html [Accessed 
August 15, 2009]. 
Gao, P. and Meury, R.H., (1996). Swelling of hydroxypropyl methylcellulose matrix 
tablets. 1. Characterisation of swelling using a novel optical imaging method. Journal of 
Pharmaceutical Sciences, 85, 725–731.  
 
Garg, S., Kandarapu, R., Vermani, K., (2003). Development Pharmaceutics of Microbicide 
Formulations. Part I: Preformulation Considerations and Challenges. AIDS Patient Care 
and STDs, 17, 17-32. 
 
Garg, S. and Tambwekar, K.R., (2003). Development pharmaceutics of microbicide 
formulations Part II. Formulation, evaluation and challenges. AIDS Patient Care and 
STDs, 17, 377-399. 
 
Garg, S., Verman, K., Anderson, R.A. and Zaneveld, L.J., (2004a). Rapidly disintegrating 
novel bioadhesive vaginal tablets of polystyrene sulfonate (PSS), a potential microbicide 
formulation. International Conference of AIDS. Abstract No. TuPeB4656. 
http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=102282478.html [Accessed November 
12, 2007]. 
 
Garg, S., Zaneveld, L.J.D., Anderson, J.R.A. and Waller, D.P., (2004b). Compositions and 
methods for trapping and inactivating pathogenic microbes and spermatozoa. United 
States Patent 6706276. http://www.freepatentsonline.com/6706276.html [Accessed June 
19, 2009]. 
 
 235 
Garg, S., Jambu L. and Vermani K., (2007). Development of Novel Sustained Release 
Bioadhesive Vaginal Tablets of Povidone Iodine. Drug Development and Industrial 
Pharmacy, 33, 1340-1349.  
 
Gavin, E., Sanna, V., Juliano, C., Benfero, C.M. and Giunchedi, P., (2002). Mucoadhesive 
vaginal tablets as veterinary system for the controlled release of an antimicrobial drug, 
acriflavine. AAPS Pharmaceutical Sciences and Technology, 3, 1-7. 
 
Genc, L., Oguzlar, C. and Güler, E., 2000. Studies on vaginal bioadhesive tablets of 
acyclovir. Pharmazie, 55, 297-299.  
 
Geonnotti, A. and Katz, D., (2006). Dynamics of HIV neutralization by a microbicide 
formulation layer: Biophysical fundamentals and transport theory. Biophysical Journal, 91, 
2121-2130. 
 
Ghaffari, A., Abdollahi, H., and Khoshayand, M.R., (2006). Performance comparison of 
neural network training algorithms in modelling of biomodal drug delivery. International 
Journal of Pharmaceutics, 327, 126-138. 
 
Ghate, D. and Edelhauser, H.F., (2006). Ocular drug delivery. Pharmaceutical 
Developmemt and Technology, 3, 275-287. 
 
Giannola, L.I., De Caro, V., Giandalia, G., Siragusa, M.G., Tripodo., Florena, A.M., 
Campisi, G., (2007). Release of naltrexone on bucal mucosa: Permeation studies, 
histological aspects and matrix system design. European Journal of Pharmaceutics and 
Biopharmaceutics, 67, 425-433.  
 
 236 
Gilsenan, P.M., Richardson, R.K., and Morris, E.R., (2003a). Associative and 
seggregative interactions between gelation and low methoxy pectin: Part I. Associative 
interactions in the absence of Ca+, Food Hydrocolloids, 17, 723-737. 
 
Gilsenan, P.M., Richardson, R.K., and Morris, E.R., (2003b). Associative and 
seggregative interactions between gelation and low methoxy pectin: Part II. Co-gelation in 
the presence of Ca+, Food Hydrocolloids, 17, 739-749.  
 
Gilsenan, P.M., Richardson, R.K., and Morris, E.R., (2003c). Associative and 
seggregative interactions between gelation and low methoxy pectin: Part III. Quantitative 
analysis of co-gel moduli, Food Hydrocolloids, 17, 751-761.  
 
Gimeno, E., Moraru, C.I, Kokini, J.L., (2003) Effects of Xanthan gum and CMC on the 
structure and texture of corn flour pellets expanded by microwave heating. Cereal 
Chemistry, 81, 100-107.  
 
Girish, K.L. aand Dhiren P.S., (2008). Evaluation of Mucilage of Hibiscus rosasinensis 
Linn as Rate Controlling Matrix for Sustained Release of Diclofenac. Drug Development 
and Industrial Pharmacy, 34, 807-816.  
 
Glare, P.A., (2001). Pain in patients with HIV infection: issues for the new millennium 
European Journal of Pain, 5, 43-48 
 
Goh, B., (2005). Syphilis. Medicine, 33, 48-51. 
 
Goldberger MA, Walter RI and Lapid LS. (1947). Absorpton of penicillin from the vagina. 
American Journal of Obstetrics & Gynecology, 53, 529-531.  
 
 237 
Grassi, G., Farra, R., Caliceti, P., Guarnieri, G., Salmaso, S., Carenza, M. and Grassi, M., 
(2005). Temperature-Sensitive Hydrogels: Potential Therapeutic Applications. American 
Journal of Drug Delivery, 3, 239-251.  
Greenberg, B., Mccorkle, R., Vlahov, D. and Selwyn P.A., (2000). Palliative care for HIV 
disease in the era of highly active antiretroviral therapy. Journal of Urban Health, 77, 150-
165. 
Greenberg M.L., (2007). Enfuvirtide: Basic science to FDA approval Entry Inhibitors in 
HIV Therapy Book. 161-177. 
 
Greenhead, P., Hayes, P., Watts, P.S.  Laing, L.G. Griffin, G .E. and Shattock R.J., 
(2000). Parameters of Human Immunodeficiency Virus Infection of Human Cervical 
Tissue and Inhibition by Vaginal Virucides. Journal of Virology, 74, 5577–5586. 
 
Greub, G., Cozzi, L.A., Ledergerber, B., Staszewski, S., Perrin, L., Miller, V., Francioli, P., 
Furrer, H., Battegay, M., Vernazza, P., Bernasconi, E., Gunthard, H.F., Hirschel, B., 
Phillips, A.N. and Telenti, A., (2001). Low-level HIV viral rebound and blips in patients 
receiving potent antiretroviral therapy.  
http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=102244305.html [Accessed August 15, 
2009].  
 
Griffiths, P.C., Paul, A., Khayat, Z Wan, K., King, S.M., Grillo, I., Schweins, R., Ferruti, P., 
Franchini J. and Duncan R., (2004). Understanding the Mechanism of Action of 
Poly(amidoamine)s as Endosomolytic Polymers:  Correlation of Physicochemical and 
Biological Properties. Biomacromolecules, 5, 1422–1427. 
 
 238 
Gunther, E.C., Stone, D.J., Gerwien, R.W., Bento, P. and Heyes, M.R., (2003). Prediction 
of clinical drug efficacy by classification of drug-induced genomic expression profiles in 
vitro. Proceedings of the National Academy of Sciences, U S A., 100, 9608–9613. 
Guoqiang, D., Batra, R., Kaul, R., Gupta, M.N. and Mattiasson, B., (1995). Alternative 
modes of precipitation of Eudragit S 100: a potential ligand carrier for affinity precipitation 
of protein. Bioseparation, 5, 339–350.  
Gupta, P., Collins, K. B., Ratner, D., Watkins, S., Naus, G. J., Landers, D. V. and 
Patterson, B. K., (2002). Memory CD4+ T cells are the earliest detectable human 
immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue 
during HIV-1 transmission in an organ culture system. Journal of Virology, 76, 9868-9876. 
Gupta, V. and Garg. R., (2009). Probiotics. Indian Journal of Medical Microbiology, 
27, 202-209. 
Gurunathan, S., El Habib, R., Baglyos, L., (2009). Use of predictive markers of HIV 
disease progression in vaccine trials. Vaccine, 27, 1997-2015.  
 
Haltrich, D. Lavssamayer B. and Steiner, W., (1994). Xylanase formation by Sclerotium 
rolfsii effect of growth substrates and development of a culture medium using statistical 
designed experiments, Applied Microbiology and Biotechnology, 42, 522–530. 
 
Hamid, B., Hassan, Z. and Shams, N., (2008). The use of polymer modification of bitumen 
for Durant hot asphalt mixtures. Journal of Applied Sciences Research, 4, 96-102. 
 
Hardy, E., Hebling, E., Sousa, M., Almeida, A. and Amaral E., (2007). Delivery of 
microbicides to the vagina: difficulties reported with the use of three devices, adherence 
to use and preferences. Contraception, 76, 126-131. 
 239 
 
Harris, D. and Robinson, J.R. (1992).  Drug delivery via the mucous membranes of the 
oral cavity, Journal of Pharmaceutical Sciences, 81, 1–10. 
 
Harrison, P.F., Rosenberg, Z. and Bowcut, J., (2003). Topical microbicides for disease 
prevention: Status and challenges. Clinical Infectious Diseases, 26, 1290-1294. 
 
Hart C.E. and Evans-Strickfaden T., (2007). HIV-1 entry inhibitors as microbicides. Entry 
Inhibitors in HIV Therapy Book, 99-117  
 
Hartmann, S.U., Berlin, C.M. and Howett, M.K., (2006). Alternative modified infant-feeding 
practices to prevent postnatal transimission of human immunodeficiency virus type 1 
through breast milk: Past, present and future. Journal of Human Lactation, 22, 75-88. 
 
Harwood, B., and Mishell, D.R., (2001). Contraceptive vaginal ring. Seminars in 
Reproductive Medicine, 19, 381–390. 
Hasan, E.I., Amro, B.I., Arafat, T. and Badwan A.A., (2003). Assessment of a controlled 
release hydrophilic matrix formulation for metoclopramide HCl. European Journal of 
Pharmaceutics and Biopharmaceutics, 55, 339-344.  
Hassanien, A., Milanova, M.G., Smolinski, T.G. et al., (2008). Computational Intelligence 
in Solving Bioinformatics Problems: Reviews, Perspectives, and Challenges. 
Computational Intelligence in Biomedicine and Bioinformatics, 151, 3-47. 
 
Hatcher, R., Trussell, J., Stewart F. et al., (2004). Contraceptive Technology. 18th revised 
edition. New York: Ardent Media, Inc. http://www.amazon.com/Contraceptive-Technology-
18th-Revised-2004/dp/0966490266 [Accessed May 25, 2007]. 
 240 
 
Hayakawa, T., Kawamura, M., Okamoto, M., Baba, M. et al., (1998). Concanavalin A-
immobilized polystyrene nanospheres capture HIV-1 virions and gp120: Potential 
approach towards prevention of viral transmission. Journal of General Virology, 56, 327-
331. 
 
Hayden, E.C., (2009). Mystery of HIV vaccine failure deepens. Nature news. doi:10.1038. 
http://www.nature.com/news/2009/090720/full/news.2009.707.html [Accessed September 
28, 2009] 
 
He, G.Q., Chen, Q.H., Ju, X.J.  and Shi, N.D., (2004). Improved elastase production by 
Bacillus sp. EL31410-further optimization and kinetics studies of culture medium for batch 
fermentation, Journal of Zhejiang University Science, 5, 149–156. 
 
Hearst, N. and Chen, S., (2004). Condom promotion for AIDS prevention in the 
developing world: is it working? Studies in Family Planning. 35, 39-47. 
 
Helfand, E., and Tagami, Y., 1972. Theory of the interface between immiscible polymers, 
Journal of Chemical Physics, 57, 1812-1815.  
 
Hemmerling, A., Potts, M., Walsh, J., (2007).  Lime juice as a candidate microbicide? An 
open-label safety trial of 10% and 20% lime juice used vaginally. Journal of Womens 
Health, 16, 1041-1051.  
 
Hendrix, C.W., Cao, Y.J. and Fuchs, E.J., (2009). Topical microbicides to prevent HIV: 
Clinical drug development challenges. Annual Review of Pharmacology and Toxicology, 
49, 349-375.  
 
 241 
Herold, B.C., Bourne, N., Marcellino, D., Kirkpatrick, R., Strauss, D.M., and Zaneveld, 
L.J.D., Waller, D.P., Anderson, R.A., Chany, C.J., Barham, B.J., Stanberry, L.R. and 
Cooper, M.D., (2000). Poly (sodium 4-styrene sulfonate): an effective candidate topical 
antimicrobial for the prevention of sexually transmitted diseases. Journal of infectious 
Diseases, 181, 770-773. 
 
Herrewege, Y.V., Michiels, J., Van Roey, J., Fransen, J.K., Kestens, L., Balzarini, J., Lewi, 
P., Vanham, G. and Janssen, P., (2004). In vitro evaluation of non-nucleoside reverse 
transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus 
microbicides. Antimicrobial Agents and Chemotherapy, 48, 337–339. 
 
Hervey, P. S. and Perry, C. M., (2000). Abacavir : A review of its clinical potential in 
patients with HIV infection. Drugs, 60, 447-479.  
 
Herzberg, M.C., Weinberg, A. and Wahl, S.M., (2006). (C3) The oral epithelial cell and 
first encounters with HIV-1. Advances in Dental Research, 19, 158-166.  
 
Highleyman, L., (2007). UsherCell microbicides provides no protection against HIV 
transmission but VivaGel yields promising early data. 4th International Conference on HIV 
Treatment, Pathogenesis and Prevention, Sydney, Australia.  
http://www.hivandhepatitis.com/recent/ 2007/020607_a.html [Accessed November 20, 
2007]. 
 
Hirbod, T. and Broliden, K., (2007). Mucosal immune responses in the genital tract of HIV-
1-exposed uninfected women. Journal of Internal Medicine, 262, 1 44 – 58. 
 242 
Hiremath, P.S, and Saha, R.N., (2008). Oral matrix tablet formulations for concomitant 
controlled release of anti-tubercular drugs: Design and in vitro evaluations. International 
Journal of Pharmaceutics, 362, 118-125. 
Holmes, L., (2000). The Internal Triangle: New Theories of Female Development. Modern 
Psychoanalysis, 25, 207-226. 
Holmes, K.K., Levine, R., Weaver, M., (2004). Effectiveness of condoms in preventing 
sexually transmitted infections. Bulletin of the World Health Organization, 82, 454-461. 
Holmes, V., Ramratnam, B., and Hartmann., (2007). Developing a microbicide containing 
CCR5 siRNA for preventing the transmission of human immunodeficiency virus type 1 
(HIV-1). Alliance for Microbicides Development, 8, 1-21. 
 
Hopfield, J.J., and Tank, D.W., (1985). “Neural” computation of decisions in optimization 
problems. Biological Cybernetics, 55, 141–146. 
 
Howett, M.K., Neely, E.B., Christensen, N.D., Wigdahl, B., Krebs, F.C., Malamud, D,, 
Patrick, S.D., Pickel, M.D., Welsh, P.A., Reed, C.A., Ward, M.G., Budgeon, L.R. and 
Kreider, J.W., (1999). A broad-spectrum microbicide with virucidal activity against sexually 
transmitted viruses. Antimicrobial Agents and Chemotherapy, 43, 314–321. 
 
Huggins G. R., Preti G., (1981). Vaginal odors and secretions. Clinical Obstetrics and 
Gynecology, 24, 355-377.  
 
Hussain, A. and Ahsan, F., (2005). The vagina as a route for systemic drug delivery.  
Journal of Controlled Release, 103, 301-313.  
 
 243 
Hussain, N., (2000). Bioadhesive Drug Delivery systems: Fundamentals, novel 
approaches and development, International Journal of Pharmaceutics, 205, 201-202.  
 
Hussain, A.S., Johnson, R.D., Vachharajan, N.N. and Ritschell, W.A., (1993). Feasibility 
of developing a neural network for prediction of human pharmacokinetic parameters from 
animal data. Pharmaceutical Research, 10, 466-469. 
 
Hwang, S., Wada, E.O., Yotsuanagi, T., Suhardja, I., Ho, N.F.H., Flynn, G.L. and Higuchi, 
W.I., (1977). Systems approach to vaginal delivery of drugs: II. In situ vaginal absorption 
of unbranched aliphatic alcohols. Journal of Pharmaceutical Sciences, 65, 1574–1578. 
 
Ibata, B., Parr, E., King, N. and M. Parr, M., (1997). Migration of foreign lymphocytes from 
the mouse vagina into the cervicovaginal mucosa and to the iliac lymph nodes. Biology of 
Reproduction, 56, 537-543. 
Idemyor, V., (2004). The concept of structured treatment interruptions in the management 
of patients with Human Immunodeficiency Virus (HIV) disease: Where Are We Currently? 
HIV Clinical Trials, 4, 79-83 
Iijima, N., Linehan, M.M., Zamora, Me., Butkus, D., Butkus, D., Dunn, R., Kehry, M.R., 
Laufer T.M. and Iwasaki A., (2008). Dendritic cells and B cells maximize mucosal Th1 
memory response to herpes simplex virus
Iseki, T., Takahashi, M., Hattori, H., Hatakeyama, T. and Hatakeyama, H., (2001). 
Viscoelastic properties of xanthan gum hydrogels annealed in the sol state. Food and 
Hydrocolloids, 15, 503-506.  
. The Journal of Experimental Medicine, 205, 
3041-3052.  
 
 244 
Iyer, V., Bendgude, N. and Poddar, S.S., (2008) Vaginal Drug Delivery. Express Pharma. 
http://www.expresspharmaonline.com/20080715/research02.shtml [Accessed 19 March 
2009].  
 
Jast, B., Li, X. and Cleary, G., (2003). Recent advances in mucoadhesive drug delivery 
systems. Drug Delivery Polymers, 1, 194-196. 
 
Jeong, B., Kim S.W. and Bae Y.H., (2002). Thermosensitive sol–gel reversible hydrogels. 
Advanced Drug Delivery Reviews,  54, 37-51.  
 
Jha, B.K., Tambe, S.S. and Kulkarni, B.D., (1995).  Estimating diffusion coefficients of 
micellar system using an ANN, Colloid and Interface Science, 170, 392–398. 
Jiang, C., Li, H., Tripp, C. P., (2003). Infrared Method for In Situ Studies of 
Polymer/Surfactant Adsorption on Silica Powders from Aqueous Solution, Appllied. 
Spectroscopy, 57, 1419-1424.  
Jiang, Y., Emau, P., Cairns, J.S., Flanary, L., Morton, W.R., McCarthy, T.D. and Tsai, 
C.C. (2005). SPL7013 gel as a topical microbicide for prevention of vaginal transmission 
of SHIV in macaques.  AIDS Research and Human Retroviruses, 21, 207-213. 
 
Jiménez-castellanos, M.R., Zia, H. and Rhodes C. T., (1993). Mucoadhesive Drug 
Delivery systems. Drug Development and Industrial Pharmacy, 19, 143-194.  
Jin, x.,  Zhang, y.,  Xiao, l. and  Zhao, z., (2008). Optimization of Extended Zero-order 
Release Gliclazide Tablets Using D-optimal Mixture Design. Yakugaku Zasshi, 128, 1475-
1483. 
 245 
Johansson, E.D.B., Luukkainen, T., Vartiainen, E., Victor, A., (1975). The effect of 
progestin R 2323 released from vaginal rings on ovarian function. Contraception, 12, 299-
307. 
 
Johnson, V.E. and Masters, W.H., (1962). Intravaginal contraceptive study: Phase I. 
Anatomy. Western Journal of Surgery, Obstetrics and Gynecology, 70, 202–207. 
 
Joshi, S.N., Katti, U., Godbole, S., Bharucha, K., Kulkarini, S., Risbud, A. and Mahendale, 
S., (2005). Phase I safety study of praneem polyherbral vaginal tablet use among HIV-
uninfected women in Pune, India. Transactions of the Royal Society of Tropical Medicine 
and Hygiene, 99, 769-774. 
 
Joshi, S.N., Dutta, S., Bell, B., et al., (2006). Phase I safety study of 0.5% PRO 2000 
vaginal gel among HIV un-infected women in Pune, India. AIDS Research and Therapy, 
3, 2-6. 
 
Junginger, H.E., (1990). Bioadhesive polymer systems for peptide delivery, Acta 
Pharmaceutica Technologica, 36, 110–126. 
 
Justin-Temu, M., Damian, F., Kinget, R. and Van Den Mooter, G., (2004). Intravaginal 
gels as Drug Delivery systems. Journal of  Women’s Health, 31, 834-843. 
 
Kaelble, D.H., 1977. A surface energy analysis of bioadhesion, Polymer, 18, 475-482. 
 
Kalugin, O.N., Volobuev, M.N., Ischenko, A.V., and Adya, A.K., 2001. Structure and 
dynamics of Na+ and Cl− salvation shells in liquid DMSO: molecular dynamics simulations. 
Journal of Molecular Liquids, 91, 135-148.  
 
 246 
Kapitza, S.B.,  Michel, B.R., van Hoogevest, P., Leigh, M.L.S. and Imanidis, G., (2007). 
Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as 
solubilizers in the Caco-2 cell model. Intentional Journal of Pharmaceutics, 66, 146-158.  
Kassaye S.G. and Katzenstein D., (2003). HIV/AIDS care and treatment in sub-Saharan 
Africa. AIDS Revision, 5,195-204. 
 
Kast, C.E., Valenta, C., Leopold, M., and Bernkop-Schnürch, A., (2002). Design and in 
vitro evaluation of a novel bioadhesive vaginal Drug Delivery system for clotrimazole, 
Journal of Controlled Release,  81, 347-354. 
 
Kathambi, K., (2008). Microbicides: Women’s weapon in the war against HIV/AIDS, 
Association  for Women’s Rights in Development (AWID). http://www.awid.org/eng/Issues 
-and-Analysis/Library/Microbicides-A-weapon-for-women-in-the-war-against-HIV-AIDS2 
[Accessed June 15, 2009]. 
 
Katsamba, P., Carroll, K. Ahlsen, G., Bahna, F., Vendome, J., Posy, S., Rajebhosale,M., 
Price, S., Jessell, T. M. Ben-Shaul, A., Shapiro,  L. and Honig, B.H. Linking molecular 
affinity and cellular specificity in cadherin-mediated adhesion. Proceedings of the National 
Academy of Sciences. 106, 1194-11599. 
 
Katsnelson, A., (2009). New wrinkle for HIV vaccine. The Scientist.com. http://www.the-
scientist.com/blog/display/55478/ [Accessed September 28, 2009]. 
 
Katz, D.F., Dunmire, E.N., Henderson, M.H., Owen, D.H. and Plenys, A.M., (1997). 
Applications of biomedical engineering in reproductive biomedicine: sensing and Drug 
Delivery to the lower female reproductive tract. Engineering in Medicine and Biology 
Society, 6, 2656 – 2658. 
 247 
Katz, D.F. and Dunmire, E.N., (1993). Cervical mucus. Problems and opportunities for 
Drug Delivery via the vagina and cervix. Advanced Drug Delivery Reviews, 11, 385–401. 
 
Kaufmann, G.R. and Cooper D.A., (2000). Antiretroviral therapy of HIV-1 infection: 
established treatment strategies and new therapeutic options. Current Opinion in 
Microbiology, 3, 508-514.  
 
Kaul, R., Pettengell, C., Sheth, P., Sunderji, S., Biringer, A., MacDonald, K., Walmsley, S. 
and Rebbapragada, A., (2008). The genital tract immune milieu: an important determinant 
of HIV susceptibility and secondary transmission. Journal of Reproductive Immunology, 
77, 32-40. 
 
Keiser, P., (2002). Role of Sequencing in Therapy Selection. Journal of Acquired Immune 
Deficiency Syndromes, 29, S19-S27. 
 
Keller, M.J., Tuyam, A., Carlucci, M.J. and Herold, B.C., (2005). Topical microbicides for 
the prevention of genital herpes infection. Antimicrobial Agents and Chemotherapy, 55, 
420-423. 
 
Kerr, M., (2007). NNRTI shows safety as a topical anti-HIV microbicide in animal tests. 
Antimicrobial Agents and Chemotherapy, 51, 1608-1615. 
 
Kessler, H.A., (2005). Triple-Nucleoside Analog Antiretroviral Therapy: Is There Still a 
Role in Clinical Practice? A Review. Medscape General Medicine, 7, 70. 
Khamanga, S.M. and Walker R.B., (2006). Evaluation of Rate of Swelling and Erosion of 
Verapamil (VRP) Sustained-Release Matrix Tablets. Drug Development and Industrial 
Pharmacy, 32, 1139 – 1148. 
 248 
Khanlou H., Yeh, V., Guyer, B. and Farthing, C., (2005). Early virologic failure in a pilot 
study evaluating the efficacy of therapy containing once-daily Abacavir, Lamivudine, and 
Tenofovir DF in treatment of Naïve HIV-infected patients. AIDS Patient Care and STDs, 
19, 135-140. 
 
Khoee, S., Hassanzadeh, S. and Goliaie, B., (2007). Effects of hydrophobic drug-
polyesteric core interactions on drug loading and release properties of poly (ethylene 
glycol) triblock core shell nanoparticles. Nanotechnology, 18, 1-9. 
 
Kim, H. and Fassihi, R., (2000). Application of a binary polymer system in drug release 
rate modulation. 1. Characterization of release mechanism. Journal of Pharmaceutical 
Sciences, 86, 316 – 322.   
 
King, M.R., (2001). Multiparticle Adhesive Dynamics. Interactions between Stably Rolling 
Cells Biophysical Journal, 81, 799-813 
 
Kirton, K.T., Roseman, T.J., Forber, A.D., (1973). Evaluation of progesterone-containing 
silicone vaginal devices in rhesus monkeys. Contraception, 8, 561-568. 
 
Kiser, P., (2006a). A molecular condom against AIDS. Science Daily. 
http://www.sciencedaily.com/releases/2006/12/061212091837.htm [Accessed March 26, 
2007]. 
 
Kiser, P., (2006b). HIV-blocking gel for women: New 'Molecular Condom' meant to 
prevent AIDS. http://www.sciencedaily.com/releases/2009/08/090810024837.htm 
[Accessed August 20, 2009]. 
 
 249 
Klasse, P.J. Shattock R. and Moore, J.P., (2008).  Antiretroviral drug-based microbicides 
to prevent HIV-1 sexual transmission. Annual Review of Medicine, 59, 455–471.  
 
Klavinskis, L.S., Daheshia, M., Karem, K., Manickan, E. and Rouse, B.T., (1999). 
Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the 
female genital and rectal and rectal tracts. Journal of Immunology, 1, 254–262. 
 
Knox, P., (2004). Knox, P., (2004). Drug Delivery device for insertion into the vagina, 
rectum or nasal cavity.  European Patent EP1200151. http://www.freepatentsonline.com/ 
EP1200151. html [Accessed May 20, 2009].  
 
Knudsen, K.D., Lauten, R.A., Kjøniksen, A., Nyström, B., (2004). Rheological and 
structural properties of aqueous solutions of a hydrophobically modified polyelectrolyte 
and its unmodified analogue. European Polymer Journal, 40, 721-733.  
 
Knuth, K., Amiji, M. and Robinson, J.R., (1993). Hydrogel delivery systems for vaginal and 
oral applications: Formulation and biological consideration. Advanced Drug Delivery 
Reviews, 11, 137–164. 
 
Kolawole, O.A., Pillay, V. and Choonara, Y.E., (2007). Novel polyamide 6,10 variants 
synthesized by modified interfacial polymerization for application as a rate-modulated 
monolithic Drug Delivery System. Journal of Bioactive and Compatible Polymers, 22, 281-
313.  
 
Kozlowski, P.A. and Neutra, M.R., (2003). The Role of mucosal immunity in prevention of 
HIV transmission. Current Molecular Medicine, 3, 217-228.  
 
 250 
Krauss, K. and Altevogt, P., (1999).  Integrin leukocyte function-associated antigen-1-
mediated cell binding can be activated by clustering of membrane rafts. Journal of 
Biological Chemistry, 274, 36921-36927. 
 
Krebs, F.C., Miller, R.S., Catalone, B.J., Welsh, P.A. Malamud, D., Howett, M.K. and 
Wigdahl, B., (2000). Sodium dodecyl sulfate and C31G as microbicidal alternatives to 
nonoxynol 9: Comparative sensitivity of primary human vaginal keratinocytes. 
Antimicrobial Agents and Chemotherapy 44, 1954-1960. 
 
Kremer, M.J., Wertz, P.W. and Squier, C.A., (2001). Permeability and barrier function of 
three porcine non-keratinized mucosae, Journal of Dental Research, 80, 851. 
 
Kristmundsdóttir, T., Árnadóttir, S.G., Bergsson, G. and Thormar, H., (2000). Development 
and evaluation of microbicidal hydrogels containing monoglyceride as the active 
ingredient. Journal of Pharmaceutical Sciences, 88, 1011-1015. 
Kumar, M.N. V.R., Kumar, N., Domb, A. J. and Arora M., (2002). Pharmaceutical 
Polymeric Controlled Drug Delivery Systems.  Advances in Polymer Science, 160, 47-
117. 
 
Kulkarni, A., Reiche J., Lendlein, A., (2007). Hydrolytic degradation of poly(rac-lactide) 
and poly[(rac-lactide)-co-glycolide] at the air-water interface. Surface and Interface 
Analysis, 39, 740-746. 
 
Lackner, A.A. and Veazey, R.S., (2007). Current concepts in AIDS pathogenesis: Insights 
from the SIV/Macaque model. Annual Review of Medicine, 58, 461-467. 
 
 251 
Lai S.K., Wang Y. and Hanes J., (2009). Mucus-penetrating nanoparticles for drug and 
gene delivery to mucosal tissues. Advanced Drug Delivery Reviews, 61, 158-171.  
 
Lamont, R.F., Jones, B.M., Mandal, D., Hay, P.E. and Sheehan, M., (2003). The efficacy 
of vaginal clindamycin for the treatment of abnormal genital tract flora in pregnancy. 
Infectious Diseases in Obstetrics and Gynecology, 11, 181–189. 
Lancashire, L.J., Lemetre C. and Ball, G.R., (2009). An introduction to artificial neural 
networks in bioinformatics—application to complex microarray and mass spectrometry 
datasets in cancer studies. Briefings in Bioinformatics, 10, 315-329. 
 
Lard-Whiteford, S.L., Matecka, D., O'Rear, J.J., Yuen, I.S., Litterst, C. and Reichelderfer, 
P., (2004). Recommendations for the Nonclinical Development of Topical Microbicides for 
Prevention of HIV Transmission: An Update. JAIDS Journal of Acquired Immune 
Deficiency Syndromes, 36, 541-552.  
 
Lau, C.,  Velasco P.P. and Johnston, M.I., (2007). A new era in HIV vaccine development. 
Expert Review of Anti-infective Therapy, 5, 205-215. 
  
Lazaridou, A. and Biliaderis, C.G., (2004). Cryogelation of cereal β-glucans: structure and 
molecular size effects. Food Hydrocolloids, 18, 933-947. 
Lazarus, J.V., Häggblom, A., Kirkegaard, L., Lundgren, J.D. and Matic S., (2008). The 
elusive search for an HIV vaccine—and what to do meanwhile. Vaccine, 26, 6491-6493. 
Le Cer, R.D., Picton, L., Argillier, J.F., Muller, G., (2004). Entrapment and release of 
sodium polystyrene sulfonate (SPS) from calcium alginate gel beads. European Polymer 
Journal, 40, 2709-2715. 
 252 
Leane, M.M., Cumming, I., Corrigan, O.I., (2003). The Use of Artificial Neural Networks 
for the selection of the most appropriate formulation and processing variables in order to 
predict the in itro dissolution of sustained release minitablets. AAPS Pharmaceutical 
Sciences and Technology, 4, 1-12.  
Ledergerber, B., Egger, M., Opravil, M., Telenti, A., Hirschel, B., Battegay, M., Vernazza, 
P., Sudre, P., Flepp, M., Furrer, H., Francioli, P. and Weber R., (1999). Clinical 
progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: 
a prospective cohort study. Swiss HIV Cohort Study. Lancet, 353, 863-868.  
Lee, C.H., Bagdon, R. and Chien, Y.W., (1996). Comparative in vitro spermicidal activity 
and synergistic effect of chelating agents with nonoxynol-9 on human sperm functionality. 
Journal of Pharmaceutical Sciences, 85, 91–95. 
 
Lee, P.I., (1980). Diffusional release of a solute from a polymeric matrix—approximate 
analytical solutions. Journal of Membrane Science, 7, 255-275. 
  
Lee, W.J., Park, J.H. and Robinson, J.R., (2000). Bioadhesive-based dosage forms: The 
next generation. Journal of Pharmaceutical Sciences, 89, 850-866. 
 
Lee, Y., Khemka, A., Yoo J. and Lee C.H., (2008). Assessment of diffusion coefficient 
from mucoadhesive barrier devices using artificial neural networks. International Journal 
of Pharmaceutics, 351, 119-26.  
 
Lehr, C.M., (2000). Lectin-mediated Drug Delivery: The second generation of 
bioadhesive, Journal of  Controlled. Release, 65, 19-29.  
 
 253 
Lehr, C.M., (1995). Bioadhesion technologies for the controlled delivery of peptide and 
protein drugs to the gastrointestinal tract. Critical Reviews in Therapeutic Drug Carrier 
Systems, 11, 177–218. 
 
Lejoyeux, F., Ponchel, G., Wouessidjewe, D.,  Peppas, N.A.  and Duchene, D., (1989).  
Bioadhesive tablets—influence of the testing medium composition on bioadhesion, Drug 
Dev. Ind. Pharm. 15, 2037–2048. 
 
Lemiale, F. and Korokhov, N., (2009). Lentiviral vectors for HIV disease prevention and 
treatment. Vaccine, 27, 3443-3449. 
 
Levine, W. C., Pope, V., Bhoomkar, A., Tambe, P., Lewis, J.S., Zaidi, A.A., Farshy, C.E., 
Mitchell, S. and Talkington, D.F., (1998). Increase in endocervical CD4 lymphocytes 
among women with nonulcerative sexually transmitted diseases. Journal of infectious 
Diseases, 177, 167-174. 
 
Levinson, P., Kaul, R., Kimani, J. Ngugi, E., Moses, S., MacDonald, K.S., Broliden, K. and 
Hirbod, T., Kibera HIV Study Group., (2009). Levels of innate immune factors in genital 
fluids: association of alpha defensins and LL-37 with genital infections and increased HIV 
acquisition. AIDS, 23, 309-317. 
 
Lew, C.W., (1994).  Controlled release pH sensitive capsule and adhesive system and 
method. US Patent 5364634. http://www.freepatentsonline.com/5364634.html [Accessed 
June 2, 2007]. 
 
Li, X., Kolltveit, K.M., Tronstad, L. and Olsen I., (2000). Systemic Diseases Caused by 
Oral Infection. Clinical Microbiology Reviews, 13, 547–558.  
 
 254 
Lin C.C. and Metters A.T., (2006). Hydrogels in controlled release Formulations: Network 
design and mathematical modeling. Advanced Drug Delivery Reviews, 58, 1379-1408.  
 
Little, S.J., Holte, S., Routy, J.P., Daar E.S., Markowitz, M., Collier, A.C., Richard A. 
Koup, R.A., Mellors, J.W., Connick, E., Conway, B., Kilby, M., Wang, L., Whitcomb, J.M., 
Hellmann, N.S. and Richman, D.D., (2002). Antiretroviral-drug resistance among patients 
recently infected with HIV. New England Journal of Medicine, 347, 385-394.  
 
Liu, J., Zhang, F. and McGinity, J.W., (2001). Properties of lipophilic matrix tablets 
containing phenylpropanolamine hydrochloride prepared by hot-melt extrusion. European 
Journal of Pharmaceutics and Biopharmaceutics, 52, 181-190. 
 
Liu, T.X., Liu, Z.H., Ma, K.X., Shen, L., Zeng, K.Y., He, C.B., (2003). Morphology, thermal 
and mechanical behavior of polyamide 6/layered-silicate nanocomposites. Composites 
Science and Technology, 63, 4331-337. 
Liu, H., Li, X., Stanton, B. Liu, H., Liang, G., Chen, X., Yang, H. and Hong Y., (2005). Risk 
Factors for Sexually Transmitted Disease Among Rural-to-Urban Migrants in China: 
Implications for HIV/Sexually Transmitted Disease Prevention. AIDS Patient Care STDS, 
19, 49-57. 
Lohr, P.A., (2007). The Future Role of Vaccines and Microbicides. Sexually Transmitted 
Diseases Book. 321-344.  
 
Longer, M.A., and Robinson, J.R., (1986). Fundamental aspects of bioadhesion, 
Pharmacy International, 7, 114-117.   
 
 255 
Lopes, C.M., Lobo, J.M.S., Pinto, J.F. and Costa, P.C., (2007). Compressed Matrix Core 
Tablet as a Quick/Slow Dual-Component Delivery System Containing Ibuprofen. AAPS 
Pharmaceutical Sciences and Technology, 8, E1-E8. 
 
Lozinsky, V.I. and Damshkaln, L.G., (2001). Study of cryostructuration of polymer 
systems. XX. Foamed poly(vinyl alcohol) cryogels. Journal of Applied Polymer Science, 
82, 1609 – 1619. 
 
Lucas, G.M., (2008). Antiretroviral adherence, drug resistance, viral fitness and HIV 
disease progression: a tangled web is woven. Journal of Antimicrobial Chemotherapy, 
doi:10.1093/jac/dki042, 1-4.  
Lucas, G.M., Chaisson, R.E. and Moore, R.D., (1999). Highly active antiretroviral therapy 
in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Annals 
of Internal Medicine, 131, 81-87.  
Madhavlal, P.G. and Manordas, P.M., (2009). Design and In Vitro Evaluation of a Novel 
Vaginal Drug Delivery System Based on Gelucire. Current Drug Delivery, 6, 159-165. 
Maggi, L., Mastromarino, P., Macchia, S., Brigidi, P., Pirovano, F., Matteuzzi, D. and 
Conte, U., (2000). Technological and biological evaluation of tablets containing different 
strains of lactobacilli for vaginal administration. European Journal of Pharmaceutics and 
Biopharmaceutics, 50, 389–395. 
 
Maguire, R.A., Bergman, N. and Phillips, D.M., (2001). Comparison of Microbicides for 
Efficacy in Protecting Mice Against Vaginal Challenge With Herpes Simplex Virus Type 2, 
Cytotoxicity, Antibacterial Properties, and Sperm Immobilization. Sexually Transmitted 
Diseases, 28, 259-265.  
 256 
Mainardes, R.M., Gremiao, M.P.D. and Evangelistica, R.C., (2006). Thermoanalytical 
study of praziquantel-loaded PLGA nanoparticles. Brazilian. Journal of Pharmaceutical 
Sciences, 42, 523-530. 
Malcolm, K.R. and Woolfson, D.A., (2006). Delivery hope on HIV-Vaginal rings for 
controlled release of microbicides. Journal of Controlled Release, 74, 52-55.  
 
Malcolm, K.R., Woolfson, D.A., Toner, C., Morrow R.J. and McCullagh, S.D., (2005). 
Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer 
vaginal rings. Journal of Antimicrobial Chemotherapy, 56, 954-956. 
 
Malik, R., Tondwal, S., Venkatesh, K.S. and Misra, A., (2008). Nanoscaffold matrices for 
size-controlled pulsatile transdermal testosterone delivery: nanosize effects on the time 
dimensions. Nanotechnology, 19, 1-6. 
 
Malow, R.M., Rosenberg, R. and Devieux, J.G., (2009). Cognitive-behavioral stress 
management interventions for ethnic-minority HIV-positive alcohol/drug abuses in 
resource limited and cultural diverse communities. American Journal of Infectious 
Diseases, 5, 48-59.  
 
Mandal, T.K., (2000). Swelling-controlled release system for the vaginal delivery of 
miconazole, European Journal of Pharmaceutics and Biopharmaceutics, 50, 337-343. 
 
Manson, K.H., Wyand, M.S., Miller, C. and Neurath, A.R., (2000). Effect of cellulose 
acetate phthalate topical cream on vaginal transmission of simian immunodeficiency virus 
in rhesus monkeys. Antimicrobial Agents and chemotherapy, 44, 3199-3302. 
 
 257 
Mastromarino, P., Macchia, S., Meggiorini, L., Trinchieri, V., Mosca, L., Perluigi, M. and 
Midulla C., (2009). Effectiveness of Lactobacillus-containing vaginal tablets in the 
treatment of symptomatic bacterial vaginosis. Clinical Microbiology  and Infection, 15, 67-
74. 
 
Mantell, J.E., Myer, L., Carballo-Diéguez, A., (2005). Microbicide acceptability research: 
current approaches and future directions. Social Science & Medicine, 60, 319-330.  
 
Marconi, V.C., Sunpath, H. and  Lu, Z., (2008). Prevalence of HIV-1 Drug Resistance 
after Failure of a First Highly Active Antiretroviral Regimen in KwaZulu Natal, South 
Africa. Clinical Infectious Diseases, 46, 1589–1597. 
 
Maria-Elisa, P., Pirovano, A. and Phillips, D.M., (2003). Carageenan formulation prevents 
macrophage trafficking from vagina: Implications for microbicide development. Biology of 
Reproduction, 69, 933–939. 
Marks, K. and Gulick, R.M., (2004). New antiretroviral agents for the treatment of HIV 
infection Current Infectious Disease Reports, 6, 333-339.  
Marin-Muller, C., Li, M., Chen, C., and Yao. O., (2009). Current Understanding and 
Potential Immunotherapy for HIV-Associated Squamous Cell Carcinoma of the Anus 
(SCCA). World Journal of Surgery, 33, 653-660.  
 
Martinez-Picado, J. and Wai, Y.T.L., (2007). Risk of selecting resistance mutations during 
treatment interruption. Current Opinion in HIV and AIDS, 2, 6-13. 
 
Marx, P., Spira, A. Gettie, A. (1996). Progesterone implants enhance SIV vaginal 
transmission and early virus load. Nature Medicine, 2, 1084-1089. 
 258 
 
Mathowitz, E.C.D. and Jacob, S.J., (1999). Bioadhesive Drug Delivery systems. In 
Encyclopaedia of Controlled Drug Delivery 1; John Wiley and Sons: New York, USA. 
 
Mayer, K.H., Karim, S.A., Kelly, C., Maslankowski,L., Rees, H., Profy, A.T., Day, J., 
Welch. J. and Rosenberg Z., (2003). The safety and tolerability of a novel vaginal 
microbicides, PRO 2000/5Gel in sexually active HIV-uninfected and abstinent HIV-
infected women. AIDS, 17, 321-329. 
 
McCormack, S.,   Hayes, R.,   Lacey, C.J.N. and   Johnson, A.M., (2001). Microbicides in 
HIV prevention. British Medical Journal, 322, 410-413. 
 
Mehta, K.A., Kislalioglu, M.S., Phuapradit, W., Malick A.W. and Shah, N.H. (2000). Effect 
of formulation and process variables on porosity parameters and release rates from a 
multi unit erosion matrix, Journal of Controlled Release, 63, 201-211. 
Mendyk, A. and Jachowicz, R., (2005). Neural network as a decision support system in 
the development of pharmaceutical formulation—focus on solid dispersions. Expert 
Systems with Applications, 28, 285-294. 
Meijer, D.K.F., Mol, W.E.M., Müller, M. and Kurz, G., (1990). Carrier-mediated transport in 
the hepatic distribution and elimination of drugs, with special reference to the category of 
organic cations. Journal of Pharmacokinetics and Pharmacodynamics, 18, 35-70. 
 
Merabet, J., Thompson, D. and  Levinson, R.S., (2005). Advancing vaginal drug delivery. 
Expert Opinion on Drug Delivery, 2, 769-777. 
 
 259 
Mikos, A.G., and Peppas, N.A., 1986. Proceedings of International Symposium on 
Controlled Release of Bioactive Materials, 13, 97.  
 
Mikos, A.G., and Peppas, N.A., (1990). Scaling concepts and molecular theories of the 
adhesion of synthetic polymers to glycoproteins, In: Lenaerts, V., and Gurny, R. (Ed.), 
Bioadhesive Drug Delivery systems. Boca Raton. Fl., 25-42.  
  
Miller, C.J., Vogel, P., Alexander, N., Sutjipto, N., Hendrickx, A. G. and Marx, P. A., 
(1992). Localization of SIV in the genital tract of chronically infected female rhesus 
macaques. American Journal of Pathology, 141, 655-660. 
Miller, C.J. and Shattock R.J., (2003). Target cells in vaginal HIV transmission. Microbes 
and Infection, 5, 59-67.  
Mishell, D.R., Lumkin, M.and Stone, S., (1972). Inhibition of ovulation with cyclic use 
progesterone-impregnanted devices. American Journal of  Obstetrics and Gynecology, 
13, 927-932. 
 
Mitchel, D., (2006).  Focus renewed on HIV microbicides, International Health 
Conference,Canada. https://www.ipm-microbicides.org/news_room/English/feature_room/ 
English/feature_stories_full.htm [Accessed June 15, 2009]. 
 
 Moore, J.P. and Shattock, R.J., (2003). Preventing HIV-1 sexual transmission—not sexy 
enough science, or no benefit to the bottom line? Journal of Antimicrobial Chemotherapy, 
52, 890–892. 
 
Moore, J.P., Kitchen S.G., Pugach, P. and Zack, J.A., (2004). The CCR5 and CXCR4 
coreceptos-central to understanding the transmission and pathogenesis of human 
 260 
immunodeficiency virus type 1 infection. Aids Research and Human Retroviruses, 20, 
111-126. 
 
Morin, S.F., Morfit, S., Majorana, A., Amamrattana, A., Goicochea, P., Mutsambi, J.M., 
Robins J.l. and Richards, T.A., (2008). Building community partnerships: case studies of 
Community Advisory Boards at research sites in Peru, Zimbabwe, and Thailand. Clinical 
Trials,  5, 147. 
 
Morrow, K., Rosen, R., Ritcher, L., Emans, A., Forbes, A., Day, J., Morar, N., 
Maslankowski. L., Profy, A.T., Kelly, C., Abdool Karim, S.S. and Mayer, K.H., (2003). The 
acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a 
phase I clinical trial. Journal of  Women’s Health, 12, 655-666. 
 
Mosher, D.F., (1990). Physiology of thrombospondin. Annual Review of Medicine, 41, 85-
89. 
 
Moyle, G., (2003). Stopping HIV fusion with enfuvirtide: the first step to extracellular 
HAART Journal of Antimicrobial Chemotherapy, 51, 213-217. 
 
MTN microbicide trials network (2009). Trial finds microbicide promising as HIV 
prevention method for women. http://www.mtnstopshiv.org/node/765 [Accessed August 
20, 2009]. 
Mukherjee, G.S., (2009). Calorimetric characterization of membrane materials based on 
polyvinyl alcohol. Journal of Thermal Analysis and Calorimetry, 96, 21-25.  
Müller, B.W., (1986). Factors which are influencing the drug liberation as well as topical 
effects, Suppositoria Wissenschaftl, Verlagsges, Stuttgart, 272–275. 
 261 
 
Mumper R.J., Bell, M.A. and Worthen, D.R., Cone, R.A., Lewis, G.R., Paull, J.R.A., 
Moench, T.R., (2009). Formulating a Sulfonated Antiviral Dendrimer in a Vaginal 
Microbicidal Gel Having Dual Mechanisms of Action. Drug Development and Industrial 
Pharmacy, 35, 515-524.  
 
Munasur, A.P., Pillay, V., Choonara, Y.E., Mackraj, I.and Govender, T., (2008). 
Comparing the mucoadhesivity and drug release mechanisms of various polymer-
containing propranolo buccal tablets. Drug Development and Industrial Pharmacy, 34, 
189-198.  
 
Murthy, N.S., (2006). Hydrogen bonding, mobility, and structural transitions in aliphatic 
polyamides. Journal of Polymer Science Part B: Polymer Physics, 44, 1763 – 1782.  
 
Nair, T.M., Tambe S.S. and Kulkarni., (1994). B.D. Application of artificial neural networks 
for prokaryotic transcription terminator prediction, FEBS Letters, 346, 273–277. 
 
Najah, A., Elshafie, A., Karim O.A. and Jaffar, O., (2009). Prediction of Johor river water 
quality parameters using artificial neural networks. European Journal of Scientific 
Research, 28, 422-435. 
 
Ndesendo, V.M.K., Meixner, W., Korsatko, W., Kortsatko-Wabnegg, B., (1996). 
Microencapsulation of chloroquine diphosphate by Eudragit RS 100. Journal of 
Microencapsulation, 13, 1-8.  
 
Ndesendo, V.M.K., Pillay, V., Choonara, Y.E., Buchmann, E., Bayever, D.N., Meyer, 
L.C.R., (2008). Current intravaginal Drug Delivery approaches employed for the 
 262 
prophylaxis of HIV/AIDS and prevention of sexually transmitted infections. AAPS 
Pharmaceutical Sciences and Technology, 9, 505-520.  
 
Ndesendo, V.M.K., Pillay, V., Choonara, Y.E., Khan, R.A., Meyer, L., Buchmann, E., 
Rosin, U., (2009). In vitro and ex vivo bioadhesivity analysis of polymeric intravaginal 
caplets using physicomechanics and computational structural modeling. International 
Journal of Pharmaceutics, 370, 151-159.  
 
Nelson, A.L., 2008. The Vagina: New options for the administration of medications. 
http://www.medscape.com/viewarticle/504375_6 [Accessed, March 10].  
 
Neurath, A.R., Srick, N. and Li, Y., (2003). Water dispersible microbicidal cellulose 
acetate phthalate film. BMC Infectious Diseases, 3, 27. 
 
Neyts, K.T.J., De Clercq, E., and Thormar, H., (2000). Hydrogels containing monocaprin 
prevent intravaginal and intracutaneous infections with HSV-2 in mice: Impact on the 
search for vaginal microbicides. Journal of Medical Virology, 61, 107-110. 
 
Nguyen, D.H., Hildreth, J.E., (2000). Evidence for budding of human immunodeficiency 
virus type 1 selectively from glycolipid-enriched membrane lipid rafts. Journal of Virology, 
2000. 74, 3264-3272. 
 
Nicoll, A., Gill, O., Peckham C.S., Ades A.E., Parry, J., Mortimer P., Goldberg D., Noone 
A., Bennett D. and Catchpole M., (2000). The public health applications of unlinked 
anonymous seroprevalence monitoring for HIV in the United Kingdom. International 
Journal of Epidemiology, 29, 1-10. 
 
 263 
Nicolazzo, J.A. and Finnin, B.C., (2008). In Vivo and In Vitro Models for Assessing Drug 
Absorption Across the Buccal Mucosa. Biotechnology: Pharmaceutical Aspects, VII, 89-
111. 
 
Nijhawan, A., Zaller, N., Cohen, D. and Rich J.D., (2009). Interventions with incarcerated 
persons. HIV Prevention, Doi:10.1016/B978-0-12-374235-3.00016-9, 444-471. 
 
Nikolic, D.S., Garcia, E. and Piguet, V., (2007).  Microbicides and other topical agents in 
the prevention of HIV and sexually transmitted infection. Expert Review of Anti-infective 
Therapy, 5, 77-88. 
Nirmal, M., (2006). Control release formulation containing a hydrophobic material as the 
sustained release agent. US Patent, 7052706. http://www.patentstorm.us/patents/70527 
06/ description .html [Accessed June 9, 2009]. 
Norris, S., (2008). HIV/AIDS - Past, Present and Future. http://www.parl.gc.ca/information/ 
http://www.parl.gc.ca/information/library/PRBpubs/prb0208-e.htm [Accessed June 16,  
2009].  
 
Novák, C., de la Loge, L. and van der Meulen, E.A., (2003). The combined contraceptive 
vaginal ring, NuvaRing: an international study of user acceptability, Contraception, 67, 
187–194. 
 
Nuovo, G., Forde, A., MacConnell, P. and  Fahrenwald, R., (1993). In situ detection pf 
PCR-amplified HIV-1 nucleic acids and tumor necrosis factor cDNA in cervical tissues. 
American Journal of Pathology, 143, 40-48. 
 
 264 
Nuttall, J., Romano, J., Douville, K. Galbreath, C. and Nel, A., (2007). The future of HIV 
prevention: Prospects for an effective anti-HIV microbicide. Infectious Disease Clinics of 
North America, 21, 219-239. 
 
Nuwayser, E.S. and Williams, D.L., (1974). Development of delivery system for 
prostaglandins. Advances in Experimental Medicine, 47, 45-164.  
 
Obiero, J.A., Mburu, M.N., Ndung'u B.M., Waititu, K.K., Mulei, I., Farah, I.O. and 
Mwethera, P.G., (2008). UniPron is A Fully Effective Non-hormonal Reversible 
Contraceptive in Baboon Model (Papio Anubis). Journal of Reproduction and 
Contraception, 19, 107-118  
 
Obioha, E.E., (2008). Exploring the cultural context of HIV/AIDS pandemic in a Nigerian 
community: Implications of cultural specific prevention programmes. Anthropology, 10, 
269-276. 
 
O'Brien, R.F., (2006). Vaginal Microbicides. MD Consult Preview, 17, 
http://www.mdconsult.com/php/about/155168591-2/pm_SubOps.html [Accessed August 
19, 2009]. 
 
Odaka, C. and Ding, A., (2009). Secretory Leukocyte Protease Inhibitor: More than Just A 
Protease Inhibitor. Current Immunology Reviews, 5, 135-142.  
 
Ogra, P.L., Faden, H. and Welliver R.C., (2001). Vaccination Strategies for Mucosal 
Immune Responses. Clinical Microbiology Reviews, 14, 430-445. 
 
Okada, H., Yashiki, T. and Mima, H., (1983). Vaginal absorption of a potent luteinizing 
hormone-releasing hormone analog (leuprolide) in rats: III. Effect of estrous cycle on 
 265 
vaginal absorption of hydrophilic model compounds, Journal of Pharmaceutical. Sciences, 
72, 173–176. 
 
Okada, H., (1991). Vaginal route of peptide and protein delivery. In: Lee VHL. ed. Peptide 
and protein Drug Delivery, 633-666. 
 
O’ Keef, B.R., (2001). Biologically active proteins from natural product extracts. Journal of  
Natural Products, 64, 1373-1381. 
 
Ohmura, T., Fukui, M., Sugiura, H., Yoneya, S., Hosono, T. and Kajiyama, A., (1991). 
Drug-release controlling coating material for long acting formulations US Patent 5028664. 
http://www.freepatentsonline.com/5028664.html [Accessed October 1, 2009). 
Oshlack, B., Wright C.and Breder C., (2009). Pharmaceutical composition containing 
gelling agent. US Patent 424456. http://www.faqs.org/patents/app/20090081287 
[Accessed June 2, 2009]. 
 
Owen, J.A.J., (1975). Physiology of the menstrual cycle, Clinical Nutrition, 28, 333–338. 
 
Owen, D.H. and Kartz, D.F., (1999). A vagina fluid simulant, Contraception, 59, 91-95. 
 
Owen, D.H., Dunmire, E.N., Planys, A.M. and Katz, D.F., (1999). Factors influencing 
nonoxynol-9 permeation and bioactivity in cervical mucus.  Journal of Controlled Release, 
60, 23–34. 
 
Owen D.H. and Katz D.F., (2005). A Review of the Physical and Chemical Properties of 
Human Semen and the formulation of a Semen Simulant. Journal of Andrology, 26, 459-
 266 
469. 
 
Paavonen, J., (1983). Physiology and ecology of the vagina. Scandinavian Journal of 
Infectious Diseases, 40, 31–35. 
 
Padian, N., Shiboski, S., Glass S. and Vittinghoff. E., (1997). Heterosexual transmission 
of human immunodeficiency viruss (HIV) in northern California: results of a ten-year 
study. American Journal of Epidemiology, 146, 350-357. 
 
Pal, S., Tak, Y.K. and Song, J.M., (2007). Does the antibacterial activity of silver 
nanoparticles depend on the shape of the nanoparticle? A study of the gram-negative 
bacterium Escherichia coli. Applied and Environmental Microbiology, 73, 1712-172. 
Palella, F.J.Jr, Delaney, K.M., Moorman, A.C. Loveless, M.O., Fuhrer, J., Satten, G.A., 
Aschman, J.A. and Holmberg, S.D., (1998). Declining morbidity and mortality among 
patients with advanced human immunodeficiency virus infection. HIV Outpatient Study 
Investigators. New England Journal of Medicine,  338, 853-860.  
Palliser, D., Chowdhury, D., Wang, Q.Y., (2006). An siRNA-based microbicide protects 
mice from lethal herpes simplex virus 2 infection. Nature, 439, 89-94.  
 
Panttinen, P., (2005) Microbicides as an option for HIV prevention, A Report for the 
International Task Force on Global Public Goods. http://www.gpgtaskforce.org/uploads/ 
files/183.pdf [Accessed June 15, 2006]. 
 
Parija, S., Nayak, S.K., Verma, S.K. and Tripathy, S.S., (2004). Studies on physico-
mechanical properties and thermal characteristics of polypropylene/layered silicate 
nanocomposites. Polymer composites, 25, 646 – 652.  
 267 
 
Park, H., and Robinson, J.R., (1987). Mechanisms of mucoadhesion of poly(acrylic acid) 
hydrogels. Pharmaceutical Research, 4, 457-464. 
 
Park, J.H., Ye, M. and Park, K., (2005). Biodegradable Polymers for Microencapsulation 
of Drugs. Molecules, 10, 146-161. 
 
Park, K., (1989). A new approach to study mucoadhesion: Colloidal gold staining. 
International Journal of Pharmaceutics, 53, 209-217.  
 
Park, K., and Robinson, J.R., (1984). Bioadhesive polymers as platforms for oral 
controlled Drug Delivery: Method to study bioadhesion, International Journal of 
Pharmaceutics. 19, 107-127.  
Parojčić, J., Ibrić, S., Djurić Z. et al., (2007). An investigation into the usefulness of 
generalized regression neural network analysis in the development of level A in vitro–in 
vivo correlation. European Journal of Pharmaceutical Sciences, 30, 264-272.   
Patel, L.G. (1984). Propanolol concentration in plasma after insertion into the vagina, 
British Medical Journal, 287, 1247–1248. 
 
Patel, R., Pillay, V. and Choonara, Y.E., (2007). A novel cellulose-based hydrophilic wafer 
matrix for rapid bioactive delivery.  Journal of Bioactive and Compatible Polymers, 22, 
119-142.  
Patel, V.F.  and Patel N.M., (2007). Statistical Evaluation of Influence of Xanthan Gum 
and Guar Gum Blends on Dipyridamole Release from Floating Matrix Tablets. Drug 
Development and Industrial Pharmacy, 33, 3, 327-334.  
 268 
Pearce-Pratt, R. and Phillips, D.M., (1996). Sulfated polysaccharides inhibit lymphocyte-
to-epithelial transmission of human immunodeficiency virus-1. Biology of Reproduction, 
54, 173-182. 
 
Pedras-Vasconcelos, J.A., Goucher, D., Puig, M. Tonelli, L.H., Wang V., Ito S. and 
Verthelyi D., (2006). CpG Oligodeoxynucleotides Protect Newborn Mice from a Lethal 
Challenge with the Neurotropic Tacaribe Arenavirus. The Journal of Immunology, 176, 
4940-4949.  
Peh, K.K., Lim C.P., Quek S.S. and Khoh, K.H., (2000). Use of Artificial Neural Networks 
to Predict Drug Dissolution Profiles and Evaluation of Network Performance Using 
Similarity Factor. Pharmaceutical Research, 17, 1384-1389. 
 
PENN Medicine News, (2009). Anti-HIV Gel Shows Promise in Large-Scale Study. 
http://www.health.upenn.edu/news/News_Releases/2009/02/anti-hiv-gel.html [Accessed 
August 19, 2009]. 
 
Penttinen, P., (2005). Microbicides as an option for HIV prevention, A Report for the 
International Task Force on Global Public Goods. http://www.gpgtaskforce.org/show_file. 
aspx?file_id=43 [Accessed February 2, 2007]. 
 
Peppas, N.A., Hansen, P.J., (2003). Crystallization kinetics of poly(vinyl alcohol. Journal 
of Applied Polymer Science, 27, 4787 – 4797.  
 
Peppas, N.A., and Buri, P.A., (1985). Surface, interfacial and molecular aspects of 
polymer bioadhesion on soft tissues, Journal of Controlled Release, 2, 257-275.  
 
 269 
Pérez, O.E, Wargon, V. and Pilosof, A.M.R., (2006). Gelation and structural 
characteristics of incompatible whey proteins/hydroxypropylmethylcellulose mixtures. 
Food Hydrocolloids, 20, 966-974.  
 
Perioli, L., Ambrogi, V., Venezia, L. Giovagnoli, S., Pagano, C. and Rossi, C., (2009). 
Formulation studies of benzydamine mucoadhesive formulations for vaginal 
administration. Drug Development and Industrial Pharmacy, 35, 769-779. 
  
Perotti, M., Pirovano, A. and Phillips, D.M., (2003). Carageenan formulation prevents 
macrophage trafficking from vagina: Implications for microbicide development. Biology of 
Reproduction, 69, 933-939. 
Peritt, D., Sesok-Pizzini, D.A., Schretzenmair, R., Macgregor, R.R., Valiante N.M., Xin Tu, 
X., Trinchieri G. and Kamoun M., (1999). C1.7 Antigen Expression on CD8+ T Cells Is 
Activation Dependent: Increased Proportion of C1.7+CD8+ T Cells in HIV-1-Infected 
Patients with Progressing Disease. The Journal of Immunology, 162, 7563-7568. 
 
Pettifor, A.E., Rees, H.V., Steffenson, A., Hlongwa-Madikizela, L., MacPhail, C., Vermaak, 
K. and Kleinschmidt, I., (2005). HIV and sexual behavior among young South Africans: a 
national survey of 15-24year olds. Reproductive Health Research Unit, University of the 
Witwatersrand. http://www.rhruco.za/images/Docs/national%20survey%20RHRU.pdf  
[Accessed November, 2007]. 
 
Phillips, D.M. and Maguire R.A., (2002). The development of microbicides for clinical use 
to prevent sexually transmitted diseases. Current Infectious Disease Reports, 4, 135-140.  
 
 270 
Picout, D.R., Richardson, R.K., and Morris, E.R., (2000a). Co-gelation of calcium 
pectinate with potato maltodextrin: Part I. Network formation on cooling, carbohydrate 
polymer, 43, 133-141.  
 
Picout, D.R., Richardson, R.K., Rolin C., Abeysekera, R.M., and Morris, E.R., (2000b). 
Ca++ induced gelation of low methoxy pectin in the presence of oxidized starch: Part I. 
Collapse of network structure. Carbohydrate polymer, 43, 113-122.  
Pignatello, R., Bucolo, C., Ferrara, P., Maltese, A., Puleo, A., Puglisi, G., (2002). Eudragit 
RS 100 nanosuspensions for the ophtalmic controlled delivery of ibuprofen. European 
Journal of Pharmaceutical Sciences, 16, 53–61. 
Pijpers, T.F.J., Mathot VBF, Goderis B, et al., (2000). High-speed calorimetry for the study 
of the kinetics of (de)vitrification, crystallization, and melting of macromolecules. 
Macromolecules, 35, 3601–3613.  
 
Pillay, V. and Fassihi, R., (1999). In vitro release modulation from crosslinked pellets for 
site-specific Drug Delivery to the gastrointestinal tract: I. Comparison of pH-responsive 
drug release and associated kinetics, Journal of Controlled Release, 59, 229-242. 
 
Pillay, V. and Fassihi, R., (2000). Electrolyte-induced compositional heterogeneity: A 
novel approach for rate-controlled oral drug delivery. Journal of Pharmaceutical Sciences, 
88, 1140–1148. 
 
Pillay, V. and Danckwerts, M.P., (2002). Textural profiling and statistical optimization of 
crosslinked calcium-alginate-pectinate-cellulose acetophthalate gelisphere matrices, 
Journal of Pharmaceutical Sciences, 91, 2559-2570.  
 
 271 
Pillay, V., Danckwerts, M.P., Muhidinov, Z. and Fassihi, R., (2005). Novel modulation of 
Drug Delivery using binary zinc-alginate-pectinate polyspheres for zero-order kinetics 
over several days: Experimental strategy to elucidate the crosslinking mechanism. Drug 
Development and Industrial Pharmacy, 31, 191-207. 
 
Pinto, J.F., Wunder, K.F., Okoloekwe, A., (2004). Evaluation of the Potential Use of 
Poly(ethylene oxide) as Tablet- and Extrudate-Forming Material. AAPS Pharmaceutical 
Sciences and Technology, 6, 1-10. 
 
Piret, J., Lamontagne, J., Bestman-Smith, J., Roy, S., Gourde, P., Désormeaux, A., 
Omar, R.F., Juhász, J. and Bergeron, M.G., (2000). In vitro and in vivo evaluations of 
sodium lauryl sulfate and dextran sulfate as microbicides against herpes simplex and 
human immunodeficiency viruses. Journal of Clinical Microbiology, 38, 110–119. 
 
Pisani, E., Garnett, G.P., Grassly, N.C., Brown, T., Stover, J., Hankins, C., Walker, N. and 
Ghys, P.D., (2003). Back to basics in HIV prevention: focus on exposure. British Medical 
Journal, 326, 1384-1387. 
Pond, W.G., and Houpt, K.A., (1988). Reproductive physiology. The Biology of the Pig, 
129-180. New York: Cornell University Press. 
Population council, (2009). The Population Council, HIV and AIDS, and Microbicides. 
http://www.popcouncil.org/microbicides/more_info.html#Phase%203%20trial [Accessed 
August 19, 2009]. 
Potts, M., Perlman, D., Mandara, M., Prata, N., Campbell, M., (2004). Is lime/lemon juice 
an effective microbicide? International Conference of AIDS, University of California, 
Berkeley, CA, United States, Abstract No. C11663. http://gateway.nlm.nih.gov/Meeting/ 
Abstracts/ma?f=102277391.html [Accessed November 21, 2007]. 
 272 
 
Pschera, H., Hjerpe, A. and Carlstroem, K., (1989). Influence of the maturity of the vaginal 
epithelium upon the absorption of vaginally administered 17b-estradiol and progesterone 
in postmenopausal women, Gynecologic and Obstetrics Investigation, 27, 204–207. 
 
Pu, Q., Ng, S., Mok, V. and Chen, S.B., (2004). Ion Bridging Effects on the 
Electroviscosity of Flexible Polyelectrolytes. Journal of Physical Chemistry B, 108, 14124–
14129.  
Pulido, F. and Arribas J.R., (2003). Treatment of advanced HIV infection. Journal of 
Antimicrobial Chemotherapy, 51, 225-227. 
Pulido, F. and Torralba M., (2002). NNRTI hepatotoxicity: efavirenz versus nevirapine. 
Journal of HIV Therapy, 7, S3-S16.  
Pusch, O.,  Boden, D., Hannify, S., Lee, F., Tucker, L.D., Boyd, M.R., Wells, J.M. and 
Ramratnam, B., (2005). Bioengineering lactic acid bacteria to secrete the HIV-1 virucide 
cyanovirin. Journal of Acquired Immune Deficiency Syndromes, 40, 512-520.  
 
Quayle, A.J., (2002).The innate and early immune response to pathogen challenge in the 
female genital tract and the pivotal role of epithelial cells. Journal of Reproductive 
Immunology, 57, 61. 
 
Quinn, F.X., Hatakeyama, T., Takahashi, M. and Hatakeyama, H., (1994). The effect of 
annealing on the conformational properties of xanthan hydrogels. Polymer, 35, 1248–
1252. 
 
Quinn, T.C. and Overbaugh, J., (2005).  HIV/AIDS in women: an expanding epidemic. 
Science, 308, 1582–1583. 
 273 
 
Quintanar-Guerrero, D., Villalobos-García, R., Alvarez-Colín, E. and Cornejo-Bravo, J. M., 
(2001). In vitro evaluation of the bioadhesive properties of hydrophobic polybasic gels 
containing N,N-dimethylaminoethyl methacrylate-co-methyl methacrylate.  Biomaterials,  
22,  957-961. 
 
Rahman, B.M., Islam, M.A., Wahed, M.I.I., Ahmed, M., Islam, R., Barman, R.K., 
Anisuzzaman, A.S.M.  and Khondkar P., (2009). In vitro studies of pentoxifylline 
controlled-release from hydrophilic matrices. Journal
 
 of Applied Sciences Research, 1, 
353-362. 
Ramjee, R., Shattock, R., Delany, S., McGowan, I., Morar, N., Gottemoeller, M., (2006). 
Microbicides. AIDS Research and Therapy, 3, 25. 
 
Ramjee, G., (2007). Microbicides in HIV prevention. Future HIV Therapy, 1, 161-170. 
 
Ramratnam, B., (2006). Bacteria in yogurt can combat HIV infection./Bacteria-In-
http://www.bio-medicine.org/medicine-news/Bacteria-In-Yogurt--Can-Combat-HIV-
Infection-7111-1/ [Accessed June 23, 2009]. 
 
Ramsey, P.S., Ogburn, P.L., Harris, D.Y., Heise, R.H. and Ramin, K.D., (2002). Effect of 
vaginal pH on efficacy of the dinoprostone gel for cervical ripening/labor induction, 
American Journal of Obstetrics and Gynecology, 187, 843–846. 
 
Rando, R.F., Obara, S., Osterling, M.C., (2006). Critical Design Features of Phenyl 
Carboxylate-Containing Polymer Microbicides. Antimicrobial Agents and Chemotherapy, 
50, 3081–3089.  
 274 
Ravi, P.R., Kotreka, U.K. and Saha, R.N., (2008). Contolled release matrix tablets of 
zidovudine: Effect of formulation variables on the in vivo drug release kinetics. AAPS 
Pharmaceutical Sciences and Technology, 9, 302-313.  
Rebbapragada, A. and Kaul, R., (2007). More than their sum in your parts: the 
mechanisms that underpin the mutually advantageous relationship between HIV and 
sexually transmitted infections. Drug Discovery Today: Disease Mechanisms, 4, 237-246. 
 
Reddy, S.P., Swart. D., Jinabhai, C.C., Amosun, S.L., James, S., Monyeki, K.D., Stevens, 
G., Morejele, N., Kambaram, N.S., Omardien, R.G., and Van den Borne, H.W., (2002). 
The 1st South African National Youth Risk Behavior Survey 2002. http://www.info.gov.za/ 
otherdocs/2003/youth/part1.pdf [Accessed May 20, 2007]. 
 
Reis, M.A.A., Sinisterra, R.D. and Belchior, J.C., (2004). An alternative approach based 
on artificial neural networks to study controlled drug release. Journal of Pharmaceutical 
Sciences, 93, 418-430. 
 
Repka, M.A., and McGinity, J.W., (2001). Bioadhesive properties of 
hydroxyproplycellulose topical films produced by hot-melt extrusion, Journal of Controlled 
Release, 70, 341-351. 
 
Ribeiro, M., Grolier, J.P.E., (1999) Temperature Modulated DSC for the Investigation of 
Polymer Materials: A brief account of recent studies. Journal of Thermal Analysis and 
Calorimetry, 57, 253-263. 
 
Richardson, B.A., Martin, H.L., Stevens, C.E., Hillier, A. K., Mwatha, B.H., Chohan, M.P., 
Nyange, M., Mandaliya, K., Ndinya-Achola, J. and Kreiss, J.K., (1998). Use of 
 275 
nonoxynolol-9 and changes in vaginal lactobacilli, Journal of Infectious Diseases, 178, 
441-445. 
 
Richardson, J.L. and Armstrong, T.I., (1999). Vaginal delivery of calcitonin by hyaluronic 
acid formulations. In: Mathiowitz E, Chickering DE and Lehr CM. eds. Bioadhesive Drug 
Delivery systems: fundamentals, novel approaches and development. Marcel Dekker, 
New York, 563–599. 
 
Richardson, J.L. and Illum, L., (1992). The vaginal route of peptide and protein drug 
delivery. Advanced Drug Delivery Reviews, 8, 341-366. 
 
Richman D.D., Havlir, D., Corbeil, J., Looney, D., Ignacio, C., Spector, S.A., Sullivan, J., 
Cheeseman, S., Barringer K. and Pauletti D., (1994).  Nevirapine resistance mutations of 
human immunodeficiency virus type 1 selected during therapy. Journal of Virology, 68, 
1660–1666. 
 
Rizkalla N. and Hildgen P., (2005). Artificial Neural Networks: Comparison of Two 
Programs for Modeling a Process of Nanoparticle Preparation. Drug Development and 
Industrial Pharmacy, 31, 1019-1033.  
 
Robinson, J.R. and Bologna, W.J., (2002). Use of polycarboxylic acid polymers to treat 
vaginal infections. US Patent 6017521. http://www.freepatentsonline.com/6017521.html 
[Accessed March 15, 2008]. 
 
Rodd, A.B., Dunstan, D.E. and Boger, D.V., (2000). Characterisation of xanthan gum 
solutions using dynamic light scattering and rheology. Carbohydrate Polymers, 42, 159–
174. 
 
 276 
Rohan L.C. and Sassi A.B., (2009). Vaginal Drug Delivery Systems for HIV Prevention. 
American Association of Pharmaceutical Scientist Journal, 11, 78-87. 
 
Rolfs, T.R., Joesoef, M.R., Hendershot, E.F. Rompalo, A.M., Augenbraun, M.H., Chiu, 
M.,Bolan, G., Johnson, S.C., French, P., Steen, E., Radolf, J.D.,  Larsen, S., Brady, W.E., 
Wagner, K.F., D'Aquilante, D.A. for The Syphilis and HIV Study Group, (1997).  A 
randomized trial of enhanced therapy for early syphilis in patients with and without human 
immunodeficiency virus infection. New England Journal of Medicine. 337, 307-314. 
 
Romano, J., Malcolm, R.K., Garg, S., Rohan, L.C., Kaptur, P.E., (2008). Microbicide 
delivery: formulation technologies and strategies. Current Opinion in HIV and AIDS, 3, 
558-566. 
 
Rosenstein, I.J., Stafford, M.K., Kitchen, V.S., Ward, H., Weber, J.N. and Taylor-
Robinson, D., (1998). Effect on normal vaginal flora of three intravaginal microbicidal 
agents potentially active against human immunodeficiency virus type 1, Journal of 
Infectious Diseases, 177, 1386-1390. 
  
Roumeliotis, G., (2006). SR Pharma claims formulation triumph in siRNA drugs. Alliance 
for Microbicide Development, 73, 542-547. 
 
Roumen, F.J.M.E. and Dieben, T.O.M., (1999). Clinical acceptability of an ethylene-vinyl-
acetate non-medicated vaginal ring. Contraception, 59, 59–62. 
 
Rouse, J.J., Mohamed, F. and van der Walle, C.F., (2007). Physical ageing and thermal 
analysis of PLGA microspheres encapsulating protein or DNA. International Journal of 
Pharmaceutics, 339, 112-120.  
 277 
Roy, D.S. and Rohera B.D., (2002). Comparative evaluation of rate of hydration and 
matrix erosion of HEC and HPC and study of drug release from their matrices. European 
Journal of Pharmaceutical Sciences, 16, 193-199.   
Roy, S., Piret, J., Gagne, N. Desormeaux, A., Omar, R.F., Tremblay, M.J., Juhasz, J., 
Bergeron, M.G., (1999). Thermoreversible gel containing sodium lauryl sulfate as a 
potential topical microbicide for the prevention of STDs/HIV. National HIV Prevention 
Conference Atlanta Georgia, USA. Abstract No. 419. http://gateway.nlm.nih. 
gov/MeetingAb-stracts/ma?f=102187614.html [Accessed November 21, 2007]. 
 
Royce, R.A.  Seña, A., Cates, W. and Cohen, M.S., (1997). Sexual transmission of HIV. 
The New England Journal of Medicine. 336, 1072–1078. 
 
Ruel-Gariepy, E. and Leroux, J., (2004). In situ-forming hydrogels-review of temperature-
sensitive systems. European journal of Pharmaceutics, 58, 2, 409-426. 
 
Rupp, R., Rosenthal, S.L. and Stanberry, L.R., (2007). VivaGel™ (SPL7013 Gel): A 
candidate dendrimer – microbicide for the prevention of HIV and HSV infection. 
International Journal of Nanomedicine, 2, 561–566. 
 
Ruscnis, S, Moonis, M., Merril, D.P. Pallai, P.V., Neidhardt, E.A., S K Singh, S.K., Willis, 
K.J., Osburne, M.S., Profy, A.T., Jenson, J.C., and Hirsch, M.S., (1996). Naphtalene 
sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 
activities. Antimicrobial Agents and Chemotherapy, 40, 234-236. 
 
Saettone, M.F., Panichi, L., Giannaccini, B. et al., (2002). Bioadhesive complexes of 
polycarbophil and azole antifungal or antiprotozoal drugs. United States Patent 6423307. 
http://www.freepatentsonline.com/6423307.html [Accessed June 19, 2009].  
 278 
 
Saïdi, H., Jenabian M. and Bélec, L., (2009). Early events in vaginal HIV transmission: 
implications in microbicide development, Future Virology, 4, 259-269.  
 
San Francisco AIDS Foundation (2008). How HIV is spread. http://www.sfaf.org/aids101 
transmi-ssion.html [Accessed June 16, 2007].  
 
Sanchez-Lafuente, C., Teresa, F.M., Fernandez-Arevalo, M., Alvarez-Fuentes, J., 
Rabasco, A.M., Mura, P., (2002). Development of sustained release matrix tablets of 
didanosine containing methacrylic and ethylcellulose polymers. International Journal of 
Pharmaceutics, 234, 213-221. 
 
Sanders, J.M. and Matthews, H.B., (1990). Vaginal absorption of polyvinyl alcohol in 
Fischer 344 rats, Human and Experimental Toxicology, 9, 71–77. 
 
Sandri, G., Rossi, S., Ferrari, F., Bonferoni M.C., Muzzarelli, C. and Caramella C., (2004). 
Assessment of chitosan derivatives as buccal and vaginal penetration enhancers. 
European Journal of Pharmaceutical Sciences, 21, 51-59. 
Sant, S., Thommes, M., and Hildgen, P., (2008). Microporous Structure and Drug Release 
Kinetics of Polymeric Nanoparticles. Langmuir, 24, 280–287. 
Santos, C.A., Jacob, J.S., Hertzog, B.A. Freedman, B.D., Press, D.L., Harnpicharnchai, P. 
 and Mathiowitz, E. (1999). Correlation of two bioadhesive assays: The averted sac 
technique and the CAHN microbalance. Journal of Controlled Release, 61, 113-122. 
 
 279 
Schroeder, G., Leska, B., and Brzezinski, B., (1998). Solvent effect for proton transfer 
reaction from dimethyl(4-nitrophenyl)malonate to cis 1,2-bis(dimethylaminomethyl) 
cyclohexane. Journal of Molecular Structure, 446, 235-239.  
 
Scorpio, D.G., Ruben D.S.,   Liao, Z., (2008). Cervicovaginal evaluation in macaques 
used as a model for topical microbicide safety studies. Journal of Medical Primatology, 
37, 65 – 73.  
 
Semalty, A., and Semalty, M., 2008. Mucoadhesive Polymers- A Review. 
http://www.pharmainfo.net/reviews/mucoadhesive-polymers-review [Accessed, February 
28]. 
 
Semalty, A., Bhojwani, M., Bhatt, G. Gupta, G.D. and Shrivastav, A.K., (2006). 
Mucoadhesive Polymers. Latest Reviews,  4, 1-5.  
 
Sen, A.K., Roy, S., Juvekar, V.A., (2007). Effect of structure on solution and interfacial 
properties of sodium polystyrene sulfonate (NaPSS). Polymer International, 56, 167-174. 
Serra, L., Doménech, J. and Peppas N.A., (2009). Engineering design and molecular 
dynamics of mucoadhesive Drug Delivery systems as targeting agents. European Journal 
of Pharmace-utics and Biopharmaceutics, 71, 519-528.  
Shafir, S.C., Sorvillo, F.J. and Smith L., (2009). Current Issues and Considerations 
Regarding Trichomoniasis and Human Immunodeficiency Virus in African-Americans. 
Clinical Microbiology Reviews, 22, 37-45. 
 
Sharma, D. and Chakraborty R., (2009). Managing HIV infection in infants, children and 
adolescents with HAART. HIV Therapy, 3, 391-404.  
 280 
Shattock, R.J., (2001). HIV infection of human cervical tissue in vitro and the effects of 
vaginal virucides. AIDS, 15, S39. 
Shen, H. and Iwasaki A., (2006). A crucial role for plasmacytoid dendritic cells in antiviral 
protection by CpG ODN–based vaginal microbicide.  The Journal of Clinical Investigation, 
116, 2237-2243.  
Shen, R., Richter, H.E., Clements, R.H., Novak, L., Huff, K., Bimczok, D., Sankaran-
Walters, S., Dandekar, S., Clapham, Paul R., Smythies, L.E., and Smith P.D., (2009). 
Macrophages in Vaginal but Not Intestinal Mucosa Are Monocyte-Like and Permissive to 
Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 83, 3258-3267.  
 
Sherwood, J.K., Zeitlin, L., Whaley, K.J, Cone, R.A. and Saltzman, W.M., (1996). 
Controlled release of antibodies for long-term topical passive immunoprotection of female 
mice against genital herpes. Nature Biotechnology, 14, 468-471. 
 
Sheung, A., Rebbapragada, A., Shin, L.Y.Y., and Dobson-Belaire, W., (2008). Mucosal 
Neisseria gonorrhoeae coinfection during HIV acquisition is associated with enhanced 
systemic HIV-specific CD8 T-cell responses. AIDS, 22, 1729-1737. 
 
Schiffman, R.M., (2004). A method for treating uterine disorders, including hyperplasic, 
hypertonic, cystic and/or neoplastic uterine gland tissue by local administration of a 
botulinum toxin to or to the vicinity of the afflicted uterine tissue. US Patent No. 
20040175399. http://www.freepatentsonline.com/y2004/0175399.html [Accessed 
September 12, 2009]  
 
Short, I., (2007). Molecular trees bear fruit. Chemistry World. http://www.rsc.org/chemistry 
world /restricted/2007/May/MolecularTreesBearFruit.asp [Accessed June 9, 2007]. 
 281 
 
Sibambo, S.R., Pillay, V. and Choonara, Y.E., (2008). A novel salted-out and 
subsequently crosslinked poly (Lactic-co-glycolic acid) polymeric scaffold applied to 
monolithic Drug Delivery. Journal of Bioactive and Compatible polymers, 23, 132-153.  
 
Sibanda, W., Pillay, V., Danckwerts, M.P., Viljoen, A.M., Van Vuuren, S. and Khan, R.A., 
(2004). Experimental design for the formulation and optimization of crossinked oilispheres 
developed for in vitro site-specific release of Mentha piperita oil, AAPS Pharmaceutical 
Sciences and Technology, 5, 1-14. 
Sibeko, B., Pillay, V., Choonara, Y.E., Khan, R.A., Modi, G., Iyuke, S.E., Naidoo, D and 
Danckwerts, M.P., (2009). Computational molecular modeling and structural 
rationalization for the design of a drug loaded PLLA/PVA biopolymeric membrane. 
Biomedical Materials, 4, 1-11.  
Siepmann, J. and Peppas, N. A., (2001). Modeling of drug release from delivery systems 
based on hydroxypropyl methylcellulose (HPMC). Advanced Drug Delivery Reviews, 48, 
139-157.  
Simoes, J.A., Citron, D.M., Aroutcheva, A., Anderson, R.A., Chany, C.J., Waller, D.P., 
Faro, S. and Zaneveld, L.J.D., (2002). Two novel vaginal microbicides (Polystyrene 
sulfonate and cellulose sulfate) inhibit Gardnerella vaginalis and anaerobes commonly 
associated with bacterial vaginosis. Antimicrobial Agents and chemotherapy, 46, 2692-
2695. 
 
Simon, J., Nachtigall, L. and Gut, R., (2008). Effective Treatment of Vaginal Atrophy with 
an Ultra-Low-Dose Estradiol Vaginal Tablet. Obstetrics & Gynecology, 112, 1053-1060. 
 
 282 
Singh, M.P., Lumpkin, J.A., Rosenblatt, J., (1995). Effect of electrostatic interactions on 
polylysine release rates from collagen matrices and comparison with model predictions. 
Journal of Controlled Release, 35, 165-179.  
Sing, Y. and Govender D., (2009). Infections in the HIV-infected child. Diagnostic 
Histopathology, 15, 251-263.  
Sinha, V.R., Kumria, R., (2003). Coating polymers for colon specific Drug Delivery. A 
comparative in vitro evaluation. Acta Pharmaceutica, 53, 41-47. 
 
Sitruk-Ware, R. (2007). New hormonal therapies and regimens in the postmenopause: 
routes of administration and timing of initiation. Climacteric, 10, 358-370. 
Skoler-Karpoff, S., Ramjee G., Ahmed, K., Altini, L., Plagianos, M.G., Friedland, B., 
Govender, S., De Kock, A., Cassim, N., Palanee, T., Dozier, G., Maguire, R. and 
Lahteenmaki, P., (2008). Efficacy of Carraguard for prevention of HIV infection in women 
in South Africa: a randomised, double-blind, placebo-controlled trial.  Lancet, 372, 1977-
1987. 
Smart, J.D., and Kellaway, I.W., 1982. In vitro techniques for measuring mucoadhesion, 
Journal of Pharmacy and Pharmacology, 34, 70-70. 
 
Smart, J.D., Kellaway, I.W., and Worthington, H.E.C., 1984. An in vitro investigation of 
muco-adhesive materials for use in controlled delivery, Journal of Pharmacy and 
Pharmacology, 36, 295-299.  
 
Smit, A.J., (2004). Medicinal and pharmaceutical uses of seaweed natural products: A 
review. Journal of Applied Psychology, 16, 245-262. 
 
 283 
Smita, J., Soma, D., Beverly, B., Albert, P., JoAnn, K., Fang, G., Missy, C., Lydia, S., 
Anjali, P., Arun, R., Sanjay, M., Steven R., J, and the HIV Prevention Trial Network 
(HPTN) 047 Protocol Tea, (2006). Phase I safety study of 0.5% PRO 2000 vaginal gel 
among HIV un-infected women in Pune, India. AIDS Research and Therapy, 3, 4. 
 
Smith, K.P.B., (1993). Estrogens and the urogenital tract. Studies on steroid hormone 
receptors and a clinical study on a new estradiol releasing vaginal ring. Acta Obstetricia et 
Gynecologica Scandinavica, 72, S1-26. 
 
Smith, B.P. and Brier, M.E., (1996).  Statistical approach to neural network model building 
for gentamicin peak predictions, Journal of Pharmaceutical Sciences, 85, 65–69. 
 
Smith, M., (2006). TMC 120 vaginal ring promising as microbicides carrier. XVI 
International Conference, Toronto Canada. http://www.natap.org/2006/IAS/IAS_65.htm 
[Accessed November 21, 2007]. 
 
Smith, R.C., Leung, A., Kim, B. and Hammond, P.T., (2009). Hydrophobic Effects in the 
Critical Destabilization and Release Dynamics of Degradable Multilayer Films. Chemistry 
of Materials, 21, 1108–1115. 
 
Soifer, H.S., Rossi, J.J. and Sætrom, P., (2007). MicroRNAs in Disease and Potential 
Therapeutic Applications. Molecular Therapy, 15, 2070–2079.  
 
Song, K.,  Kim, Y. and Chang, G., (2006). Rheology of concentrated xanthan gum 
solutions: Steady shear flow behavior. Fibers and Polymers, 7, 129-138. 
 
 284 
Soukoulis, C., Panagiotidis, P., Koureli, R. and Tzia, C., (2007). Industrial Yogurt 
Manufacture: Monitoring of Fermentation Process and Improvement of Final Product 
Quality. Journal of Dairy Science, 90, 2641-2654. 
 
Spencer, S.E., Valentin-Bon, I.E., Whaley, K. and Jerse A.E., (2004). Inhibition of 
Neisseria gonorrhoeae Genital Tract Infection by Leading-Candidate Topical Microbicides 
in a Mouse Model. Journal of infectious diseases, 189, 410-419. 
 
Spinillo, A., Gardella, B., Zanchi, S. Roccio, M., Preti and E., (2008). Determinants of 
Genital Shedding of Human Immunodeficiency Virus: A Review. Current Women's Health 
Reviews, 4, 118-123. 
 
Spira, A. I., Marx, P. A., Patterson, K. B., Mahoney, J., Koup, R.A., Wolinsky, S.M., Ho, 
D.D., (1996). Cellular targets of infection and route of viral dissemination after an 
intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. The 
Journal of Experimental Medicine, 183, 215-25. 
 
Squier, C.A., Mantz, M.J., Schlievert , P.M. and Catherine C. Davis, C.C., (2008). Porcine 
vagina Ex Vivo as a model for studying permeability and pathogenesis in mucosa. Journal 
of Pharmaceutical Sciences, 97, 9-21. 
Sriamornsak, P., Thirawong, N., Weerapol, Y., Nunthanid, J. and Sungthongjeen S., 
(2007). Swelling and erosion of pectin matrix tablets and their impact on drug release 
behaviour. European Journal of Pharmaceutics and Biopharmaceutics, 67, 211-219. 
Staff, P., (2002). Strategies for interrupting the transmission of genital and neonatal HSV 
infection. The journal of the IHMF, 11, 1470-1537. 
 
 285 
Stafford, M. K., Ward, H., Flanagan, A., Rosenstein, I. J., Taylor-Robinson, D., Smith, 
J.R., Weber, J., Kitchen, V.S., (1998). Safety study of nonoxynol-9 as a vaginal 
microbicide: evidence of adverse effects. Journal of acquired immune deficiency 
syndromes and human retrovirology, 17, 327-331. 
 
Stanic, A. and Grana J.C., (2009). Review of antiretroviral agents for the treatment of HIV 
infection. Formulary, 44, 47–54. 
 
Stanic, A. and Schneider, T.K., (2005). Overview of antiretroviral agents in 2005. Journal 
of Pharmacy Practice, 18, 228. 
 
Steinberg, M.S., (1996).  Adhesion in development: An historical overview, 
Developmental Biology, 180, 377–388. 
 
Steinberg, M.S., (2007). Differential adhesion in morphogenesis: a modern view. Current 
Opinion in Genetics & Development, 17, 4, 281-286  
 
Stone, A., (2002). MICROBICIDES: A new approach to preventing HIV and other sexually           
transmitted infections.  Nature Reviews Drug Discovery, 1, 977-985. 
Sudhakar Y., Kuotsu K. and Bandyopadhya A.K., (2006). Buccal bioadhesive drug 
delivery — A promising option for orally less efficient drugs.  Journal of Controlled 
Release, 114,  5-40. 
Sugama, T., Kukacka, L.E., Carciello, N., (1984).  Nature of interfacial interaction 
mechanisms between polyacrylic acid macromolecules and oxide metal surfaces. Journal 
of Materials Science, 19, 4045-4056. 
 286 
Sun, Y., Peng, Y., Chen, Y., Chen, Y. and Shukla, A.J., (2003). Application of artificial 
neural networks in the design of controlled release Drug Delivery systems. Advanced 
Drug Delivery Reviews, 55, 1201-1215.  
Sundstrom, J.B., Ellis, J.E., Hair, G.A., Kirshenbaum A.S. et al, (2007). Human tissue 
mast cells are an inducible reservoir of persistent HIV infection. Blood, 109, 5293-5300. 
Takahara, J., Takayama K. and Nagai T., (1997). Multi-objective simulataneous 
otpimization besed  on artificial neural networks in sustained release formulation. Journal 
of Controlled Release, 49, 11-20. 
 
Takayama, K., Takahara, J., Fujikawa, M., Ichikawa, H. and Nagai, T., (1999). Formula 
optimization on artificial neural networks in transdermal Drug Delivery. Journal of 
Controlled Release, 6, 161-170. 
 
Tambwekar, K. R., Gunjan, Verman, K., Kandarapu, R., Zaneveld, L.J.D. and Garg, S., 
(2002). Effect of different bioadhesive polymers on performance characteristics of vaginal 
tablets, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. 
Nagar, Punjab-160062, India. 
 
Tan, X. and Philips, D., (1996). Cell-mediated infection of cervix derived epithelial cells 
with primary isolates of human immunodeficiency virus. Archives of Virology. 141, 1177-
1189. 
 
Tang, C., Yin, C., Pen, Y. Zhang M. nd Lifang Wu, L., (2005). rporous hydrogels 
composites based on aqueous Carbopol® solution (SPHCcs): Synthesis, characterization 
and in vitro bioadhesive force studies. European Polymer Journal, 41, 557-562. 
 287 
Teixeira, M., Alonso M.J., Pinto, M.M.M. and Barbosa C.M., (2005). Development and 
characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-
methoxyxanthone. European Journal of Pharmaceutics and Biopharmaceutics 
 59, 491-500.  
Thaineua, V., Viravaidya, M., Short, R., (2003). AIDS Information Services. Lemons & 
AIDS  Project History http://www.aids.net.au/lemons-news-thai-aust-bg.htm [Accessed 
June 22, 2009].  
 
Thapa, P., Stevens, H.N.E., Baillie, A.J., (2009). In vitro drug release studies from a novel 
lyophilized nasal dosage form. Kathmandu University Journal of Engineering, Science 
and Technology, 5, 71-86. 
Thirlwell, C., Debashis Sarker, D., Stebbing, J., Bower M., (2003). Acquired 
Immunodeficiency Syndrome–Related Lymphoma in the Era of Highly Active Antiretroviral 
Therapy. Clinical Lymphoma & Myeloma, 4, 86-92 
 
Thom, A., (2007). South Africa: Microbicide trial failure. 
http://allafrica.com/stories/200702010864 htm [Accessed February 2, 2007]. 
 
Thompson, I.O.C., van der Bijl, P., van Wyk, C.W. and van Eyk, A.D., (2001).  A 
comparative light-microscopic, electron-microscopic and chemical study of human vaginal 
and buccal epithelium, Archives of Oral Biology, 46, 1091–1098. 
 
Thompson, M.M. and  Samuels S.C., (2002). Neurosyphilis: is it still a clinically relevant 
form of dementia? Expert Review of Neurotherapeutics, 2, 665-668.  
 
 288 
Thormar, H., Bergsson, G., Gunnarsson, E., Georgsson, G., Witvrouw, M. Steingrimsson, 
O.  De Clercq, E. and Kristmundsdottir, T.  (1999). Hydrogels containing monocaprin have 
potent microbicidal activities against sexually transmitted viruses and bacteria in vitro. 
Sexually Transmitted Infections, 75, 181-185. 
Tiwari, S.B., Murthy, T.K., Pai, M.R., Mehta, P.R., Chowdary, P.B., (2003). Controlled 
release formulation of tramadol hydrochloride using hydrophilic and hydrophobic matrix 
system. AAPS Pharmaceutical Sciences and Technology, 4, 1-6.  
Todd, C., Alibayeva, G., Sanchez, J. Bautista, C., Carr, J. and Earhart, K.  (2006). 
Utilization of contraception and abortion and its relationship to HIV infection among 
female sex workers in Tashkent, Uzbekistan. Contraception, 74, 318-323. 
Trapani, A., Laquintana V., Denora, N. and Lopedota, A., (2007). Eudragit RS 100 
microparticles containing 2-hydroxypropyl-β-cyclodextrin and glutathione: 
Physicochemical characterization, drug release and transport studies. European Journal 
of Pharmaceutical Sciences, 30, 64-74.  
 
Tsai, C.C., Emau, P., Jiang, Y., Tian, B., Morton, W.R., Gustafson, K.R. and Boyd M.R., 
(2003). Cyanovirin-N gel as a topical microbicide prevents rectal transmission of 
SHIV89.6P in macaques. AIDS Research and Human Retroviruses, 19, 535-541. 
 
Turpin, J., (2006). Yoghurt could help fend off HIV. New Scientist Magazine, 17, 2572.  
Uckun F.M. and D'Cruz O.J., (1999). Prophylactic contraceptives for HIV/AIDS. Human 
Reproduction Update, 5, 506-514. 
Uckun F.M. and D'Cruz O.J., (2004).  Clinical development of microbicides for the 
prevention of HIV infection. Current Pharmaceutical Design, 10, 315-336. 
 
 289 
Ugwoke, M.I., Exaud, S., Van Den Mooter, G., Verbeke, N., and Kinget, R., (1999). 
Bioavailability of apomorphine following intranasal administration of mucoadhesive Drug 
Delivery systems in pigs. European Journal of Pharmaceutical Sciences, 9, 213-219.  
 
Umamaheshwari, R.B., Ramteke, S., Jain, N.K., (2004). Anti–Helicobacter Pylori Effect of 
Mucoadhesive Nanoparticles Bearing Amoxicillin in Experimental Gerbils Model. AAPS 
Pharmaceutical Sciences and Technology, 5, 1-9.  
 
UNAIDS, (2007).  AIDS Epidemic Update. http://www.globalhealth.org/hiv_aids/global_ 
view/ [Accessed June 24, 2009]. 
 
UNAIDS, (2007). UNAIDS Revises Global HIV/AIDS Estimates. The Foundation for AIDS 
Research. http://www.amfar.org/hill/article.aspx?id=882 [Accessed 23 May, 2009].  
 
UNAIDS/WHO, (2006a). Overview of the global AIDS epidemic. Report on the global 
AIDS epidemic. http://www.cmaj.ca/cgi/content/full/176/12/172 [Accessed June 8, 2006]. 
 
UNAIDS/WHO, (2006b). Number of People Worldwide Living With HIV/AIDS Increases in 
All Regions; Nearly 40 Million People Have Virus. http://www.thebody.com/content/ 
art38849.html [Accessed June 24, 2009].  
UNFPA, (2006). Top Level Push to Tackle Priorities in Sexual and Reproductive Health. 
http://www.unfpa.org/news/news.cfm?ID=812 [Accessed June 24, 2009]. 
USAID Health, (2009). Condom Use: How It Relates to HIV and STI Prevention. 
http://www.usaid.gov/our_work/global_health/aids/TechAreas/prevention/condomfactshee
t.html [Accessed September 13, 2009].  
 
 290 
Valenta, C., Constantia, E., Kast, C.E., Harich, I., Bernkop-Schnürch, A., (2001). 
Development and in vitro evaluation of a mucoadhesive vaginal delivery system for 
progesterone.  Journal of Controlled Release, 77, 323-332. 
 
Valenta, C., (2005). The use of mucoadhesive polymers in vaginal delivery. Advanced 
Drug Delivery Reviews. 57, 1692-1712. 
 
Valenta, C., Kast, C.E., Harich, I., and Bernkop-Schnürch, A., 2001. Development and in 
vitro evaluation of a mucoadhesive vaginal delivery system for progesterone, Journal of 
Controlled Release, 77, 323-332. 
 
Valenta, C., Marschütz, M., Egyed, C. and Bernkop-Schnürch, A., 2002. Evaluation of the 
inhibitory effect of thiolated poly(acrylates) on vaginal membrane bound aminopeptidase, 
Journal of Pharmacy and Pharmacology, 54, 603-610.  
 
Valore, E. V., Park C. H., Igreti S. L., Ganz T., (2002). Antimicrobial components of 
vaginal fluid. American Journal of Obstetrics and Gynecology, 187, 561-568. 
 
van Damme, L., Wright, A. and Depraetene, K., (2000). A phase I study of a novel 
potential intravaginal microbicides, PRO 2000, in healthy sexually inactive women. 
Sexually Transmitted Infections, 76, 126. 
 
van Damme, L., Adriens, E. and Ramjee, G., (2002). The evaluation of the local tolerance 
of vaginal formulations with or without nonxynolol-9 using the slug mucosal irritation test. 
Contraception, 66, 369-375. 
 
van Damme L., (2002a). Special report: Microbicides. Heatlh and Sexuality, 7, 5-9.  
 
 291 
van Damme, L., (2002b)  Alliance for microbicide development. Health and Sexuality 
Microbicides. Special report, 1-8. https://www.arhp.org/healthcareproviders/onlinepublicati 
 ons/healthand sexuality/micro [Accessed October 10, 2006].  
 
van der Wijgert, J., Fullem, A., Kelly, G., Mehendale, S., Kumwenda, N., Rugpao, S., 
Joshi, S., Taha, T., Nelson, K. and Padian, N., (2001). Phase I trial of the topical 
microbicide buffer gel: Safety results from four international sites. Journal of Acquired 
Immune Deficiency Syndromes, 26, 21-27. 
van Eyk, A.D. and van der Bijl, P., (2005). Porcine vaginal mucosa as an in vitro 
permeability model for human vaginal mucosa. International Journal of Pharmaceutics, 
305, 105-111.  
van Laarhoven, J.A.H., Kruft, M.A.B., Vromans, H., (2002). In vitro release properties of 
etonogestrol and ethinyl estradiol from a contraceptive vaginal ring. International Journal 
of Pharmaceutics, 232, 163-173. 
 
Varma, M., Singla, A. K.  and. Dhawan, S., (2004). Release of Diltiazem Hydrochloride 
from Hydrophilic Matrices of Polyethylene Oxide and Carbopol. Drug Development and 
Industrial Pharmacy, 30, 545-553.  
 
Vasir, J.K., Tambwekar, K. and Garg, S., (2003). Bioadhesive microspheres as a 
controlled Drug Delivery system. International Journal of Pharmaceutics, 255, 13-32.  
 
Venkataraman, N., Cole, A.L., Svoboda, P., Pohl, J. and Cole A.M., (2005). Cationic 
Polypeptides Are Required for Anti-HIV-1 Activity of Human Vaginal Fluid. The Journal of 
Immunology, 175, 7560-7567.  
 
 292 
Verhelst, R., Verstraelen, H., Claeys, G. Verschraegen, G., Van Simaey, L., De Ganck, 
C., De Backer, E., Temmerman, M. and Vaneechoutte M., (2005). Comparison between 
Gram stain and culture for the characterization of vaginal microflora: defination of  distinct 
gade that resembles grade I microflora and revised categorization of grade I microflora. 
BMC Microbiology, 5, doi:10.1186/1471-2180-5-61. 
 
Verhoeven, E., Vervaet, C. and Remon, J.P., (2006). Xanthan gum to tailor drug release 
of sustained-release ethylcellulose mini-matrices prepared via hot-melt extrusion: in vitro 
and in vivo evaluation. European Journal of Pharmaceutics and Biopharmaceutics, 63, 
320-330.   
 
Verhofstede, C., Demecheleer, E., De Cabooter, N., Gaillard, P., Mwanyumba, F., Claeys, 
P., Chohan, V., Mandaliya, K., Temmerman, M., and Plum J., (2003). Diversity of the 
Human Immunodeficiency Virus Type 1 (HIV-1) env Sequence after Vertical Transmission 
in Mother-Child Pairs Infected with HIV-1 Subtype A. Journal of Virology, 77, 3050–3057. 
 
Verman., K. and Garg, S., (2000). The scope and potential of vaginal drug delivery, 
Pharmaceutical Sciences Technology Today, 3, 359-364.  
 
Vermani, K., Garg S.  and. Zaneveld L.J.D., (2002). Assemblies for In Vitro Measurement 
of Bioadhesive Strength and Retention Characteristics in Simulated Vaginal Environment. 
Drug Development and Industrial Pharmacy, 28, 1133-1146.  
 
Vermesh, M.  Fossum, G.T. and Kletzky, O.A., (1998). Vaginal bromocriptine: 
pharmacology and effect on serum prolactin in normal women, Obstetrics and. 
Gynecology, 72, 693–698. 
 
 293 
Viridén, A., Wittgren, B., Larsson, A., (2009). Investigation of critical polymer properties 
for polymer release and swelling of HPMC matrix tablets. European Journal of 
Pharmaceutical Sciences, 36, 297-309.  
 
Vishalakshi, B., (1995). The effect of the charge density and structure of the polymer on 
the dye-binding characteristics of some cationic polyelectrolytes. Journal of Polymer 
Science Part A: Polymer Chemistry, 33, 365-371.  
 
Vitali, B., Pugliese, C., Biagi, E. Candela, M., Turroni, S., Bellen, G., Gilbert G. G. 
Donders, G.G.G. and Brigidi P., (2007). Dynamics of Vaginal Bacterial Communities in 
Women Developing Bacterial Vaginosis, Candidiasis, or No Infection, Analyzed by PCR-
Denaturing Gradient Gel Electrophoresis and Real-Time PCR. Applied and Environmental 
Microbiology, 73, 5731–5741.  
Vlachou, M., Naseef, H., Efentakis, M., Tarantili P.A. and Andreopoulos, A.G., (2001). 
Swelling Properties of Various Polymers Used in Controlled Release Systems. Journal of 
Biomaterials Applications, 15, 293-306.   
Voravuthikunchai, S.P., Bilasoi, S. and Supamala, O., (2006). Antagonistic activity against 
pathogenic bacteria by human vaginal lactobacilli. Anaerobe, 12, 221–226.  
 
Vrijens B. and Urquhart J., (2005). Patient adherence to prescribed antimicrobial drug 
dosing regimens. Journal of Antimicrobial Chemotherapy, 55, 616-627.  
 
Wagner, G., R. and Levin J., (1978). Vaginal fluid. E. S. Hafez, and T. N. Evans, eds. In 
The Human Vagina, 2, 121-137.  
 
 294 
Vueba, M.L., Batista de Carvalho, L.A.E., Veiga, F., Sousa, J.J. and Pina M.E., (2004). 
Influence of cellulose ether polymers on ketoprofen release from hydrophilic matrix 
tablets. European Journal of Pharmaceutics, 58, 51-59. 
 
Wang, Y. and Lee C., (2002). Characterization of a female controlled Drug Delivery 
system for microbicides. Contraception, 66, 281-287. 
 
Wang, Y. and Lee, H.C., (2004). Effects of intrinsic variables on release of sodium 
dodecyl sulfate from a female controlled Drug Delivery system. International journal of 
Pharmaceutics, 282, 173-181. 
 
Wang, L. and Tang, X., (2008). A novel ketoconazole bioadhesive effervescent tablet for 
vaginal delivery: Design, in vitro and ‘in vivo’ evaluation. International Journal of 
Pharmaceutics, 350, 181-187.  
 
Wang, Z., Li, X., Su, D., Li, Y., Wu L., Wang, Y. and Wu, W., (2009). Residue depletion of 
Imidocarb in swine tissue. Journal of Agricultural and. Food Chemistry, 57, 2324–2328. 
 
Ward, R.L., Ashley, C.S., (1979). pH modification of the effects of detergents on the 
stability of enteric viruses. Applied and Environmental Microbiology, 38, 314–322. 
Ward, G. and Courts, A.  (1977). The science and technology of gelatin.  London ; New 
York : Academic Press, 1977. http://catalogue.nla.gov.au/Record/828694 [Accessed 
August 24, 2009]. 
Warner, L, Hatcher, R.A., Steiner, M.J., (2004). Male Condoms. In: Hatcher RA, Trussel 
J, Stewart F, et al, editors. Contraceptive Technology. New York: Ardent Media Inc. 331-
353. 
 295 
Washington, N., Washington, C. and Wilson, C.G., (2001). Vaginal and intrauterine Drug 
Delivery. In: Washington N, Washington C and Wilson CG. Eds. Physiological 
pharmaceutics: barriers to drug absorption: Taylor and Francis, London, 271–281. 
 
Weber, J., Desai, K. and Darbyshire, J., (2005). The development of vaginal microbicides 
for      the prevention of HIV transmission, PLo Medicine, 2, e142. 
 
WebMD, (2008). Vaginal Wet Mount. Women Health. http://women.webmd.com/vaginal-
wet-mount [Accessed September 9, 2009]. 
 
Weeks, M.R., Mosack, K.E.  Abbott, M., Sylla, L.N., Valdes, B., and Prince M., (2004). 
Microbicide Acceptability Among High-Risk Urban U.S. Women: Experiences and 
Perceptions of Sexually Transmitted HIV Prevention. Sexually Transmitted Diseases, 31, 
682–690.  
 
Weinstein, J.N., Kohn, K.W., Grever, M.R. Viswanadhan, V. N., Rubinstein, L.V., 
Monks, A. P., Scudiero, D.A., Welch, L., Koutsoukos, A.D., Chiausa, A.J., Paull, K.D., 
(1992). Neural computing in cancer drug development: predicting mechanism of action. 
Science, 258, 447–451. 
 
Weller, S. and Davis, K., (2002). Condom effectiveness in reducing heterosexual HIV 
transmission. Cochrane Database Systematic Review. 1, CD003255. 
 
Wen, X., Wang T., Wang, Z., Li, L., and Zhao C., (2008). Preparation of konjac 
glucomannan hydrogels as DNA-controlled release matrix. International Journal of 
Biological Macromolecules, 42, 256-263  
 
 296 
Wertz, P.W. and Squier, C.A., (1991). Cellular and molecular basis of barrier function in 
oral epithelium, Critical Reviews in Therapeutic Drug Carrier Systems. 8, 237–269. 
 
Whaley, K. J.  and Zeitlin, L., (2005). Preventing transmission: plant-derived microbicides 
and mucosal vaccines for reproductive health. Vaccine, 23, 1819-1822. 
  
WHO, (2006). Antiretroviral therapy for HIV infection in adults and adolescents. 
http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf [Accessed August 17, 2009]. 
 
WHO, (2007). Sexually transmitted infections. People and planet.net. People and 
reproductive health. http://www.peopleandplanet.net/doc.php?id=211 [Accessed June 17, 
2009]. 
 
WHO Facts sheets, (2007). Sexually transmitted infections (STIs). 
 http://www.who.int/mediacent-re/factsheets/fs110/en/ [Accessed June 17, 2009].  
 
Wilcox, C.M. and Saag, M.S., (2008).  Gastrointestinal complications of HIV infection: 
changing priorities in the HAART era. An International Journal of Gastroenterology and 
Hepatology, 57, 861-870. 
Williams, A., (2003).  Theoretical aspects of transdermal drug delivery. In: A. Williams, 
Editor, Transdermal and Topical Drug Delivery, Pharmaceutical Press, London, 35–40. 
Willits, R.K. and Saltzman, W.M., (2001). Synthetic polymers alter the structure of cervical 
mucus. Biomaterials, 22, 445–452. 
 
Wilber, W.R., Guo, J.and Greenberg, E.S., (2003). Directly compressed solid dosage 
particles.  European Patent EP1276466, http://www.freepatentsonline.com/ EP1276466. 
 297 
html [Accessed August 28, 2009]. 
 
Wira C.R. and Fahey J.V., (2004). The innate immune system: gatekeeper to the female 
reproductive tract. Immunology, 111, 13–15. 
 
Wong, C.F., Yuen, K.H., and Peh, K.K., 1999. Formulation and evaluation of controlled 
release Eudragit® buccal patches, International Journal of Pharmaceutics, 178, 11-22. 
 
Woodley, J., (2001). Bioadhesion: new possibilities for drug adhesion? Clinical 
Pharmacokinetics, 40, 77–84. 
 
Woolfson, A.D., Malcolm, R.K., Gallagher, R., (2000). Drug Delivery by the intravaginal 
route. Critical Reviews in Therapeutic Drug Carrier Systems, 17, 509–55. 
 
Woolfson, A.D., Malcom, R.K., Morrow, R.J., Tonner, C.F. and Mc Cullag, S.D., (2006). 
Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV 
microbicides. International Journal of Pharmaceutics, 325, 82-89. 
 
Workman, M., (2003). The cellular basis of bacterial infection. Critical Care Nursing 
Clinics of North America, 15, 1-11.  
 
Wortley, P. and. Flemming, P., (1997). AIDS in women in the United States. Journal of the 
American Medical Association, 278, 911-916 
 
Wu, F. and Jin, T., (2008). Polymer-Based Sustained-Release Dosage Forms for Protein 
Drugs, Challenges, and Recent Advances. AAPS Pharmaceutical Sciences and 
Technology, 9, 1218-1229. 
 298 
 
Xiaowen, L., Lagenaur, L.A. and Simpson, D.A., (2006). Engineered vaginal Lactobacillus 
strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. 
Antimicrobial Agents and chemotherapy, 50, 3250-3259. 
 
Xu, X., Patel, D.A.  Vanessa, K. et al., (2009). Can Routine Neonatal Circumcision Help 
Prevent Human Immunodeficiency Virus Transmission in the United States? American 
Journal of Men's Health, 3, 79-84. 
 
Yacaman, M.J., Elechiquerra, J.L., Lara, H.H. and Burt, J.L., (2006). Protein-noble metal 
nanoparticles. WO/2006/053225. http://www.wipo.int/pctdb/en/wo.jsp?wo=2006053225 
[Accessed June 5, 2007]. 
Yan, C., Wu, G. and Lin, S., (2006). Alkaline blend polymer electrolytes based on 
polyvinyl alcohol (PVA)/tetraethyl ammonium chloride (TEAC). Journal of Applied 
Electrochemistry, 36, 655-661. 
Yang, Y.,  Tai, N.L and Yu, W.Y., (2005). ART artificial neural networks based adaptive 
phase selector. Electric Power Systems Research,  76, 115-120.  
Yang, T. and Zaman, M.H., (2007). Free energy landscape of receptor-mediated cell 
adhesion. Journal of Chemical Physics, 126, 045103. 
Yang Y., Liu C. and Wu, H., (2008). Preparation and properties of poly(vinyl 
alcohol)/exfoliated α-zirconium phosphate nanocomposite films.  Polymer Testing, 28, 
371-377. 
Yasukawa, T., Ogura Y., Kimura H. et al., (2006). Drug delivery from ocular implants. 
Expert Opinion on Drug Delivery, 3, 261-273. 
 
 299 
Yim, K.C.,  Carroll, C.J., Tuyama, A., (2005). The Cotton Rat Provides a Novel Model To 
Study Genital Herpes Infection and To Evaluate Preventive Strategies. Journal of 
Virology, 79, 14632–14639.  
 
Yiv, S., Li, M., D’Cruz, O. and Uckun, F.M., (2006). Gel-microencapsulation formulations. 
USP Patent 7064114. http://www.patentstorm.us/patents/7064114.html [Accessed 
October 15, 2007].  
Yoo, J., Dharmala K. and Lee, C.H., (2006). The physicodynamic properties of 
mucoadhesive polymeric films developed as female controlled Drug Delivery system. 
International Journal of Pharmaceutics, 309, 139-145.  
Youle, M., Staszweski, S., Clotet, B., (2006). Concomitant Use of an Active Boosted 
Protease Inhibitor with Enfuvirtide in Treatment-Experienced, HIV-Infected Individuals: 
Recent Data and Consensus Recommendations. HIV Clinical Trials, 7, 86-96. 
Yu, D., Branford-White, C., Ma, Z., Zhu, L., Li, X. and Yang, X.L., (2009). Novel Drug 
Delivery devices for providing linear release profiles fabricated by 3DP. International 
Journal of Pharmaceutics, 370, 160-166.   
Yu, Z., and Quinn, P.J., 1998. Solvation effects of dimethyl sulfoxide on the structure of 
phospholipids bi-layers, Biophysical. Chemistry, 70, 35-39.  
 
Yuzgec, U., Becerikli, Y and Turker, M., (2008). Dynamic neural-networks-based-model-
predictive control of an industrial baker’s yeast drying process. IEEE Transactions on 
Neural Networks, 19, 1231-1241. 
 
 300 
Zacharopoulos, V.R. and Phillips, D.M., (1997). Vaginal formulations of carrageenan 
protect mice from herpes simplex virus infection. Clinical and diagnostic laboratory 
immunology, 4, 465–468. 
 
Zaneveld, L.J.D., Waller, D.P., Anderson, R.A., Chany, C., Rencher, W.F., Feathergill, K., 
Diao, K., Doncel, G.F., Herold, B. and Cooper, M., (2002). Efficacy and safety of a new 
vaginal contraceptive antimicrobial formulation containing high molecular weight poly 
(sodium 4-styrenesulfonate). Biology of Reproduction, 66, 886-894. 
Zang, H., Dornadula, G., Beumount, M. et al., (1998). Human immunodeficiency virus 
type 1 in semen of men receiving highly active antiretroviral therapy. New England 
Journal of Medicine, 339, 1803-1809. 
Zhang, Z., Schuler,T., Zupancic, M., Wietgrefe, S., Staskus, K. A., Reimann, K. A.  
Reinhart, T. A.,  Rogan, M., Cavert, W., Miller, C. J., Veazey, R. S., Notermans, D., Little, 
S.,  Danner, S. A.,  Richman, D. D.,  Havlir, D.,  Wong, J.,  Jordan, H. L.,  Schacker, T. 
W., Racz, P.,  Tenner-Racz, K.,  Letvin, N. L.,  Wolinsky, S. and Haase, A. T., (1999). 
Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T 
cells. Science, 286, 1353-1357.  
 
Zeitlin, L., Cone, R.A. and Whaley, K.J., (1999). Monoclonal antibodies for preventing 
mucosal transmission of epidemic infectious diseases. Emerging Infectious Diseases, 5, 
54-64. 
 
Zuckerman, R. A., Whittington, W.L.H., Celum C.L. et al., (2003). Factors Associated with 
Oropharyngeal Human Immunodeficiency Virus Shedding. The Journal of Infectious 
Diseases, 188, 142–145.  
 
 301 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDICES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 302 
APPENDIX A  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACTS OF PAPERS PUBLISHED/SUBMITTED FROM THIS THESIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 303 
APPENDIX A1  
 
 
 
 
 
 
 
 
 
 
 
APPENDIX A2  
 
 
 
 
 
 
 
 304 
APPENDIX A2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 305 
APPENDIX A3  
 
Submitted 
Investigation of the Physicochemical and Physicomechanical Properties of 
an Optimized Intravaginal Bioadhesive Polymeric Device in the Pig Model  
 
Valence M. K. Ndesendo¹, Viness Pillay¹*, Yahya E. Choonara1, Lisa C. du Toit1, Leith 
Meyer1 , Riaz A. Khan2, Eckhart Buchmann3, and Uwe Rosin4  
 
1University of the Witwatersrand, 7 York Road, Parktown, 2193, Johannesburg, South 
Africa 
2Integral University, Department of Industrial Chemistry, Lucknow, 226026, India 
3Chris Hani Baragwanath Hospital, Department of Gynaecology and Obstetrics, 
Bertsham,    2013, Johannesburg, South Africa 
4PharmaNatura (Pty) Ltd., Research and Development Unit, Sandton, 2012, South Africa 
*Corresponding Author: viness.pillay@wits.ac.za 
 
Abstract 
The purpose of this study was to develop and evaluate the bioadhesivity, diffusivity, 
thermal stability and the in vitro drug release an Intravaginal Bioadhesive Polymeric 
Device (IBPD) loaded with 3'-azido-3'-deoxythymidine (AZT) and polystyrene sulfonate 
(PSS). Biodegradable and biocompatible polymers namely, modified polyamide 6,10, 
poly(lactic-co-glycolic acid), polyacrylic acid, polyvinyl alcohol and ethylcellulose were 
blended with model drugs AZT and PSS (separately and in combination) as well as radio-
opaque barium sulfate (BaSO4) and then compressed into robust caplet devices on a 
tableting press at a pressure of 5 tons. One set of devices was coated with 2%w/v PAA 
while the other remained uncoated. Thermal analysis was performed on the constituent 
polymers as well the IBPD employing temperature modulated differential scanning 
calorimetry. The micro-environmental pH changes within simulated vaginal fluid due to the 
degrading constituents of the IBPD were monitored using a Multi- Purpose Titrator (MPT-
2) instrument. Textural profile analysis indicated that the mucoadhesivity of the PAA-
coated devices (3.699±0.464N; 0.0098±0.0004J) was higher than that of the uncoated 
devices (1.198±0.150N; 0.0019±0.0001J). In addition, BaSO4 facilitated x-ray imaging 
revealed that the IBPD adhered to pig vaginal tissue over the experimental period of 30 
days in vivo. Controlled drug release kinetics was obtained over 72 days, and this was 
attributed to the superior physicomechanical properties of the polymer blend selected. A 
characteristic bi-phasic response in pH was within a range of 3.5-5.5 was maintained 
indicating that the IBPD did not significantly alter the pH within the simulated vaginal fluid. 
This was certainly enabled by PLGA upon breaking down into its constituent units, i.e. 
lactic and glycolic acids.  During a 24-hour permeation study, an increase in drug flux for 
both AZT (0.84 mg.cm−2.h−1) and PSS (0.72 mg.cm−2.h−1) was realized up to 12 hours and 
thereafter a steady-state was reached. This indicated that a large proportion of AZT and 
PSS were retained within the vaginal tissue beyond steady-state. The permeation and 
dissolution dynamics were mechanistically deduced based on a chemometric and 
molecular structure modeling approach. Overall, results suggested that the IBPD may be 
sufficiently bioadhesive with desirable physicochemical and physicomechanical stability 
for use as a prolonged intravaginal drug delivery device. 
 
Keywords: Intravaginal drug delivery, Microbicidal polymeric device, Mucoadhesivity, 
Controlled release, Physicochemical and physicomechanical characterization   
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Abstract 
The purpose of this study was to determine the concentration of drug in plasma and 
vaginal tissues from a pig model administered with a 3'-azido-3'-deoxythymidine (AZT) 
and Polystyrene Sulfonate (PSS)-loaded Intravaginal Bioadhesive Polymeric Device 
(IBPD), intended to be used as homeo-prophylactic agent against HIV and STIs. In 
addition, histopathological evaluation was undertaken on the vaginal epithelium to assess 
the potential for toxicity. Biocompatible polymers namely modified polyamide 6,10, 
poly(lactic-co-glycolic acid), polyacrylic acid, polyvinylalcohol and ethylcellulose were 
blended with model drugs AZT and PSS, compressed into caplet shaped IBPDs and then 
intravaginally administered into the pig model. The study employed twenty pigs which 
were divided into four groups of five each (i.e. control, placebo, AZT-containing and the 
PSS-containing group). The IBPDs were deeply inserted into the posterior fornix of the 
vagina of group 2, 3 and 4 pigs using a novel applicator under anesthesia. Plasma 
samples (10mL) were taken from the jugular vein of each pig at day 0, 3, 7, 14, 21 and 
28. AZT and PSS were extracted via Solid Phase Extraction (SPE) and subjected to Ultra 
Performance Liquid Chromatography (UPLC) analysis. At day 28 each pig was 
euthanized to remove the vaginal tissue which was digested with subtilisin, extracted and 
subjected to AZT and PSS content analysis. Histopathological evaluation was conducted 
on vaginal epithelium, lamina propria as well as submucosa and vaginal wall. The mean 
drug concentration in the vaginal tissue at day 28 was 1.2148±0.062mg/mL (N=5) for AZT 
and 1.4004±0.071mg/mL (N=5) for PSS, while the plasma concentration was 
0.332±0.014mg/mL (N=5) for AZT and 0.256±0.013mg/mL (N=5) for PSS. This is an 
indication that the majority of the drug was retained in the vaginal tissue. For each pig, the 
vaginal tissue drug concentration at three vaginal sites (namely anterior, middle and 
posterior) was approximately the same (P>0.05). On average, PSS presented with the 
highest vaginal tissue drug concentration at the 28th day. These results may be attributed 
to the hydrophobicity and high matrix resilience of the polymers employed coupled with 
the presence of strong intermolecular forces in PSS. This findings correlated well 
(R2=0.99) with the results obtained from AZT/ PSS content analysis in blood samples from 
day 1-28 where AZT ranged between 0.012-0.332mg/mL and PSS between 0.009-0.256 
(N=5). The histopathological events were negative to mild levels in most cases. AZT and 
PSS concentration in the pig blood and vaginal tissue and the histopathological findings 
suggests that the developed caplets may be suitable for intravaginal drug delivery that 
may be useful for the prevention of female-related disease conditions. 
 
Keywords: Histopathological evaluation, HIV/AIDS, STIs, Microbicidal drug delivery 
system, UPLC analysis. 
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Abstract 
This study aimed at elucidating the synergistic polymer combination that govern the 
matrix integrity, controlled release kinetics and the release mechanisms of the loaded 
drugs in an Intravaginal Bioadhesive Polymeric Device (IBPD), using Artificial Neural 
Networks (ANN) approach. Fifteen formulations derived from hydrophilic and hydrophobic 
polymer combinations were blended with the model drugs 3'-azido-3'-deoxythymidine 
(AZT) and Polystyrene Sulfonate (PSS) and then compressed into caplet shaped devices 
on a Manesty D3B 16 station tableting press (Manesty D3B L249LQ, Liverpool, England) 
at a compression pressure of 5 tons. In process validation tests were performed to ensure 
that the IBPDs had desirable quality attributes in terms of matrix hardness, uniformity in 
mass and friability. Matrix erosion test was conducted to the formulations at pH 4.5 to 
assess their matrix integrity. In vitro drug release evaluation was conducted on the AZT 
and PSS-loaded IBPDs in simulated vaginal fluid (pH 4.5; 37°C) and samples were 
analysed by UV spectroscopy (Cecil Instruments, Cambridge, England). Artificial Neural 
Networks (ANN) was used to enable the selection of the appropriate polymers for 
developing the IBPD. Robust devices with mass uniformity=800±0.48mg, matrix hardness 
of BHN values ranging from 2.687-4.981N/mm2 and an average friability of 0.21% were 
produced. The tested formulations presented with good matrix integrity with matrix 
erosion percentage ranging from 1.21-7.68. Zero order release kinetics was obtained over 
a prolonged period ranging from 24 hours to 72 days. Polymers employed were 
polyamide 6,10, poly(lactic-co-glycolic acid), polyethylene oxide, polyacrylic acid, 
carrageenan, ethycellulose, polyvinylalcohol, xanthan gum, gelatin, beeswax, Eudragit® 
S100 and Eudragit® RS 100. ANNs elucidated that among these polymers a combination 
comprised of modified polyamide 6,10, poly(lactic-co-glycolic acid), polyvinylalcohol, 
poly(acrylic acid) and ethycellulose was the most appropriate polymer combination for 
formulation optimization of the IBPD. This combination presented with the highest degree 
of matrix integrity that contributed highly to the good drug release kinetics obtained. 
Results revealed a highly satisfactory fit for the input variables (R2 = 0.99) for matrix 
erosion. A linear correlation between the matrix loss and drug release was also realized 
(R2 = 0.99). 
Keywords: Artificial neural networks, Controlled drug release, Micro-environmental pH, 
Matrix integrity, Matrix erosion, Optimization.  
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Abstract 
The purpose of this study was to screen various polymers through extensive 
preformulation investigations to ultimately obtain a lead polymer combination that can be 
employed in designing desirable Intravaginal Bioadhesive Polymeric Device (IBPD). 
Hydrophilic and hydrophobic polymers at different combinations were blended and 
compressed into caplet shaped devices at a force of 5 tons. One of the hydrophilic 
polymers was a modified synthetic product of polyamide 6,10 (mPA 6,10). The devices 
were subjected to in-process validation tests and thereafter to preformulation 
investigational screening using a One Variable at a Time (OVAT) approach. A series of 
swelling tests were conducted on 62 formulations that were derived from 18 polymers, to 
investigate which formulation had the optimal swelling at both simulated and seminal 
vaginal fluids. Each formulation was weighed, immersed into both vaginal and semen 
fluids and then placed in an orbital shaking incubator, maintained at 20rpm (37ºC) for 24 
hours. After 24 hours each device was removed from the orbital shaking incubator, gently 
blotted on filter paper and re-weighed. The swelling behavior was determined in terms of 
the equilibrium swelling ratio (ESR) which was the critical indicator of the formulation’s 
matrix stability (i.e. the degree of matrix robustness), and was used as a screening 
parameter for each formulation. The developed devices were sufficiently strong and 
robust with a mean hardness of 286±0.01N, mean weight 600±0.48mg and a mean 
friability of 0.31±0.04% which was within the limits. Through OVAT approach, 15 suitable 
formulations (out of 62) with ESRs ranging from 0.011-0.084. Through extensive 
screening of the developmental formulations using an OVAT approach, robust and strong 
devices with substantial matrix integrity were produced, as evidenced by the swelling 
equilibrium ratios. Fifteen lead formulations with minimal swelling tendencies were 
obtained. F62 which is comprised of mPA 6,10, (150mg), PLGA (400mg), EC (200mg), 
PVA (25mg) and PAA (25mg) appeared to be the most suited in terms of minimal swelling 
capacity and highest stability.  Overall, the results suggested that PA 6,10, PLGA, EC, 
PVA and PAA at an appropriate weight ratio may be suitable for development of an IBPD. 
 
Keywords: OVAT, Intravaginal Bioadhesive Polymeric Device (IBPD), Developmental 
design, Differential scanning calorimetry, Matrix swelling. 
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Purpose 
To determine the drug concentration in both plasma and vaginal tissue in a pig model 
inserted with a zidovudine (AZT)-loaded Intravaginal Polymeric Platform (IPP) for the 
prophylaxis and/or prevention of HIV and STIs. In addition, histopathological and 
morphological evaluation was undertaken on the vaginal mucosa to assess the potential 
for toxicity. 
 
Methods 
Biocompatible polymers namely PLGA, ethylcellulose (EC) and PAA were blended with 
model drug AZT, compressed into caplet shaped IPPs and then intravaginally inserted 
into the pig model. Fifteen pigs divided into 3 groups (control, placebo and AZT-loaded 
IPPs) of 5 pigs each were employed for this study. The IPPs were inserted into the 
posterior fornix of the vagina (group 2 and 3) using a novel applicator under anesthesia. 
Plasma samples (10mL) were taken from the jugular vein of each pig at day 0, 3, 7, 14, 
21 and 28. AZT was extracted via Solid Phase Extraction (SPE) and subjected to Ultra 
Performance Liquid Chromatography (UPLC) analysis using a phenyl column (1.7µm; 
2.1×50mm). A gradient method was used with a binary mobile phase (water/acetonitrile) 
varying from 60:40 at to, 5:95 at t1-2.6min, and 60:40 at t3.5-3.6min with an injection volume of 
2µL, a flow rate=0.5mL/min and UV detection set at 267nm.  At day 28 each pig was 
euthanized to remove the vaginal tissue which was digested with subtilisin, extracted and 
then subjected to AZT content analysis using UPLC. Histopathological and morphological 
evaluation involved assessment of the epithelial histological lesions, the lamina propria, 
as well as submucosa and vaginal wall.  
 
Results and Discussion 
AZT content in the porcine vaginal tissue from day 0-28 ranged between 56-67% (N=5) 
indicating that AZT was substantially retained within the vaginal tissue. This was 
attributed to the high matrix integrity of the IPP that was imposed by the networked 
microstructure that was formed by the hydrophobic and hydrophilic polymers employed. 
This finding correlates (R2=0.99) with the results obtained from AZT content analysis in 
blood samples where AZT content was minimal and ranged between 22-37% (N=5). 
Histopathological and morphological evaluation revealed that hyperplasia, exocytosis, 
exudates on the mucosal surface, ulceration, polymorphonuclear infiltration and 
perivascular ranged from negative to mild-moderate levels. 
 
Conclusions 
 AZT concentration in the plasma and vaginal tissue as well as the histopathological and 
morphological findings suggests that the developed IPP may be suitable for intravaginal 
drug delivery. 
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Introduction: 
The global HIV/AIDS epidemic calls for the need to search ideal microbicides for curbing 
transmucosal transmission of HIV and STI pathogens. The aim of this study therefore was 
to develop an Intravaginal Bioadhesive Polymeric Device (IBPD) loaded with zidovudine 
(AZT) and polystyrene sulfonate (PSS) for the prevention of HIV and STIs. 
 
Methods: 
Suitable polymers were blended with model drugs AZT, PSS, barium sulfate (BaSO4) then 
compressed into IBDPs, and thereafter subjected to in vitro drug release analysis, ex vivo 
drug flux analysis and ex vivo and in vivo bioadhesivity testing. Furthermore, the IBPDS 
were also subjected to in vivo drug content analysis as well toxicity evaluation in the pig 
model 
 
Results: 
Controlled drug release was obtained over a period of 72 days. A suitable ex vivo drug 
flux and ex vivo bioadhesivity was obtained. The IBPDs could adhere to the vaginal tissue 
over 30 days. Most of the drug was retained in the vaginal tissue (77%) with only little 
quantity crossing to the blood (22%). Histopathological and histomorphological evaluation 
indicated that the IBPDs were non-toxic. 
 
Conclusions: 
Results suggest that the developed IBPDs may be suitable for use as a localized 
intravaginal drug delivery system for the potential prevention of HIV infection and STIs.  
 
Ethical clearance No. 2007/25/05. 
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Abstract 
This study focussed on the formulation and evaluation of polymeric nanoparticles adopting various 
preparation approaches and attempts to explicate the mechanisms of nanoparticle formation employing 
molecular modeling and chemometrical computations. Nanoparticles were formulated using three different 
approaches such as an Emulsification/Solvent Evaporation (ESE), Emulsification/Surfactant/Solvent 
Evaporation (ESSE) and Ionic Gelification (IG) approaches. The ESE approach comprised the emulsification 
of an aqueous and organic solution, while sorbitan monooleate was added as a surfactant during the ESSE 
approach. Cation-induced crosslinking of hydrophilic alginate was employed for the IG approach. Fourier 
Transform Infrared (FT-IR) analysis was performed to elucidate any changes in the structural backbone of 
the native polymers due to nanoparticle formation. The size and morphology of nanoparticles were analysed 
by Zetasize analysis and Scanning Electron Microscopy (SEM) with photomicrographs taken at several 
magnifications. Step-wise molecular simulation models revealed the mechanisms of nanoparticle formation 
to occur via solvation, surface interactions, crosslinking/precipitation initiation and surface-volume 
minimization with sphericalization and interlaced network formation. The size distribution of the 
nanoparticles were manipulated by the surfactant introduction The addition of sorbitan monooleate prevented 
coalescence of particles, resulting in stable nano-emulsions with distinct particle morphologies and particle 
sizes and zeta potential values in the region of 200nm and -40mV, respectively. The IG approach also 
produced stable nano-emulsion with a higher yield of nanoparticles with superior size and stability control of 
confined nanoparticles. Both the ESSE and IG approaches were found to be suitable for producing stable 
nano-emulsions that may potentially be employed for the novel delivery of various drug molecules. 
 
Keywords: Polymeric nanoparticles, alginate, poly(lactide-co-glycolide), polymeric characterization, 
surfactant, crosslinking, emulsification, drug delivery 
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Abstract 
 
Parkinson's and motor neurone diseases are ruthless nerve disorders. While the etiology 
of these diseases is not yet fully known the drugs so far available for treating these 
conditions are still not as effective and often have serious side-effects. The greatest 
challenge in treating these conditions lies in the difficulties involved in delivering drugs to 
the brain which is due to the resistance imposed by arachnoid tight junctions, choroid 
plexus and blood brain barrier (BBB). Treatment strategies, such as use of alternative 
drugs (e.g. Levo dopa instead of dopamine), viral vectors, gene, and lipid therapy have 
not been as successful, due to either the inability to cross the BBB, or development of 
side effects or triggering of immune responses. Nanotechnology poses to be a likely 
solution to these challenges. Thus far, nanotechnology has enabled the creation of smart 
nanomaterials and microdevices that can deliver drug molecules (e.g. dopamine) to the 
nervous system conveniently. This review article addresses various avenues in which 
nanotechnology has been involved in the management of Parkinson’s and Motor neurone 
disease to date, with specific emphasis on nano-based therapeutic modalities that can 
limit and reverse neuropathological disease states, support and promote functional 
regeneration of damaged neurons, provide neuroprotection, as well as facilitate the 
delivery of drugs and small molecules across BBB. Nano-surgery as well as the diagnosis 
of Parkinson’s and motor neurone diseases through nano-based techniques has also 
been discussed. 
 
Keywords: Parkinson's disease, Motor neurone disease, Dopamine, Brain delivery, Nano-
based drug delivery systems. 
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Abstract 
In conscious and co-operating patients, oral drug delivery remains the preferable route of 
drug administration. However, not all drugs possess the desirable physicochemical and 
pharmacokinetic properties which favour oral administration mainly due to poor 
bioavailability. This has in some cases led to the choice of other routes of administration, 
which may compromise the convenience and increase the risk of non-compliance. Poor 
bioavailability has necessitated the administration of higher than normally required oral 
doses which often leads to economic wastages, risk of toxicity, erratic and unpredictable 
responses. The challenge over the years has been to design techniques that will allow 
oral administration of most drugs, irrespective of their properties and yet achieve a 
therapeutic systemic availability. This will be a worthy achievement since over 90% of 
therapeutic compounds are known to possess oral bioavailability limitations. In this 
review, an attempt has been made to explore various approaches that have been used in 
the recent years to improve oral drug bioavailability, including physical and chemical 
means. Design of prodrugs to bypass metabolism or enhance solubility as well as 
modification of formulation techniques such as use of additives, permeation enhancers, 
solubilizers, emulsifiers and non aqueous vehicles have been discussed. Pharmaceutical 
application of nanotechnology, which is an emerging area in drug delivery, has also been 
addressed. This review sought to assess each method aimed at enhancing the oral 
bioavailability of drugs in terms of the purpose, scientific basis, limitations, commercial 
application as well as the areas for further research improvement. 
 
Keywords: Absorption, Bioavailability, Cytochrome P450, Efflux transporters, Enzymes, 
Inhibitors, Permeation enhancers, P-glycoproteins, Pre-systemic metabolism 
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Abstract:  
 
Membrane technology is broadly applied in the medical field. The ability of membranous 
systems to effectively control the movement of chemical entities is pivotal to their 
significant potential for use in both drug delivery and surgical/medical applications. An 
alteration in the physical properties of a polymer in response to a change in environmental 
conditions is a behavior that can be utilized to prepare 'smart' drug delivery systems. 
Stimuli-responsive or 'smart' polymers are polymers that upon exposure to small changes 
in the environment undergo rapid changes in their microstructure. A stimulus, such as a 
change in pH or temperature, thus serves as a trigger for the release of drug from 
membranous drug delivery systems that are formulated from stimuli-responsive polymers. 
This article has sought to review the use of stimuli-responsive polymers that have found 
application in membranous drug delivery systems. Polymers responsive to pH and 
temperature have been extensively addressed in this review since they are considered 
the most important stimuli that may be exploited for use in drug delivery, and biomedical 
applications such as in tissue engineering. In addition, dual-responsive and glucose-
responsive membranes have also been addressed as membranes responsive to diverse 
stimuli. 
 
Keywords: Membranous drug delivery systems, stimuli-responsive polymers, dual 
responsive membranes, glucose responsive membranes, pH, temperature, "On-off" 
gating mechanisms. 
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Abstract 
The aim of this study was to develop a polymeric wafer system targeted for gradual 
oramucosal drug delivery. The mucoadhesive polymer pectin was crosslinked with 
various salts such as calcium chloride, barium chloride and zinc sulphate for the 
production of the wafers and subjected to three methods of lyophilization. A simultaneous 
qualitative and quantitative analysis of the wafer surface morphology and porosity was 
undertaken. In addition, vibrational transitions, the thermal behavior as predicted by 
temperature modulated differential scanning calorimetry, textural attributes, and in vitro 
drug release behavior of the highly water soluble model drug, diphenhydramine HCl, from 
the various wafer systems were systematically characterized. The techniques employed 
yielded wafers of varying porosities. Crosslinked pectin wafers generally demonstrated a 
smaller pore size (having a mean diameter of 107.63Å compared to 180.53Å for non-
crosslinked pectin wafers); due to the highly interconnected matrix structure afforded by 
the formation of inter- and intra-molecular crosslinks between the pectin chains. The drug 
release capabilities of the wafers varied markedly with the approach employed in the 
production of the wafers. Non-crosslinked wafers released 82.5% of drug within 30 
minutes. Wafers that included a crosslinking step in their formulation design showed a 
more gradual release of drug. Furthermore, wafers crosslinked after the lyophilization 
process controlled drug release more efficiently than those that were crosslinked before 
lyophilization. Vibrational and thermal analysis confirmed the crosslinking effect and 
resultant drug release capabilities of the wafer systems. There was a strong negative 
correlation between the normalized pore size of the wafers and their resilience (R2=0.99). 
It was established that Å), possessed the propensity to form a number of ionic bridges 
between pectin monomers in intra- and inter-molecular associations producing an 
interconnected wafer matrix, culminating in wafers of high porosity (0.048cm2/g) on 
lyophilization.  
 
Keywords: Oramucosal, wafer matrix, mucoadhesive polymer, gradual drug release, 
lyophilization, crosslinking, porosity, physicochemical, physicomechanical 
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Abstract 
 
Background:  
Despite the fact that Parkinson’s disease (PD) was discovered almost 200 years ago, its 
treatment and management remains an immense challenge since progressive loss of 
dopaminergic nigral neurons, motor complications experienced by the patients as the 
disease progresses and drawbacks of pharmacotherapeutic management still persists. 
Various therapeutic agents have been employed in the management of PD, including 
levodopa (L-dopa), selegiline, amantadine, bromocriptine, entacapone, pramipexole 
dihydrochloride and more recently istradefylline and rasagiline. Of all agents, L-dopa 
though the oldest, remains the most effective. L-dopa is easier to administer, better 
tolerated, less expensive and is required by almost all PD patients. However, L-dopa’s 
efficacy in advanced PD is significantly reduced due to metabolism, subsequent low 
bioavailability and irregular fluctuations in its plasma levels. To date, significant strides 
have been made to improve the delivery of L-dopa in order to enhance its bioavailability 
and reduce plasma fluctuations as well as motor complications experienced by patients 
purportedly due to pulsatile stimulation of the striatal dopamine receptors.  
 
Objective: 
The ultimate aim was to critically assess the attempts made thus far directed at improving 
L-dopa absorption, bioavailability and maintenance of constant plasma concentrations, 
including the drug delivery technologies implicated.  
 
Methods:  
Drug delivery systems that have been instituted for the delivery of L-dopa include 
immediate release formulations, liquid formulations, dispersible tablets, controlled release 
formulations, dual release formulations, microspheres, infusion and transdermal delivery, 
among others. In this review, the L-dopa loaded drug delivery systems developed over 
the past three decades were elaborated on.  
 
Conclusion:  
This review highlights the fact that neuropharmaceutics is at a precipice, which is 
expected to spur investigators to take that leap to enable the generation of innovative 
delivery systems for the effective management of PD. 
 
Keywords: Bioavailability, Conventional dosage forms, Drug delivery systems, Levodopa, 
Microspheres, Motor complications, Neuropharmaceutics, Nanotechnology, Parkinson’s 
disease, Pulmonary delivery, Transdermal delivery.   
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Abstract  
 
The effective treatment of solid tumors still continues to be a great challenge to clinicians 
despite the development of novel drugs. In order to improve the clinical efficacy of the 
existing chemotherapeutics agents, researchers have considered the possibility of local 
treatment at the site of the solid tumor. The greatest advantage of this localised delivery is 
the significantly fewer side effects experienced by the patient. In the past, the peri- or 
intra- tumoral delivery of chemotherapeutics agents was mainly based on implants that 
used to be inserted surgically into the affected region. In the recent years, in situ forming 
implants have attracted considerable interest. These are polymeric systems which are 
injected as solutions into the tumor site using commercially available syringes and 
needles. The injected solution forms an implant at the tumor site as a result of local 
environmental stimuli and hence removes the need for surgical implantation. However, 
while these implants have been shown to improve the treatment of various solid tumors, 
the ideal implant is yet to be formulated. To date, it is only a few implants that are 
biodegradable and able to deliver the chemotherapeutic agent over a prolonged period of 
time. Many of these implants also have an undesirable initial burst release effect. This 
review summarises the attempts that have so far been made in the development of 
polymeric implants for the treatment of solid tumors. 
 
Keywords: Chemotherapy, Environmental stimuli, Implant, Polymeric systems, Solid 
tumors. 
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Abstract 
Recent pharmaceutical research has focused on controlled drug delivery as an advantage 
over conventional methods. Adequate controlled plasma drug levels, reduced side effects 
as well as improved patient compliance are some of the benefits that these systems may 
offer. Controlled delivery systems that can provide zero-order drug delivery have the 
potential for maximizing efficacy while minimizing dose frequency and toxicity. Thus, zero-
order drug release is ideal in a large area of drug delivery which has therefore led into the 
development of various technologies with such drug release patterns. Systems such as 
multilayered tablets and other geometrically altered devices have been created to perform 
this function. One of the principles of multilayered tablets involves creating a constant 
surface area for release. Polymeric materials play an important role in the functioning of 
these systems. Technologies so far developed include among others, Geomatrix® 
multilayered tablets which utilizes specific polymers that may act as barriers to control 
drug release; Procise®  which has a core with an aperture that can be modified to achieve 
various types of drug release, core-in-cup tablets where the core matrix is coated on one 
surface while the circumference forms a cup around it, donut-shaped devices which have 
a hole in the middle, Dome Matrix® and “release modules assemblage” which can offer 
alternating drug release patterns. This review discusses the novel altered geometric 
system technologies that have been developed to provide controlled drug release, also 
focusing on polymers that have been employed in such developments. 
 
Keywords:  
Controlled drug delivery, geometrically altered devices, multilayered tablets, Polymeric 
materials, “Release modules assemblage”. 
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Abstract 
 
Electro-spinning of polymers is a unique technology which produces very fine fibres using 
electrostatic repulsive forces obtained from applying an electrical potential to a liquid. The 
resultant fibres have much smaller diameters in comparison with fibres obtained using 
different methods. Electro-spun fibres have found application in many and varied fields 
such as drug and gene delivery, tissue engineering, wound dressing, electronics, filtration 
as well as absorption and adsorption. This review will cover the various processing 
parameters which play a role in electro-spinning, including the applied voltage, solution 
flow rate, solution viscosity, solvents, solution conductivity, capillary-to-collector distances 
and the influence of surfactants. A main focus will be on the application of electro-spun 
fibres in drug delivery, where researchers have already investigated the use of these 
fibres in transdermal delivery systems, long-term implants and grafts. Different methods of 
drug incorporation will be discussed as well as numerous polymers which have been 
successfully utilised in this field, including cellulose acetate, poly(ε-caprolactone), 
poly(ethylene oxide), poly(vinyl alcohol), gelatin, poly(d,l-lactide-co-glycolide), poly(lactic 
acid), poly(l-lactic acid), polyurethane, poly(ethylene-co-vinyl acetate), poly(ethylene 
glycol), and poly(acrylic acid).  
 
Keywords: Electro-spinning, drug delivery, electrospun fibres, electrospun scaffolds, 
parameters, 
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Abstract 
 
The purpose of this study was to fabricate pediatric wafers containing 3'-azido-3'-
deoxythymidine (AZT) as an antiretroviral (ARV) drug for the treatment of HIV/AIDS in 
pediatric patients. Oramucosal drug delivery systems have many advantages over the 
other routes mainly because of the ability to circumvent the pitfalls of traditional drug 
delivery systems by directly entering the systemic circulation via the internal jugular vein. 
A 5% hydroxypropylcellulose solution and a separate 1% carbopol solution were allowed 
to homogenize, these solutions were then combined in a ratio of 1:1. Approximately 
200mg of AZT needed to be delivered to each cylindrical well of the wafer mould. Other 
excipients employed included mannitol and lactose as bulking agents, sodium starch 
glycolate as a disintegrant and glycine as an anti-collapsing agent. Cylindrical wells were 
lubricated with a mineral oil. 1.5mL of the final solution was transferred into each well 
under continuous stirring. The formulation was then frozen for a period of 24 hours at   
negative 60ºC. Thereafter, the formulation was lyophilized for a period of 48 hours. 
Extensive in vitro and ex-vivo studies including disintegration test, determination of DLC 
and DEE, drug release analysis and bioadhesivity testing were conducted on the wafer 
systems. An optimal formulation consisting of a ratio of 1:2 (HPC/C934), glycine (0.03g) 
as an anti-collapsing agent and sodium starch glycolate (4%w/w) as a disintegrant was 
obtained. This optimal formulation had a disintegration time as short as 6.7 seconds, a 
high DLC (190.4mg) and a desirable DEE (95.175%). A zero order drug release kinetics 
was realized (optimal formulation) and almost the whole quantity of drug was released 
within 10 seconds. The developed wafers were substantially bioadhesive. The Peak 
Adhesion Force and the work of adhesion (AUCFD) for the optimal wafer system were 
PAF=0.193±0.004N and AUCFD=0.104±0.006J respectively. The developed pediatric a 
wafers may be suitable for the treatment of pediatric HIV/AIDS. 
 
Keywords: Bioadhesivity, HIV/AIDS, Drug loading capacity, Drug entrapment efficiency, 
Disentergration time. 
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Abstract The purpose of this research was to develop poly (DL-lactide) (PLA)/Eudragit S 100 (ES 100) 
nanoparticles (NP) with the potential to serve as carrier systems for methotrexate (MTX) an anticancer drug. 
The nanoparticles were prepared by double emulsion solvent evaporation technique. A 3-Factor Box 
Behnken design was applied for preparing various nanoparticle formulations. The size of the nanoparticles 
varied from 211 nm to 378.3 nm and the nanoparticle recovery varied from 36.8 mg to 86.2 mg. Most 
formulations showed a poly-dispersity index (PdI) value less than 0.5 indicating that the nanoparticle size 
distribution was homogenous within the formulations. The drug loading capacities (DLC) of the 
nanoparticles were very low with the maximum being 12 % for the optimized formulation. In order to 
improve the drug loading capacity of the optimized formulation, we adsorbed the drug onto the nanoparticles 
matrix by incubating the nanoparticles in a concentrated MTX solution. By so doing, we successfully 
improved drug loading to 98 %. Fourier-Transform Infrared (FTIR) studies showed that MTX was present in 
the nanoparticles. The nanoparticles showed an initial burst release with 50% of MTX released in 24 hours, 
thereafter the release was prolonged for 84 hours. Scanning electron micrographs revealed almost spherical 
solid nanoparticles with a smooth surface and transmission electron micrographs showed the presence MTX 
within the nanoparticles. 
 
Keywords: Poly (DL-lactide) (PLA), Eudragit S 100 (ES 100), Methotrexate (MTX) and Drug loading 
capacity (DLC)  
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Abstract 
The purpose of this study was to develop a prolonged-release drug delivery device for 
site-specific delivery of a newly researched neuroprotective agent, namely nicotine. The 
device was formulated as a novel reinforced crosslinked composite polymeric system with 
the potential for implantation into the substantia nigra pars compacta of the brain to 
provide site-specific drug delivery for the treatment of Parkinson’s disease. Polymers with 
biocompatible and bioerodible characteristics were selected to incorporate nicotine within 
electrolyte-crosslinked alginate- hydroxyethylcellulose gelispheres compressed within a 
release-rate modulating external polymeric matrix, comprising either 
hydroxypropylcellulose, polyethylene oxide and poly(lactic-co-glycolic) acid to further 
attenuate nicotine release. The degradation and erosional behavior of the discs following 
exposure to simulated CSF are also conducted to elucidate their influence on drug 
release. Kinetic modeling of drug release data was performed to understand the 
predominant mechanisms involved in controlling nicotine release from the device. Zero-
order drug release was observed for a period of 50 days in simulated cerebrospinal fluid 
from the device comprising poly(lactic-co-glycolic) acid as the external matrix.  
 
Keywords: Alginate gelispheres, textural analysis, crosslinked matrices, kinetic modeling, 
PLGA discs, prolonged release, BHN, powder flow properties 
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ANIMAL ETHICS CLEARANCE CERTIFICATE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The rabbit model was changed to pig 
model due the pig vagina more closely 
resembling that of the human (see 
Modifications and Extensions to 
Experiments approval next page).  
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